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Summary 
African sleeping sickness is one of the most neglected tropical diseases. Transmitted by 
the tsetse fly it exclusively occurs in sub-Saharan Africa. It is caused by two different 
parasite subspecies causing two different forms of African sleeping sickness. 
Trypanosoma brucei gambiense is prevalent in West and Central Africa while 
Trypanosoma brucei rhodesiense is prevalent in East and South Africa. Sleeping sickness 
is classified in two main stages. In the first stage, the parasites reside in the lymph and 
blood system. In the second stage, the parasites additionally infect the brain. Untreated 
sleeping sickness is fatal.  Drugs are available for this fearsome disease, however, most 
of them are old and have many drawbacks, such as severe adverse effects, treatment 
failures and complicated treatment schedules, which is a problem in remote rural areas 
where the disease primarily occurs.  
 
African sleeping sickness is a communicable disease that can be controlled. In 1998, 
there were an estimated 300,000 cases. By 2012 the prevalence has decreased to about 
30,000, by different control measures such as vector control, improved surveillance and 
free drug distribution. Elimination seems possible, but safe and effective drugs are 
needed to reach this goal. One of the current drugs is the diamidine pentamidine which is 
in use since the early 1940s. However, it works only in patients with first stage disease 
and it has to be injected.  
 
The Consortium for Parasitic Drug Development (CPDD) was founded in the year 2000 
to find novel diamidines with better characteristics than the existing drugs. We improved 
oral absorption, which makes it possible to use pills instead of injections, and central 
nervous system (CNS) penetration. One compound (pafuramidine) has been tested in 
patients with first stage infections. It was the first compound that cured sleeping sickness 
orally, which is of great help for rural areas. Unfortunately, pafuramidine caused kidney 
and liver problems, and it did not cure second stage infections. In the meantime, we have 
identified superior compounds especially for the second stage.  
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As described in Chapter 3, two compounds, the prodrugs DB868 and DB844, given 
orally, cured all mice with CNS infections. However, both prodrugs were too toxic at the 
high doses required to cure both stages in monkeys.  Nevertheless, DB868 is a good 
candidate drug to cure first stage sleeping sickness by an oral treatment, as demonstrated 
in mice and monkeys with first stage infections. Chapter 4 shows data of another CNS 
potent prodrug, DB1227 which was, however, less effective than DB868 in CNS infected 
mice. 
 
Chapters 3, 7, 8 and 9 deal with two unmasked diamidines, DB829 and 28DAP010, 
which were highly effective in mice with second stage infections after i.p. injection. This 
was unexpected since diamidines are rather unlikely to cross the blood brain barrier in 
sufficient concentrations by diffusion. These two diamidines may penetrate into the brain 
by specific transporter proteins. The advantage of the two diamidines is that both cure 
with a short treatment course which could shorten the time of hospitalization of the 
patients. We have already tested DB829 in monkeys with promising results. It was safe 
and effective at low doses and a short treatment schedule in monkeys with second stage 
disease. 28DAP010 seems to be similarly effective as DB829 on both T. brucei 
subspecies in vitro and in mouse models. 
 
In Chapter 6 we established a new in vitro method to measure the kinetics of drug action 
on pathogenic protozoa on a real time basis. We exploited the capacity of viable cells to 
produce heat and measured the heat flow using microcalorimetry. 28DAP010 inhibited 
the heat production of trypanosome cultures faster than DB829. The parasite clearance 
time of 28DAP010 was also faster than of DB829 in mice. The required effective 
treatment duration was still similar in mice with single dose for first stage and 5 days for 
second stage infections.  
 
Upcoming efficacy studies will reveal if 28DAP010 is as curative in monkeys as DB829 
and toxicity studies of 28DAP010 and DB829 side by side will shed light on their 
toxicity profile. These studies will help to select the better of these two compounds as a 
clinical drug candidate for the treatment of second stage sleeping sickness. 
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Zusammenfassung 
Die Afrikanische Schlafkrankheit ist eine Tropenkrankheit, welche durch die Tsetsefliege 
übertragen wird und daher ausschliesslich im tropischen Afrika vorkommt. Sie gehört zu 
den vernachlässigsten Krankheiten überhaupt und wird deshalb auch “vergessene 
Seuche“ genannt. Der Erreger ist ein einzelliger Parasit. Es gibt zwei verschiedene 
Unterarten, die zu etwas unterschiedlichen Schlafkrankheitsformen führen. Ohne 
wirksame Medikamentenbehandlung sind beide Formen tödlich. Trypanosoma brucei 
gambiense kommt nur in West- und Zentralafrika vor, während Trypanosoma brucei 
rhodesiense in Ost- und Südafrika zu finden ist. Der Krankheitsverlauf kann in zwei 
Stadien unterteilt werden. Im ersten Stadium findet man die Parasiten im Blut- und 
Lymphsystem und im zweiten Stadium zusätzlich im Gehirn. Zwar gibt es für diese 
Krankheit Medikamente, jedoch sind die meisten davon veraltet, haben ausgeprägte 
Nebenwirkungen und sind wegen Rückfällen oder der komplizierten und aufwendigen 
Behandlung problematisch. 
 
Die Bekämpfung der Afrikanischen Schlafkrankheit ist möglich. 1998 gab es geschätzt 
etwa 300.000 Krankheitsfälle. Durch verbesserte Überwachung mit anschliessender 
medizinischer Behandlung der Infizierten, kostenlose Medikamentenverteilung und 
Vektorkontrolle, liess sich die Krankheit auf etwa 30.000 Krankheitsfälle im Jahr 2012, 
eindämmen. Für eine Eliminierung sind wirksame und verträgliche Medikamente 
notwendig. Ein Diamidin, das schon seit den frühen 40-er Jahren eingesetzt wird ist 
Pentamidin. Es wirkt noch heute, aber nur in Patienten die sich im ersten Stadium 
befinden, zudem muss es injiziert werden. 
 
Im Jahr 2000 wurde das Konsortium CPDD, für die Entwicklung neuer Wirkstoffe zur 
Behandlung parasitärer Erkrankungen, vor allem für die Schlafkrankheit, gegründet. 
Neuartige Diamidine mit verbesserten Eigenschaften wurden gesucht und es war uns 
möglich, die orale Bioverfügbarkeit und die Bluthirnschrankengängigkeit, chemisch zu 
verbessern. Pafuramidin, war einer der neuen Wirkstoffe, das erste oral einzunehmende 
Medikament gegen Schlafkrankheit, das im Menschen getestet wurde. Ein orales 
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Medikament hat grosse Vorteile für diese Krankheit, die hauptsächlich in abgelegenen 
Gebieten Afrikas vorkommt, wo ein ausgebautes Gesundheitssystem oft fehlt. 
 
Pafuramidin heilte nur das erste Schlafkrankheitsstadium und dabei wurden Leber- und 
Nieren-Unverträglichkeiten festgestellt. Während der klinischen Studie testeten wir 
weitere Diamidine und fanden verbesserte Substanzen, vor allem bezüglich der 
Wirksamkeit des zweiten Krankheitsstadiums. Kapitel 3 und 4 beschreibt die 
wirksamsten Moleküle, die das Zweitstadium bei oraler Verabreichung heilten. Diese 
Moleküle, DB844, DB868, DB1227, aber auch das Pafuramidin sind Medikamenten-
vorstufen (Prodrugs). Diese wurden entwickelt, um die orale Aufnahme und Gehirn-
gängigkeit zu verbessern.  Die aktivsten waren DB868 und DB844 in Mäusen, jedoch 
zeigten beide Moleküle toxische Wirkungen im Affen ohne dabei ausreichend die 
Gehirninfektion zu heilen. Dennoch war DB868 im Affenmodell deutlich besser 
verträglich als Pafuramidin und ist somit ein guter Ersatzkandidat für eine orale 
Wirkstoffentwicklung fürs erste Stadium. 
 
Unerwartet konnten wir jedoch zwei Diamidine (ohne Vorstufenergänzung) 
identifizieren, die ebenfalls Mäuse mit Gehirninfektionen heilten. Da Diamidine unter 
physiologischen Bedingungen protoniert sind, ist es unwahrscheinlich, dass sie durch die 
Bluthirnschranke diffundieren. Möglicherweise werden sie über spezifische 
Mechanismen ins Gehirn transportiert. Kapitel 3, 7, 8 und 9 befassen sich mit den beiden 
aktivsten Diamidinen, DB829 und 28DAP010. Ihre hohe Wirkung und die kurze 
Behandlungszeit nach parenteraler Verabreichung (i.p. oder i.m) sind vielversprechend. 
DB829 war gut verträglich und wirksam bei niedrigen Dosen und heilte die infizierten 
Affen mit dem zweiten Krankheitsstadium bereits bei einer 5-tägigen Behandlung. In 
vitro und im Mausmodel war 28DAP010 auf beide Trypanosomen Unterarten ähnlich 
wirksam wie DB829. 
 
Um die Wirkungszeit neuer Substanzen auf Trypanosomen zu testen, entwickelten wir 
eine neue Methode, die in Kapitel 6 beschrieben wird. Dabei nutzten wir die Eigenschaft 
der Zellen, Wärme zu produzieren und massen diese mit einem Kalorimeter auf Echtzeit. 
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28DAP010 reduzierte die Wärmeentwicklung einer Trypanosomenkultur deutlich 
schneller als DB829. Auch in infizierten Mäusen wirkte 28DAP010 schneller. Die 
Behandlungsdauer und Dosierung war bei beiden Diamidinen trotzdem vergleichbar. 
Eine Einzeldosis heilte das erste und eine 5-tägige Behandlung das zweite Stadium in 
Mäusen. 
 
Weitere Studien sind nötig, um die Wirksamkeit von 28DAP010 im Affenmodel zu 
überprüfen und die Verträglichkeit beider Diamidine zu analysieren.  Diese Ergebnisse 
werden zeigen, welches der bessere klinische Kandidat für die Behandlung des zweiten 
Schlafkrankheitsstadiums sein wird. 
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Introduction  
 
African sleeping sickness, also known as Human African Trypanosomiasis (HAT), is a 
parasitic disease in humans. Since it is prevalent only in sub-Saharan Africa, it is 
neglected, even though it is a fatal disease. HAT is currently endemic in 23 countries 
with about 70 million people at risk of infection (Simarro et al., 2012, 2010). The illness 
is caused by flagellated protozoans of the genus Trypanosoma, and by two different 
subspecies of Trypanosoma brucei, T. b. gambiense and T. b. rhodesiense belonging to 
the order Kinetoplastida, family Trypanosomatidae. These parasites are 20 to 30 µm long 
and 1.5 to 3.5 µm wide and live and multiply extracellularly in the blood and tissue fluids 
of the infected patients. The different subspecies cause slightly different diseases. T. b. 
gambiense, prevalent in west and central Africa cause West African Sleeping sickness or 
Gambian Trypanosomiasis which is a more chronic disease killing the patient in around 
three years (Checchi et al., 2008). T. b. rhodesiense prevalent in east Africa causes East 
African Sleeping sickness, also known as Rhodesian Trypanosomiasis, which is usually 
an acute disease causing death within several months unless treated (Brun et al., 2010; 
Odiit et al., 1997). HAT is classified in two stages. In the first, also known as 
hemolymphatic stage, the parasites reside in the blood and lymph system. In the second, 
cerebral or meningo-encephalitic stage, the parasites have crossed the blood brain barrier 
(BBB) and invaded additionally the cerebrospinal fluid (CSF) and the central nervous 
system (CNS). 
 
The symptoms of HAT vary and differ between T. b. gambiense and T. b. rhodesiense 
infected patients and the different disease stages (Chappuis et al., 2005). The absence of 
specific signs hamper the screening and the diagnosis of the disease, especially of the 
early stage of the HAT (Maurice, 2013). One symptom is the trypanosome chancre of 2 
to 5 cm in diameter. It is a red sore skin lesion caused by an inflammatory reaction at the 
site of the bite of the tsetse where the trypanosomes multiply locally before entering the 
lymphatic system.  Unfortunately, it is mostly observed only in T. b. rhodesiense infected 
patients and even there only occasionally (≈ 19%) (Brun et al., 2010).  Winterbottom’s 
sign (posterior cervical lymphadenopathy), a swelling of lymph nodes along the back of 
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the neck is another symptom for HAT (Chappuis et al., 2005). It is caused by 
trypanosomes in the lymphatic fluid causing inflammation. Winterbottom’s sign is seen 
in the first stage of HAT, more often in T. b. gambiense than in T. b. rhodesiense infected 
patients. Other symptoms are less specific, e.g. irregular fever, headache, myalgia, 
fatigue, adenopathy, and pruritus or a relatively asymptotic phase that can last for several 
months or sometimes even years in T. b. gambiense (Chappuis et al., 2005; Stuart et al., 
2008). The second stage is a result of a chronic meningo-encephalitis. It starts with 
progressive mental deteriorations proceeding to coma and finally death if untreated. The 
sleep disorder, a dysregulation of the circadian rhythm and a fragmentation of the 
sleep/wake cycle, are characteristic symptoms, especially in T. b. gambiense infected 
patients, which gave HAT its name sleeping sickness (Brun et al., 2010). Severe 
psychiatric and neurological symptoms accompany the second stage such as 
psychological and behavioral changes and sensory disturbances. Motor weakness, 
walking difficulties and speech disorders increase also with the number of white blood 
cells (WBC) in the CSF (Blum et al., 2006).  As the symptoms for HAT are not specific 
enough to diagnose the disease, blood and lymph is analyzed for a parasitological 
confirmation (direct observation of trypanosomes) of suspected HAT patients, and in case 
of positive, a CSF examination for the stage determination (Chappuis et al., 2005). 
 
Trypanosoma brucei spp are transmitted by the bite of an infected tsetse fly (Glossina 
spp.). There are nearly 30 Glossina species and subspecies of which G. palpalis is the 
main group transmitting T. b. gambiense and G. morsitans and G. fuscipes mainly are 
responsible for transmitting T. b. rhodesiense. The vector is the reason why HAT only 
occurs in Africa as the tsetse fly habitats are restricted to sub-Saharan Africa (Brun et al., 
2010) (Figure 1). Transmission is not easy. The developmental cycle in the tsetse fly is 
complex and involves different parasite stages or forms with morphological and 
biochemical changes until the fly becomes infective with metacyclic trypanosome forms 
in the lumen of the salivary glands. The process takes around 3 to 4 weeks from the 
infectious blood meal until the fly is able to transmit.  In addition the infection rate in 
tsetse is very low, usually below 1% (Solano et al., 2013).  Therefore vector control is an 
efficient means to reduce the prevalence of the disease (Solano et al., 2013). 
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Figure 1:  The Atlas of human African 
trypanosomiasis (Simarro et al., 2010). 
Sleeping sickness transmission takes place 
in sub-Saharan Africa, in discrete ‘foci’ 
within the geographic distribution of the 
tsetse fly. Several of the 36 countries 
considered as endemic have not reported 
any cases in recent years. In the last 10 
years, HAT was reported in 23 African 
countries (Simarro et al., 2010). 
 
 
 
 
 
 
The prevalence of HAT has dropped over 10-fold since the end of the last century 
(Simarro et al., 2008). However, it is estimated by the World Health Organisation (WHO) 
that there are still around 30,000 infected patients as 7197 new cases were reported in 
2012 despite the sustained control efforts (World Health Organisation, 2013). It is not the 
first time that HAT has been diminished. By the end of the 1960s, the disease had been 
almost eliminated by large-scale screening and different intervention programs. Then – 
just over one decade ago - by the end of the 1990s, the numbers were again alarmingly 
high with about 300,000 to 450,000 estimated patients (Barrett, 2006, 1999)  (Figure 2). 
The main reason for the “rise and falls” of the numbers of the HAT patients are the level 
of interventions taken to control the disease.  Active case finding by systematic screening 
in at-risk populations followed by an effective treatment of the patients is most important, 
for the individual but also to reduce the disease reservoir (Simarro et al., 2008). Vector 
control is complementary approach to reduce the prevalence and to contribute to the 
elimination of the disease. 
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Figure 2: Rise and fall of sleeping sickness with reported HAT cases per year. In times of low surveillance 
(1990s) the estimated prevalence was about twelve-fold the reported number of cases. Today a factor of 3 
is sufficient to reach credible estimates as the surveillance rate has been increased. Diagram adapted from 
(Schofield and Kabayo, 2008; Simarro et al., 2008). 
 
Better diagnostics and better drugs are still important prerequisites to control HAT. The 
parasite numbers are low, especially in T. b. gambiense infected patients. Therefore a 
parasitological confirmation (in large scale) is still a challenge. A three step approach is 
used to diagnose suspected T. b. gambiense patients: screening, parasitological 
confirmation, and staging (Brun et al., 2010; Chappuis et al., 2005; Wastling and 
Welburn, 2011). A serological test for the presence of antibodies (Card Agglutination 
Test for Trypanosomiasis, CATT) that is cheap and easy to use is available for the 
screening of T. b. gambiense HAT but not yet for T. b. rhodesiense. For both subspecies 
and especially for T. b. rhodesiense, a parasitological confirmation is required for HAT 
diagnosis.  Different parasitological methods, which rely on microscopic search for 
parasites, are available to analyze samples from blood or enlarged lymph nodes (or CSF 
for second stage diagnosis) (Wastling and Welburn, 2011).  The most sensitive is the 
mini-anion exchange centrifugation technique (mAECT), a concentration technique, 
yielding in an analytical sensitivity of 50 parasites per mL of blood (Büscher et al., 2009) 
Sensitivity might still not be sufficient in some T. b. gambiense HAT patients with low 
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parasite loads, and it is tedious and time-consuming.  A first rapid test kit (SD BIOLINE 
HAT test) using parasite antigens has been developed with support of FIND. An 
evaluation of its performance is ongoing (FIND, 2013). The LAMP test, a diagnostic kit 
for qualitative detection of the parasite's DNA by loop-mediated isothermal 
amplification, seems to be promising. But this test is also not 100% specific and it has not 
been evaluated yet under field conditions (Mitashi et al., 2013). There is still need for a 
confirmed ideal diagnostic test for HAT that is affordable, user-friendly, without the need 
of special equipment, fast, and accurate (Lejon et al., 2013).  The staging of HAT is far 
from optimal. Since a second stage treatment is more toxic (especially melarsoprol) and 
the treatment more expensive or complicated (NECT), the stage of the disease has to be 
determined prior to treatment. Currently, cerebrospinal fluid (CSF) is taken from the 
patient by lumbar puncture, which is very painful for the patient. Second stage is 
determined either if parasites are observed in the CSF and/or if the leukocyte count 
(white blood cells) exceeds 5 cells per µL (Chappuis et al., 2005; Wastling and Welburn, 
2011). Studies to improve diagnostic tools are ongoing.   
 
Vaccines are not available for HAT and it is highly unlikely that they can be developed 
due to the antigenic variation of the parasite (Stuart et al., 2008). This mechanism enables 
the parasites to evade the immune response of the mammalian host. The trypomastigote 
blood-stream forms are completely covered by identical copies of glycoproteins that 
protect the parasite against lysis by serum components. Specific antibodies can kill the 
cells after recognition. However, the parasite is able to switch (in 0.1% of the 
trypanosome divisions) to new antigenically distinct glycoproteins (variable surface 
glycoproteins, VSG) (Morrison et al., 2009; Turner and Barry, 1989). The parasites with 
a new VSG cannot be detected and neutralized by the humoral immune response to the 
previous VSG and will proliferate in the patient until the next generation of specific 
antibodies is generated. This leads to a fluctuating number of trypanosomes (parasitemia 
waves) that can be observed in the blood of patients or animals (Stuart et al., 2008). 
 
Drugs are available for HAT. Treatment recommendations vary according to the 
trypanosome subspecies and the stage of the disease.  Drugs for first stage disease are 
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pentamidine for T. b. gambiense and suramin for T. b. rhodesiense infections (Table 1). 
Both are still successful as treatment failures are rare (≈ 95% cures). However, both have 
to be administered parenterally as both drugs have a low oral bioavailability. First-line 
treatments for second stage disease are a combination of nifurtimox and eflornithine 
(NECT) for T. b. gambiense and melarsoprol for T. b. rhodesiense patients (Table 1). 
Especially melarsoprol, an arsenical compound, is highly toxic. About 8% of the patients 
are killed by its adverse reactions. Additionally, treatment failures have been reported to 
levels up to around 30% in some HAT foci (Barrett et al., 2007). The treatment is painful, 
as melarsoprol is a 3.6% solution in propylene glycol which irritates at the site of 
injection, and the drug has to be administered by slow intravenous (i.v.) injections over 
10 days (Kuepfer et al., 2012). Melarsoprol treatment is difficult to bear. NECT is less 
toxic and more effective than melarsoprol. However, eflornithine is very expensive and 
only effective on T. b. gambiense (Iten et al., 1995). The combination therapy is half oral 
since nifurtimox can be taken orally, but the partner drug, eflornithine, has to be 
administered intravenously by infusion. So all treatments require good health systems 
including skilled staff, which can be a problem in remote rural areas where African 
sleeping sickness is primarily found. 
 
Table 1: HAT first-line treatment recommendations 
 
T. b. gambiense T. b. rhodesiense 
1st stage Pentamidine Suramin 
2nd stage Nifurtimox + Eflornithine (NECT) Melarsoprol 
 
 
Drug resistance is an issue and one of the reasons why drug discovery should continue 
especially for the treatment of second stage disease. NECT, which was introduced in 
2009, is still effective. However, treatment failures have been reported already for 
eflornithine when it was used as a monotherapy (Balasegaram et al., 2009), and 
nifurtimox is not very effective in its own against African trypanosomes (Kaiser et al., 
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2011). Resistance may develop in the near future also to NECT - the currently best 
treatment option for second stage T. b. gambiense HAT. Therefore, drug discovery 
should continue to avoid a revival of HAT after loss of efficacy of one of the current 
drugs. 
 
Two potential new candidate drugs have entered clinical testing for HAT.  Fexinidazole, 
a nitroimidazole entered clinical testing phase II/III and the benzoxaborole SCYX-7158 
entered phase I. Both compounds can be administered by an oral route and are being 
developed for a new treatment for second stage disease. This is a great improvement 
compared to the situation 10 years ago (Mäser et al., 2012). However, two compounds 
entering the clinical trials might not be enough to ensure a new treatment option for 
second stage sleeping sickness, since about 75% of candidate drugs do not complete drug 
development (DiMasi and Grabowski, 2007).  
 
Diamidines have a long history in drug development for treatment of African sleeping 
sickness.  Trypanocidal activity of the first diamidine, the hypoglycaemic drug synthalin 
(Figure 2), has been shown in rodents already in 1935 (Steverding, 2010). Since blood-
stream trypanosomes consume enormous amount of sugar for their metabolism, the 
activity of synthalin was thought to be due to starving of the parasites. In 1937, Yorke 
and Lourie discovered that synthalin itself is trypanocidal and its activity is not attributed 
to its hypoglycaemic effect (Lourie and Yorke, 1937; Steverding, 2010). Thereafter, a 
large number of aromatic diamidines were prepared among which were the two phenyl 
containing diamidines, stilbamidine and pentamidine (Steverding, 2010). Both were 
highly active against HAT. Pentamidine is still in use as first stage drug in T. b. 
gambiense patients since the 1940s. Interestingly, one of its adverse reactions is still 
hypoglycaemia – related to its previous rational. The use of Stilbamidine has been 
abandoned due to neurological toxicity in some patients (Steverding, 2010).  
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Figure 2: Development of diamidines for HAT. 
Synthalin was the first diamidine discovered with 
trypanocidal activity. The aromatic diamidines, 
Stilbamidine and pentamidine are both highly active 
against first stage HAT. DB75 is a novel diamidine 
and the active molecule of the methamidoxime 
prodrug DB289, which was the first oral drug for 
treatment of first stage sleeping sickness tested in 
clinical trials (Figure adapted from Steverding (2010)). 
 
 
 
 
 
 
 
Pentamidine is an interesting compound.  No increased treatment failures have been 
reported so far though it has been in use for first stage T. b. gambiense HAT since the end 
1930s (Baker et al., 2013). Pentamidine is not only active on African trypanosomes but 
has a broad spectrum of antimicrobial activities (Werbovetz, 2006). It is also in clinical 
use for antimony-resistant leishmaniasis and Pneumocystis jirovecii pneumonia (a 
fungus) (Croft et al., 2005; Sands et al., 1985; Sattler et al., 1988; Soeiro et al., 2008; 
Werbovetz, 2006). Pentamidine was shown to be active also on other pathogens such as 
Plasmodium falciparum (Bell et al., 1990), even on chloroquine resistant P. falciparum 
parasites in vitro (Stead et al., 2001), but is not in clinical use for malaria due to its poor 
oral bioavailability (Werbovetz, 2006).   
 
The mechanism of action is still unclear and it may differ in different organisms (Mathis 
et al., 2007; Werbovetz, 2006). It has been shown that pentamidine, Furamidine and 
several other diamidines are transported into trypanosomes and plasmodia to high 
intracellular concentrations  and these compounds bind to the minor groove at AT-rich 
sites of the parasite DNA (Bray et al., 2003; Mathis et al., 2007; Wilson et al., 2008) 
(Figure 3). The trypanosomes’ kinetoplast minicircles are particularly AT rich and hence 
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a good target for diamidine binding. Kinetoplast destruction within 24 h of exposure has 
been observed with pentamidine and furamidine and the loss of the kinetoplast precedes 
trypanosome death. DNA binding correlates to some extent with trypanocidal activity but 
it is probably not the primary or exclusive drug target (Barrett et al., 2013; Werbovetz, 
2006; Wilson et al., 2008). The mitochondrion as drug target in blood-stream form 
trypanosomes was questioned as blood-stream forms depend for energy generation only 
on glycolysis and because dyskinetoplastic trypanosomes exist (Schnaufer et al., 2002; 
Soeiro et al., 2013; Werbovetz, 2006). However, inhibition of the mitochondrial 
topoisomerase II, which is involved in kDNA expression and replication, seems to be 
involved in the trypanocidal activity against blood-stream form T. brucei. Blockage of 
topoisomerase II expression by RNA interference was lethal also in blood-stream 
trypanosomes (Soeiro et al., 2013; Wang and Englund, 2001). The mode of action of 
diamidines has still not been revealed. It is most likely that diamidines have multiple 
targets rather than a single bioreceptor to kill the parasite. That would explain also why 
resistance to pentamidine has been linked so far only to transporters involved in 
accumulation of the drug (Baker et al., 2013). 
 
Figure 3: Fluorescence microscopy after uptake of novel 
diamidines with innate fluorescence properties. DB75 and 
its aza-analogues DB820 and DB829 have been shown to 
localize not only to the DNA-containing nucleus and 
kinetoplast of trypanosomes but also to acidocalcisomes. 
DB829 is also accumulating to high concentrations in the 
trypanosomes. However, its fluorescence is quenched after 
binding (by 86%), making it more difficult to study its 
uptake rate and its intracellular distribution by fluorescence 
microscopy. Arrows: nucleus, circle: kinetoplast, 
arrowhead: acidocalcisomes. (Figure adapted from Mathis 
et al., (2007). 
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Other diamidines with antiprotozoal activity are diminazene (Peregrine and Mamman, 
1993) and isometamidium (a monoamidine) which are used to treat animal 
trypanosomiasis (nagana) and propamidine, effective against Acanthamoeba species 
(Seal, 2003). The continuing interest in aromatic diamidines with improved properties to 
find new drug candidates for HAT is therefore of no surprise. 
 
Over 2000 novel diamidines have been synthesized since the 1970s alone by Boykin et al 
at the Georgia State University and by Tidwell et al at the University of North Carolina. 
Interest in pentamidine analogues and their prodrugs has spread beyond these two groups 
(Kotthaus et al., 2011; Porcheddu et al., 2012; Rodríguez et al., 2008). But so far nobody 
else has identified compounds that were more effective in animal models than the ones 
synthesized by Boykin et al or Tidwell et al., in particular for the treatment of second 
stage infections. 
 
In 1977, Das and Boykin reported the antitrypanosomal activity of DB75, also named 
furamidine (Figure 2), and started with this the era of novel diamidines for HAT (Das and 
Boykin, 1977). This compound is highly active in vitro against African trypanosomes and 
in infected mice by parenteral administration. However, since diamidines are positively 
charged at physiological pH, their predicted membrane permeability is low (Ansede et 
al., 2004). This reduces their ability to cross sufficiently i) the gastrointestinal tract 
(leading to a poor oral absorption) and ii) the blood brain barrier (BBB), which is 
required to cure second stage disease. To enhance the oral bioavailability and central 
nervous system (CNS) penetration, prodrugs of diamidines were synthesized. These 
prodrugs had the cationic moiety masked which decreases its pKa value (acid 
dissociation constant) (Werbovetz, 2006). The prodrugs are inactive in vitro, but after 
absorption, are metabolized to the active molecule by the body’s own enzymes (Midgley 
et al., 2007). The prodrug approach indeed improved the desired characteristics especially 
when methamidoxime groups were attached to the molecule. DB289, also named 
pafuramidine maleate, is a methamidoxime prodrug of DB75 and the most prominent 
example of this approach.  Pafuramidine has shown good oral bioavailability and good 
efficacy in vivo (Wenzler et al., 2009).  In the year 2000, pafuramidine was selected by 
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the Consortium for Parasitic Drug Development (CPDD) and entered clinical trials to be 
tested for the treatment of first stage T. b. gambiense HAT as the first oral drug 
developed (ever) for this disease (Burri, 2010).  
 
A good, new drug has to fulfill two requirements. First, it has to be effective and second, 
safe. On the one hand, pafuramidine was very successful. It cured many patients during 
the clinical trials with the advantage of its oral administration route. Pafuramidine was as 
effective as pentamidine in the phase III clinical trial, and its safety profile was 
inconspicuous  (Burri, 2010). However, during a phase III trial, an additional supportive 
Phase I study was conducted for registration with the Food and Drug Administration 
(FDA). This additional safety assessment was required because the treatment was 
extended during phase IIb, from 5 days to 10 days to enhance its efficacy. To cover safety 
not only for first stage HAT but also for a 2nd disease (Pneumocystis pneumonia), the 
additional phase I was conducted not only for 10 days, as necessary for HAT, but for 14 
days as necessary for Pneumocystis pneumonia (Burri, 2010). During the supportive 
phase I study, severe hepato- and a delayed renal-toxicity that appeared several days after 
the last drug administration, was discovered in healthy volunteers. As a consequence, the 
clinical development program for this promising prodrug, pafuramidine, was 
discontinued (Burri, 2010; Harrill et al., 2012; Paine et al., 2010). 
 
Efficacy of pafuramidine was not only assessed in humans in T. b. gambiense (Burri, 
2010) and Pneumocystis jirovecii infected patients (Chen et al., 2007) but also in an 
open-label, pilot phase II trial in malaria patients infected with P. falciparum or P. vivax 
(Yeramian et al., 2005). Pafuramidine cured orally 90% of the patients (9/10) with P. 
vivax and 96% (22/23) with acute, uncomplicated P. falciparum infections when treated 
with 100 mg orally twice a day for 5 days in Thailand (Yeramian et al., 2005). These 
examples show that the prodrug approach with methamidoxime is working well in 
principle. 
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Within this PhD thesis, we searched for new backup compounds among the diamidine 
series for sleeping sickness, in particular compounds that cure second stage HAT. Second 
stage efficacy of a new sleeping sickness drug is important as the current second stage 
drugs have more disadvantages than the first stage drugs and because the majority of 
patients are diagnosed when they already have developed CNS infections (Pépin and 
Mpia, 2005).  In particular a treatment that is simpler to implement and cheaper than the 
first-line therapy NECT (Simarro et al., 2012) will be of great help.  
 
We screened for prodrugs that are effective orally in first and second stage mouse 
models. Additionally we assessed if active diamidines could be used directly to treat 
second stage disease without the need of a prodrug substitution. Further biological 
characterization of the best novel diamidines included activity against different T. brucei 
trypanosome subspecies, especially different T. b. gambiense strains since the majority of 
patients (≥ 98%) are due to T. b. gambiense infections (World Health Organisation, 
2013). 
 
Cross resistance between diamidines and melamine-based arsenicals such as melarsoprol 
has been observed already since the 1950s (Williamson and Rollo, 1959) and seems to be 
linked to drug uptake by common transporters located at the trypanosome surface.  
Melarsoprol treatment failures in the field and loss of pentamidine susceptibility in vitro 
have been observed. Therefore, cross resistance of novel diamidines with pentamidine or 
with melarsoprol had to be explored. 
 
Another aim was to establish a new methodology to monitor the kinetics of drug action in 
vitro on a real-time basis. All these studies are important as their information will be 
considered for deciding which compound should be pursued to preclinical or clinical 
testing for the treatment of second stage HAT. 
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Introduction
The future looked grim for antiparasitic drug development
at the end of the last century, with pharma having with-
drawn since decades for want of return and academia
lacking the means to develop new compounds themselves.
The crisis was resolved by the creation of product-devel-
opment-partnerships dedicated to the discovery and de-
velopment of new drugs, such as the Medicines for Malaria
Venture (www.mmv.org) or the Drugs for Neglected Dis-
eases initiative (www.dndi.org). A substantial role was
played by the Bill and Melinda Gates Foundation
(http://www.gatesfoundation.org). So far, these initiatives
have successfully brought to market new formulations and
combinations of existing drugs. Here we focus on the
development of new drugs, reviewing the compounds that
are currently in clinical trials against Plasmodium falciparum,
the causative agent of malaria tropica, and TrypanosomaCurrent Opinion in Pharmacology 2012, 12:562–566 29brucei spp., causative agents of sleeping sickness. Both are
vector-borne blood parasites, transmitted by Anopheles mos-
quitoes and tsetse flies, respectively.
Drug candidates for malaria
The need for new antimalarials is persistent in spite of the
comparably large number of available drugs [1], owing to
the propensity of P. falciparum to become drug resistant.
Activity against drug-resistant P. falciparum isolates is
therefore a must for a new lead compound. Further
requirements in the target product profile of a new anti-
malarial are oral bioavailability, low price, activity against
P. vivax and other human-pathogenic species of Plasmo-
dium, and ideally cure by a single dose. Ability to block
transmission (i.e. activity against the gametocyte stages)
is another important point in line with the malaria era-
dication agenda [2].
Synthetic peroxides
Artemisinin (Figure 1) from Artemisia annua and its semi-
synthetic derivatives are amongst the most effective and
rapidly acting antimalarials available to date. They are
sesquiterpene lactones containing an endoperoxide
bridge that, when opened by chemical reduction, is
thought to react with and alkylate heme and target
proteins in the parasite. The extremely short half-life
of artemisinins in the human body requires application
twice daily. In the quest for fully synthetic peroxides with
better pharmacokinetics, a research team from the Uni-
versity of Nebraska Medical Center, the Swiss Tropical
and Public Health Institute, and the Centre for Drug
Candidate Optimisation (Melbourne), created a series of
over 700 adamantane-based ozonides, most of which had
low nanomolar activity and striking antiplasmodial selec-
tivity in vitro. The first clinical candidate, OZ277 (Arter-
olane, Figure 1), was recently registered by Ranbaxy
Laboratories Ltd. for antimalarial combination therapy
in India. The next-generation ozonide OZ439 (Figure 1)
combined excellent activity with a longer half-life of
elimination. In established preclinical models of malaria,
OZ439 was more effective than the semisynthetic arte-
misinin artesunate and other comparator drugs, resulting
in cures of P. berghei infected mice with a single oral dose
of 20 mg/kg [3]. Since OZ439 and other peroxide anti-
malarials have similar in vitro potencies, the outstanding
efficacy of OZ439 is thought to be the result of its
prolonged plasma exposure, which has been demon-
strated in both preclinical animal models and in human
volunteers. OZ439 recently completed Phase I clinical
trials, where it was shown to be safe and well-tolerated.www.sciencedirect.com
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Structures of the discussed antimalarial drugs and candidates.A phase IIa trial is running (www.mmv.org/research-de-
velopment/science-portfolio) and OZ439 has demon-
strated equally good efficacy in the treatment of P.
falciparum and P. vivax patients. Owing to its safety
and exceptional pharmacokinetic properties, the syn-
thetic OZ439 has the potential to achieve MMV’s goal
of a single-dose oral cure. Apart from the peroxide
bond, OZ439 has no similarity to the artemisinins
(Figure 1), which raises hopes that it will be active againstTable 1
Overview on the discussed drug candidates
Malaria drug candidat
OZ439 NITD6
In vitro IC50
a 3 nM 0.5–1.4
In vitro selectivityb >10 000 >10 00
Oral bioavailability 76%
(rat)
100%
(mouse
Curative dose in the mouse model (mg/kg) 20
oral, 1 day
100
oral, 1
State of development Phase II Phase 
a Against P. falciparum (malaria candidates) or T. brucei (HAT candidates)
b Compared to mammalian fibroblasts.
www.sciencedirect.com 30artemisinin-resistant parasites. This, however, remains
to be tested.
Spiroindolones
In search of completely new antimalarial chemotypes the
NGBS Consortium consisting of the Novartis Institute for
Tropical Diseases (Singapore), the Genomics Institute of
the Novartis Research Foundation, the Biomedical
Primate Research Centre (Netherlands), and the Swiss
Tropical and Public Health Institute screened a library of
about 12 000 natural products, and synthetic compounds
with structural features of natural products, against P.
falciparum in vitro. This yielded 275 hits with submicro-
molar activity, of which the spirotetrahydro-b-carbolines
(or spiroindolones) were selected for further development
[4,5]. The optimized candidate NITD609 (Figure 1)
had IC50 values around 1 nM against all tested P. falci-
parum strains, including resistant isolates. An incorpora-
tion assay with radiolabeled methionine and cysteine
revealed that NITD609, in contrast to other antimalarials,
blocked protein synthesis in P. falciparum parasites within
1 h of exposure, suggesting a distinct mode of action. The
P-type ATPase PfATP4 had been implicated based on
drug resistance studies, but the exact mechanism of
action of NITD609 remains unknown. NITD609 has
excellent oral bioavailability and was curative in the P.
berghei mouse model at a single dose of 100 mg/kg [4].
The compound displays a promising early safety profile
and no cardiotoxicity or genotoxicity liabilities. NITD609
has successfully passed first testing in man and is the first
molecule with a novel mechanism of action to enter Phase
IIa studies for malaria in the last 20 years (www.mmv.org/
research-development/science-portfolio), nourishing the
hope for a next generation treatment (Table 1).
Drug candidates for sleeping sickness
The need for new drugs against sleeping sickness, also
called human African trypanosomiasis (HAT), stems
mainly from the toxicity and unfavorable pharmacologic
properties of the available drugs. This in turn raises an
ethical dilemma: does a new drug merely need to bees HAT drug candidates
09 Fexinidazole SCYX-7518 DB829
 nM 0.7–3.3 mM 0.2–1 mM 19 nM
0 >100 >100 >10 000
)
41%
(mouse)
55%
(mouse)
presumably very low
 day
100 bid
oral, 5 days
CNS model
25 bid
oral, 7 days
CNS model
20
ip, 10 days
CNS model
IIa Phase I Phase I Preclinical
.
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564 Anti-infectivessubstantially safer than the currently used ones, or will it
have to meet the highest safety standards? The latter will
be particularly difficult to attain for the treatment of the
second stage of the disease, when the parasites have
invaded the CNS, for this requires drugs to pass the
blood–brain barrier as well.
Nitroimidazoles
DNDi undertook a systematic review and profiling of
nitroheterocyclic molecules at a time when most pharma
had abandoned this old and proven class of antimicrobials.
Metronidazole, tinidazole or ornidazole are some nitroi-
midazoles on the market, and nifurtimox (Figure 2) in
combination with eflornithine is used to treat second-
stage HAT [6]. Screening of more than 700 nitroheter-
ocyclics against T. brucei rediscovered fexinidazole
(Figure 2) as a drug candidate [7]. Originally developed
as an antimicrobial by Hoechst, fexinidazole had been
shown to be active against trypanosomes in the 1980s [8,9]
but never made it to clinical testing. Fexinidazole has a
positive Ames test; to mammalian cells, however, it is not
mutagenic [7]. In mammals, fexinidazole is rapidly
absorbed and metabolized to fexinidazole-sulfoxide and
fexinidazole-sulfone. All three compounds cross the
blood brain barrier and possess trypanocidal activity, with
IC50 ranging from 0.7 to 3.3 mM against both drug-sensi-
tive and drug-resistant T. brucei spp. isolates [10]. Fex-
inidazole cures the T. b. rhodesiense and T. b. gambienseFigure 2
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given on 4 consecutive days, and the CNS model at an
intraperitoneal dose of 50 mg/kg bid or an oral dose of
100 mg/kg bid, both given for five consecutive days [7].
A phase I clinical trial was performed in 2009 without
specific issues of concern. A phase II/III study to inves-
tigate the efficacy and safety of fexinidazole will start mid
2012. Patients will be treated orally for 10 days with a
daily single dose (www.dndi.org/portfolio/fexinidazo-
le.html).
Benzoxaboroles
The oxaboroles are a promising new class of antimicro-
bials developed by Anacor Pharmaceuticals (Palo Alto,
CA), a company specialized in boron chemistry. Screen-
ing an oxaborole library against T. brucei at Scynexis
(Research Triangle Park, NC) brought forward benzox-
aborole 6-carboxamides as new leads [11]. The com-
pound SCYX-6759 was the most potent in this first
screening campaign. It showed good in vitro potency
and cured the acute and the CNS mouse models. Further
optimization was focused on improvement of brain per-
meability and pharmacokinetics, yielding SCYX-7158
(Figure 2) as a clinical drug candidate [12]. It is a fast
acting compound with IC50 against T. b. rhodesiense and T.
b. gambiense strains between 0.2 and 1 mM. SCYX-7158
has a good oral bioavailability and blood–brain-barrier
permeability. It cures the acute T. brucei mouse modelDB75 
DB829 
Pentamidine NH2NH2
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stage model at an oral dose of 25 mg/kg given for 7
consecutive days [12]. Toxicity and ADME investi-
gations were unproblematic and SCYX-7158 got the
clearance for a Phase I clinical trial that started in March
2012 (press release DNDi March 12th 2012).
Diamidines
The trypanocidal potential of aromatic diamidines has
long been known and pentamidine (Figure 2), introduced
in 1941, is still the drug of choice to treat 1st stage T. b.
gambiense infections [13,14]. The Consortium for Para-
sitic Drug Development (www.thecpdd.org) has screened
over 2000 new diamidines against T. brucei, 517 of which
had an IC50 below 200 nM and an in vitro selectivity
above 1000. An initial lead, DB75 (furamidine, Figure 2)
synthesized by David Boykin (Georgia State University,
USA), had excellent efficacy but lacked oral bioavailabil-
ity and blood–brain barrier penetration [15]. These
limitations were overcome by the corresponding methox-
ime prodrug DB289 (pafuramidine [16]), which became
the first trypanocide to enter clinical trials as an oral drug.
In a phase III clinical trial for 1st stage HAT, oral
pafuramidine for 10 consecutive days was almost as
effective as pentamidine injected i.m., and the safety
profile was inconspicuous [17]. But when an additional
phase I trial was conducted testing a 14 days schedule that
would cover the treatment of pneumocystosis, renal
toxicity was observed about 8 weeks post treatment. This
stopped pafuramidine for HAT and other indications.
However, the pafuramidine backup program revealed
several even more potent diamidines, especially against
the 2nd stage of the disease. DB868, an aza analogue of
DB289, cures mice with CNS infections [15] and is well
tolerated in monkeys. Surprisingly, two diamidines were
able to cure CNS infections without prior masking of the
amidine groups. The parent compound DB829 (Figure 2)
was the first diamidine that cured the acute as well as the
late-stage mouse model [15], and also cured CNS-
infected vervet monkeys [18].
Conclusion
The last novel chemotypes introduced into the clinics were
atovaquone/proguanil for malaria in 1996, and eflornithine
for sleeping sickness in 1990. Now there is reason for hope
that new drugs will become available within the next three
to five years. The process is more straightforward for
sleeping sickness that can be treated by monotherapy.
New antimalarials should always be administered as com-
binations to reduce the risk of drug resistance development
[19], and hence the identification of suitable partners may
complicate drug development and registration. Neverthe-
less, new drugs against malaria and sleeping sickness are
finally tangible and we are confident that some of the drug
candidates described above will make it to the market.
Considering, however, how difficult it has become for a
drug to obtain FDA approval and how little it takes to kill it,www.sciencedirect.com 32it is pivotal to keep full drug development pipelines and
sustain early drug discovery programs against P. falciparum
and T. brucei.
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African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for treatment have strong
liabilities. It is essential to find new, effective, and less toxic drugs, ideally with oral application, to control the
disease. In this study, the aromatic diamidine DB75 (furamidine) and two aza analogs, DB820 and DB829
(CPD-0801), as well as their methoxyamidine prodrugs and amidoxime metabolites, were evaluated against
African trypanosomes. The active parent diamidines showed similar in vitro profiles against different Trypano-
soma brucei strains, melarsoprol- and pentamidine-resistant lines, and a P2 transporter knockout strain
(AT1KO), with DB75 as the most trypanocidal molecule. In the T. b. rhodesiense strain STIB900 acute mouse
model, the aza analogs DB820 and DB829 demonstrated activities superior to that of DB75. The aza prodrugs
DB844 and DB868, as well as two metabolites of DB844, were orally more potent in the T. b. brucei strain
GVR35 mouse central nervous system (CNS) model than DB289 (pafuramidine maleate). Unexpectedly, the
parent diamidine DB829 showed high activity in the mouse CNS model by the intraperitoneal route. In
conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further
development of a second-stage African sleeping sickness drug.
Sleeping sickness, also called human African trypanosomia-
sis (HAT), is a vector-borne parasitic disease caused by
Trypanosoma brucei subspecies, which are unicellular flagel-
lated protozoans. Depending on the subspecies, there are two
different forms of the disease which show different clinical
features. West African sleeping sickness, a more chronic dis-
ease caused by T. b. gambiense, is prevalent in West and Cen-
tral Africa. East African sleeping sickness, a more acute and
virulent disease caused by T. b. rhodesiense, is endemic in East
and Southern Africa (7). The disease is transmitted by the bite
of an infected tsetse fly. Tsetse flies and, consequently, the
disease are found in remote rural areas of sub-Saharan Africa.
The number of sleeping sickness cases decreased in recent
years to 12,000 reported cases (28) and 50,000 to 70,000
estimated cases (35) due to improved HAT control.
There are two stages of the disease. In the first stage, the
parasites reside and proliferate in the hemolymphatic system.
In the second, encephalitic stage, the parasites cross the blood-
brain barrier (BBB) and infect the central nervous system
(CNS) and the cerebrospinal fluid. The second stage is difficult
to treat, as the BBB is a barrier for most drugs, preventing
trypanocidal levels of those agents in the CNS and cerebrospi-
nal fluid. If untreated, the disease is invariably fatal. HAT
exclusively affects the world’s poorest populations, making
drug development against this tropical disease economically
unattractive for pharmaceutical industries (7, 30, 33). As a
consequence, HAT has become one of the most neglected
tropical diseases. The drugs currently in use against HAT are
unsatisfactory, especially those for the second stage. All drugs
suffer from poor oral bioavailability and must be administered
parenterally, causing compliance problems in rural areas where
health systems are poorly developed or nonexistent. Additionally,
the treatment schedule is long and laborious and the adverse
events severe or even lethal. Up to 5% of the patients treated with
the second-stage drug melarsoprol die of a reactive encephalop-
athy (18). Drug resistance is also of growing concern and, espe-
cially for the encephalitic stage, there are no appropriate treat-
ment options available after treatment failures. Consequently,
new drugs are desperately needed to combat this disease.
One of the drugs currently in use for the hemolymphatic stage
is the aromatic diamidine pentamidine. It has a broad spectrum of
antiparasitic activities and is also used clinically against antimony-
resistant leishmaniasis and against Pneumocystis jiroveci infection,
mostly in AIDS patients (29). This old drug has been used since
the early 1940s for the treatment of first-stage T. b. gambiense
HAT (13). The use of pentamidine is partially restricted due to its
lack of oral bioavailability and its toxicity.
The aim of this work was to develop novel aromatic diami-
dines that are effective for first-stage disease (oral administra-
tion) or are effective for second-stage HAT (oral or parenteral
administration). A leading structure is DB75 [furamidine; 2,5-
bis(4-aminophenyl)-furan], which has a broad spectrum of an-
tiparasitic activity covering P. jiroveci, Leishmania spp., Giardia
intestinalis, Plasmodium falciparum, and Trypanosoma spp. The
diphenylfuran diamidines represent an important class of
DNA minor groove binders (32, 34). The selective and rapid
uptake leads to high drug accumulation in the parasite (21, 22).
However, like most of the aromatic diamidines, furamidine
and its analogs have low oral bioavailability due to their pos-
* Corresponding author. Mailing address: Swiss Tropical Institute,
Socinstrasse 57, P.O. Box, CH-4002 Basel, Switzerland. Phone: 41
612848165. Fax: 41 612848101. E-mail: tanja.wenzler@unibas.ch.
 Published ahead of print on 20 July 2009.
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itively charged amidine groups and are therefore orally not
effective. To improve the oral bioavailability, prodrugs were
synthesized. After oral absorption through the gastrointestinal
barrier, they are metabolized to their active trypanocidal parent
drugs. This approach was successful for DB75 and its prodrug
DB289 [pafuramidine maleate; 2,5-bis(4-amidinophenyl)-furan-
bis-O-methlylamidoxime], which became the first oral drug for
sleeping sickness to enter clinical trials for the first stage. In a
pivotal phase III trial, 273 patients were enrolled between August
2005 and March 2007. In October 2008, an additional phase I
study of healthy volunteers was initiated to complete the safety
assessment for registration of DB289 for sleeping sickness and
Pneumocystis jiroveci. In the extended phase I trial, more severe
liver toxicity and delayed renal insufficiency were observed in a
number of participants and, as a consequence, the DB289 devel-
opment program was discontinued (25). The mechanism of tox-
icity of DB289, particularly the delayed renal toxicity, is currently
being further studied in animal models.
Many analogs of DB75/DB289 have been synthesized and
tested in vitro and in vivo to find a new clinical candidate,
especially for second-stage disease. Several of those analogs
were effective in our stringent T. b. rhodesiense strain STIB900
acute mouse model (2). However, only a very few have shown
good activity in the T. b. brucei strain GVR35 mouse CNS
model. DB289 resulted in cures of 60% of GVR35-infected
mice, but it was not effective in the vervet monkey CNS model
(24). Though it was able to cure one-third of monkeys with an
early CNS infection when treatment was initiated on day 14
postinfection, it was not curative when treatment was delayed
to day 28 postinfection, a time point when brain infection is
well established (24). DB289 can therefore not be considered
a clinical candidate for second-stage disease, but its aza ana-
logs have more potential and were evaluated in this study.
MATERIALS AND METHODS
Materials. Pentamidine isethionate and diminazene aceturate were purchased
from Sigma-Aldrich; melarsoprol (Aventis) was provided by WHO; and DB75
and DB289 were provided by Immtech Pharmaceuticals. DB820, DB844, DB829,
and DB868 were provided by David Boykin; their synthesis has been reported
(16). The intermediates DB290, DB775, DB821, DB840, DB1058, DB1284, and
DB1679 were also provided by David Boykin. Synthesis has been reported for
DB290 (10), DB775 (1), DB821 (16), DB840 (16), and DB1058 and DB1284
(15). The synthesis of DB1679 has not been published yet.
Preparation of compounds. Compounds were dissolved in 100% dimethyl sul-
foxide (DMSO) and finally diluted in culture medium prior to the assay. The DMSO
concentration never exceeded 1% in the in vitro assays. For in vivo experiments, the
compounds were dissolved in DMSO and further diluted with distilled H2O to a final
DMSO concentration of 10% prior to administration to animals.
Parasites. (i) T. b. rhodesiense. T. b. rhodesiense strain STIB900 is a derivative
of strain STIB704. The strain was isolated from a patient in Ifakara, Tanzania, in
1982. STIB900 is used for routine in vitro screening and for the acute mouse
model which mimics the first stage of HAT (31). STIB900mel and STIB900pent
are melarsoprol- and pentamidine-resistant populations, respectively. When
tested along with these drug-resistant lines, STIB900 was named STIB900wt.
These resistant lines were generated by growing STIB900 in increasing subcu-
rative drug concentrations (8).
(ii) T. b. gambiense. The T. b. gambiense strains used include STIB930, a
derivate of strain TH1/78E(031), which was isolated from a patient in Coˆte
d’Ivoire in 1978 (14); strain ITMAP141267, which was isolated from a patient in
the Democratic Republic of Congo in 1960 (5); and strain K03048, which was
isolated from a patient in South Sudan in 2003 (20).
(iii) T. b. brucei. The T. b. brucei strains used include BS221, a derivative of
strain S427 that was isolated in Uganda in 1960; strain AT1KO, a P2 transporter
knockout of the T. b. brucei strain BS221 (23); and strain GVR35, isolated from
a wildebeest in the Serengeti in 1966 (primary isolate S10) (17).
In vitro growth inhibition assays using T. brucei subspecies. The 50% inhib-
itory concentrations (IC50s) were determined by using the Alamar blue assay
(27) and were carried out three times independently and in duplicate. Briefly, the
compounds were tested in minimum essential medium with Earle’s salts, sup-
plemented according to the protocol of Baltz et al. (6) with the following mod-
ifications: 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate, 0.5 mM hypoxanthine,
and 15% heat-inactivated horse serum for T. b. rhodesiense and T. b. brucei and
15% human serum plus 5% fetal calf serum for T. b. gambiense. Serial drug
dilutions were prepared in 96-well microtiter plates, and each well was inoculated
with 2,000 bloodstream forms for T. b. rhodesiense or T. b. brucei assay and with
5,000 trypanosomes for T. b. gambiense assay. The drug exposure was at 37°C
under a humidified 5% CO2 atmosphere for 70 h. Ten microliters of the viability
marker Alamar blue (12.5 mg resazurin [Sigma] dissolved in 100 ml phosphate-
buffered saline) was then added to each well, and the plates incubated for an
additional 2 to 6 h until the signal/background fluorescence ratio was about 10
for T. b. rhodesiense and T. b. brucei or about 5 for T. b. gambiense isolates. The
plates were read in a Spectramax Gemini XS microplate fluorescence scanner
(Molecular Devices) using an excitation wavelength of 536 nm and an emission
wavelength of 588 nm. The IC50s were calculated from the sigmoidal inhibition
curves using SoftmaxPro software.
In vivo experiments. Adult female NMRI mice were obtained from RCC,
Ittingen, Switzerland. They weighed between 20 and 25 g at the beginning of the
study and were housed under standard conditions with food pellets and water ad
libitum. All protocols and procedures used in the current study were reviewed
and approved by the local veterinary authorities of the Canton Basel-Stadt,
Switzerland.
STIB900 acute mouse model. The STIB900 acute mouse model mimics the
first stage of the disease. Experiments were performed as previously reported
(31), with minor modifications. Briefly, female NMRI mice were infected intra-
peritoneally (i.p.) with 2  104 STIB900 bloodstream forms. Experimental
groups of four mice were treated i.p. with parent diamidines or orally (per os
[p.o.]) with prodrugs on four consecutive days from day 3 to 6 postinfection. A
control group was infected but remained untreated. The tail blood of all mice was
checked for parasitemia until 60 days after infection. Surviving and aparasitemic
mice at day 60 were considered cured and then euthanized. The day of death of
the animals was recorded (including the cured mice, as 60) to calculate the
mean survival time in days (MSD).
GVR35 mouse CNS model. The GVR35 mouse CNS model mimics the second
stage of the disease. Five female NMRI mice per experimental group were used.
Each mouse was inoculated i.p. with 2  104 bloodstream forms. The treatment
was i.p. for parent compounds and p.o. for prodrugs on five consecutive days
from day 21 to 25 postinfection. Some experimental groups were treated for 10
consecutive days (day 21 to 30 postinfection). A control group was treated on day
21 with a single dose of diminazene aceturate at 40 mg/kg of body weight i.p.,
which is subcurative since it clears the trypanosomes only in the hemolymphatic
system and not in the CNS, leading to a subsequent reappearance of trypano-
somes in the blood (17). Parasitemia was monitored twice in the first week after
treatment followed by once a week until 180 days postinfection. Mice were
considered cured when there was no parasitemia relapse detected in the tail
blood over the 180-day observation period. Surviving mice were euthanized on
day 180, and the day of death of the animals recorded (including the cured mice,
as 180) to calculate the MSD.
RESULTS
In vitro results. The standard drugs melarsoprol, pentami-
dine, and DB75 (furamidine) were tested along with DB820
and DB829 against different T. brucei subspecies isolates in
vitro (Table 1). In vitro data for the prodrugs are not included,
but all were tested against T. b. rhodesiense STIB900wt and it
was confirmed that all prodrugs were inactive (IC50  3,000
ng/ml). All other compounds were highly active, with IC50s of
6.5 ng/ml (14 nM) against the reference strain STIB900wt.
DB829 was less active than DB75 and DB820 or the two
standard drugs. The activity ranking was confirmed repetitively
by several additional in vitro experiments.
All compounds were found to be highly active against three
different T. b. gambiense isolates (IC50  40 ng/ml [85 nM]),
with the activity ranking seen before (DB75  DB820 
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DB829). The sensitivities of the T. b. gambiense isolates were
similar for the drugs used, except for pentamidine. K03048
showed an elevated IC50 of 15.5 ng/ml, which is 14 times higher
than the IC50 for STIB930. The in vitro susceptibilities of T. b.
brucei BS221 were comparable to those of STIB900 for all
compounds tested. AT1KO, the P2 transporter knockout of
BS221, was less susceptible than the wild type. Pentamidine
and melarsoprol demonstrated 4- to 5-fold losses of activity,
while the three diphenylfuran diamidines revealed losses of
activity of 13- to 18-fold (Table 2). The drug susceptibilities of
the melarsoprol- and pentamidine-resistant STIB900 lines to
all tested compounds were strongly reduced, but the highest
cross-resistance was observed between melarsoprol and pentam-
idine. The melarsoprol-resistant trypanosomes showed a high
level of resistance to pentamidine (resistance index, 100), as
high as that of the pentamidine-resistant line. Melarsoprol resis-
tance was high (42-fold) in the melarsoprol-resistant trypano-
somes but lower than their pentamidine resistance and lower than
in the pentamidine-resistant line. Levels of cross-resistance to the
three diphenylfuran diamidines were significantly lower and com-
parable for the pentamidine- and the melarsoprol-resistant lines,
with ratios of activities against STIB900pen/STIB900wt and
STIB900mel/STIB900wt of 10 to 20. All three diphenylfuran dia-
midines were still highly active against both resistant lines, with
IC50s of 15 to 68 ng/ml. Again, DB829 was less potent than DB75.
In vivo STIB900 acute model results. Furamidine and pent-
amidine showed similar efficacies at doses of 20 mg/kg i.p. on
four consecutive days in the in vivo STIB900 acute model, with
three/four and two/four mice cured, respectively (Table 3). The
aza analogs, DB820 and DB829, were both substantially more
potent in this acute model than pentamidine and furamidine,
although their levels of activity in vitro were lower. We ob-
tained good dose responses and comparable efficacies of both
aza compounds with i.p. administration despite the in vitro
activity of DB829 being lower than that of DB820. The dime-
thoxyamidine prodrugs DB844, DB868, and DB289 (Fig. 1)
were all able to cure four/four mice when tested orally in the
STIB900 mouse model (Table 3). DB844 was also tested at a
single dose of 20 mg/kg p.o. and gave three/four cures (data not
presented). Dose responses clearly show that DB844 was more
active than DB868, although their parent drugs had compara-
ble in vivo efficacies.
In vivo GVR35 CNS model results. The prodrug DB289
showed good CNS activity in the in vivo GVR35 CNS model,
with three/five mice cured at a dose of 100 mg/kg p.o. on five
consecutive days (Table 4). Treatment for 10 days at 50 mg/kg
represents an identical total dose but was less effective. DB844
was the first prodrug that cured all mice in the GVR35 mouse
CNS model, at a dose of 100 mg/kg on five consecutive days
administered by the oral route. It was additionally evaluated
with 10-day treatments at different dosages. At 50 mg/kg p.o.
on 10 consecutive days, cures of three/five mice were achieved;
at 25 mg/kg, one/five was cured; and at 10 mg/kg, all mice
relapsed with an MSD comparable to that of diminazene ace-
turate-treated control mice. DB868 had a similar efficacy and
also cured all mice at a dose of 100 mg/kg p.o on five consec-
utive days. The extended 10-day treatment with four different
doses resulted in good dose responses, highlighting the high
CNS activity of DB868. At 100 mg/kg p.o. on 10 consecutive
days, all mice were cured; at 50 mg/kg, four/five mice were
cured; at 25 mg/kg, one/five mice was cured; and at 10 mg/kg,
all mice relapsed, with an MSD similar to that of the control
mice. The data show that although DB844 was more active
than DB868 in the STIB900 acute mouse model, they were
equally active in the mouse CNS model.
The parent compounds DB75, DB820, and DB829 were also
evaluated in the GVR35 mouse CNS model. DB75 did not
cure mice at 20 mg/kg i.p. on five consecutive days, but it did
extend the survival to 92.25 days postinfection, which is a slight
improvement over the survival in the control group treated at
40 mg/kg on one day with diminazene aceturate. DB75 admin-
istered for 10 days at 25 mg/kg i.p. was toxic and killed all mice.
TABLE 1. In vitro antitrypanosomal activity against different trypanosome subspecies and a P2 transporter knockout (AT1KO)
Compound
IC50 (ng/ml) for indicated strain
T. b. rhodesiense T. b. gambiense T. b. brucei
STIB900wt STIB900pent STIB900mel K03048 ITMAP141267 STIB930 BS221 AT1KO
Melarsoprol 1.4 28.2 56.7 3.1 2.7 5.3 3.6 18.7
Pentamidine 1.2 133.6 124.5 15.5 4.2 1.1 0.9 4.1
DB75 1.0 14.3 19.0 4.2 3.1 5.1 1.2 15.8
DB820 2.4 22.5 29.2 8.4 5.7 8.4 2.8 42.9
DB829 6.5 67.9 64.3 39.5 16.2 35.1 6.0 106.4
TABLE 2. In vitro activity indices of different isolates versus that of reference strain STIB900 or BS221
Compound
Activity index against indicated strain pair
STIB900wt/
STIB900wt
STIB900pent/
STIB900wt
STIB900mel/
STIB900wt
K03048/
STIB900wt
ITMAP141267/
STIB900wt
STIB930/
STIB900wt AT1KO/BS221
Melarsoprol 1 20.9 42.0 2.3 2.0 3.9 5.2
Pentamidine 1 113.1 105.4 13.1 3.6 0.9 4.3
DB75 1 14.7 19.5 4.3 3.2 5.3 13.1
DB820 1 9.6 12.4 3.5 2.4 3.5 15.4
DB829 1 10.5 10.0 6.1 2.5 5.4 17.8
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Treatment at 12.5 mg/kg on 10 consecutive days was tolerated
and cured one/four mice. DB820 at 20 mg/kg i.p. on five con-
secutive days did not cure, but it extended the survival of the
mice to 100 days. At an identical daily dose in the extended
10-day treatment, one/five mice was cured without any toxicity
observed. DB829 was the first and is still the only diamidine
that cured single mice at a dose of 20 mg/kg i.p. on five con-
secutive days, and it cured all infected mice when administered
for 10 days at 20 mg/kg i.p. The high CNS activity of DB829
was unexpected and is still unique among diamidines.
In vivo STIB900 acute model results for metabolites. The
monoamidoxime/monomethoxyamidine metabolites (M1s) (Fig.
2) of the dimethoxyamidine prodrugs DB289, DB844, and
DB868 retain prodrug characteristics due to their monoami-
doxime/monomethoxyamidine groups and were therefore ad-
ministered p.o. in the mouse models. All M1s did show oral
activity and cured at least some mice at 50 mg/kg p.o. on four
consecutive days in the STIB900 acute mouse model (Table 5).
DB775, the M1 of DB289, showed the least efficacy. The M1s
of DB844, DB1284 and DB1058, retained excellent activities
and cured all mice at 25 mg/kg p.o. on four consecutive days.
Testing at the very low dose of 5 mg/kg p.o. on four consecutive
days showed that DB1058 was even more active than DB1284.
DB1679, the M1 of DB868, was also highly active and cured all
mice at 25 mg/kg p.o. on four consecutive days. All diami-
doxime metabolites (M2s) were considerably less active in vivo.
None of them gave any cures in the STIB900 acute mouse
model at the tested doses of 75 mg/kg (DB840) or 100 mg/kg
p.o. on four consecutive days (DB290 and DB821).
In vivo GVR35 mouse CNS model results for M1s. The aza
M1s were highly active in the acute mouse model and were
therefore also studied for their CNS activity in the GVR35
mouse CNS model, at 100 mg/kg p.o. on five consecutive days
(Table 6). Only DB775, the M1 of DB289, was not tested due
to inferior STIB900 activity in vivo. Both M1s of DB844,
DB1058 and DB1284, showed high CNS activities. DB1058
cured four/five mice and DB1284 cured all mice at 100 mg/kg
p.o. on five consecutive days. DB1679, the M1 of DB868, also
showed CNS potency (one/five mice cured at 100 mg/kg p.o. on
five consecutive days), but its activity was clearly less than those
of its prodrug DB868 and the M1s of DB844.
DISCUSSION
Treatment of second-stage HAT still depends on only two
drugs, the organoarsenical melarsoprol and eflornithine. Me-
larsoprol is still the first-line drug for HAT in many countries.
This arsenical compound is highly toxic and has severe adverse
TABLE 3. In vivo antitrypanosomal activity in the STIB900 acute mouse model
Type of compound
(method of
administration)
Dosea
Resultb for indicated compound
No. of
mice cured MSD
No. of
mice cured MSD
No. of
mice cured MSD
No. of
mice cured MSD
Parent (i.p.) DB75 DB820 DB829 Pentamidine
20 3/4 57.75 4/4 60 4/4 60 2/4 57.5
10 ND 4/4 60 4/4 60 ND
5 1/4 46 3/4 54.5 3/4 49.5 2/4 45
2.5 ND 2/4 49 2/4 60 ND
0.5 ND 0/4 29 1/4 31 ND
Prodrug (p.o.) DB289 DB844 DB868
50 4/4 60 ND 4/4 60
25 4/4 60 4/4 60 2/4 42
5 3/4 ND 3/4 50.25 1/4 40.25
2.5 1/4 ND 0/4 19.5 ND
a Dose (mg/kg) was administered on four consecutive days.
b Cure was defined as survival for more than 60 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse; infected but untreated control mice died between day 6 and day 10 postinfection. ND, not determined.
FIG. 1. Dimethoxyamidine prodrugs and their active parent diamidines.
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effects which lead to fatalities in 5% of the patients treated
(18). Additionally, there are alarming reports of treatment
failures of up to 30% (7). Recent reports also indicate emerg-
ing resistance against eflornithine, the only alternative drug for
second-stage HAT, with treatment failure rates already up to
16% (4). Nifurtimox, a drug against Chagas disease, is not very
active against African trypanosomes as monotherapy, but in
combination with melarsoprol and, especially, eflornithine,
very promising results could be seen in clinical trials (9, 12, 26).
The combination therapy may not work for isolates with some
degree of resistance to melarsoprol or eflornithine. In a worst-
case scenario, there could be no effective drug available for
second-stage HAT in less than a decade. New safe and effec-
tive drugs are urgently needed for both disease stages to treat
thousands of patients.
So far, no resistance has been reported in the field for
pentamidine, although this drug has been in use for first-stage
T. b. gambiense HAT for decades (23). This makes pentami-
dine an attractive molecule for analog-based drug discovery.
To overcome the low oral bioavailability and the lack of CNS
penetration, prodrugs were designed for this study.
In comparing the IC50s of the aromatic diamidines DB75,
DB820, and DB829, it became obvious that DB829 had higher
IC50s than DB75 and DB820 against all trypanosome strains
TABLE 4. In vivo antitrypanosomal activity in the GVR35 CNS mouse model
Type of compound
(method of
administration)
Dose (mg/
kg)/ no. of
days
administered
Resulta for indicated compound
No. of mice
cured MSD or range
No. of mice
cured MSD
No. of mice
cured MSD
Parent (i.p.) DB75 DB820 DB829
20/5 0/4b 92.25 0/4b 102.5 1/4b 132.3
20/10 Toxicd NA 1/5 128.2 4/4b 180
10/10 1/4c 112c ND 0/5 95.6
Prodrug (p.o.) DB289 DB844 DB868
100/5 3/5 167.8 5/5 180 5/5 180
50/5 0/5 153.6 1/5 176.6 ND
25/5 0/5 75.4 0/5 117.6 0/4b 95.8
100/10 ND ND 5/5 180
50/10 1/5 172.2 3/5 180 4/5 153.4
25/10 0/5 146.6 1/5 149.6 1/5 132.4
10/10 ND 0/5 75.25 0/5 70.0
Control (i.p.) Melarsoprol or diminazene
aceturate
15e/5 4/5 175.4
10e/5 1/5 148.6
5e/5 0/5 80.8
40f/1 0/5 47–83
a Cure was defined as survival for more than 180 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse. ND, not determined. NA, not applicable.
b One mouse died during or directly after treatment (day 21 to day 28).
c DB75 was tested at 12.5 mg/kg i.p. for 10 consecutive days and cured one/four mice.
d DB75 tested at 25 mg/kg i.p. for 10 consecutive days was toxic.
e Melarsoprol.
f Diminazene aceturate. MSD of the diminazene aceturate-treated control group was 47 to 83 in different experiments.
FIG. 2. Monoamidoxime/monomethoxyamidine metabolites (M1s) and diamidoxime metabolites (M2s).
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tested. All three diamidines were less active against the T. b.
gambiense isolates (3- to 6-fold), the P2-transporter knockout
of BS221 (15-fold), and the laboratory-induced drug-resis-
tant lines of STIB900 (10- to 20-fold) (Table 2). The T. b.
gambiense strain K03048 from South Sudan revealed a differ-
ent sensitivity to pentamidine than the old drug-sensitive T. b.
gambiense strain STIB930. Pentamidine resistance in the field
has not been demonstrated; however, a reduced pentamidine
susceptibility of K03048 was observed previously with a differ-
ent in vitro method (hypoxanthine incorporation assay over
48 h) (20). K03048 was isolated from a patient in Ibba, Sudan,
an area with high melarsoprol failure rates. This isolate, how-
ever, is melarsoprol sensitive in vitro and in the mouse model
(20). The drug response of K03048 to the diamidines was
comparable to those of the other two T. b. gambiense isolates.
The two STIB900 lines selected for resistance to melarsoprol
and pentamidine had 10- to 20-fold-increased IC50s against the
three diamidines. Molecular analysis revealed that the try-
panosomes selected for melarsoprol resistance have lost the
TbAT1 gene that codes for the P2 transporter (23), while in the
pentamidine-selected trypanosomes, the TbAT1 gene was still
present (8). Whether its P2 transporter is functionally ex-
pressed has not yet been investigated. Comparable resistance
indices of the diphenylfuran diamidines for melarsoprol-resis-
tant/wild type and AT1KO/wild type strains indicate that the
moderate cross-resistance can probably be attributed to the
loss of the P2 transporter only. The higher pentamidine resis-
tance of the two resistant STIB900 lines indicates that there
are additional alterations involved which cause loss of pentam-
idine sensitivity but not loss of sensitivity against the diphe-
nylfuran diamidines. The P2 transporter has been identified as
the primary uptake route for DB75 (19), but at least one other
transporter participates in its uptake as well. In contrast, me-
larsoprol and pentamidine show only minor differences in ac-
tivities in AT1KO and its wild type (at least two transporters
involved in drug uptake). Bridges at al. have shown that the
high-affinity pentamidine transporter (HAPT1) was absent
from their high-level pentamidine-resistant and melarsoprol-
resistant trypanosomes (11). If the high-level resistance of the
melarsoprol- and pentamidine-selected STIB900 lines is simi-
larly caused by a concomitant loss of TbAT1 and HAPT1, then
the comparable loss of sensitivity of AT1KO indicates that
HAPT1 is not involved or has only a minor impact on the
uptake of furamidine and its aza analogs. The second major
route of uptake has not yet been identified. Selective drug
uptake can develop resistance, but on the other hand, it also
facilitates selective uptake and drug accumulation by the par-
asite.
TABLE 5. In vivo activity of intermediates in the STIB900 acute mouse model
Prodrug Dosea
Resultb for indicated drug intermediate
No. of mice
cured MSD
No. of mice
cured MSD
No. of mice
cured MSD
DB289 DB775 DB290
100 ND 0/4 50
50 1/4 56 ND
15 0/4 30.25 ND
DB844 DB1284 DB1058 DB821
100 ND 4/4 60 0/4 54
25 4/4 60 4/4 60 ND
5 1/4 39.5 3/4 52.75 ND
DB868 DB1679 DB840
75 ND 0/4 18
25 4/4 60 ND
5 0/3c 29.7 ND
a Dose (mg/kg) was administered p.o. on four consecutive days.
b Cure was defined as survival for more than 60 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse; infected but untreated control mice died between day 6 and 10 postinfection. ND, not determined.
c One mouse died due to p.o. application, with no toxicity observed.
TABLE 6. In vivo activities of M1s versus those of dimethoxyamidine prodrugs in the GVR35 CNS model
Dosea
Resultb for indicated compound:
DB844c DB1058 DB1284 DB868 DB1679
No. of
mice
cured
MSD
No. of
mice
cured
MSD
No. of
mice
cured
MSD
No. of
mice
cured
MSD
No. of
mice
cured
MSD
100 5/5 180 4/5 180 5/5 180 5/5 180 1/5 140.4
75 3/4, 1/5 180, 172 1/5 166 2/5 164.8 ND ND
50 1/5 176.6 ND 1/5 157.2 ND ND
a Dose (mg/kg) was administered p.o. on five consecutive days.
b Cure was defined as survival for more than 180 days after infection without showing a parasitemia relapse. MSD (mean survival days) was determined for mice with
and without parasitemia relapse. ND, not determined.
c DB844 has been tested twice at 75 mg/kg on five consecutive days; the 3/4 result is from a previous experiment, and the 1/5 result is from an experiment that included
both M1s, DB1058 and DB1284.
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DB820 and DB829 show in vivo activities superior to those
of DB75 and pentamidine in both the acute and the mouse
CNS model. Both aza parent compounds demonstrated com-
parable efficacies with no signs of overt toxicity after i.p. ad-
ministration in the STIB900 acute mouse model. Both aza
prodrugs, DB844 and DB868, were almost as efficacious as
DB289 in the acute mouse model and were well tolerated at all
doses tested. DB844 was more potent than DB868, although
the parent compounds revealed similar efficacies. According to
their efficacies in the acute model, both prodrugs could have
the potential to serve as backup drugs to replace DB289 as the
next oral drug to treat first-stage disease. However, the main
focus and urgency is on finding a new treatment for second-
stage HAT and an option for treatment after treatment fail-
ures with melarsoprol or eflornithine. The ideal solution would
be one drug with the target product profile of a first-stage drug
that could be used for both stages, thus rendering the painful
lumbar puncture so far required for staging unnecessary.
DB868 was equally as potent as DB844 in the GVR35 mouse
CNS model, despite its lower level of activity in the acute
model. Both prodrugs have potential as oral drugs for second-
stage sleeping sickness, according to their high CNS activity in
the mouse model. However, safety studies of DB844 in the
vervet monkey model for HAT demonstrated dose-dependent
toxicity, especially, dose-limiting gastrointestinal toxicity, not
previously observed with DB289 (John Thuita, personal com-
munication). At 10 and 20 mg/kg p.o. for 10 days, it caused
tissue damage in the gastrointestinal tract and liver, whereas at
5 mg/kg for 10 days, the clinical signs and hematological pa-
rameters were normal. But at 5 mg/kg, only three/eight vervet
monkeys with CNS infection were cured (John Thuita, per-
sonal communication). The observed toxicity stopped further
investigations of DB844. Recent toxicity studies of vervet mon-
keys have been completed for DB868. No signs of overt toxicity
were observed in animals dosed for 10 days at 10 mg/kg or even
30 mg/kg p.o. (John Thuita, personal communication). DB868
does remain a promising preclinical candidate as it is substan-
tially better tolerated than DB844 and DB289.
The high CNS activity of DB829 after i.p. administration was
a surprise. This is the first parent diamidine that could cure all
mice tested in the mouse CNS model. Passive diffusion across
the BBB to reach sufficient concentrations in the CNS is un-
likely for such a positively charged molecule. The transport is
more likely to be mediated by specific transporters located in
the BBB. Parenteral administration is an acceptable route of
administration for second-stage HAT considering the fatal
outcome without effective treatment.
The M1s of DB844 and DB868 were similarly active when
administered orally in the acute mouse model and were almost
as potent as their prodrugs. They could serve as orally active
prodrug alternatives. DB1284 (metabolite of DB844) was
slightly less active than the other metabolite, DB1058. The
amidoxime metabolites of DB844 and DB868 lost the oral
activity of the prodrugs. Previously, diamidoxime prodrugs
have been shown to be less potent in the STIB900 acute model
in several but not all cases (2, 16).
The M1s of DB844 and DB868 were also active in the mouse
CNS model. Interestingly, DB1284, which was less active in the
acute mouse model, did show a slightly higher efficacy in the
mouse CNS model than DB1058 when tested at 75 mg/kg p.o.
on five consecutive days. The bioactivation of the M1 to its
active principle is abbreviated and therefore simplified in com-
parison to that of the dimethoxyamidine prodrug. It is conceiv-
able to replace the prodrug with the M1 if other selection
criteria, such as toxicity, simple pharmacokinetics, and cost of
goods, are superior. DB1679, the M1 of DB868, is less CNS
potent than DB868 and is therefore currently not considered
an alternative candidate.
DB868, DB1058, and DB1284 are similarly CNS active in
GVR35-infected mice and are candidates for an oral treatment
for second-stage HAT. Their parent drugs showed comparable
in vitro drug resistance and subspecies profiles. So far, DB868
has been the favored prodrug since its parent, DB829, is CNS
active itself and its metabolism is simpler than that of its
asymmetric analog (3). However, in several clinical trials with
DB289, a highly variable pharmacokinetic profile was ob-
served; it can be speculated that this may be due to the com-
plicated metabolic prodrug activation (Christian Burri, per-
sonal communication). As parenterally administered DB829
penetrates the BBB, the pharmacokinetics will be much sim-
plified compared to those of a prodrug treatment and predic-
tions of optimized treatment regimes more reliable and there-
fore safer. Parenteral treatment for second-stage disease is
acceptable, and DB829 may have potential to become the next
new treatment option for second-stage HAT. To determine if
it is indeed a leading preclinical candidate drug, extensive
toxicity and efficacy studies for parenteral DB829 (CPD-0801)
must be performed with vervet monkeys.
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Dicationic 2,6-diphenylpyrazines, aza-analogues and prodrugs were synthesized; evaluated for DNA
affinity, activity against Trypanosoma brucei rhodesiense (T. b. r.) and Plasmodium falciparum (P. f.)
in vitro, efficacy in T. b. r. STIB900 acute and T. b. brucei GVR35 CNS mouse models. Most diamidines gave
poly(dA-dT)2 DTm values greater than pentamidine, IC50 values: T. b. r. (4.8–37 nM) and P. f. (10–52 nM).
Most diamidines and prodrugs gave cures for STIB900 model (11, 19a and 24b 4/4 cures); 12 3/4 cures for
GVR35 model. Metabolic stability half-life values for O-methylamidoxime prodrugs did not correlate with
STIB900 results.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Tropical protozoan diseases, such as malaria and human African
trypanosomiasis (HAT), affect millions of people in large parts of
the world.1 Malaria caused by Plasmodium falciparum (P. f.) leads
to 665,000 deaths each year.2 HAT (or sleeping sickness), another
devastating disease, is caused by Trypanosoma brucei rhodesience
(T. b. r.) and Trypanosoma brucei gambiense (T. b. g.), which is even-
tually fatal without treatment. There are below 10,000 reported
cases and 30,000 estimated cases of HAT a year mostly in sub-Sah-
aran Africa.3,4 HAT has two stages: an early stage in which the par-
asites reside and proliferate in the hemolymphatic system and a
second stage in which the parasites cross the blood–brain barrier
(BBB) and infect the central nervous system (CNS).5 The drugs cur-
rently in use against both malaria and HAT are far from satisfac-
tory; most drugs suffer from poor oral bioavailability and severe
side effects. For example, the second stage HAT drug melarsoprol
causes a reactive encephalopathy which leads to death in 5% of
treated patients.6 Furthermore, for both diseases the cases of treat-
ment failure because of drug resistance have increased in recent
years. For second stage HAT, there are only two drugs melarsoproland eflornithine available for monotherapy and NECT a combina-
tion therapy with niturtimox and eflornithine.7 Therefore, there
is an urgent need for development of more effective, orally avail-
able and less toxic drugs against these tropical protozoan diseases.
Although numerous DNA binding aromatic diamidines exhibit
potent antiprotozoal activity against these tropical diseases, pent-
amidine 1 (Fig. 1) is the only one which has seen significant clinical
use in humans.8 Pentamidine has been used to treat first stage T. b.
g. HAT, antimony-resistant leishmaniasis, and Pneumocystis jiroveci
pneumonia. Because the amidine groups are protonated at physio-
logical pH, pentamidine has low oral availability and requires par-
enteral administration, which makes its clinical use difficult in
remote regions. Furamidine 2a (Fig. 1), a diphenyl furan diamidine
analogue, is the active metabolite of the di-O-methylamidoxime
prodrug pafuramidine 2c (Fig. 1) which reached phase III clinical
trials against first-stage HAT and P. jiroveci pneumonia, and phase
II clinical trials against malaria.1,5,8,9 Due to hepatic and renal tox-
icity of pafuramidine in humans observed in an additional safety
study paralleling the phase III trials, the further development of
pafuramidine has been terminated. Introduction of a nitrogen atom
into one or both of the terminal phenyl rings of furamidine re-
sulted in aza-analogues of furamidine 3a and 4a (Fig. 1), which exi-
hibited more potent in vivo activities against HAT than
pentamidine and furamidine.10,11 The O-methylamidoxime
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Figure 1. Aromatic diamidine antiprotozoal agents.
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quite effective in the second stage HAT GVR35 CNS mouse model5
and 3c was effective in a vervet monkey model of second stage
HAT.12 As yet, only very few compounds have shown good activity
in the GVR35 CNS mouse model. Since the aza-analogue 4c is bet-
ter tolerated than 3c in toxicity studies in vervet monkeys,5 it is
under further evaluation as a possible preclinical candidate for
treatment of the second stage HAT. Unexpectedly, the parent
diamidine 4a also showed potent activity in the CNS mouse model
on intraperitoneal injection; therefore, 4a may have potential to
become a treatment option for second stage HAT.5
Due to the promising results from the furamidine series, a large
number of furamidine related diamidines have been synthe-
sized.8,13 Recently, we have described a series of linear terphenyl
diamidine 5 (Fig. 1) and their aza-analogues (e.g. 6), which showed
significant DNA minor groove binding affinity and low nanomolar
antiprotozoal activity against T. b. r. and P. f.14,15 The in vivo effi-
cacy for three of those aza-analogues in the T. b. r. STIB900 acute
mouse model is much superior to that of furamidine, and compa-
rable to the azafuramidines. Unfortunately, the di-amidoximes
and di-O-methylamidoxime prodrugs of the terphenyl dicationic
analogues showed poor bioconversion and were not effective on
oral administration.13f In this study we have explored a series of
novel curved dicationic 2,6-diarylpyrazines, their aza-analogues
and their prodrugs which are isomeric with their linear 2,5-pyra-
zines.14,15 Herein, we describe the synthesis, DNA binding affinity,
in vitro activities against T. b. r. and P. f. and in vivo activities in the
T. b. r. STIB900 acute mouse model and T. b. brucei GVR35 CNS
mouse model for these curved 2,6-diarylpyrazines.
2. Chemistry
The synthesis of the parent dicationic 2,6-diphenylpyrazine 10
begins with Suzuki coupling of 2,6-dichloropyrazine (7) with
4-cyanophenylboronic acid (8) to yield the diphenylpyrazine di-
nitrile9 (Scheme1).14–15 Thedi-nitrile9was converted to thediami-
dine 10 by the action of lithium trimethylsilylamide [LiN(TMS)2] in
THF. The di-amidoxime prodrug 11was obtained by reaction of the
di-nitrile 9 with hydroxylamine and followed by O-methylation
with dimethylsulfate in the presences of lithium hydroxide to yield
the corresponding di-O-methylamidoxime prodrug 12.10
Employing the related Stille coupling process starting with 2,6-
di(tri-n-butylstannyl)pyrazine the symmetrical di-nitriles 14a and4414b were made in one step (Scheme 2).16 The di-nitriles 14a–b
were converted to the diamidines 15a–b using LiN[TMS]2 as previ-
ously mentioned.
The dissymmetric mono-aza analogues 19a–b were made as
outlined in Scheme 3. The pyridyl rings are introduced in the first
step by performing Stille coupling between 2-chloro-6-(tri-n-
butylstannyl)pyrazine and the appropriate bromocyanopyridines
16a–b.16 Subsequently, a Suzuki reaction between the 6-(pyri-
dyl)-2-chloropyrazines 17a–b and 4-cyanophenylboronic acid
yields the dissymmetric di-nitriles 18a–b. The di-nitriles were con-
verted into the corresponding diamidines 19a–b, the amidoxines
20a,b and the O-methylamidoximes 21a–b as discussed previously
for Scheme 1.
The synthesis of the symmetrical di-aza analogues is presented
in Scheme 4. It this case the needed di-nitriles 22a–b are made di-
rectly by Stille coupling of the bromocyanopridines 16a–b with
2,6-di(tri-n-butylstannyl)pyrazine. The di-nitriles were converted
into the corresponding diamidines 23a–b, the amidoxines 24a–b
and the O-methylamidoximes 25a–b as discussed previously for
Scheme 1.
3. Biology
The results for the evaluation of the dicationic 2,6-diarylpyr-
azine analogues and their prodrugs against T. b. r. and P. f. and their
DNA binding affinities are shown in Table 1. For comparative pur-
poses, the analogous data for pentamidine (1), furamidine (2a),
azafuramidines 3a, 4a and 2,5-diphenyl pyrazine diamidine (6)
are also included in Table 1.10,15
The interaction of diamidines with nuclear and kinetoplast DNA
has been shown to be an important part of their mode of antipar-
asitic action.8f The DTm values of these dicationic 2,6-diphenylpyr-
azines and their aza-analogues range from high values of 15.1 C to
low ones of 5.1 C, as shown in Table 1. The parent diamidine 10
showed a DTm value of 15.1 C, which is lower than that of furam-
idine (2a) (DTm = 25 C) and higher than that of pentamidine (1)
(DTm = 12.6 C). In comparison to 2a the DTm value of 10 is consis-
tent with its increased hydrophilic property as a result of the addi-
tional two nitrogen atoms in the central pyrazine ring of 10. This
result may further suggest that the hydrophobic component is
important for minor groove DNA binding. The DTm value
(15.1 C) for 10 is higher than that of the linear 2,5-isomer 6
(DTm = 8.0 C). One possible explanation for this result may be that
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6734 L. Hu et al. / Bioorg. Med. Chem. 21 (2013) 6732–6741compound 10 presents an approximately crescent shape which
more closely fits the curvature of the DNA minor groove, similar45to furamidine; and the linear isomer 6 needs incorporation of a
water molecule in the complex to simulate the curved structure
Table 1
DNA affinities and antiprotozoan activity for 2,6-diarylpyrazine diamidines
N
N
X
YY
X
NR2 NR2
NH2H2N
R1 R1
I
N
N
Y
X
NR2 NR2
NH2H2N
II
Code Structure type X Y R1 R2 DTma (C) T. b. r. IC50b (nM) P. f. IC50b (nM) Cytotoxicity IC50c (nM)
1 pentamidne / / / / / 12.6 2.2 46.4 2100
2a / / / / / 25 4.5 15.5 6400
3a / / / / / 19.3 6.5 6.5 77,900
4a / / / / / 15.5 21 83 83,000
6 / / / / / 8.0 18 0.4 42,500
10 I CH CH H H 15.1 5.8 10 80,800
11 I CH CH H OH / 7950 870 2900
12 I CH CH H OMe / 18,900 410 58,700
15a I CH CH Me H 5.1 462 323 117,000
15b I CH CH F H 8.2 27 27 29,800
19a II N CH / H 13.1 14 52 117,000
20a II N CH / OH / 7780 8400 24,600
21a II N CH / OMe / 25,300 5600 >180,000
19b II CH N / H 15.1 6.0 10 34,100
20b II CH N / OH / 10,800 453 5000
21b II CH N / OMe / 194,000 453 >185,000
23a I N CH H H 11.2 37 31 139,000
24a I N CH H OH / 90,600 7010 >196,000
25a I N CH H OMe / 119,600 7390 20,100
23b I CH N H H 12.1 4.8 85 24,400
24b I CH N H OH / 95,400 785 >190,000
25b I CH N H OMe / 7870 328 >212,000
a Increase in thermal melting of poly(dA-dT)2; see Refs. 24.
b The T. b. r. (Trypanosoma brucei rhodesiense) strain was STIB900, and the P. f. (Plasmodium falciparum) strain was K1. The IC50 values are the mean of two independent
assays. Individual values differed by less than 50% of the mean see Ref. 17.
c Cytotoxicity was evaluated using cultured L6 rat myoblast cells; see Refs. 17.
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L. Hu et al. / Bioorg. Med. Chem. 21 (2013) 6732–6741 6735of DNA minor groove.18 The compounds 15a and 15b, methyl and
fluorine substituted analogues, showed much lower DTm values,
which may be due to their twisted shape. Introduction of a46nitrogen atommeta to the amidine group in one or both of the phe-
nyl rings in the parent compound 10 leads to decreased DNA bind-
ing affinity: compound 19a with one nitrogen resulted in a 2 C
Table 2
In vitro and in vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidines in the
STIB900 mouse modela
Code T. b. r. IC50 (nM) Dosageb (ip, mg/kg) Curesc Survivald (days)
1 2.2 20 2/4 >57.5
5 1/4 >38
2a 4.5 20 3/4 >57.75
5 1/4 >46
3a 6.5 20 4/4 >60
5 3/4 >54.5
4a 21 20 4/4 >60
5 3/4 >49.5
6 18 5 0/4 36.5
10 5.8 5 3/4 >53.5
15a 462 / / /
15b 27 5 0/4 >41
19a 14 5 4/4 >60
19b 6 5 2/4 >60
23a 37 5 2/4 >53.75
23b 4.8 5 1/4 >36.5
a See Refs. 5 and 17 for details of STIB900 mouse model.
b Daily dosage was administered for 4 days; ip, intraperitoneal.
c Number of mice that survive and are parasite free for 60 days.
d Average days of survival; untreated control expires between day 7 and 9 post-
infection.
Table 3
In vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidine prodrugs in the
STIB900 mouse modela
Codeb Dosagec (po, mg/kg) Curesd Survivale (days)
2b(2a) 100 0/4 50
2c(2a) 25 4/4 >60
10 4/4 >60
3c(3a) 25 4/4 >60
4c(4a) 25 2/4 >42
11(10) 25 4/4 >60
10 0/4 22.5
12(10) 25 3/4 >53.5
10 3/4 >56.5
20a(19a) 25 2/4 >45.75
21a(19a) 25 3/4 >57.5
10 1/4 >49
20b(19b) 25 2/4 >50
21b(19b) 25 2/4 >50
24a(23a) 25 0/4 23.75
25a(23a) 25 2/4 >38.75
24b(23b) 25 4/4 >60
10 1/4 >33.75
25b(23b) 25 1/4 >43.25
a See Refs. 5 and 17 for details of STIB900 mouse model.
b Code for parent of prodrug in parenthesis.
c Daily dosage was administered for 4 days.
d Number of mice that survive and are parasite free for 60 days.
e Average days of survival; untreated control expires between day 7 and 9 post-
infection.
6736 L. Hu et al. / Bioorg. Med. Chem. 21 (2013) 6732–6741decrease inDTm value and compound 23awith two nitrogen atoms
gave a DTm value with a 3.9 C decrease. However, their corre-
sponding ortho-isomers 19b and 23b showed a smaller influence
on the DNA binding affinity: compound 19b, with one nitrogen
atom, showed the same DTm value as that of the parent compound
10 and compound 23b, with two nitrogen atoms, showed a DTm
value reduced by 3.0 C. These results are consistent with the effect
of nitrogen substitution relationships found in the previous study
of the aza-analogues of furamdine (2a).10 It is also noteworthy that
the compounds which exhibit the higher DTm values showed the
higher antitrypanosomal activity whereas weaker binding com-
pounds show lower activity (see below) which is consistent with
previous observations that while a threshold level of binding ap-
pears essential for activity a direct correlation between DNA affin-
ity and in vitro activity is neither expected nor found.8f A similar
trend was not found for the antiplasmodial activity.
These 2,6-diarylpyrazine diamidines exhibited significant
in vitro antitrypanosomal and antiplasmodial activity at the low
nanomolar level. The parent dicationic 2,6-diphenylpyrazine 10
showed an IC50 value of 6 nM against T. b. r., comparable to that
of pentamidine and furamidine. The antiplasmodial activity of 10
(IC50 = 10 nM) is approximately fivefold more active than pentam-
idine and slightly less active than furamidine. The antiprotozoal
activity of 10 is similar to that of the azafuramidine 3a. Compared
to the isomer 2,5-dicationic diphenylpyrazine 6, there are signifi-
cant differences: the 2,6-isomer 10 was three times more active
than 2,5-isomer 6 against T. b. r.; conversely, 10 was 25-fold less
potent than 6 against P. f. The 2,6-isomer 10 lost the good selectiv-
ity for P. f. versus T. b. r. for which the 2,5-isomer 6 showed 45-fold
selectivity for P. f., compared to T. b. r. These differences may be
due, in part, to the fact that the 2,6-diphenyl pyrazine diamidine
10 is an approximately crescent shaped molecule which more clo-
sely fits the curvature of the DNA minor groove, much similar to
furamidine;8,19 however, its dicationic isomer 2,5-diphenylpyr-
azine 6 is a linear molecule which presumably requires the incor-
poration of a water molecule into the recognition complex to
simulate the curved structure of DNA minor groove.18 The intro-
duction of a methyl group or fluorine atom into the meta-position
to the amidine group on both of the phenyl rings yielded com-
pounds 15a and 15b which showed more than a sixty and fourfold
loss of their antiprotozoal activities against T. b. r. and P. f., respec-
tively. Compound 19a and 23a, in which a nitrogen atom has been
placed meta to the amidine group in one or both of the phenyl
rings, showed a two and sixfold decrease in potency compared to
the parent diamidine 10 against T. b. r. and a ten- and sixfold de-
creased potency against P. f. The two analogues 19b and 23b, in
which the nitrogen atoms are ortho to the amidine, exhibited
equivalent potency against T. b. r. and a similar or eightfold de-
crease in activity against P. f., compared to the parent compound
10. It is noted that the compounds 19b and 23b in which the nitro-
gen atoms are ortho to the amidine exhibited higher activity
against T. b. r. than the corresponding meta-isomers 19a and 23a.
However, a similar trend was not found for P. f. activity. Ten poten-
tial di-amidoxime and di-O-methylamidoxime prodrugs of the
dicationic 2,6-diphenylpyrazine and aza-analogues were prepared.
As expected, these amidoximes and O-methylamidoxime prodrugs
showed low antiprotozoal activity when tested in vitro due to the
absence of metabolizing enzymes.10
Given the promising in vitro T. b. r. activity of these new diami-
dines, except the methyl analogue 15a which showed only moder-
ate antitrypanosomial activity, we have evaluated them and their
prodrugs in the stringent STIB900 acute mouse model for T. b. r.
which mimics first stage disease.5,9,17 Since the diamidines exhibit
quite high pKa values (10–11) and therefore unlikely to cross the
intestinal barrier they were administered intraperitoneally; the
prodrugs were designed to enhance oral bioavailability and hence47were given orally. The results are shown in Table 2 (diamidines)
and Table 3 (prodrugs).
For comparative purposes Tables 2 and 3 also contain in vivo
data for the dicationic analogues pentamidine (1), furamidine
(2a), azafuramidines 3a and 4a, the dicationic 2,5-diphenylpyr-
azine 6 and the prodrugs 2b, 2c, 3c and 4c in the same mouse
model.10,15,22 On intraperitoneal dosing at 5 mg/kg all of the tested
dications show a significant increase in survival time for the trea-
ted animals compared to untreated controls. The parent compound
10 gave 3/4 cures at a dose of 5 mg/kg, which is superior to that of
pentamidine (1) and furamidine (2a) (1/4 cure), and is as effective
as the azafuramidines 3a and 4a (3/4 cure). The linear 2,5-isomer 6
was less effective and gave no cure but did show an increase in
mean survival time. The fluorine substituted analogue 15b gave
Table 4
In vitro metabolic stability of 2,6-diarylpyrazine diamidine prodrugs
Code Mouse t1/2b (min) Human t1/2b (min)
2b 29 ± 10a NDc
2c 150 ± 10d 6.8 ± 2d
11 1.9 ± 0.1a ND
12 26 ± 6 8.6 ± 0.9
20a 30 ± 4a ND
21a 210 ± 100 7.6 ± 0.3
20b 36 ± 5a ND
21b 35 ± 6 6.5 ± 1.2
24a 20 ± 0.4a ND
25a 200 ± 70 70 ± 23
24b 51 ± 1.4a ND
25b 59 ± 10 14 ± 6
a Bis-amidoxime prodrugs were incubated with mouse liver S9 fraction, instead
of liver microsomes.
b Mean ± standard deviations of triplicate determinations.
c ND, not determined.
d Substrate concentration for 2c was 3 lM and its t1/2 was shown as mean and
range of duplicate determinations.
Table 5
In vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidine prodrugs in the
GVR35 CNS mouse modela
Codeb Dosage (po, mg/kg)/no. of days
administered
No. of mice
curedc
MSDd
2ce(2a) 100/5 3/5 >167.8
3ce(3a) 100/5 5/5 >180
4ce(4a) 100/5 5/5 >180
11(10) 100/5 0/5 69
12(10) 100/5 2/5 >173.8
100/10 3/4 >180.0
24b(23b) 100/5 0/5 67.2
25a(23a) 100/5 0/5 95.2
a See Ref. 5 for details of GVR35 CNS mouse model.
b Code for parent of prodrug in parenthesis.
c Cure defined as survival for more than 180 days after infection without showing
a parasitemia relapse.
d MSD (mean survival days) was determined for mice with and without parasi-
temia relapse.
e Data from Ref. 5.
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er in vitro activity against T. b. r. The four aza-analogues 19a, 19b,
23a and 23b exhibited identical or better results to that for furam-
idine at a dose of 5 mg/kg. The best result obtained was for com-
pound 19a, which showed 4/4 cures at a dose of 5 mg/kg. It is
noteworthy that although compounds 19a and 23a, in which the
nitrogen atom is meta to the amidine group, exhibited a significant
loss of in vitro potency against T. b. r. compared to their isomeric
compounds 19b and 23b, in which the nitrogen atom is ortho to
the amidine, the in vivo efficacy of 19a (4/4 cure) and 23a (2/4
cure) was superior to the ortho isomers 19b (2/4 cure) and 23b
(1/4 cure). This result may be due to pharmacokinetic differences
between the ortho and meta isomers and/or the differential
involvement of transporters. In general, the results for the aza-pyr-
azine analogues are consistent with those observed for the aza-
furamidine system.10
Although previous studies of di-amidoxime and di-O-meth-
ylamidoxime prodrugs of the linear terphenyl diamidine analogues
showed poor bioconversion and were not curative on oral admin-
istration,13f all the di-amidoxime and di-O-methylamidoxime pro-
drugs of the dicationic 2,6-diphenylpyrazine and aza-analogues
showed activity when they were administered orally to the mice
during this study. In vitro metabolic stability studies using mouse
liver microsomes showed that di-O-methylamidoxime prodrugs
were biotransformed at different rates, with 12, 21b, and 25b
showing shorter half-life than 21a and 25a (Table 4). However, this
difference did not translate into activity in the STIB900 mouse
model, as the latter generally gave more cures, with the exception
of 12 (Table 3). This disconnect is likely due to a recent finding that
intrahepatic binding and efflux of diamidines formed in the hepa-
tocytes, rather than enzymatic biotransformation of prodrugs,
determined the disposition of active diamidine metabolites.20 It
should also be noted that there was a marked interspecies differ-
ence in the metabolic stability of di-O-methylamidoxime prodrugs,
as liver microsomes derived from humans metabolized the pro-
drugs much faster than those from mice (Table 4). This could be
due to species differences in the enzyme activity and expression le-
vel of CYP4F/cyp4f enzymes, which were shown to be responsible
for catalyzing the primary O-demethylation of the di-O-meth-
ylamidoxime pafuramidine in the human liver and intestinal
microsomes.21
Very interestingly, treatment with the amidoxime produgs 11
and 24b resulted in cures of all mice at the oral dose of 25 mg/
kg, superior to the corresponding O-methylamidoxime prodrugs
12 (3/4 cure) and 25b (1/4 cure) at the same dosage. Both of the48amidoximes 11 and 24b are more potent than the amidoxime pro-
drug 2b of furamidine which gave no cure at an oral dose of
100 mg/kg (Table 3).22 These results do not parallel those observed
in the furamidine series, which showed that the O-methylamidox-
imes are more effective than the amidoximes.10 The O-meth-
ylamidoxime prodrug 12 of the parent compound 10 gave 3/4
cures at the oral dose of 10 mg/kg. To evaluate the bioconversion
of the di-amidoxime prodrugs, mouse liver S9 fractions were used
as they contain cytochrome b5 and cytochrome b5 reductase, which
are likely required to reduce amidoxime to amidine.23 All di-ami-
doxime prodrugs examined in this study were efficiently metabo-
lized (half-lives ranged from 2 to 51 min; Table 4), supporting their
potential as prodrugs to generate active diamidine metabolites
in vivo, but failed to explain the superiority of oral 24b over other
di-amidoximes (except 11) in the STIB900 mouse model. As dis-
cussed above, this observation underscores the role of intrahepatic
binding and efflux from hepatocytes, rather than bioconversion, in
determining the disposition and activity of active diamidine
metabolites in vivo.
Given the potent in vivo activity found in the T. b. r. STIB900
acute mouse model 11 and 12 were selected for study in the T. b.
brucei GVR35 mouse model for second stage disease.5 In sharp con-
trast to the results found in the STIB900 model, 11 was not effec-
tive at a dosage of 100 mg/kg for 5 days in the GVR35 model
providing no cures and only a modest increase (69 days) in survival
time (Table 5). This shows that compound 11 is only able to re-
move trypanosomes from the hemolymphatic compartment. How-
ever, at the same dosage 12 gave 2/5 cures. To achieve cures in the
CNS mouse model drugs must cross the blood brain barrier and
reach trypanocidal levels in the CSF and CNS. These additional bar-
riers often result in CNS drug levels lower than that in blood.
Hence, to attempt to compensate for this circumstance where pos-
sible we further test with increased doses. When the dosing of 12
was extended to 10 days 3/4 cures were noted showing that this
compound is penetrating into the brain in sufficient concentration
to cure CNS infection. The activity of 12 in the GVR35 CNS model,
with 2/5 mice cured at dosage of 100 mg/kg for 5 days compares
favorably with that for pafuramidine 2c which showed 3/5 cured
at the same dosage with the five day regimen. The efficacy of 12
is somewhat reduced from that of the O-methylamidoxime pro-
drug 4c for treatment of second stage HAT which gave 5/5 cures
at the same dosage (Table 5).5 Nevertheless, prodrug 12 is one of
only a very few compounds which have shown good activity in this
CNS model. The compounds 24b and 25a were also selected for
study in the T. b. brucei GVR35 CNS mouse model. Both compounds
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they extended the survival time of mice similarly to control mice
treated with diminazine (at 40 mg/kg ip single dose) which is a
diamidine curing only first stage disease. The results for the ami-
doxime and O-methylamidoxime prodrugs of this series of dica-
tions provides stimulation for further evaluation of their efficacy
and toxicity.
4. Conclusions
A series of dicationic 2,6-diphenylpyrazines and aza analogues
have been prepared which exhibited DNA binding which is consis-
tent with a role in their mode of action, showed potent in vitro
activity against both T. b. r. and P. f., and gave promising results
on intraperitoneal administration in the stringent T. b. r. STIB900
mouse model. The diamidines 10 and 19a exhibited in vivo efficacy
(3/4 or 4/4 cures at 5 mg/kg dosage, ip) in the STIB900model, supe-
rior to that of furamidine (2a), and comparable to or better than
the azafuramidines 3a and 4a. Eight of the ten prodrugs of the dic-
atonic 2,6-diphenylpyrazine and aza-analogues showed good oral
activity, giving cures in the STIB900 acute mouse model. The po-
tent O-methylamidoxime prodrug 12 also showed good in vivo oral
efficacy in the GVR35 second stage mouse model. This series of
dicationic 2,6-diphenylpyrazine analogues and their prodrugs mer-
it further evaluation for treatment of both stages of HAT.
5. Experimental section
5.1. Biology
5.1.1. Efficacy studies
The in vitro assays17 with T. b. r. STIB 900 and P. f. K1 strain as
well as the efficacy studies in an acute mouse model for T. b. r. STIB
9005 were carried out as previously reported. The studies in the T.
b. brucei GVR35 mouse model for second stage disease were per-
formed as previously described.5 All protocols and procedures for
the mouse models used in the current study were reviewed and
approved by the local veterinary authorities of Canton Basel-Stadt,
Switzerland. The data was generated at the time the determination
of survival was still accepted by the authorities.
5.1.2. Tm Measurements
Thermal melting experiments were conducted with a Cary
300 spectrophotometer. Cuvettes for the experiment were
mounted in a thermal block and the solution temperatures mon-
itored by a thermistor in the reference cuvette. Temperatures
were maintained under computer control and increased at
0.5 C/min. The experiments were conducted in 1 cm path length
quartz curvettes in CAC 10 buffer (cacodylic acid 10 mM, EDTA
1 mM, NaCl 100 mM with NaOH added to give pH 7.0). The con-
centrations of DNA were determined by measuring its absor-
bance at 260 nm. A ratio of 0.3 mol compound per mole of
DNA was used for the complex and DNA alone was used as a
control. DTm values were determined by the peak in first deriv-
ative curves (dA/dT).24
5.1.3. In vitro metabolic stability assays
The procedures used were similar to a reported method.23a
Substrate stock solutions were prepared in DMSO. DMSO content
was kept at 0.5% (v/v) in final incubations. Incubation mixtures
(final volume 0.25 mL) consisted of 10 lM substrate and
0.5 mg/mL pooled liver microsomes from human or mouse
(XenoTech, Lenexa, KS) for O-methylamidoxime prodrugs, or li-
ver S9 fraction from mouse for amidoxime prodrugs. Reactions
were carried out in 100 mM phosphate buffer (pH 7.4)49containing 3.3 mM MgCl2. Mouse liver S9 fractions were pre-
pared from male Swiss Webster mice (25–30 g) as previously
reported.25 Briefly, four volumes of 0.25 M sucrose containing
0.1 M KCl and 1 mM EDTA was added to mouse liver and
homogenized on ice with a sonic dismembrator (Fisher Scientific,
Fair Lawn, NJ). The homogenate was centrifuged at 9000g for
20 min at 4 C and then the supernatant fraction (S9 fraction)
was collected and aliquoted before storing at 78 C. After a 5-
min pre-equilibration period at 37 C, the metabolic stability
reactions (in triplicate) were initiated by adding the cofactor
(1 mM b-NADPH for microsomal incubations or a cocktail of
1 mM b-NADPH, 1 mM NADH, and 3.3 mM UDPGA for incuba-
tions with S9 fractions) and kept at 37 C. Aliquots (100 ll) of
the reaction mixtures were removed at 0, 15, 30, and 60 min
and individually mixed with 100 ll of ice-cold acetonitrile. The
mixtures were vortex-mixed, and precipitated protein was re-
moved by centrifugation at 1400g for 15 min. The supernatant
fractions were analyzed immediately by HPLC/UV.21 In vitro
half-lives were obtained using the one-phase exponential decay
model with plateau set at zero (GraphPad Prism 5.0, San Diego,
CA).
5.2. Chemistry
5.2.1. General materials and methods
Melting points were determined on a Mel-Temp 3.0 melting
point apparatus, and are uncorrected. TLC analysis was carried
out on silica gel 60 F254 precoated aluminum sheets using UV light
for detection. 1H and 13C NMR spectra were recorded on a Varian
Unity Plus 300 MHz or Bruker 400 MHz spectrometer using indi-
cated solvents. Mass spectra was obtained from the Georgia State
University Mass Spectrometry Laboratory, Atlanta, GA. Elemental
analysis were performed by Atlantic Microlab Inc., Norcross, GA,
and are within ±0.4 of the theoretical values. The compounds re-
ported as salts frequently analyzed correctly for fractional moles
of water and/or other solvents; in each case 1H NMR spectra was
consistent with the analysis. All chemicals and solvents were pur-
chased from Aldrich Chemical Co., VWR International, or Combi-
Blocks, Inc.
2,6-Di-(40-cyanophenyl)pyrazine (9). To a stirred solution of 2,6-
dichloropyrazine (7, 2.0 g, 13.4 mmol) in toluene (56 mL) under
nitrogen atmosphere at 80 C was added 27 mL of 2 M aqueous
solution of Na2CO3 followed by 4-cyanophenylboronic acid 8
(4.34 g, 29.5 mmol) in 30 mL of methanol. After 30 min, tetra-
kis(triphenylphosphine) palladium (1.34 g, 1.16 mmol) was added
to the reaction mixture. The reaction mixture was stirred overnight
at 80 C. After cooling to room temperature, water was added to
the mixture. The solution was filtered, and the precipitate was
washed with water and MeOH. The crude product was purified
by recrystallization to afford the title compound 9 (2.92 g, 77%
yield); mp 298.5–299 C. 1H NMR (DMSO-d6): d 8.04 (d,
J = 8.1 Hz, 4H), 8.47 (d, J = 8.1 Hz, 4H), 9.41 (s, 2H). 13C NMR
(DMSO-d6): d 148.8, 142.1, 139.9, 133.0, 127.7, 118.6, 112.6. MS:
m/z 282 (M+). Anal. Calcd for C18H10N4: C, 76.58; H, 3.57; N,
19.85. Found: C, 76.33; H, 3.55; N, 19.76.
2,6-Di-(40-amidinophenyl)pyrazine hydrochloride (10). The above
dinitrile 9 (0.14 g, 0.48 mmol), suspended in freshly distilled THF
(4 mL), was treated with lithium trimethylsilylamide (1 M solution
in THF, 2.5 mL, 2.5 mmol), and the reaction was allowed to stir
overnight. The reaction mixture was then cooled to 0 C and to
which was added HCl saturated ethanol (3 mL), whereupon a pre-
cipitate started forming. The mixture was allowed to stir overnight,
after which it was diluted with ether, and the precipitate was fil-
tered. The diamidine was purified by neutralization with 1 N NaOH
followed by filtration of the resultant solid and washing with
water. Finally, the free base was stirred with ethanolic HCl over-
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dried to give the diamidine salt 10 (0.14 g, 76% yield); mp >300 C.
1H NMR (DMSO-d6): d 8.05 (d, J = 7.6 Hz, 4H), 8.53 (d, J = 7.6 Hz,
4H), 9.31 (s, 4H), 9.48 (s, 2H), 9.57 (s, 4H). 13C NMR (DMSO-d6): d
165.1, 149.1, 141.6, 140.5, 129.0, 128.9, 127.2. Anal. Calcd for
C18H16N6-2.0HCl-2.3H2O: C, 50.19; H, 5.29; N, 19.51. Found: C,
50.31; H, 4.92; N, 19.18.
2,6-Di-(40-N-hydroxyamidinophenyl)pyrazine hydrochloride (11).
A mixture of hydroxylamine hydrochloride (4.9 g, 70.8 mmol) in
anhydrous DMSO (60 mL) was cooled to 5 C under nitrogen.
Potassium tert-butoxide (7.95 g, 70.8 mmol) was added in portions
and the mixture was stirred for 30 min. To this mixture was added
the above dinitrile 9 (1.0 g, 3.54 mmol) and the mixture was stirred
overnight. The reaction mixture was poured slowly into a beaker
with ice water and stirred for 15 min. The white precipitate was fil-
tered and washed with water to afford the free base of 11. The free
base was stirred with ethanolic HCl overnight and diluted with
ether, and the precipitate which formed was collected by filtration
to give the title compound HCl salt 11 in 87% yield; mp >300 C. 1H
NMR (DMSO-d6): d 3.86 (s, 6H), 4.64 (s, 2H), 7.96 (d, J = 8.4 Hz, 4H),
8.51 (d, J = 8.4 Hz, 4H), 9.25 (s, 4H), 9.43 (s, 2H), 11.42 (s, 2H), 13.13
(s, 2H). 13C NMR (DMSO-d6): d 158.8, 149.1, 141.8, 140.0, 128.9,
127.3, 126.7. Anal. Calcd for C18H16N6O2-2.2HCl-2.0H2O: C, 46.53;
H, 4.82; N, 18.09. Found: C, 46.59; H, 4.45; N, 17.80.
2,6-Di-(40-N-methoxyamidinophenyl)pyrazine hydrochloride (12).
A solution of lithium hydroxide monohydrate (0.24 g, 5.74 mmol)
in water (4 mL) was added dropwise to the mixture of the free base
of the above di-amidoxime 11 (0.43 g, 1.44 mmol) in DMF (26 mL)
at room temperature. The reaction mixture was stirred for 30 min
at room temperature. Dimethylsulfate (0.45 g, 3.59 mmol) was
added to the reaction mixture and the mixture was stirred at room
temperature overnight. The reaction mixture was poured slowly
into a beaker with ice water and stirred for 15 min. The precipitate
was filtered and washed with water to afford the free base of 12.
The free base was stirred with ethanolic HCl overnight and diluted
with ether, and the precipitate which formed was collected by fil-
tration to give the title compound 12 in 58% yield; mp 244–246 C.
1H NMR (DMSO-d6): d 3.49 (s, 8H), 3.83 (s, 6H), 7.90 (d, J = 8.4 Hz,
4H), 8.38 (d, J = 8.4 Hz, 4H), 9.33 (s, 2H). 13C NMR (DMSO-d6): d
156.7, 149.2, 141.6, 139.3, 128.5, 128.2, 127.1, 63.1. Anal. Calcd
for C20H20N6O2-2.0HCl-1.5H2O: C, 50.43; H, 5.29; N, 17.64. Found:
C, 50.28; H, 5.17; N, 17.46.
2,6-Di-(40-amidino-20-methylphenyl)pyrazine hydrochloride
(15a). A solution of 2,6-di(tri-n-butylstannyl)pyrazine (77%
purity)16 (4.04 g, 4.68 mmol), 4-bromo-3-methylbenzonitrile 13a
(2.02 g, 10.30 mmol), tetrakis(triphenylphosphine) palladium
(0.56 g, 0.56 mmol) in degassed xylene (80 mL) was heated at
120 C under nitrogen atmosphere for 24 h. After cooling to room
temperature, the mixture was filtered and the precipitate was
washed with xylene and ether. The crude product was purified
by recrystallization (DMF) to afford compound 14a in 62% yield
[mp 239–141 C (dec). 1H NMR (DMSO-d6): d 2.43 (s, 6H), 7.74
(d, J = 8.1 Hz, 2H), 7.83 (d, J = 8.1 Hz, 2H), 7.89 (s, 2H), 8.95 (s,
2H). 13C NMR (DMSO-d6): d 151.8, 143.5, 140.8, 137.8, 134.4,
131.0, 129.9, 118.5, 111.8, 19.8] and it was used directly in the next
step without further characterization.
The same procedure described for the preparation of 10 was
used starting with the above dinitrile 14a; 52% yield; mp 250–
252 C (dec). 1H NMR (DMSO-d6): d 2.46 (s, 6H), 7.80 (d,
J = 8.1 Hz, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.89 (s, 2H), 8.98 (s, 2H),
9.32 (s, 4H), 9.52 (s, 4H). 13C NMR (DMSO-d6): d 165.2, 152.1,
143.4, 141.2, 137.1, 130.6, 130.6, 128.6, 125.9, 20.2. Anal. Calcd
for C20H20N6-2.5HCl-1.0H2O: C, 52.96; H, 5.44; N, 18.53. Found:
C, 52.96; H, 5.31; N, 18.26.
2,6-Di-(40-amidino-20-fluorophenyl)pyrazine hydrochloride (15b).
The same procedure described above for the preparation of 14a50was used starting with 4-bromo-3-fluorobenzonitrile 13b; to give
14b 62% yield [mp >300 C. 1H NMR (DMSO-d6): d 8.12–8.16 (m,
2H), 8.37 (d, J = 8.4 Hz, 2H), 8.49 (d, J = 10.4 Hz, 2H), 9.48 (s, 2H).
HRMS: m/z 319.0800 (M+1) (calculated for C18H9N4F2, 319.0795)]
and it was used directly in the next step without further
characterization.
The same procedure described for the preparation of 10 was
used starting with the above dinitrile 14b; 60% yield; mp
>300 C. 1H NMR (DMSO-d6): d 7.89–7.92 (m, 2H), 8.37 (d,
J = 8.4 Hz, 2H), 8.44 (d, J = 12.4 Hz, 2H), 9.46 (s, 4H), 9.49 (s, 2H),
9.63 (s, 4H). 13C NMR (DMSO-d6): d 161.9, 159.2 (d, J = 248.2 Hz),
147.9 (d, J = 2.3 Hz), 142.0, 141.6 (d, J = 8.6 Hz), 130.7, 122.8 (d,
J = 2.9 Hz), 118.3 (d, J = 13.7 Hz), 114.4 (d, J = 23.5 Hz). HRMS: m/z
353.1311 (M+1) (calculated for C18H15N6F2, 353.1326). Anal. Calcd
for C18H14F2N6-2.0HCl-1.3H2O: C, 48.18; H, 4.18; N, 18.73. Found:
C, 48.37; H, 4.11; N, 18.67.
2-Chloro-6-(50-cyanopyridin-20-yl)pyrazine (17a). A solution of 2-
chloro-6-(tri-n-butylstannyl)pyrazine16 (3.62 g, 9.0 mmol), 2-bro-
mo-5-cyanopyridine 16a (1.67 g, 9.0 mmol), tetrakis(triphenyl-
phosphine) palladium (0.52 g, 0.45 mmol) in degassed xylene
(20 mL) was heated at 120 C under nitrogen atmosphere over-
night. After cooling to room temperature, the mixture was filtered.
Most of the solvent was removed under reduced pressure; the pre-
cipitate which formed was filtered and washed with xylene and
ether. The crude product was purified by column chromatography
on silica gel (eluent hexane/ethyl acetate (5/1)) to give the title
compound 17a in 67% yield; mp 148–150 C. 1H NMR (DMSO-
d6): d 8.41 (d, J = 8.4 Hz, 1H), 8.51 (dd, J = 2.0, 8.4 Hz, 1H), 8.97 (s,
1H), 9.20 (d, J = 2.0 Hz, 1H), 9.51 (s, 1H). 13C NMR (DMSO-d6): d
154.9, 152.6, 148.5, 147.9, 145.7, 141.7, 141.0, 121.2, 116.7,
110.1. Anal. Calcd for C10H5ClN4: C, 55.44; H, 2.33; N, 25.86. Found:
C, 55.55; H, 2.28; N, 25.83.
2-(40-Cyanophenyl)-6-(50-cyanopyridin-20-yl)pyrazine (18a). The
same procedure described for 2,6-di-(40-cyanophenyl)pyrazine 9
was used by employing 2-chloro-6-(50-cyanopyridin-20-yl)pyra-
zine 17a and 4-cyanophenylboronic acid 8 to furnish the com-
pound 18a in 71% yield; mp 293–295 C. 1H NMR (DMSO-d6): d
8.04 (d, J = 8.4 Hz, 2H), 8.50 (d, J = 8.4 Hz, 2H), 8.53 (dd, J = 2.0,
8.4 Hz, 1H), 8.71 (d, J = 8.4 Hz, 1H), 9.19 (d, J = 2.0 Hz, 1H), 9.48
(s, 1H), 9.57 (s, 1H). HRMS: m/z 284.0930 (M+1) (calculated for
C17H10N5, 284.0936). Anal. Calcd for C17H9N5: C, 72.08; H, 3.20;
N, 24.75. Found: C, 71.85; H, 3.17; N, 24.64.
2-(40-Amidinophenyl)-6-(50-amidinopyridin-20-yl)pyrazine hydro-
chloride (19a). The same procedure described for the preparation
of 10 was used starting with the above dinitrile 18a; 90% yield;
mp 296–298 C (dec). 1H NMR (DMSO-d6): d 8.05 (d, J = 8.4 Hz,
2H), 8.46 (dd, J = 2.0, 8.4 Hz, 1H), 8.58 (d, J = 8.4 Hz, 2H), 8.77 (d,
J = 8.4 Hz, 1H), 9.17 (d, J = 2.0 Hz, 1H), 9.27 (s, 2H), 9.40 (s, 2H),
9.56 (s, 2H), 9.56 (s, 1H), 9.62 (s, 1H), 9.73 (s, 2H). 13C NMR
(DMSO-d6): d 165.1, 163.7, 157.2, 149.0, 148.9, 148.2, 143.5,
142.1, 140.1, 137.9, 129.2, 128.9, 127.4, 125.2, 120.9. Anal. Calcd
for C17H15N7-3.0HCl-1.7H2O: C, 44.64; H, 4.72; N, 21.44. Found:
C, 44.67; H, 4.52; N, 21.44.
2-(40-N-Hydroxyamidinophenyl)-6-(50-N-hydroxyamidinopyridin-
20-yl)pyrazine hydrochloride (20a). The same procedure described
for the preparation of 11was used starting with the above dinitrile
18a; yield 89%; mp 283–285 C (dec). 1H NMR (DMSO-d6): d 3.43
(s, 8H), 7.95 (d, J = 8.4 Hz, 2H), 8.36 (dd, J = 2.0, 8.4 Hz, 1H), 8.52
(d, J = 8.4 Hz, 2H), 8.68 (d, J = 8.4 Hz, 1H), 9.08 (d, J = 2.0 Hz, 1H),
9.47 (s, 1H), 9.57 (s, 1H). 13C NMR (DMSO-d6): d 158.8, 156.9,
156.8, 149.0, 148.7, 148.2, 143.4, 142.0, 139.8, 137.9, 128.9,
127.5, 126.8, 122.9, 121.1. Anal. Calcd for C17H15N7O2-3.0HCl-
0.8H2O: C, 43.16; H, 4.18; N, 20.72. Found: C, 43.15; H, 4.22; N,
20.62.
2-(40-N-Methoxyamidinophenyl)-6-(50-N-methoxyamidinopyri-
din-20-yl)pyrazine hydrochloride (21a). The same procedure
6740 L. Hu et al. / Bioorg. Med. Chem. 21 (2013) 6732–6741described for the preparation of 12 was used starting with the
above compound 20a; 29% yield; mp 213–215 C (dec). 1H NMR
(DMSO-d6): d 3.43 (s, 8H), 3.83 (s, 3H), 3.85 (s, 3H), 7.92 (d,
J = 8.4 Hz, 2H), 8.29 (dd, J = 2.0, 8.4 Hz, 1H), 8.39 (d, J = 8.4 Hz,
2H), 8.57 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 2.0 Hz, 1H), 9.38 (s, 1H),
9.52 (s, 1H). 13C NMR (DMSO-d6): d 157.5, 155.1, 152.7, 149.0,
148.4, 147.7, 143.0, 141.8, 139.5, 136.6, 128.7, 127.4, 127.3,
126.1, 121.0, 63.4, 62.3. Anal. Calcd for C19H19N7O2-3.0HCl-
0.7H2O: C, 45.70; H, 4.72; N, 19.63. Found: C, 45.91; H, 4.67; N,
19.29.
2-Chloro-6-(20-cyanopyridin-50-yl)pyrazine (17b). The same pro-
cedure described for 2-chloro-6-(50-cyanopyridin-20-yl)pyrazine
17a was used by employing 2-chloro-6-(tri-n-butylstannyl)pyra-
zine16 and 2-bromo-5-cyanopyridine 16b to furnish the title com-
pound 17b in 52% yield; mp 149–151 C. 1H NMR (DMSO-d6): d
8.24 (d, J = 8.4 Hz, 1H), 8.71 (dd, J = 2.0, 8.4 Hz, 1H), 8.91 (s, 1H),
9.45 (d, J = 2.0 Hz, 1H), 9.46 (s, 1H). 13C NMR (DMSO-d6): d 149.4,
148.1, 147.7, 144.7, 141.3, 136.0, 133.5, 133.4, 129.2, 117.3. Anal.
Calcd for C10H5ClN4: C, 55.44; H, 2.33; N, 25.86. Found: C, 55.67;
H, 2.30; N, 25.60.
2-(40-Amidinophenyl)-6-(20-amidinopyridin-50-yl)pyrazine hydro-
chloride (19b). The same procedure described for 2,6-di-(40-cyano-
phenyl)pyrazine 9 was used by employing 2-chloro-6-(20-
cyanopyridin-50-yl)pyrazine 17b and 4-cyanophenylboronic acid
8 to furnish the compound 18b in 88% yield [mp 271–273 C. 1H
NMR (DMSO-d6): d 8.06 (d, J = 8.4 Hz, 2H), 8.26 (d, J = 8.4 Hz, 1H),
8.51 (d, J = 8.4 Hz, 2H), 8.90 (dd, J = 2.0, 8.4 Hz, 1H), 9.48 (s, 1H),
9.50 (s, 1H), 9.63 (d, J = 2.0 Hz, 1H). 13C NMR (DMSO-d6): d 149.5,
149.0, 147.0, 142.6, 142.4, 139.6, 135.9, 134.6, 133.3, 133.0,
129.2, 127.8, 118.6, 117.4, 112.7] and it was used directly in the
next step without further characterization.
The same procedure described for the preparation of 10 was
used starting with the above dinitrile 18b; yield 87%; mp
>300 C. 1H NMR (DMSO-d6): d 8.04 (d, J = 8.8 Hz, 2H), 8.52 (d,
J = 8.4 Hz, 1H), 8.55 (d, J = 8.8 Hz, 2H), 9.02 (dd, J = 2.0, 8.4 Hz,
1H), 9.21 (s, 2H), 9.46 (s, 2H), 9.51 (s, 2H), 9.51 (s, 1H), 9.54 (s,
1H), 9.65 (d, J = 2.0 Hz, 1H), 9.70 (s, 2H). 13C NMR (DMSO-d6): d
165.1, 161.6, 149.3, 148.1, 147.2, 144.7, 142.6, 142.4, 140.2,
136.4, 135.3, 129.3, 128.9, 127.4, 123.6. Anal. Calcd for C17H15N7-
2.0HCl-1.55H2O: C, 48.83; H, 4.84; N, 23.44. Found: C, 49.15; H,
4.78; N, 23.07.
2-(40-N-Hydroxyamidinophenyl)-6-(20-N-hydroxyamidinopyridin-
50-yl)pyrazine hydrochloride (20b). The same procedure described
for the preparation of 11was used starting with the above dinitrile
18b; yield 87%; mp 291–293 C (dec). 1H NMR (DMSO-d6): d 3.44
(s, 4H), 7.95 (d, J = 8.4 Hz, 2H), 8.24 (d, J = 8.4 Hz, 1H), 8.53 (d,
J = 8.8 Hz, 2H), 8.87 (dd, J = 2.0, 8.4 Hz, 1H), 9.21 (s, 2H), 9.45 (s,
1H), 9.49 (s, 1H), 9.56 (d, J = 2.0 Hz, 1H), 11.01 (s, 1H), 11.20 (s,
1H). 13C NMR (DMSO-d6): d 158.7, 154.7, 149.2, 147.9, 147.4,
145.0, 142.3, 142.1, 139.7, 136.0, 134.4, 128.9, 127.4, 126.8,
123.0. Anal. Calcd for C17H15N7O2-2.0HCl-1.4H2O: C, 45.63; H,
4.46; N, 21.91. Found: C, 45.99; H, 4.40; N, 21.56.
2-(40-N-Methoxyamidinophenyl)-6-(20-N-methoxyamidinopyri-
din-50-yl)pyrazine hydrochloride (21b). The same procedure de-
scribed for the preparation of 12 was used starting with the
above compound 20b; yield 37%; mp 160–162 C (dec). 1H NMR
(DMSO-d6): d 3.86 (s, 3H), 3.88 (s, 3H), 3.89 (s, 8H), 7.96 (d,
J = 8.0 Hz, 2H), 8.10 (d, J = 8.4 Hz, 1H), 8.46 (d, J = 8.0 Hz, 2H),
8.87 (dd, J = 2.0, 8.4 Hz, 1H), 9.41 (s, 1H), 9.43 (s, 1H), 9.47 (d,
J = 2.0 Hz, 1H). 13C NMR (DMSO-d6): d 157.3, 150.7, 149.3, 148.3,
147.9, 147.2, 141.8, 141.7, 139.5, 135.5, 132.8, 128.7, 127.6,
127.2, 121.1, 63.4, 62.0. Anal. Calcd for C19H19N7O2-2.0HCl-
2.0H2O: C, 46.92; H, 5.18; N, 20.16. Found: C, 46.98; H, 5.09; N,
19.93.
2,6-Di-(50-cyanopyridin-20-yl)pyrazine (22a). The same proce-
dure described for 2,6-di-(40-cyano-20-methylphenyl)pyrazine5114a was used by employing 2,6-di(tri-n-butylstannyl)pyrazine
and 2-bromo-5-cyanopyridine 16a to furnish the title compound
22a in 58% yield; mp 264–266 C (dec).1H NMR (DMSO-d6): d
8.69 (dd, J = 2.1, 8.4 Hz, 2H), 8.80 (d, J = 8.4 Hz, 2H), 9.23 (s, 2H),
9.67 (d, J = 2.1 Hz, 2H). 13C NMR (DMSO-d6): d 155.9, 152.6,
147.8, 143.8, 141.6, 121.4, 116.9, 110.0. Anal. Calcd for C16H8N6:
C, 67.60; H, 2.84; N, 29.56. Found: C, 67.41; H, 2.73; N, 29.31.
2,6-Di-(50-amidinopyridin-20-yl)pyrazine hydrochloride (23a). The
same procedure described for the preparation of 10was used start-
ing with the above dinitrile 22a; 50% yield; mp 277–279 C (dec).
1H NMR (DMSO-d6): d 8.48 (dd, J = 2.4, 8.4 Hz, 2H), 8.86 (d,
J = 8.1 Hz, 2H), 9.18 (d, J = 2.4 Hz, 2H), 9.41 (s, 4H), 9.72 (s, 2H),
9.74 (s, 4H). 13C NMR (DMSO-d6): d 163.7, 156.9, 149.0, 148.1,
143.6, 138.0, 125.2, 121.1. Anal. Calcd for C16H14N8-2.0HCl-
2.5H2O: C, 44.05; H, 4.85; N, 25.68. Found: C, 44.08; H, 4.67; N,
25.39.
2,6-Di-(50-N-hydroxyamidinopyridin-20-yl)pyrazine hydrochloride
(24a). The same procedure described for the preparation of 11
was used starting with the above dinitrile 22a in 97% yield; mp
274–276 C (dec).1H NMR (DMSO-d6-D2O): d 3.52 (s, 6H), 8.32
(dd, J = 2.0, 8.4 Hz, 2H), 8.74 (d, J = 8.4 Hz, 2H), 9.03 (d, J = 2.0 Hz,
2H), 9.65 (s, 2H), 11.08 (s, 2H). 13C NMR (DMSO-d6): d 156.4,
156.2, 148.6, 148.1, 143.4, 137.6, 123.5, 121.2. Anal. Calcd for
C16H14N8O2-2.0HCl-2.1H2O: C, 41.68; H, 4.42; N, 24.30. Found: C,
41.71; H, 4.30; N, 24.30.
2,6-Di-(50-N-methoxyamidinopyridin-20-yl)pyrazine hydrochloride
(25a). The same procedure described for the preparation of 12 was
used starting with the above compound 24a; yield 58%; mp 216–
218 C (dec). 1H NMR (DMSO-d6): d 3.82 (s, 6H), 4.00 (s, 6H), 6.70
(s, 2H), 8.27 (dd, J = 1.8, 8.4 Hz, 2H), 8.64 (d, J = 8.4 Hz, 2H), 9.04
(d, J = 1.8 Hz, 2H), 9.61 (s, 2H). 13C NMR (DMSO-d6): d 154.5,
151.4, 148.4, 147.4, 142.8, 135.9, 127.2, 121.1, 61.9. Anal. Calcd
for C18H18N8O2-3.0HCl-2.3H2O: C, 40.85; H, 4.88; N, 21.17. Found:
C, 41.01; H, 4.89; N, 21.07.
2,6-Di-(20-cyanopyridin-50-yl)pyrazine (22b). The same proce-
dure described for 2,6-di-(40-cyano-20-methylphenyl)pyrazine
14a was used by employing 2,6-di(tri-n-butylstannyl)pyrazine
and 5-bromo-2-cyanopyridine 16b to furnish the title compound
22b; 70% yield; mp >300 C. 1H NMR (DMSO-d6): d 8.27 (d,
J = 8.0 Hz, 2H), 8.94 (dd, J = 2.0, 8.0 Hz, 2H), 9.54 (s, 2H), 9.66 (d,
J = 2.0 Hz, 2H). 13C NMR (DMSO-d6): d149.6, 147.2, 143.0, 136.1,
134.4, 133.4, 129.2, 117.4. Anal. Calcd for C16H8N6: C, 67.60; H,
2.84; N, 29.56. Found: C, 67.34; H, 2.73; N, 29.28.
2,6-Di-(20-amidinopyridin-50-yl)pyrazine hydrochloride (23b). The
same procedure described for the preparation of 10was used start-
ing with the above dinitrile 22b; 83% yield; mp 249–251 C (dec).
1H NMR (DMSO-d6): d 8.58 (d, J = 8.1 Hz, 2H), 9.06 (dd, J = 1.2,
8.1 Hz, 2H), 9.59 (s, 4H), 9.61 (s, 2H), 9.68 (d, J = 1.2 Hz, 2H), 9.78
(s, 4H). 13C NMR (DMSO-d6): d 151.3, 147.9, 147.6, 147.3, 142.0,
135.6, 133.0, 121.5. Anal. Calcd for C16H14N8-2.0HCl-1.4H2O: C,
46.14; H, 4.55; N, 26.91. Found: C, 46.42; H, 4.52; N, 26.52.
2,6-Di-(20-N-hydroxyamidinopyridin-50-yl)pyrazine hydrochloride
(24b). The same procedure described for the preparation of 11
was used starting with the above dinitrile 22b; 69% yield; mp
280–282 C (dec). 1H NMR (DMSO-d6): d 8.40 (dd, J = 2.1, 8.4 Hz,
2H), 8.80 (d, J = 8.4 Hz, 2H), 8.82 (s, 2H), 9.10 (d, J = 2.1 Hz, 2H),
9.68 (s, 2H), 11.28 (s, 2H). 13C NMR (DMSO-d6): d 155.0, 148.0,
147.6, 144.8, 142.7, 136.2, 134.4, 123.2. Anal. Calcd for
C16H14N8O2-3.0HCl-0.75H2O: C, 40.61; H, 3.94; N, 23.68. Found:
C, 40.81; H, 4.18; N, 23.35.
2,6-Di-(20-N-methoxyamidinopyridin-50-yl)pyrazine hydrochloride
(25b). The same procedure described for the preparation of 12 was
used starting with the above compound 24b; 50% yield; mp 89–
91 C. 1H NMR (DMSO-d6): d 3.85 (s, 6H), 8.07 (d, J = 8.4 Hz, 2H),
8.72 (dd, J = 2.4, 8.4 Hz, 2H), 9.43 (s, 2H), 9.46 (d, J = 2.4 Hz, 2H).
13C NMR (DMSO-d6): d 150.1, 149.0, 148.3, 146.9, 141.5, 135.0,
L. Hu et al. / Bioorg. Med. Chem. 21 (2013) 6732–6741 6741131.8, 119.9, 61.2. Anal. Calcd for C18H18N8O2-2.0HCl-0.7H2O: C,
46.60; H, 4.65; N, 24.15. Found: C, 46.80; H, 4.79; N, 23.95.
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Abstract
The predominant mechanism of drug resistance in African trypanosomes is decreased drug uptake due to loss-of-function
mutations in the genes for the transporters that mediate drug import. The role of transporters as determinants of drug
susceptibility is well documented from laboratory-selected Trypanosoma brucei mutants. But clinical isolates, especially of T.
b. gambiense, are less amenable to experimental investigation since they do not readily grow in culture without prior
adaptation. Here we analyze a selected panel of 16 T. brucei ssp. field isolates that (i) have been adapted to axenic in vitro
cultivation and (ii) mostly stem from treatment-refractory cases. For each isolate, we quantify the sensitivity to melarsoprol,
pentamidine, and diminazene, and sequence the genomic loci of the transporter genes TbAT1 and TbAQP2. The former
encodes the well-characterized aminopurine permease P2 which transports several trypanocides including melarsoprol,
pentamidine, and diminazene. We find that diminazene-resistant field isolates of T. b. brucei and T. b. rhodesiense carry the
same set of point mutations in TbAT1 that was previously described from lab mutants. Aquaglyceroporin 2 has only recently
been identified as a second transporter involved in melarsoprol/pentamidine cross-resistance. Here we describe two
different kinds of TbAQP2 mutations found in T. b. gambiense field isolates: simple loss of TbAQP2, or loss of wild-type
TbAQP2 allele combined with the formation of a novel type of TbAQP2/3 chimera. The identified mutant T. b. gambiense are
40- to 50-fold less sensitive to pentamidine and 3- to 5-times less sensitive to melarsoprol than the reference isolates. We
thus demonstrate for the first time that rearrangements of the TbAQP2/TbAQP3 locus accompanied by TbAQP2 gene loss
also occur in the field, and that the T. b. gambiense carrying such mutations correlate with a significantly reduced
susceptibility to pentamidine and melarsoprol.
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Introduction
The chemotherapy of human African trypanosomiasis (HAT,
also known as sleeping sickness) currently relies on suramin or
pentamidine for the first, haemolymphatic stage and on melarso-
prol or eflornithine/nifurtimox combination therapy (NECT) for
the second stage, when the trypanosomes have invaded the central
nervous system (CNS) [1]. All five drugs have unfavorable
pharmacokinetics and adverse effects. Melarsoprol is particularly
toxic, causing severe encephalopathies in over 5% of the treated
patients [2]. And yet, melarsoprol is the only treatment for late-
stage T. b. rhodesiense infections. New and safer drugs are at various
stages of (pre)clinical development, thanks largely to the Drugs for
Neglected Diseases initiative (www.dndi.org). Two molecules that
have successfully passed clinical Phase I trials are now being tested
in patients: the nitroimidazole fexinidazole [3,4] and the
benzoxaborole SCYX-7158 [5,6]. Both are orally available and
cure 2nd stage T. b. brucei infections in a mouse model [7].
However, until new drugs for HAT are on the market, the current
ones – problematic as they are – need to be used in a sustainable
way. This requires an understanding of the mechanisms of drug
resistance.
The mechanisms of drug resistance in African trypanosomes
have been studied in the lab for over 100 years [8]. Two
observations were made recurrently, namely (i) reduced drug
uptake by drug resistant trypanosomes [9–14] and (ii) cross-
resistance between melarsoprol and pentamidine [15,16]. Both
phenomena were attributed to the fact that melarsoprol and
pentamidine are taken up by trypanosomes via the same
transporters, which appeared to be lacking in drug-resistant
mutants. The first transporter identified was called P2 since it was
one of two purine nucleoside transporters identified [17,18]. It is
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encoded by the gene TbAT1 for adenine/adenosine transporter 1
[19]. Homozygous genetic deletion of TbAT1 in bloodstream-form
T. b. brucei resulted in pentamidine and melarsoprol cross-resistance,
albeit only by a factor of about 2.5 [20]. This weak phenotype,
together with the fact that the TbAT12/2 mutants still exhibited
saturable drug import [21], indicated that further transporters are
involved in melarsoprol-pentamidine cross-resistance [16,21,22].
One such transporter was recently identified, the aquaglyceroporin
TbAQP2 [23,24]. Aquaporins and aquaglyceroporins belong to the
major intrinsic protein (MIP) family and form channels that
facilitate transmembrane transport of water and small non-ionic
solutes such as glycerol and urea [25]. The three aquaporins of T.
brucei (TbAQP1-3) are thought to physiologically function as
osmoregulators and are involved in glycerol transport [26].
Aquaporins were described to mediate uptake of arsenite in
mammalian cells [27] and in Leishmania, and loss of aquaporin
function was implicated in heavy metal resistance [28]. Homozy-
gous genetic deletion of TbAQP2 in bloodstream-form T. b. brucei
increased the IC50 towards melarsoprol and pentamidine by about
2- and 15- fold, respectively [24]. Moreover, a T. b. brucei lab mutant
selected for high-level pentamidine resistance [21] carried a
chimeric TbAQP2 gene, where 272 nucleotides had been replaced
by the corresponding sequence from a neighboring, very similar
gene TbAQP3 [24]. Differences in the TbAQP2/TbAQP3 tandem
locus on chromosome 10 were also observed between the reference
genome sequences of T. b. gambiense DAL972 [29] and T. b. brucei
TREU927 [23,30]. They possess identical versions of TbAQP2 but
differ in TbAQP3 [31]. More recent field isolates of T. brucei ssp. have
so far not been genotyped regarding their TbAQP2/TbAQP3 locus.
The genotypic status of TbAT1, located proximal to a telomere
on chromosome 5 [32], has been more intensely investigated.
Point mutations in TbAT1 were described, both in selected lab
strains and in clinical T. brucei ssp. isolates, which rendered the
gene non-functional when expressed in yeast [19]. The occurrence
of these mutations correlated to a certain degree with melarsoprol
treatment failure in 2nd stage T. b. gambiense HAT patients [33–36].
However, the relationship between polymorphisms in TbAT1,
drug susceptibility, and treatment failure in patients is not fully
resolved as the TbAT1 mutant T. b. gambiense were not analyzed
phenotypically. Such investigations are notoriously difficult since
clinical T. b. gambiense isolates are hard to obtain (given the
inaccessibility of HAT foci and the poor success rate of isolation
and adaptation in rodents) and cannot readily be propagated in
axenic culture. Here we concentrate on clinical T. brucei ssp.
isolates from drug refractory cases that have been adapted to
axenic in vitro cultivation, aiming to investigate whether mutations
at the known melarsoprol and pentamidine transporter loci also
occur in the field – and if so, whether such mutations are
accompanied by loss of drug susceptibility.
Materials and Methods
Trypanosoma brucei ssp. isolates
The 16 analyzed isolates are described in Table 1 (origin) and
Table 2 (clinical outcome). For more details on the recent isolates
from the DRC please refer to Table S4 of Pyana et al (2011) [37].
All have previously been adapted to axenic cultivation. T. b. brucei
and T. b. rhodesiense isolates were cultured in minimum essential
medium (MEM) with Earle’s salts with the addition of 0.2 mM 2-
mercaptoethanol, 1 mM Na-pyruvate, 0.5 mM hypoxanthine,
and 15% heat-inactivated horse serum as described by Baltz et al
(1985) [38]. T. b. gambiense strains were cultured in IMDM
medium supplemented according to Hirumi and Hirumi (1989)
[39], plus 0.2 mM 2-mercaptoethanol, 15% heat-inactivated fetal
calf serum and 5% human serum. The cultures were maintained
under a humidified 5% CO2 atmosphere at 37uC and were
subpassaged 3 times a week to ensure growth in the exponential
(log) phase.
Phenotyping
Drug sensitivity was determined with the Alamar blue assay as
described by Ra¨z et al (1997) [40], using the redox-sensitive dye
resazurin as an indicator of cell number and viability. The
trypanosomes were cultivated in 96-well microtiter plates in serial
dilutions of drugs for 70 h. 10 ul of resazurin (125 ug/ml (Sigma)
dissolved in PBS pH 7.2) was added to each well. The plates were
further incubated for 2–4 hours for T. b. rhodesiense and T. b. brucei,
and 6–8 hours for T. b. gambiense, before being read with a
SpectraMax Gemini XS microplate fluorescence scanner (Molec-
ular Devices) at an excitation wavelength of 536 nm and an
emission wavelength of 588 nm. IC50 values were calculated by
non-linear regression to a sigmoidal inhibition curve using
SoftMax Pro software (V. 5.2). The IC50 values given in Table 2
are averages 6 standard deviation of at least 3 independent assays
(n = 3–12), each determined in duplicate. Melarsoprol (Sanofi-
Aventis) was obtained from WHO. Pentamidine isothionate and
diminazene aceturate were purchased from Sigma.
Genotyping
Genomic DNA was isolated from 10 ml dense trypanosome
cultures. The cells were spun down and the pellets resuspended in
300 ml 10 mM TrisHCl pH 8, 1 mM EDTA and 3 ml 10% SDS
was added before incubating for 10–15 min at 55uC. After 5 min
incubation 3 ml of pronase mix (20 mg/ml, Sigma) was added to
increase the stability of the extracted DNA. 90 ml of ice cold 5 M
potassium acetate was added and the mixture was incubated for
5 min on ice. After spinning down for 5 minutes at max speed in a
microfuge, the supernatant was transferred to a new tube and
DNA was precipitated in 2–2.5 volumes of absolute ethanol,
washed in 70% ethanol and dissolved in 20 ml ddH2O. PCR was
performed with Taq polymerase (Solis BioDyne, Estonia); the
primers and annealing temperatures are summarized in Table S1.
Author Summary
Human African Trypanosomiasis, or sleeping sickness, is a
fatal disease restricted to sub-Saharan Africa, caused by
Trypanosoma brucei gambiense and T. b. rhodesiense. The
treatment relies on chemotherapy exclusively. Drug
resistance in T. brucei was investigated mainly in labora-
tory-selected lines and found to be linked to mutations in
transporters. The adenosine transporter TbAT1 and the
aquaglyceroporin TbAQP2 have been implicated in sensi-
tivity to melarsoprol and pentamidine. Mutations in these
transporters rendered trypanosomes less susceptible to
either drug. Here we analyze T. brucei isolates from the
field, focusing on isolates from patients where melarsoprol
treatment has failed. We genotype those isolates to test for
mutations in TbAQP2 or TbAT1, and phenotype for
sensitivity to pentamidine and melarsoprol. Six T. b.
gambiense isolates were found to carry mutations in
TbAQP2. These isolates stemmed from relapse patients and
exhibited significantly reduced sensitivity to pentamidine
and melarsoprol as determined in cell culture. These
findings indicate that mutations in TbAQP2 are present in
the field, correlate with loss of sensitivity to pentamidine
and melarsoprol, and might be responsible for melarsoprol
treatment failures.
Transporter Mutations in T. brucei Field Isolates
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PCR products were run on a 0.8% agarose gel and purified on a
silica membrane column (Nucleospin gel and PCR clean up,
Macherey Nagel, Germany). The purified PCR products were
directly sequenced (Microsynth, Switzerland or GATC, Germany)
with the same primers as used for PCR amplification. Only the
TbAQP2/TbAQP3 locus of T. b. gambiense K03048 produced two
PCR products, which were cloned in pCR2.1-TOPO (Invitrogen).
The assembled sequences were submitted to GenBank; accession
numbers are listed in Table S2.
Results
A panel of Trypanosoma brucei ssp. field isolates
To be able to compare – and possibly correlate – genotype and
phenotype of T. brucei ssp., we assembled a set of 16 isolates that
had been adapted to axenic in vitro cultivation as blood-stream
forms. These included 5 recent T. b. gambiense isolates from the
Democratic Republic of the Congo (DRC), 2 older isolates from
the Republic of Coˆte d’Ivoire and one isolate from South Sudan,
Table 1. Origin of the analyzed T. brucei isolates.
Isolate Species Origin Reference
STIB 930 Tbg Republic of Coˆte d’Ivoire, 1978 [49]
ITMAP 141267 Tbg Democratic Republic of the Congo, 1960 [50]
STIB 756 Tbg Liberia, 1981 [51]
STIB 891 Tbg Uganda, 1995 [33]
DAL 870R Tbg Republic of Coˆte d’Ivoire, 1985 [52]
DAL 898R Tbg Republic of Coˆte d’Ivoire, 1985 [52]
K03048 Tbg South Sudan, 2003 [53]
45 BT (MHOM/CD/INRB/2006/1) Tbg Democratic Republic of the Congo, 2006 [37]
130 BT (MHOM/CD/STI/2006/02) Tbg Democratic Republic of the Congo, 2006 [37]
349 BT (MHOM/CD/INRB/2006/16) Tbg Democratic Republic of the Congo, 2006 [37]
349 AT (MHOM/CD/INRB/2006/19) Tbg Democratic Republic of the Congo, 2006 [37]
40 AT (MHOM/CD/INRB/2006/07) Tbg Democratic Republic of the Congo, 2006 [37]
STIB 900 Tbr Tanzania, 1982 [52]
STIB 871 Tbr Uganda, 1994 [54]
STIB 940 Tbb Somalia, 1985 [42,55]
STIB 950 Tbb Somalia, 1985 [41]
doi:10.1371/journal.pntd.0002475.t001
Table 2. Drug sensitivity (IC50 6 SD in nM), genotypic status of TbAT1 and TbAQP2, and clinical outcome of melarsoprol treatment
of the patients.
Isolate MelB Pentamidine Diminazene TbAT1 TbAQP2 Clinics
STIB 930 9.664.5 1.960.7 21.068.5 Ref Ref Cure
ITMAP 141267 15.068.1 8.363.4 9.964.4 WT WT Cure
STIB 756 6.261.1 1.360.7 24.767.9 WT WT Unknown
STIB 891 5.360.9 1.761.4 23.362.7 WT WT Unknown
DAL 870R 4.461.7 1.161.0 5.362.2 WT WT Relapse
DAL 898R 8.965.9 1.761.2 22.7616.8 WT WT Relapse
K03048 24.869.2 81.2621.9 58.0633.6 WT deletion/chimeric Relapse
45 BT 25.968.6 91.8629.7 37.5610.8 WT chimeric Relapse
130 BT 42.3617.6 76.9622.3 12.364.5 WT chimeric Probable relapse
349 BT 26.2611.3 71.9612.4 20.063.2 WT chimeric Relapse
349 AT 25.6611.8 81.9631.8 15.461.0 WT chimeric Relapse
40 AT 22.068.0 72.2621.1 39.9616.7 WT chimeric Relapse
STIB 900 4.662.6 3.260.9 3.861.5 Ref Ref Cure
STIB 871 4.461.3 2.561.0 2016163 R allele WT Cure
STIB 940 13.667.0 3.462.0 3406218 R allele WT n.a.
STIB 950 27.669.4 1.860.4 102653.6 R allele WT n.a.
WT= identical to reference (Ref) strain, being STIB 930 for T. b. gambiense isolates and STIB 900 for T. b. brucei and T. b. rhodesiense strains.
doi:10.1371/journal.pntd.0002475.t002
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which were all isolated from patients who had relapsed after
melarsoprol chemotherapy. Other T. b. gambiense isolates from the
DRC, northwestern Uganda, and Liberia were from patients who
were successfully treated with melarsoprol or the treatment
outcome is unknown. T. b. gambiense STIB 930 is a fully drug-
susceptible lab strain that was used as a reference strain. We
further included the field isolates T. b. brucei STIB 940, T. b. brucei
STIB 950 and T. b. rhodesiense STIB 871, which are multidrug-
resistant to isometamidium, diminazene and tubercidin. The fully
drug-susceptible reference strain T. b. rhodesiense STIB 900 was
included as a reference. The different isolates and their origin are
summarized in Table 1. All isolates were genotyped regarding
TbAQP2 and TbAT1.
Naturally occurring mutations in TbAQP2
When the TbAQP2/TbAQP3 genomic locus was amplified by
PCR from the 16 T. brucei ssp. isolates, all the recent T. b. gambiense
isolates from the DRC (40 AT, 45 BT, 130 BT, 349 BT and 349
AT) exhibited a smaller band than expected for the wild-type
locus. Direct sequencing of the PCR product in each of the five
isolates revealed only one gene at the locus: a chimeric version of
TbAQP2 and TbAQP3. The first 813 bp of the open reading frame
perfectly matched TbAQP2 while the remaining 126 bp derived
from TbAQP3 (Figure 1C). These 126 bp perfectly matched to
TbAQP3 of T. b. rhodesiense STIB 900 but this exact sequence is not
found in the published genome of T. b. gambiense DAL 972. Note
that the present TbAQP2-TbAQP3 chimeric gene (Figure 1C)
differs from the one described by Baker et al. from a pentamidine-
selected T. b. brucei lab mutant (Figure 1B; [24]). T. b. gambiense
K03048 from the South Sudan also gave rise to an abnormal
pattern upon PCR amplification of the TbAQP2/TbAQP3 locus
from genomic DNA: a distinctly smaller double band instead of
the expected product, indicative of heterozygosity. The smaller
band contained the upstream region of TbAQP2 followed by the
open reading frame of TbAQP3 while the TbAQP2 open reading
frame was missing (Figure 1D). The larger band contained a
TbAQP2/3 chimera similar to that encountered in the T. b.
gambiense isolates of the DRC (Figure 1C). Point mutations in
TbAQP2 were encountered in the multidrug-resistant field isolates
T. b. brucei STIB 940, T. b. brucei STIB 950 and T. b. rhodesiense
STIB 871, all of which had the same 4 SNPs in TbAQP2 compared
to the T. b. brucei 927 reference gene (Tb927.10.14170), leading to
the amino acid change threonine159 to alanine (Figure 1E).
However, the same 4 SNPs also occurred in our drug-susceptible
reference strain T. b. rhodesiense STIB 900, so they are not likely to
be involved in the mdr phenotype [41,42] of these isolates. All other
isolates analyzed had a wild-type copy of TbAQP2. The identified
sequence polymorphisms are summarized in Table 2, GenBank
accession numbers are in Table S2.
Naturally occurring mutations in TbAT1
All of the 12 analyzed T. b. gambiense isolates were identical in
TbAT1 sequence to the reference STIB 930 as well as to the
genome strain DAL972. The previously described TbAT1R allele
[19,33] was found in the 3 mdr lines T. b. brucei STIB 940, T. b.
brucei STIB 950 and T. b. rhodesiense STIB 871. TbAT1R carries 5
coding and 4 silent mutations and a codon deletion as compared to
the reference sequence (STIB 900), and the resultant protein
appeared to be non-functional when expressed in Saccharomyces
cerevisiae [19] or re-expressed in a tbat1 null T. b. brucei (De Koning,
unpublished results). The remainder of the isolates did not possess
mutations in TbAT1 when compared to the respective reference
isolate. The GenBank accession numbers of all the sequences are
in Table S2.
Correlating TbAQP2 and TbAT1 genotype to drug
susceptibility
Drug sensitivities of the bloodstream-forms of all isolates were
determined in vitro regarding melarsoprol, pentamidine, and
diminazene. The five T. b. gambiense that possessed the chimeric
TbAQP2/3 gene (45 BT, 130 BT, 349 BT, 349 AT, 40 AT), as well
as K03048 which carries a deletion of TbAQP2 in one allele, in
addition to one chimeric TbAQP2/3 allele, all showed a similar
drug sensitivity profile with markedly increased IC50 values
towards pentamidine and, to a lesser extent, also melarsoprol
(Figure 2). IC50 values were in the range of 70–92 nM for
pentamidine and 22–42 nM for melarsoprol (Table 2); compared
to the median of the four drug sensitive T. b. gambiense lines STIB
930, STIB 891, STIB 756 and ITMAP 141267, this corresponds
to a 40- to 52-fold decrease in susceptibility to pentamidine and a
2.8- to 5.3-fold decrease for melarsoprol. The higher IC50 values of
Figure 1. Schematic view of the TbAQP2/TbAQP3 locus on chromosome 10. A) Reference locus of T. b. brucei TREU927, T. b. gambiense STIB
930 and T. b. gambiense DAL972 (minor differences in TbAQP3 are not highlighted). B) Chimera of TbAQP2 and TbAQP3 as described by Baker et al.
(2012) [24] for the in vitro selected, pentamidine-resistant T. b. brucei line B48. C) Chimera of TbAQP2 and TbAQP3 plus loss of TbAQP3 in T. b.
gambiense 40 AT, 45 BT, 130 BT, 349 BT, and 349 AT, and in one K03048 allele. D) Deletion of the TbAQP2 ORF in the other T. b. gambiense K03048
allele. E) TbAQP2 polymorphisms (C474A, G475A, C477T, T480C) in several T. b. rhodesiense and T. b. brucei isolates from East Africa (STIB 900, STIB 950,
STIB 940, and STIB 871).
doi:10.1371/journal.pntd.0002475.g001
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the isolates that carried a mutation in TbAQP2 (n = 6) compared to
the remainder (n = 10) were statistically significant both with
respect to pentamidine (p = 0.0002, two-tailed Mann-Whitney test)
and melarsoprol (p = 0.0047); no association was observed
regarding TbAQP2 status and sensitivity to diminazene. However,
the isolates that carried the known resistance allele TbAT1R (i.e.
STIB 940, STIB 950 and STIB 871) exhibited strongly increased
IC50 values to diminazene (p = 0.01, two-tailed Mann-Whitney
test) but not to pentamidine (Figure 2, Table 2). T. b. brucei STIB
950 also had an elevated IC50 against melarsoprol (Figure 2), but
over all three TbAT1R isolates there was no significant effect on
melarsoprol susceptibility.
Across all 16 T. brucei isolates, pentamidine sensitivity positively
correlated with that to melarsoprol (Spearman’s rank correlation
coefficient of 0.67, p = 0.005) while there was no correlation
between the two structurally related diamidines, pentamidine and
diminazene (Figure 2).
Discussion
It is an intriguing phenomenon with African trypanosomes that
drug resistance is predominantly linked to reduced drug import,
typically arising from loss of function mutation of a non-essential
transporter [12,19,24]. Here we investigated the aminopurine
transporter TbAT1 and the aquaglyceroporin TbAQP2, two
proteins known to be involved in uptake of – and susceptibility to –
melarsoprol and diamidines in bloodstream-form T. brucei. While
there is evidence for a link between TbAT1 mutations and
melarsoprol treatment failure in the field [33–36], the more
recently identified gene TbAQP2 has so far not been analyzed in a
clinical setting. TbAQP2 is dispensable for growth in culture [24]
and partial gene replacement of TbAQP2 with TbAQP3 was
observed in a pentamidine-selected T. b. brucei lab mutant [24] that
displayed reduced infectivity to rodents [21]. However, it was
unknown whether similar mutations also occur in the field, as they
might bear a fitness cost in patients or during transmission by the
tsetse fly. Concentrating on a panel of clinical T. brucei ssp. isolates
that (i) derived from treatment-refractory cases and (ii) had been
adapted to axenic in vitro culture, we have genotyped their TbAT1
and TbAQP2 loci, and phenotyped their in vitro sensitivity towards
melarsoprol, pentamidine and diminazene. Our aim was to
explore whether TbAQP2 mutations occur in the field and if so,
whether mutant isolates exhibit reduced drug susceptibility.
Five of the analyzed T. b. gambiense isolates, all from melarsoprol
relapse patients of Dipumba Hospital in Mbuji-Mayi, DRC,
carried only one gene at the TbAQP2/TbAQP3 tandem locus, an
unprecedented TbAQP2/3 chimera. The high degree of sequence
similarity between TbAPQ2 and TbAQP3 allows for homologous
recombination between the two genes, leading to chimerization
and gene loss. TbAQP2 has a unique selectivity filter with unusual
NSA/NPS motifs instead of the characteristic NPA/NPA that
occur in the vast majority of MIP family members [43] including
TbAQP1 and TbAQP3 [24]. The published, pentamidine-
resistant T. b. brucei lab mutant possessed a TbAQP2/3 chimera
whose C-terminal filter triplet was from TbAQP3, suggesting that
the unusual NPS triplet may be involved in pentamidine transport.
However, the presently described pentamidine-resistant T. b.
gambiense isolates carry a TbAQP2/3 chimera encoding a predicted
protein with both selectivity filter triplets from TbAQP2. We
hypothesize that the TbAQP2/3 chimera observed in the T. b.
gambiense isolates fails to contribute to pentamidine and melarso-
prol susceptibility despite having the proposed selectivity filter
residues of TbAQP2. Functional expression of the chimeric gene
in tbaqp2 null cells will be necessary to test this hypothesis.
The occurrence of rearrangements at the TbAQP2/TbAQP3
locus correlated with reduced susceptibility to pentamidine and, to
a lesser extent, melarsoprol. Thus field isolates also exhibit the well
known cross-resistance between melarsoprol and pentamidine
[15,16,31], while no cross-resistance was observed to diminazene
aceturate. This is in agreement with TbAT1 being the primary
uptake route for diminazene [44,45] and consistent with results
obtained using TbAQP22/2 cells, which showed no resistance to
the rigid diamidines diminazene or DB75 [24], as opposed to
pentamidine which has a highly flexible structure. It is also
noteworthy that T. b. rhodesiense STIB 871 and T. b. brucei STIB
940 are susceptible to melarsoprol and pentamidine in vitro
although both carry the TbAT1r allele. Loss of TbAT1 function
has been described without mutations in the open reading frame of
Figure 2. In vitro drug sensitivities. 50% inhibitory concentrations (IC50) as determined with the Alamar blue assay. Susceptibility to pentamidine
correlates with that to melarsoprol but not diminazene. TbAT1 and TbAQP2 genotypes are indicated.
doi:10.1371/journal.pntd.0002475.g002
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the gene [32]. However, since in the present study all isolates with
a ‘wild-type’ TbAT1 ORF were fully susceptible to diminazene, we
conclude that they possess a functional TbAT1 (i.e. P2) transporter.
Trypanosoma congolense and T. vivax appear to lack an AT1 orthologue
[46], therefore diminazene transport and resistance must have a
different mechanism in these livestock parasites.
The plasma levels of pentamidine in treated patients peak about
1 hour after injection and vary extensively from 0.42 mM to
13 mM, while the mean elimination half-life after multiple
applications is approximately 12 days [47]. Thus, since pentam-
idine is very potent, even a 50-fold increase in IC50 of pentamidine
as observed here for the T. b. gambiense isolates with mutations in
TbAQP2, is unlikely to jeopardize the success of treatment. With
melarsoprol, however, the obtainable drug levels are more critical.
Only 1–2% of the maximal plasma levels are seen in the CSF [48],
and a 5-fold reduced sensitivity to melarsoprol might allow
trypanosomes to survive in the CSF during melarsoprol therapy.
Thus mutations in TbAQP2 might indeed be responsible for
melarsoprol treatment failures with T. b. gambiense. However, two
of the T. b. gambiense isolates from relapse patients (DAL 870R and
DAL 898 R) were sensitive to melarsoprol and pentamidine, and
they possessed wild-type copies of TbAT1 and TbAQP2, indicating
that factors other than drug resistance can contribute to treatment
failures. Larger sample sizes will be required to test the significance
of TbAQP2 for successful treatment. We show here for the first
time that a TbAQP2/3 chimera as well as loss of TbAQP2 occurs in
T. b. gambiense clinical isolates, and that the presence of such
rearrangements at the TbAQP2/TbAQP3 locus is accompanied by
a 40- to 50-fold loss in pentamidine sensitivity and a 3- to 5-fold
loss in melarsoprol sensitivity. We recommend genotyping of the
TbAQP2/TbAQP3 locus to be integrated into larger field trials such
as clinical studies with drug candidates.
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Abstract
Isothermal microcalorimetry is an established tool to measure heat flow of physical, chemical or biological processes. The
metabolism of viable cells produces heat, and if sufficient cells are present, their heat production can be assessed by this
method. In this study, we investigated the heat flow of two medically important protozoans, Trypanosoma brucei
rhodesiense and Plasmodium falciparum. Heat flow signals obtained for these pathogens allowed us to monitor parasite
growth on a real-time basis as the signals correlated with the number of viable cells. To showcase the potential of
microcalorimetry for measuring drug action on pathogenic organisms, we tested the method with three antitrypanosomal
drugs, melarsoprol, suramin and pentamidine and three antiplasmodial drugs, chloroquine, artemether and dihydroarte-
misinin, each at two concentrations on the respective parasite. With the real time measurement, inhibition was observed
immediately by a reduced heat flow compared to that in untreated control samples. The onset of drug action, the degree of
inhibition and the time to death of the parasite culture could conveniently be monitored over several days.
Microcalorimetry is a valuable element to be added to the toolbox for drug discovery for protozoal diseases such as
human African trypanosomiasis and malaria. The method could probably be adapted to other protozoan parasites,
especially those growing extracellularly.
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Introduction
Human African trypanosomiasis (HAT), also known as African
sleeping sickness, and malaria are important tropical diseases caused
by protozoan parasites. HAT threatens millions of people living in
sub-Saharan Africa [1]. In recent years, the number of cases
dropped due to improved control measures such as trapping of
tsetse flies, active surveillance and appropriate treatment of patients,
and is currently estimated at 30,000 cases annually [2]. However,
the disease may reemerge, if control is neglected. African sleeping
sickness is fatal without treatment, so the availability of effective
drugs is vital. Malaria has a higher public health impact with 225
million infections and almost 800’000 deaths annually [3]. The most
affected populations are children and pregnant women in Africa.
Effective drugs are available for prophylaxis and treatment, but
drug resistant parasites represent a major challenge. Therefore, new
drugs for both diseases are needed on a continuous basis particularly
since no effective vaccine is yet available for either of these diseases,
so drug development is of crucial importance.
Drug discovery and development requires rapid methods for
screening large number of compounds. For both trypanosomes
and malaria parasites, in vitro drug activity tests are available.
These are routinely performed in 96-well microtiter plates with a
drug exposure time of 72 hours. For Trypanosoma brucei spp.
bloodstream forms are cultivated axenically. Parasite inhibition is
determined in a simple and cost-effective way using the viability
marker Alamar blue (resazurin) [4]. P. falciparum is cultured as
asexual erythrocytic stages, and parasite growth inhibition is
classically assessed by measuring the uptake of tritium-labelled
hypoxanthine [5]. Using these assays, the antiprotozoal activity of
added compounds, expressed as 50% inhibitory concentration
(IC50) can be determined. These methods can also be used to
determine the time of onset of drug action and the time to kill,
which are of great importance for subsequent in vivo studies.
However, following changes over time using these currently
available in vitro tests is not very accurate and is particularly labor
intensive.
An alternative method of estimating growth inhibition is
isothermal microcalorimetry. This nonspecific technique allows
direct measurement of heat generated by biological processes in
living cells. Growth of microorganisms results in an increase of
heat flow over time which is documented by a continuous real-
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time electronic signal. The method has already been used to study
heat production of bacteria, mammalian cells and worms [6–10].
For example, bacteria produce on average 1–3 pW heat per viable
cell [6,11]. The detection time depends on the sensitivity of the
instrument as well as the initial number of living cells, their growth
rate and the amount of heat produced per cell [12,7]. To our
knowledge, this technique has not been applied yet to any
pathogenic protozoa.
In the present study, we established microcalorimetry as a new
tool for a rapid determination of effects of drugs on Trypanosoma
brucei rhodesiense and Plasmodium falciparum. We used the real-time
measurements of metabolic heat flow produced by these protozo-
an parasites, to measure the time of the onset of action at different
drug concentrations and also the time to death of the parasite
population.
Materials and Methods
Culture of T. b. rhodesiense and preparation of
calorimetry ampoules
Bloodstream forms of the T. b. rhodesiense strain STIB900 were
cultivated in Minimum Essential Medium with Earle’s salts,
supplemented according to Baltz et al. [13] with the following
modifications: 0.2 mM 2-mercaptoethanol, 1 mM sodium pyru-
vate, 0.5 mM hypoxanthine and 15% heat-inactivated horse
serum. For calorimetry, trypanosomes were washed and diluted
with fresh culture medium to give the desired initial cell density
then transferred to 4 ml sterile glass ampoules which were
hermetically sealed with a rubber septum.
For the determination of a suitable cell density to use to obtain
growth curves, ampoules were filled with 3 ml trypanosome
culture containing 104, 105 and 106 cells/ml initial densities, each
in triplicate. Culture medium without trypanosomes served as
negative control. Continuous heat measurements (1/sec) were
conducted over a period of up to 6 days. For determination of
parasite densities at different time points, small aliquots (<50 ml)
were collected through the rubber septum of the hermetically
closed ampoules using a 1 ml syringe. Cell counting of motile
trypanosomes was performed microscopically using a Neubauer
chamber.
The influence of the sample volume was evaluated using an
initial density of 105 cells/ml, and 1 ml, 2 ml and 3 ml of culture
medium each in triplicate.
The standard drugs suramin, pentamidine and melarsoprol
were selected to monitor drug action. Eflornithine was excluded
because of its weak in vitro activity against African trypanosomes.
We used a multiple of the IC50 value of each drug since time to kill
can not be determined with an IC50 (determined over 72 hrs) or
lower concentrations. For the investigation of drug activity,
trypanosome cultures were diluted with fresh culture medium to
a density of 105 cells/ml. Each ampoule was filled with 3 ml cell
suspension and supplemented with suramin, pentamidine or
melarsoprol at concentrations corresponding to 56 IC50 or 256
IC50 (for actual concentrations in ng/ml see table 1). Each
measurement was performed in triplicate. The IC50 values were
determined prior the experiment as previously described [14].
Culture of P. falciparum and preparation of calorimetry
ampoules
The P. falciparum strain NF54 was cultivated as previously
described [15,16]. An aliquot of 0.5 ml of unsynchronized P.
falciparum culture with 10% parasitemia and 5% hematocrit was
mixed with fresh human erythrocytes and culture medium to give
the desired initial parasitemia and 5% hematocrit.
Samples with an initial parasitemia of 1.0, 0.5, 0.25 and 0.125%
were tested to find the optimal initial parasitemia for the
evaluation of fast-acting drugs. In addition, the influence of the
volume on the thermal profile was evaluated using 4 ml-ampoules
filled with 0.5, 1.0, 2.0 or 3.0 ml of unsynchronized culture with
an initial parasitemia of 0.5% and 5% hematocrit. This was done
Author Summary
Microcalorimetry is a technology developed to record
minute changes in temperature as a result of physical,
chemical or biological reactions over time. The method has
been applied to bacterial and eukaryotic cells and it was
found that the metabolic activity of living cells in a culture
medium produces enough heat flow to be measured.
Protozoan parasites, some of which cause tropical diseases
such as African sleeping sickness or malaria, are larger cells
than bacteria and are metabolically very active. We
explored the applicability of heat flow measurement to
follow the growth of a parasite population and to study
the effect of drugs. We first established optimal parame-
ters for obtaining heat flow curves of a growing parasite
culture. Then we added antiparasitic drugs at two
concentrations and followed the heat flow curves over
several days. Thus we could determine the time of onset of
drug action and the time until all parasites stopped
producing heat (time to kill). The microcalorimeter
measurements once per second allowed a continuous
monitoring of changes in the parasite population. This
novel tool is accurate and simple to use, and will certainly
prove to be of great value for the discovery and
development of new drugs for protozoan parasites.
Table 1. Heat flow parameters of T. b. rhodesiense culture exposed to pentamidine, melarsoprol or suramin at two concentrations.
Drugs Concentration Onset of action (hours) Time to peak (hours) Peak heat flow (mW) Time to base level (hours)
Drug-free control - - 30 8.0 120
Pentamidine 56 IC50 (8.5 ng/ml) #3 3 2.2 28
Pentamidine 256 IC50 (42.5 ng/ml) #3 3 2.0 22
Melarsoprol 56 IC50 (11.0 ng/ml) 6 9 4.1 .120
Melarsoprol 256 IC50 (55.0 ng/ml) #3 3 1.7 12
Suramin 56 IC50 (833 ng/ml) 5 9 4.3 42
Suramin 256 IC50 (4165 ng/ml) 5 9 4.0 32
doi:10.1371/journal.pntd.0001668.t001
Microcalorimetry to Monitor Antiprotozoal Activity
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because erythrocytes settle rapidly, so different volumes of culture
medium in a 4 ml ampoule might influence parasite development
owing to differences in oxygen supply and availability of nutrients.
Ampoules filled with non-infected erythrocytes (5% hematocrit)
were used in triplicate as negative controls. Continuous heat
measurements were conducted over a period of 5 days.
Parasitemia was assessed by microscopic counting of Giemsa-
stained smears prepared from samples aspirated at defined time
points with a syringe through the rubber septum of the closed
ampoules.
For the drug test, aliquots of stock solutions of the drugs were
mixed with fresh P. falciparum culture to give the desired
concentration and then distributed into sterile calorimetry
ampoules. The antiplasmodial drugs chloroquine, artemether
and dihydroartemisinin were tested at concentrations correspond-
ing to 36and 106the published IC50 values [17]. Dilutions of the
10 mg/ml stock solutions were freshly prepared in culture
medium, immediately before the start of the experiment.
Calorimetric equipment and measurements
An isothermal calorimetry instrument (Thermal Activity Mon-
itor, Model 3102 TAM III, TA Instruments, New Castle, DE,
USA) equipped with 48 channels was used to measure heat flow
continuously at 37uC. The temperature of the instrument was
maintained within 0.00001uC. The calorimetric sensitivity accord-
ing to the manufacturer is 60.2 mW. The calorimeter continu-
ously measured heat generated or absorbed by test or control
samples in air-tight 4 ml glass ampoules sealed with a rubber
septum. The gas phase was ambient air. For each series of
measurements, ampoules were introduced into the calorimeter
and remained at least 15 minutes in the thermal equilibration
position at 37uC before they were lowered into the measurement
position. Due to short-term thermal disturbance after introduction
of the samples into the measuring position of the calorimeter the
heat signal of the first 1 hour was considered unspecific. For the
study of the relationship between heat flow events and the number
of parasites in the sample, ampoules were removed at defined time
points and aliquots of the samples were aspirated with a 1 ml
syringe through the rubber septum, and the parasites counted.
Analysis of calorimetric data
Thermal changes in each ampoule were recorded as a
continuous electronic signal (in Watts), which is proportional to
the heat production rate. After measurement, data were reduced
from 1 second to 1 minute intervals and exported. Data reduction
is optional and can be set individually to any degree after each
experiment. Data analysis was accomplished using the manufac-
turer’s software (TAM Assistant, TA Instruments, New Castle,
DE, USA) and Origin 7.5 (Microcal, Northampton, MA, USA).
For the analysis of time points one hour of incubation time was
added to the time of the calorimetric measurement. This time was
needed for preparation of the ampoules, their transfer from the
bench to the calorimeter and for equilibration in the calorimeter
prior the measurement.
Results
Influence of initial density of T. b. rhodesiense cultures on
heat flow
We plotted heat flow (in mW) over time in all present
experiments as the heat flow data can be used as a proxy for the
number of viable trypanosome cells.
Figure 1 shows the heat flow over time from 3 ml samples in
closed 4 ml glass ampoules of T. b. rhodesiense containing three
different initial trypanosome densities of 104, 105 and 106 cells/ml.
With an initial trypanosome density of 104 cells/ml, a lag phase
was observed before the exponential growth phase started. A
stationary phase was reached after 48 hours. After 72 hours, the
culture overgrew, which led to a decline of the heat flow. With an
initial trypanosome density of 105 cells/ml, the exponential phase
started immediately, and the stationary phase as well as the dying
off phase was observed one day earlier than with 104 cells/ml. The
maximum trypanosome density in the ampoules containing the
cells was reached at maximum heat flow of around 8 mW.
At the lower initial trypanosome densities of 104/ml and 105/
ml, the heat flow increased continuously and only minor
amplitude oscillations occurred when the maximum heat flow
was reached (above 8 mW). With 106 cells/ml initial trypanosome
density, unexpected heat flow oscillations were noted during the
first 24 hours. A first peak of up to 26 mW was observed 2.5 hours
after the start of the experiment (Figure 1). Then, the heat flow
dropped and an oscillating heat flow started with continuously
decreasing amplitudes during the first 24 hours. After 48 hours,
the culture overgrew and the heat flow was close to the base level.
Parallel determinations of cell counts showed that the increase
in heat production was consistent with the increase in cell numbers
and the heat flow curves were similar to the growth curves
obtained by cell counting (data not shown). The following decrease
in heat production is due to decreasing numbers of viable cells
combined with decreasing metabolic activity of the cells over time.
The intra- and inter-experimental reproducibility was evaluated
by running three independent measurements. Each was performed
on different days, in triplicates and with trypanosome cultures
freshly diluted to the desired densities. As expected, the
reproducibility was higher within one experiment than between
experiments. However, reproducibility was good also between
different experiments, as illustrated in Figure 1, which shows the
mean heat flow curves of triplicates of each experiment.
In the subsequent experiments for monitoring drug action, a
trypanosome density of 105 cells/ml was chosen to avoid the lag
phase observed with 104 cells/ml and to avoid the strong
oscillations originating from samples with 106 cells/ml initial
density. A further disadvantage of using 106 cells/ml is that only a
very limited growth is possible, since the maximum trypanosome
density under ideal culture conditions is ,26106 cells/ml.
Figure 1. Calorimetric measurements of T. b. rhodesiense at
different initial densities. Heat flow curves of T. b. rhodesiense at
initial densities of 106 cells/ml (red), 105 cells/ml (blue) and 104 cells/ml
(green) in medium without the addition of drugs. All curves are means
of triplicate measurements. The curves with the same initial trypano-
some densities were measured in three independent experiments
performed on different days.
doi:10.1371/journal.pntd.0001668.g001
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The time-courses for heat flow using 0.5 ml, 1 ml, 2 ml and
3 ml of cell culture at an initial density of 105 cells/ml were all in a
similar range (data not shown). As the largest volume contained
the highest total number of cells and therefore produced the
highest heat flow peak, a volume of 3 ml was chosen for the
following experiments.
Influence of antitrypanosomal drugs on the heat flow of
T. b. rhodesiense
The standard drugs suramin, pentamidine and melarsoprol
were selected to monitor drug action.
The heat flow of cultures containing melarsoprol (Figure 2B),
pentamidine (Figure 2C) and suramin (Figure 2D) in concentra-
tions corresponding to 56 IC50 and 256 IC50 was measured in
parallel to that of control cultures containing no drug. Whereas the
heat signal of the control cultures increased continuously to a peak
value of 8 mW after 24–36 hours, curves for all drug containing
samples reached markedly lower peaks, at earlier time points
(Figure 2A and Table 1). Inhibition depended on the drug used,
and its concentration. During the first 3 hours of measurement,
the heat production of all samples increased in a similar way. The
onset of action of the drugs was marked by a divergence in the
continuously increasing heat flow curves of the drug containing
specimens from the curves for the control specimens (blue curves).
For all three drugs, the onset of action was within the first 6 hours
of drug incubation (Figure 2A and Table 1). Then after the peak
the heat flow continuously declined over a few hours until the heat
production was reduced to the level of the sterile medium control
(base level). The time required to reach this point, when the
parasite culture was completely inactivated, was the time to kill.
The fastest antitrypanosomal effect was observed with melarsoprol
at 256 IC50, with a decline in heat production starting within the
first 3 hours and reaching base line after 12 hours of incubation.
The slowest acting drug among those tested was suramin. The
heat production of suramin-treated trypanosomes started to
decline after 9 hours of drug incubation. The heat flow was
reduced to the base level after 32 hours at 256 IC50 and after
42 hours at 56 IC50 concentrations.
Influence of different culture volumes of P. falciparum on
heat flow
Blood stages of Plasmodium falciparum were cultured using human
erythrocytes in culture medium [15,16]. In our samples, erythro-
cytes settled and accumulated at the bottom of the vial within a
few hours. This could tend to reduce the availability of both
oxygen and nutrients, and produce an accumulation of metabo-
lites. Both these effects might lead to decreased viability of the
cells. The cultures used to evaluate the influence of different
sample volumes in the 4 ml closed glass ampoules all had the same
concentration of cells and the same initial parasitemia. The largest
volume tested contained the highest overall number of cells and
thus produced the highest amount of heat. The course of the heat
flow curves was more or less similar for the different sample
volumes tested (data not shown). However, with 3 ml or 2 ml
Figure 2. Calorimetric measurements of T. b. rhodesiense exposed to different drugs. Heat flow curves of T. b. rhodesiense at initial densities
of 105 cells/ml in medium without drugs (blue) or with drugs at two different concentrations, and a medium control without trypanosomes (black).
All measurements were performed in triplicate. A: summary, all three compounds at 56 IC50 and 256 IC50; B: Melarsoprol at 56 IC50 (light green) and
256 IC50 (dark green); C: Pentamidine at 56 IC50 (light violet) and 256 IC50 (dark violet); D: Suramin at 56 IC50 (magenta) and 256 IC50 (red).
doi:10.1371/journal.pntd.0001668.g002
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samples, there was an initial pre-peak at 3–4 hours followed by a
sharp drop at 7 hours before the heat flow increased again to
reach the main peak, whereas with the 1 ml samples the heat flow
signal increased steadily from the start of measurement until the
main peak at ,10 mW, and the heat flow curves of samples
containing infected erythrocytes could easily be distinguished from
those for uninfected erythrocytes (controls) immediately after the
start of the measurement. This was not the case for the samples
with 0.5 ml, the lowest volume tested. We therefore chose a
volume of 1 ml at 5% hematocrit for the following experiments.
Influence of initial density of P. falciparum on heat flow
The heat production of 1 ml specimens containing erythrocytes
(5% hematocrit) infected with P. falciparum at initial levels of
parasitemia varying between 0.125%–1.0% increased, reached a
peak and declined afterwards at all densities. The average time to
peak was dependent on the initial parasitemia with the shortest
time to peak being measured in the specimens with the highest
initial parasitemia (1.0%: 43 h, 0.5%: 57 h, 0.25%: 72 h, 0.125%:
81 h) (Figure 3). Microscopic observation of the culture by Giemsa
staining confirmed that the decreasing heat flow after the peak was
due to dying of the parasites (data not shown). For the subsequent
experiments we chose an initial parasitemia of 0.5%. With this
concentration the heat flow reached a maximum peak value
(9 mW) among the initial parasitemia levels tested. The time to
reach the peak was approximately 57 hours.
Influence of antimalarial drugs on the heat flow of P.
falciparum
The influence of three standard drugs was measured using 1 ml
of a non-synchronous P. falciparum culture with 0.5% initial
parasitemia. The previously determined IC50 values of 5.1 (60.8)
ng/ml for chloroquine, 1.2 (60.1) ng/ml for artemether [17] and
0.76 (60.04) ng/ml for dihydroartemisinin were taken as a
reference. Figure 4 shows the heat flow curves of a typical
measurement in triplicate containing drugs at 36 and 106 the
IC50. At 106IC50 all drugs reduced the heat flow compared to the
increasing heat flow observed in the drug free control (Figure 4A).
The curves were highly reproducible. The most effective drug
tested was dihydroartemisinin at 106 IC50 (Figure 4B), where the
heat flow curves blended with those of the negative controls,
containing uninfected erythrocytes. Chloroquine at 106 IC50
started to repress the parasite-specific heat production around
6 hours after measurement started. Afterwards the heat signal
decreased continuously and matched the signal from uninfected
erythrocytes from 48 hours onwards (Figure 4C). At 106 IC50,
artemether appeared to be the least effective antiplasmodial drug
of the ones tested. During 30 hours of measurement the heat flow
signal was comparable with that of the samples with chloroquine
at 106 IC50. However, plasmodial activity could be observed
afterwards by an increasing heat flow leading to a low peak of
4.5 mW at 85 hours (Figure 4D). At the lower concentrations (36
IC50), dihydroartemisinin was again more effective than chloro-
quine and artemether, which both led to similar heat flow curves
comparable to those for the drug-free control.
Discussion
The calorimetric approach described here, offers the possibility
of obtaining real-time measurements in up to 48 samples in
parallel. This is not possible with conventional drug activity assays,
where inhibition is measured at a single time point. Estimation of
the time of drug action requires several assays with different drug
exposure times, making such analysis highly labour-intensive.
Isothermal microcalorimetry allows a more accurate determina-
tion of the onset of action and the time to kill based on the
continuous measurement of the heat flow (16/sec). Calorimetry is
an unspecific tool, which cannot discriminate between metabol-
ically inactive cells and dead cells, but it does allow the continuous
monitoring of metabolic changes in a parasite population with
little effort. It can be used to gain additional information when
combined with established drug sensitivity assays.
In our study, we have plotted heat flow over time as the heat
flow is proportional to microbial activity [6]. We considered that
the heat flow correlates also with the number of viable (i.e.,
metabolically active) cells because metabolic activity of each
trypanosome cell is expected to be more or less constant until it
reaches the dying off phase with the decrease of metabolic activity
per cell. A similar effect was observed with CHO 320 cells by
Kemp et al [10]. An integration of the heat flow leads to a heat
over time curve. Heat is proportional to total biomass produced or
the quantity of a metabolic product released [6]. As we were
interested in viable cells only, we used heat flow data (and not heat
data) for our analysis.
In our microcalorimetric experiments, we found that the time to
maximum heat flow varied according to the initial parasite density
and the sample volume used. Optimization of these parameters led
us to use a volume of 3 ml for T. b. rhodesiense with an initial
trypanosome density of 105 cells/ml and of 1 ml for P. falciparum
with an initial hematocrit of 5% and a parasitemia of 0.5%. At
these conditions, the heat flow signals were in the mW range which
is well above the detection limit, which was specified by the
manufacturer as 200 nW.
A limitation of this new methodology is the airtight sealing of
the ampoules which is required for a proper measurement but
could potentially affect the action of drugs, since no exchange of
the gas phase or the culture medium is possible. Metabolic
production of CO2 can lead to an acidification of the culture
medium, as oxygen supply is limited. After a prolonged time of
growth the conditions are likely to become non-physiological,
therefore the period of accurate measurement is limited. After this,
thermal effects might be misinterpreted. The samples were filled
into the ampoules at normal laboratory conditions. Therefore the
gas phase in each ampoule was normal ambient air rather than the
special gas mixtures used for parasite cultures. An improvement of
Figure 3. Calorimetric measurements of P. falciparum at
different initial parasitemia. Heat flow curves of P. falciparum in
1 ml culture samples with 5% hematocrit and initial parasitemia of 1%
(red), 0.5% (blue), 0.25% (green) or 0.125% (yellow). Control measure-
ments were performed with samples containing uninfected erythro-
cytes only (black) and culture medium without any cells (pink). All
measurements were performed in triplicate.
doi:10.1371/journal.pntd.0001668.g003
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the culture conditions in the ampoules could be achieved by
replacing the air in the ampoules by the gas used for trypanosome
culture (5% CO2 in ambient air) or the special mixture used for
malaria parasite cultures (4% CO2, 3% O2, 93% N2). However,
no considerable deleterious effect of ambient air could be observed
in our experiments over the maximum measurement period of 5
days. If further optimization of gas exchange is necessary for other
experiments, a modified cap for the ampoules with a porous silicon
rubber membrane could be used to allow gas exchange but no
water evaporation [18].
The parasites used in our study are cultured under different
conditions. African trypanosomes, as extracellular parasites, offer the
advantage of axenic cultivation. There was therefore no background
due to other cells to interfere with the heat flow signal, which allowed
direct interpretation. P. falciparum, on the other hand, is an
intracellular parasite. Non-infected erythrocytes produced a back-
ground heat level. They gave a rather constant heat flow between 1
and 2 mW. However, this background did not interfere with the
interpretation of the heat flow curves produced by the parasite-
infected erythrocytes (Figure 3). Another difference between the two
parasites is the multiplication rate. Trypanosomes are mobile and
replicate by binary fission, while P. falciparum after infecting the
erythrocyte undergoes multiple replications and destroys the host
cell. Erythrocytes tended to settle rapidly at the bottom of the
ampoule, which may explain why smaller volumes (1 ml) of P.
falciparum cultures in the calorimetric ampoules gave better signals.
When dense cultures of T. b. rhodesiense (106 cells/ml) were used,
they exhibited synchronized oscillations in heat production with a
period of about 4 hours (Figure 1). These oscillations were highly
reproducible even though the cultures themselves had not been
synchronized prior to the experiments. Oscillations were also
induced in samples with low initial trypanosome density when
aliquots were taken for parasite counting or when the cell
suspensions were mixed once they had reached a high trypano-
some density. The oscillations were not dependent on the cell cycle
as the generation time of T. b. rhodesiense is 8 to 9 hours. The
oscillations may reflect underlying metabolic changes; glycolytic
oscillations have been observed before in microcalorimetric studies
by Lamprecht [19] in systems far from equilibrium. The author
detected correlations of heat flow oscillations with NAD/NADH+
absorption in S. cerevisiae [19]. Analysis of the cause of heat flow
oscillations in trypanosome cultures would be of interest but is
beyond the scope of the current study. To avoid interference with
drug inhibition by these oscillations, lower trypanosome densities
were used for all experiments studying drug action.
Using the optimal conditions described, three antitrypanosomal
and three antiplasmodial drugs were used to demonstrate that
microcalorimetry is a helpful tool to monitor drug action against
the two pathogenic protozoans on a real time basis. With only two
concentrations per drug, we could observe the rate of action of
each of the drugs tested and also the differences between them.
Among the antitrypanosomal drugs, melarsoprol was found to be
Figure 4. Calorimetric measurements of P. falciparum exposed to different drugs. Heat flow curves of P. falciparum in culture with 5%
hematocrit and an initial parasitemia of 0.5% without drugs (blue) or with drugs at two different concentrations. Control measurements were
performed with samples containing uninfected erythrocytes only (black). All measurements were performed in triplicate. A: summary, all three
compounds at 36 IC50 and 106 IC50; B: Dihydroartemisinin at 36 IC50 (magenta) and 106 IC50 (red). C: Chloroquine at 36 IC50 (light violet) and 106
IC50 (dark violet); D: Artemether at 36 IC50 (light green) and 106 IC50 (dark green).
doi:10.1371/journal.pntd.0001668.g004
Microcalorimetry to Monitor Antiprotozoal Activity
www.plosntds.org June 2012 | Volume 6 | Issue 6 | e166866
the fastest acting, followed by pentamidine and then by suramin.
This ranking is in agreement with data obtained by the standard
drug assays with different drug exposure times where the
difference of IC50 values at 24 and 48 hours was smallest for
melarsoprol (unpublished data). Similar studies have been
performed with the antiplasmodial drugs. For P. falciparum, the
microcalorimetric results are in agreement with data employing
the standard [3H]hypoxanthine incorporation assay [20]. In our
studies chloroquine and artemether showed pronounced parasite
growth inhibition ($94%) after incubations of 6 hours or longer at
concentrations of 106 the IC50.
The method can be used with more than two different drug
concentrations, which would enable the inhibition kinetics of a
compound to be fully described, with an accuracy far greater than
that of standard drug assays.
Another method which allows the determination of the time for
a drug to exert its activity is real-time high content imaging. With
this method, a higher throughput and more information can be
obtained than with microcalorimetry. However, this results in a
huge amount of data as pictures are taken instead of measuring a
single value at each time point. Transmission light microscopy
might not be sufficient to measure viability of trypanosomes, which
are small and highly motile, or of plasmodia, which are
intracellular, without any markers. Isothermal microcalorimetry
has the further advantage that it is a label-free technique, therefore
no interventions with the samples such as fixation, staining, or
insertion of reporter genes in the parasites are required. Heat flow
measurements can give information beyond viability and density
such as indications of metabolic state [6,19].
In spite of its many advantages, it is not likely that
microcalorimetry will replace the routine screening assays which
are currently used to determine antiprotozoal activities of new
compounds. With conventional standard assays a higher through-
put can be generated, using 96 well or even 384 well formats.
However, microcalorimetry is a promising tool for gathering
information about selected compounds beyond the IC50, such as
the time until onset of action. Measuring this can be a challenge
for fast acting compounds that begin to affect growth within the
first 3 to 4 hours. In our studies with trypanosomes we found that
the time for the preparation of the specimens, their transfer, and
the equilibration time in the calorimeter could overlap with the
time of onset of action. This problem could be reduced by using an
injection system which allows equilibration in the calorimeter prior
to the injection of the compounds (personal communication
Matthias Rottmann).
The new approach to studying the effect of drugs, as described
for the two model organisms T. b. rhodesiense and P. falciparum, may
be applicable also for other protozoan parasites. Resistance or
sensitivity analysis of different parasite isolates or screening for
resistance development may be an additional interesting field for
the use of microcalorimetry. Real-time drug inhibition data can be
used in combination with pharmacokinetic and pharmacodynamic
data as a helpful tool to predict the outcome of in vivo experiments
in the field of drug discovery.
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Pharmacokinetics, Trypanosoma brucei gambiense Efficacy, and Time
of Drug Action of DB829, a Preclinical Candidate for Treatment of
Second-Stage Human African Trypanosomiasis
Tanja Wenzler,a,b Sihyung Yang,c Olivier Braissant,d,e David W. Boykin,f Reto Brun,a,b Michael Zhuo Wangc
Medical Parasitology & Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerlanda; University of Basel, Basel, Switzerlandb; Department of
Pharmaceutical Chemistry, School of Pharmacy, The University of Kansas, Lawrence, Kansas, USAc; Laboratory of Biomechanics and Biocalorimetry (LOB2), Faculty of
Medicine, University of Basel, Basel, Switzerlandd; Department of Urology, University Hospital Basel, Basel, Switzerlande; Department of Chemistry, Georgia State University,
Atlanta, Georgia, USAf
Human African trypanosomiasis (HAT, also called sleeping sickness), a neglected tropical disease endemic to sub-Saharan Af-
rica, is caused by the parasites Trypanosoma brucei gambiense and T. brucei rhodesiense. Current drugs against this disease
have significant limitations, including toxicity, increasing resistance, and/or a complicated parenteral treatment regimen. DB829
is a novel aza-diamidine that demonstrated excellent efficacy in mice infected with T. b. rhodesiense or T. b. brucei parasites.
The current study examined the pharmacokinetics, in vitro and in vivo activity against T. b. gambiense, and time of drug action
of DB829 in comparison to pentamidine. DB829 showed outstanding in vivo efficacy in mice infected with parasites of T. b.
gambiense strains, despite having higher in vitro 50% inhibitory concentrations (IC50s) than against T. b. rhodesiense strain
STIB900. A single dose of DB829 administered intraperitoneally (5 mg/kg of body weight) cured all mice infected with different
T. b. gambiense strains. No cross-resistance was observed between DB829 and pentamidine in T. b. gambiense strains isolated
frommelarsoprol-refractory patients. Compared to pentamidine, DB829 showed a greater systemic exposure when adminis-
tered intraperitoneally, partially contributing to its improved efficacy. Isothermal microcalorimetry and in vivo time-to-kill
studies revealed that DB829 is a slower-acting trypanocidal compound than pentamidine. A single dose of DB829 (20 mg/kg)
administered intraperitoneally clears parasites frommouse blood within 2 to 5 days. In summary, DB829 is a promising preclin-
ical candidate for the treatment of first- and second-stage HAT caused by both Trypanosoma brucei subspecies.
Human African trypanosomiasis (HAT), also known as sleep-ing sickness, is a neglected tropical disease threatening the
health of millions of people in the poorest regions of sub-Saharan
Africa (1). HAT is fatal if left untreated. The disease is caused by
two subspecies of the unicellular parasite Trypanosoma brucei, T.
b. gambiense and T. b. rhodesiense, and is transmitted through the
bite of an infected tsetse fly. Two clinical stages are defined. In the
first stage, the parasites reside in the blood and lymph system,
whereas in the second stage, the parasites cross the blood-brain
barrier (BBB) and infect the central nervous system (CNS). The
disease was almost eliminated around 1960, but it reemerged as a
result of political instability and lack of an adequate health care
and control system (2). The most recent epidemic occurred in the
1990s, when the number of estimated cases in 1998was alarmingly
high, with about 300,000 cases per year (3). Since the turn of the
millennium, the number of infections has declined due to inter-
ventions to control the disease, such as trapping tsetse flies, sur-
veillance, and appropriate treatment of patients (2, 4). The num-
ber of actual cases in 2009 was estimated at 30,000 annually by the
World Health Organization. Control measures have to be main-
tained by all means, otherwise the disease will reemerge, as history
has shown (2, 4).
The availability of effective drugs is crucial for HAT control
and elimination, as chemotherapy is the only option for cure.
Vaccines are not available for HAT and are unlikely to be devel-
oped, mainly because of the antigenic variation of the surface gly-
coproteins of the parasites (5–7). There are four drugs available as
monotherapies (two for the first stage and two for the second
stage) to treat the disease, and all require parenteral administra-
tion, which is a significant problem in the remote rural areas of
Africa, where HAT primarily occurs. Moreover, drugs used to
treat second-stage HAT (i.e., melarsoprol and eflornithine) are
unsatisfactory due to severe adverse reactions, increasing treat-
ment failures, and/or complicated treatment schedules requiring
frequent infusion. Hence, new or improved chemotherapies are
needed, especially for second-stage HAT.
One of the compounds used to treat first-stage HAT is the
aromatic diamidine drug pentamidine (Fig. 1). It was discovered
in 1941 and has been used against T. b. gambiense infections for 7
decades. It is still highly efficacious, as shown by the fact that no
increase in treatment failures has been reported (6). The di-
amidine structure of pentamidine seems to be essential for its
antiparasitic activity, which is primarily based on binding to the
parasite DNA (8). The exactmechanism of action, however, is still
unknown. During the last 4 decades, our research has focused on
the identification of novel diamidines with improved efficacy, oral
bioavailability, and BBB penetration. One of the first lead com-
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pounds was furamidine (DB75), which is highly active in vitro as
well as in vivo but has poor oral bioavailability. Its methami-
doxime prodrug, pafuramidine (DB289 maleate), has good oral
bioavailability (9) and good oral efficacy in T. b. rhodesiense-in-
fected mice (10). Pafuramidine was selected by the Consortium
for Parasitic Drug Development (CPDD) in 2000 to enter clinical
trials as the first oral drug to be tested for first-stage HAT. During
a phase III clinical trial, this compound was as effective as pent-
amidine and its safety profile was inconspicuous (11). However,
during a phase I clinical trial for safety with an extended treatment
regimen, reversible hepatotoxicity and delayed-onset renal insuf-
ficiency were observed, which led to the discontinuation of pa-
furamidine development (12).
Further screening of novel diamidines and prodrugs has con-
tinued in order to identify compounds that are safer, offer the
possibility of oral administration, and are in particular active in
the CNS for second-stage HAT (10, 13, 14). The prodrug ap-
proach was originally employed to improve oral absorption by
masking the positive charge of amidine moieties but also had po-
tential to improve drug delivery across the BBB, a prerequisite to
cure patients with second-stage infections. Several diamidine pro-
drugs have been tested in the GVR35 CNSmousemodel, in which
DB844 and DB868 administered orally cured CNS infections in
mice (10). DB844 and DB868 have been further tested in the
vervet monkeymodel of second-stage HAT, and results have been
reported recently (15, 16). DB868 was significantly better toler-
ated in vervet monkeys than was DB844 and could be a promising
oral drug candidate, especially for first-stage disease (17).
The active metabolite of the prodrug DB868 is DB829 (or
CPD-0801 [Fig. 1]). It is a cationic aza-diamidine, potent in vitro
against T. b. rhodesiense STIB900 parasites (50% inhibitory con-
centration [IC50], 20 nM). DB829 is of special interest, because
when administered intraperitoneally it cured mice with second-
stage infections (with T. b. brucei) (10). This indicated that it was
able to cross the BBB. DB829 therefore represents a new class of
cationic diamidines that are CNS active and holds promise for the
direct use of active diamidines to treat second-stage HAT. This
potentially avoids any detrimental effects of the prodrug strategy,
such as variable prodrug activation between different patients,
which would simplify pharmacokinetic predictions and dosage
selection.
The aimof this studywas to characterize the pharmacokinetics,
in vitro and in vivo activity against T. b. gambiense, and time of
drug action of the CNS-active diamidine DB829. Since more than
98% of HAT cases are due to T. b. gambiense infections currently
(18), it is imperative to determine the effectiveness of DB829
against T. b. gambiense parasites. Isothermal microcalorimetry
(19) was employed tomonitor in vitro parasite killing rate (time of
drug action) of DB829 on a real-time basis. Lastly, the in vivo
parasite clearance time and pharmacokinetics of DB829 in mice
were determined. These results are important factors to be con-
sidered for further development of DB829 and related com-
pounds to treat African sleeping sickness.
MATERIALS AND METHODS
Materials. Pentamidine isethionate was purchased from Sigma-Aldrich
(St. Louis, MO). Synthesis of DB829 (or CPD-0801; hydrochloride salt
form) and deuterium-labeled DB75 (DB75-d8; deuterated phenyl rings;
internal standard) has been previously reported (20, 21). CPD-0801 and
CPD-0802 are both synonyms for DB829. The different codes indicate
their different salt forms. CPD-0801 is the hydrochloride salt form, and
CPD-0802 is the diacetate salt formofDB829. Only the hydrochloride salt
form of DB829 was used in this study.
Animals for pharmacokinetic studies. Protocols for the animal stud-
ies were approved by the Institutional Animal Care andUseCommittee of
the University of Kansas. Male Swiss Webster mice (weighing 20 to 25 g)
were purchased from the Charles River Laboratories (O’Fallon, MO).
Mice were housed in a clean room under filtered, pathogen-free air, in a
12-h light/dark cycle, and with food pellets and water available ad libitum.
Pharmacokinetics of DB829 and pentamidine after i.v. and i.p. ad-
ministration in mice. DB829 and pentamidine were first dissolved in
sterile water and further diluted with saline (1:1, vol/vol) to the desired
concentrations. This prevented the precipitation that occurred if the com-
pounds were added directly to saline. The dose level for intravenous (i.v.)
administration was 7.5 mol/kg body weight (approximately 2.3 mg/kg
for DB829 and 2.6 mg/kg for pentamidine), which was well tolerated in a
preliminary overt toxicity study inmice. The dose level for intraperitoneal
(i.p.) administrationwas 20mg/kg (approximately 65mol/kg forDB829
and 59mol/kg for pentamidine), whichwas the higher of two doses used
in the following efficacy study and was selected to directly evaluate if
pharmacokinetics played a role in determining in vivo efficacy of the two
compounds. The dose volume was 5 ml/kg. Blood samples were collected
via submandibular bleeding (0.04 ml per bleed) for serial sampling or
cardiac puncture (0.8ml of blood) for terminal sampling. To accurately
determine the concentration-time curve near and shortly after the time to
maximum concentration of drug in plasma (Tmax) and terminal elimina-
tion half-life (t1/2), the time points for blood sampling included 0.0167,
0.0833 (two additional time points for i.v. administration), 0.25, 0.5, 1, 2,
4, 6, 8, 12, 24, 48, and 72 h following drug administration, and three mice
were used for blood sampling at each time point. Plasma was separated by
centrifugation in lithium heparin-coated Microvet tubes (Sarstedt Inc.,
Newton, NC) or Microtainer tubes (BD Biosciences, Franklin Lakes, NJ).
Plasma samples were stored at20°C until ultraperformance liquid chro-
matography-tandem mass spectrometry (UPLC-MS/MS) analysis.
Unbound fraction inmouse plasma.Theunbound fraction ofDB829
and pentamidine in mouse plasma was determined using rapid equilib-
rium dialysis devices (Thermo Scientific Pierce, Rockford, IL) as previ-
ously described (22). Blank mouse plasma was spiked with DB829 or
pentamidine to give a final concentration of 1M,belowwhich they spent
the majority of time after a single i.v. or i.p. administration of the tested
doses. Spiked plasma (in triplicate) was incubated for 6 h at 37°C to allow
equilibration with a phosphate-buffered saline (100 mM, pH 7.4) and
then analyzed for total and unbound concentrations by UPLC-MS/MS.
UPLC-MS/MS analysis. (i) Sample preparation. Plasma samples (2
l) were mixed with 200 l of 7:1 (vol/vol) methanol-water containing
0.1% trifluoroacetic acid and internal standard (1 nMDB75-d8) and then
vortex mixed for 30 s, followed by centrifugation (2,800  g) to pellet
proteins. The supernatant was transferred to a new tube and dried using a
96-well microplate evaporator (Apricot Designs Inc., Covina, CA) under
N2 at 50°C and reconstituted with 100 l of 15% methanol containing
0.1% trifluoroacetic acid.
(ii) Determination of drug concentration.The reconstituted samples
(5-l injection volume) were analyzed for drug concentration using
a Waters Xevo TQ-S mass spectrometer (Foster City, CA) coupled with a
Waters Acquity UPLC I-Class system. Compounds were separated on a
Waters UPLC BEH C18 column (2.1 by 50 mm, 1.7 m) equilibrated at
FIG 1 Chemical structures of DB829 and pentamidine.
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50°C. UPLC mobile phases consisted of water containing 0.1% formic
acid (A) andmethanol containing 0.1% formic acid (B). After a 0.15-min
initial holding period at 5% B, the mobile phase composition started with
5% B and was increased to 60% B over 2.2 min with a flow rate of 0.4
ml/min. Then, the column was washed with 90% B for 0.5 min and was
reequilibratedwith5%B for 1.1minbefore thenext samplewas injected.The
characteristic single-reaction monitoring (SRM) transitions for DB829,
pentamidine, and DB75-d8 were m/z 307.1¡273.1, 341.4¡120.1, and
313.2¡296.3, respectively, under positive electrospray ionization mode.
The calibration curves forDB829 and pentamidine ranged from0.5 nM to
50Mand 2.5 nM to 50M, respectively, for plasma samples. The inter-
day coefficient of variation (CV) and accuracy were determined by mea-
suring the same preparation of three standards three times on different
days. At concentrations of 5, 500, and 10,000 nM, the intraday CV and
average accuracy of DB829 quantification were 8.4% and 91%, 9.4% and
104%, and 3.6% and 99%, respectively. The interday CV and average
accuracy of pentamidine quantification were 7.4% and 108% (at 5 nM),
4.7% and 93% (at 500 nM), and 8.1% and 97% at (at 10,000 nM), respec-
tively.
(iii) Pharmacokinetic analysis.The area under the plasma concentra-
tion-time curve (AUC), terminal elimination half-life (t1/2), maximum
concentration of drug in plasma (Cmax), and time to reach Cmax (Tmax)
were calculated using the trapezoidal rule-extrapolationmethod andnon-
compartmental analysis (WinNonlin Version 5.0; Pharsight, Mountain
View, CA).
Antitrypanosomal activity of DB829 and pentamidine in vitro. (i)
Preparation of compounds. Compounds were dissolved in 100% di-
methyl sulfoxide (DMSO) and finally diluted in culture medium prior to
the in vitro assay. The DMSO concentration never exceeded 1% in the in
vitro alamarBlue assays at the highest drug concentration. For microcalo-
rimetry assays, theDMSOconcentrationwas kept at 0.1% in all samples to
avoid any DMSO effect on the membrane permeability of the trypano-
somes. Melarsoprol was diluted in water instead of DMSO. For in vivo
experiments, the compounds were dissolved in DMSO and further di-
luted with distilled water to a final DMSO concentration of 10% prior to
administration to the animals.
(ii) Parasites. The T. b. rhodesiense strain STIB900 is a derivative of
strain STIB704 (23), which was isolated from a patient in Ifakara, Tanza-
nia, in 1982. STIB900 was used for routine in vitro screening and for the
standard acute mouse model, which mimics the first stage of HAT. Strain
STIB799, also known as KETRI 243, is a T. b. rhodesiense strain isolated
from a patient from Busoga in Uganda in 1961 after four treatment fail-
ures with melarsoprol (24).
The T. b. gambiense strains used within this study were STIB930, IT-
MAP141267, 130R, 45R, 349R,DAL898R, K03048, and 40R (Table 1).We
included more isolates from the Democratic Republic of the Congo
(DRC) in our panel of different strains, as most of the T. b. gambiense
infections occur in this central African country (25, 26). The strains la-
beled with an “R” were isolated from patients after a melarsoprol treat-
ment failure. STIB930 (also named STIB754) is a derivative of the strain
TH1/78E(031),which was isolated from a patient in Cote d’Ivoire in 1978
(27). ITMAP141267, was isolated from a patient in DRC in 1960 (28).
Strain 130R was isolated from a patient in DRC in 2005 after two treat-
ment failures with melarsoprol. The first relapse was detected 8 months
after a 3-day melarsoprol treatment, and the second relapse was detected
1 year after a melarsoprol-nifurtimox combination therapy (29). Strain
45R was isolated from a patient in DRC in 2005 after two treatment fail-
ures with melarsoprol. The first relapse was detected 1 year after a 3-day
melarsoprol treatment, and the second relapse was detected 8 months
after a melarsoprol-nifurtimox combination therapy (29). Strain 40R was
also isolated from a patient in DRC in 2005, 6 months after failure of the
10-day melarsoprol treatment (29). The strain 349R was isolated from a
patient inDRC in 2006 after a treatment failure with a 10-daymelarsoprol
treatment (29). DAL898R was isolated from a patient in Cote d’Ivoire in
1985 after melarsoprol treatment failure (23). DAL898R was the only
strain that had previously shown an increased IC50 formelarsoprol among
the panel of tested DAL (Daloa in Cote d’Ivoire) isolates (23). Strain
K03048 was isolated from a patient in South Sudan in 2003 (30).
(iii) In vitro growth inhibition assays using T. brucei subspecies.
The 50% inhibitory concentrations were determined using the alamar-
Blue assay as described by Raz et al. (31), with minor modifications. As-
sayswere carried out at least three times independently, set up on different
days and each time in duplicate. Coefficients of variation of these assays
were less than 50%. Different culture and assay media were used for T. b.
gambiense and for T. b. rhodesiense. For T. b. rhodesiense, the compounds
were tested in minimum essential medium with Earle’s salts, supple-
mented according to the protocol of Baltz et al. (32) with the following
modifications: 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate, 0.5 mM
hypoxanthine, and 15% heat-inactivated horse serum. For T. b. gam-
biense, a modified protocol of Hirumi and Hirumi (33) was used: Iscove’s
modified Dulbecco’s medium (IMDM) was supplemented with 0.2 mM
2-mercaptoethanol, 1mMNa-pyruvate, 0.5mMhypoxanthine, 0.05mM
bathocuproindisulfate, 1.5 mM L-cysteine-HCl, 2 mM L-glutamine, and
5% heat-inactivated human serum plus 15% heat-inactivated fetal calf
serum.
Serial drug dilutions were prepared in 96-well microtiter plates, and
each well was inoculated with 2,000 bloodstream forms for the T. b. rho-
desiense isolates and with 2,500 bloodstream forms for the T. b. gambiense
isolates. Drug treatment was carried out for 70 h for T. b. rhodesiense and
68 h for T. b. gambiense. Ten microliters of the viability marker alamar-
Blue (12.5 mg resazurin dissolved in 100 ml phosphate-buffered saline)
was then added to each well, and the plates were incubated for an addi-
tional 2 to 6 h until the signal/background fluorescence ratio was about 10
for T. b. rhodesiense isolates or about 5 for T. b. gambiense isolates. The
plates were read in a SpectraMax Gemini XS microplate fluorescence
scanner (Molecular Devices, Sunnyvale, CA) using an excitation wave-
length of 536 nm and an emission wavelength of 588 nm. The IC50s were
calculated from the sigmoidal inhibition curves using SoftmaxPro soft-
ware.
(iv) Microcalorimetry studies using T. brucei subspecies. In vitro
time of drug action was monitored using isothermal microcalorimetry.
Previous experiments have shown that heat flow data can be used as a
proxy for the number of viable cells (34), defined as trypanosomes still
moving under the microscope. With this method, the time to the onset of
drug action and the time to kill the parasite population can be determined
on a real-time basis (19). The same culture media were used for the T. b.
rhodesiense strain and for the T. b. gambiense strains as for the in vitro
growth inhibition assays. Strain STIB900 was used as a representative for
T. b. rhodesiense and STIB930 (and sometimes ITMAP141267) for T. b.
gambiense.
For experiments with permanent drug exposure, bloodstream try-
panosomes (2 ml at 5  104 organisms/ml per ampoule) were placed in
4-ml ampoules and spiked with DB829 or pentamidine at different con-
centrations with a final DMSO concentration of 0.1% (vol/vol). The
trypanocidal drug melarsoprol was dissolved in water and included as a
nondiamidine control for the first experiments with STIB900. Trypano-
TABLE 1 T. b. gambiense isolates
Trypanosome straina Yr of isolation Origin
STIB930/STIB754 1978 Cote d’Ivoire
ITMAP141267 1960 DRC
130R 2005 DRC
40R 2005 DRC
45R 2005 DRC
349R 2006 DRC
DAL898R 1985 Cote d’Ivoire
K03048 2003 South Sudan
a Strains labeled with an “R” were isolated from patients after a relapse with a
melarsoprol treatment.
Wenzler et al.
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some-free negative controls contained only culture medium. After the
ampoules had been inserted into the isothermal microcalorimetry instru-
ment (Thermal Activity Monitor, model 249 TAM III; TA Instruments,
New Castle, DE), heat flow was continuously measured (1 reading/sec-
ond) at 37°C. Each experiment with permanent drug exposure was set up
in triplicate and repeated 3 times.
(v) Inoculum studies. For studies of drug effects on different parasite
densities in the inoculum, the parasite density was reduced to 1 104/ml
bloodstream trypanosomes and supplemented with DB829 or pentami-
dine at the desired concentrations. Inhibition of growth and viability was
compared with the samples containing the standard inoculum of 5 
104/ml bloodstream trypanosomes and the same drug concentrations.
Inoculum experiments with higher parasite densities were omitted, as the
heat flow oscillations, which appear at high initial densities, interfere with
drug action (19).
(vi) Drug washout experiments. For the 24-h exposure experiment,
trypanosomes (T. b. rhodesiense strain STIB900 and T. b. gambiense strain
STIB930) were incubated with DB829 for 24 h at 37°C and then washed
twice at 1,850 g for 10min to remove the compound. Subsequently, the
washed trypanosomes were resuspended in drug-free culture medium
and transferred to ampoules and inserted into the isothermal microcalo-
rimetry instrument. The drug dilution factor after two washing steps was
estimated to be 1,800-fold. The drug-free control samples (drug free,
washed) were washed identically to the drug-containing samples. Each
24-h exposure experiment was set up in triplicate for each assay and re-
peated 2 times.
(vii)Analysis ofmicrocalorimetryheat flowdata.Themetabolic heat
production rate in each ampoule was recorded continuously. The electric
signal was calibrated to obtain a reading in watts. To facilitate data han-
dling, the recorded data were resampled to obtain an effective sampling
frequency of 1 data point per 90 s, using the manufacturer’s software
(TAM assistant version v1.2.4.0), and exported toMicrosoft Excel. A time
correction was needed for the preparation of the ampoules and the trans-
fer from the bench to the calorimeter prior to equilibration in the calo-
rimeter and the measurement. The correction was achieved by adding 45
min to the time recorded by the microcalorimeter. Resulting data were
plotted as heat flow (inW) over time. Each single curve for heat flow (in
W) over time was analyzed using software R (The R Foundation for Sta-
tistical Computing, Vienna, Austria). Due tometabolic oscillations clearly
visible in the heat flow curves, a cubic spline was applied to smooth the
data prior to parameter determination (i.e., onset of drug action, time to
peak, and time to kill). The time to onset of drug actionwas determined as
the time at which a divergence between the heat flow rate of the drug-free
controls and the drug-containing specimens could be observed (19). The
time to peakwas determined as the timepoint atwhich themaximumheat
flow was observed for each sample. The reversal shows the time after
which a decrease of the parasite density is expected. The time to kill the
parasite population was defined as the time point at which the heat pro-
ductionwas reduced to the level of the sterilemedium control (base level).
At this time, the metabolic heat production of the culture was below the
detection limit, suggesting that most of the parasites were inactivated.
Typically, a heat flow of 8 W was recorded at the maximum density of
1  106 to 1.5  106 trypanosomes/ml, and the microcalorimeter had a
detection limit around 100 to 200 nW. The surviving population at the
detection limit was about 1.25% to 2.5% of the maximum density, repre-
senting a density of4 104 trypanosomes/ml.
Finally, the growth rate () of each culture was calculated using the
data of heat over time (i.e., the integrated heat flow data over time). For
this calculation, the Gompertz growth model (35) was fitted over the
whole curve using software R and the Grofit package (36) as described
previously (37, 38). Although both heat and heat flow data can be used for
the determination of the growth rate, the long thermal equilibration pe-
riod and the metabolic oscillations observed previously (19) can interfere
with the curve-fitting process when using the heat flow data. Therefore, in
our case, the calculated growth rate is more precisely determined when
using the heat data. The growth rates calculated by this approach cannot
be directly compared to the growth rate of exponential phase determined
by a conventional approach, because processes such as lysis or chemical
processes due to the nature of the medium might also contribute to the
overall heat signal. The growth rate calculated based on the heat released
by the metabolic activity in the culture should be considered a proxy for
the conventional growth rate (34).
In vivo assays. (i) Measurement of efficacy and time to kill. Adult
female NMRI mice were obtained from Janvier, France. They weighed
between 20 and 25 g at the beginning of the study and were housed under
standard conditions with food pellets and water ad libitum. All protocols
and procedures used in the current study were reviewed and approved by
the local veterinary authorities of the Canton Basel-Stadt, Switzerland.
(ii) Mouse model to measure drug efficacy against T. b. rhodesiense
STIB900. Experiments were performed as previously reported (10) with
minor modifications. Briefly, 72 h prior to drug administration, female
NMRI mice (n  4 per group) were infected i.p. with 5  103 STIB900
bloodstream forms. Drug administration (i.p.) began on day 3 postinfec-
tion and continued for four consecutive days (for a total of 4 doses) for a
standard treatment regimen. Since a full dose-response curve had been
previously determined for DB829 (10), only an effective dose (4  5
mg/kg i.p.) was tested here for DB829. An additional, higher dose (4 20
mg/kg i.p.) was tested for pentamidine due to its inferior in vivo efficacy.
For single-dose treatment, drug administration took place on day 3 only.
A control groupwas infected but remaineduntreated. Since theminimum
curative dose of DB829was 4 5 to 10mg/kg i.p. (10), we chose 20mg/kg
i.p. for the single-dose study, expecting that this dose would give a decent
activitywithout eliciting any toxicity. An additional, lower dose at 5mg/kg
was also tested to probe the minimal curative single dose. The same dose
regimen was used for pentamidine. All mice were monitored for para-
sitemia bymicroscopic examination of tail blood until 60 days after infec-
tion when surviving, and aparasitemic mice were considered cured. Mice
with a parasitemia relapse prior to 60 days were not considered cured, and
the time to parasite relapse was recorded to calculate the mean relapse
time (MRD) in days postinfection.
(iii) Mouse model to measure drug efficacy against T. b. gambiense.
Female NMRI mice (n 4 per group) were immunosuppressed with 200
mg/kg cyclophosphamide (Endoxan; Baxter, Deerfield, IL) 2 days prior to
infection with 105 bloodstream forms with one of the four T. b. gambiense
strains (i.e., ITMAP141267, STIB930, 130R, or 45R) (Table 1). Immuno-
suppressionwith cyclophosphamide followed once aweek until the end of
the experiment. Drug administration (i.p.) began on day 3 postinfection
and continued for four consecutive days (for a total of 4 doses) for a
standard treatment regimen. For single-dose treatment, drug administra-
tion took place on day 3 only. A control group was infected but remained
untreated. The same dose regimens as those for T. b. rhodesiense STIB900
infections were evaluated for acute T. b. gambiense infections. Surviving
and aparasitemicmice at day 90 postinfection were considered cured, and
the time to parasite relapse was recorded to calculateMRD in days postin-
fection.
(iv) In vivo time to kill.Trypanosome infection and immunosuppres-
sion (for T. b. gambiense-infected mice) were carried out as described
above for the efficacy experiments. The parasite load varied between the
different mouse models, which was also observed in the efficacy experi-
ments. The parasitemia was higher in STIB900-infected and STIB930-
infected mice than in ITMAP141267-infected mice due to better adapta-
tion of the parasites in mice. Mice were treated with a single dose of 20
mg/kg i.p. 3 days postinfection, the same dose as that used in the pharma-
cokinetic studies. At this dose, DB829 cured all acute T. b. rhodesiense and
gambiense infections in mice, whereas pentamidine initially cleared para-
sites, but 2/4 mice infected with T. b. rhodesiense STIB900 later relapsed.
The first microscopic parasitemia examination was 24 h after treatment
(as DB829 is a slow-acting compound) and was followed by two exami-
nations per day until all parasites had disappeared. When parasite detec-
tion by microscopy was not sensitive enough to detect any parasites, a
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hematocrit buffy coat examination was performed. The first time point at
which no trypanosomes were detected on the microscopic slide or in the
buffy coat was considered the clearance time (or time to kill) in mice. The
detection limit by buffy coat examination was102 trypanosomes/ml of
blood. Mice were kept and further observed by tail blood examination
until the end of the experiment to verify whether the administered dose
was curative in the infected mice.
RESULTS
Pharmacokinetics of DB829 and pentamidine after i.p. and i.v.
administration in mice. The mean concentration in plasma over
time profiles of DB829 and pentamidine after a single i.p. or i.v.
dose were determined to compare the systemic exposure and
other pharmacokinetic properties of the two compounds (Fig. 2
and Table 2). The profiles exhibited a biphasic decline with an
initial distribution phase and a terminal elimination phase. About
1 min after i.v. administration at 7.5 mol/kg (or approximately
2.3 mg/kg for DB829 and 2.6 mg/kg for pentamidine), concentra-
tion in plasma reached 36.1 and 14.3 M and then declined to
below 0.1 M within 4 to 8 h for DB829 and 0.5 to 1 h for pent-
amidine. DB829 and pentamidine stayed above their IC50s of 20
and 3 nM (against T. b. rhodesiense strain STIB900) for at least 12
h (60 nM for DB829 and 18 nM for pentamidine at 12 h) before
decreasing slightly below the IC50s by 24 h (19 and 2 nM at 24 h,
respectively). The total body clearance of DB829 was considerably
smaller (by 84%) than that of pentamidine. Both compounds ap-
peared to be extensively tissue bound, as indicated by large vol-
umes of distribution (Table 2). The observed terminal plasma
half-lives were 18.1 h for DB829 and 6.8 h for pentamidine, and
the systemic exposure (as determined by AUC) of DB829 was
6.4-fold greater than that of pentamidine. Furthermore, the un-
bound fraction of DB829 in mouse plasma was 4.8-fold greater
than that of pentamidine (Table 2).
After i.p. administration at 20mg/kg, DB829 and pentamidine
were absorbed into the systemic circulation. DB829 reached a
Cmax of 31.6Mat 0.5 h and pentamidine aCmax of 6.7Mat 0.25
h postdosing (Table 2). Although both compounds stayed above
their IC50s against strain STIB900 for the entire 72-h experimental
period and had similar terminal half-lives, DB829 achieved signif-
icantly greater exposure; AUC was 6.2-fold greater and Cmax 4.7-
fold greater than for pentamidine.
In vitro activity of DB829 and pentamidine against different
trypanosome isolates. In vitro activity was originally determined
against bloodstream trypanosomes of T. b. rhodesiense reference
strain STIB900 using the alamarBlue assay and a 72-h drug expo-
sure time (10). As most sleeping sickness cases are due to T. b.
gambiense infections, here we tested DB829 and pentamidine
against a panel of different T. b. gambiense isolates. Among them
were isolates from different regions, older and more recent iso-
lates, and isolates from relapse patients after melarsoprol treat-
ment (Table 1). DB829 was less potent against T. b. gambiense
isolates (IC50 in the range of 69 to 314 nM) than against the T. b.
rhodesiense reference strain STIB900 (IC50, 20 nM) (Table 3 and
Fig. 3), as well as T. b. rhodesiense strain STIB799 (IC50, 27 nM)
(unpublished data) and T. b. brucei strain BS221 (IC50,14 nM)
(10). This indicates a reduced in vitro potency of DB829 against
theT. b. gambiense subspecies. Among theT. b. gambiense isolates,
TABLE 2 Pharmacokinetics of DB829 and pentamidine in uninfected
mice
Route Parameter,a unit DB829 Pentamidine
i.v. Dose, mol/kg (mg/kg) 7.5 (2.3) 7.5 (2.6)
Cmax, M 36.1 14.3
AUClast, mol/liter · h 7.5 1.2
AUC0–, mol/liter · h 7.6 1.2
t1/2, h 18 6.8
CL, liter/h/kg 0.99 6.3
Vz, liter/kg 26 66
MRT, h 7.0 3.7
i.p. Dose, mol/kg (mg/kg) 65 (20) 58 (20)
Cmax, M 31.6 6.66
Tmax, h 0.5 0.25
AUClast, mol/liter · h 72 11
AUC0–, mol/liter · h 74 12
t1/2, h 21 34
fu, P, % 40	 8.2 8.4	 1.2
a Abbreviations: Cmax, maximum concentration; Tmax, time to reach Cmax; AUClast,
area under the curve from time zero to the last measurable concentration; AUC0–,
area under the curve from time zero to infinite time; t½, terminal elimination half-life;
CL, total body clearance; Vz, volume of distribution; MRT, mean residence time; fu, P,
unbound fraction in mouse plasma (mean	 standard deviation).
FIG 2 Concentration-time profiles of DB829 (circles) and pentamidine (tri-
angles) in plasma following intravenous (A) or intraperitoneal (B) adminis-
tration to uninfected mice. A single dose of DB829 (or pentamidine) was
administered at 7.5 mol/kg i.v. or 20 mg/kg i.p. Symbols and error bars
represent means and standard errors (SEs), respectively, of triplicate determi-
nations.
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there was no clear relationship between melarsoprol treatment
failure (strains marked with “R”) and reduced potency of DB829,
whereas pentamidine appeared to be less active against recently
isolated strains (Table 3 andFig. 3). For example,DB829wasmore
potent against three “R” strains (130R, 349R, andDAL898R) than
the reference melarsoprol-sensitive strain STIB930. Furthermore,
pentamidine exhibited reduced trypanocidal activity (IC50, 40
nM) against strains recently isolated (after the year 2000), i.e.,
40R, 45R, 130R, 349R, and K03048. ITMAP141267 was the oldest
strain (isolated in 1960 in DRC) tested in this study, and it was the
strain most sensitive to DB829 and among those most sensitive to
pentamidine. However, no correlation in reduced trypanocidal
activity among T. b. gambiense strains was observed between
DB829 and pentamidine (Pearson r2  0.14, P  0.37; Fig. 3),
suggesting lack of cross-resistance.
In vivo efficacy in T. b. gambiense-infected mice. To investi-
gate whether potency against T. b. gambiense was lower than
against T. b. rhodesiense in vivo as well as in vitro, we tested DB829
and pentamidine in mice infected with four different T. b. gam-
biense isolates and compared their activities with those obtained in
the T. b. rhodesiense STIB900 mouse model. Both compounds
weremore efficacious inmice infected withT. b. gambiense strains
than withT. b. rhodesiense strain STIB900 (Table 3). In contrast to
the trend observed in vitro, DB829 cured T. b. gambiense-infected
mice at lower doses than it cured T. b. rhodesiense STIB900-in-
fected mice. DB829 was curative (3/3 or 4/4 mice) at 1 5 mg/kg
i.p. in the T. b. gambiense-infected mice (ITMAP141267 or
STIB930), whereas the same dose was not sufficient to cure all
(only 2/4)T. b. rhodesiense STIB900-infectedmice. Similarly, pen-
tamidine was curative (4/4 mice) at 1 20 mg/kg i.p. in all mice
infected with any of the four T. b. gambiense strains, whereas this
dose cured only 2/4 mice infected with T. b. rhodesiense STIB900.
Both compounds were efficacious inmice infected withT. b. gam-
biense strains associated with melarsoprol treatment failure (i.e.,
130R and 45R; Table 3), suggesting lack of cross-resistance with
melarsoprol in vivo.
Comparison of the two drugs showed that despite being less
potent in vitro, DB829 was more active than pentamidine in vivo.
The lowest curative dose of DB829 in STIB900-infected mice was
4 5 mg/kg i.p. or 1 20 mg/kg i.p., but pentamidine was only
partially curative (2/4 mice) at 4 20 mg/kg i.p. (Table 3). For T.
b. gambiense-infected mice, DB829 was completely curative at all
doses tested, even with a single dose of 5 mg/kg i.p. In contrast, it
took a higher dose of 1 20mg/kg i.p. for pentamidine to achieve
a complete cure. These in vivo experiments highlight the high in
vivo potency of DB829, especially against T. b. gambiense infec-
tions.
In addition to testing i.p. administration, we also evaluated the
efficacy ofDB829 via i.v. or oral (p.o.) administration based on the
observed pharmacokinetics of the compound. The maximum
concentration of DB829 in plasma following an i.v. dose of 7.5
mol/kg (or 2.3 mg/kg) was similar (36.1 versus 31.6 M) to that
after an i.p. dose of 65mol/kg (or 20 mg/kg) (Table 2). Previous
experiments had demonstrated that DB829 could be absorbed af-
ter oral administration, reaching a Cmax of 83 nM following a
single dose of 100 mol/kg (or 31 mg/kg) (14). Hence, we tested
FIG 3 In vitro activities of DB829 and pentamidine against different T. b.
gambiense strains. Symbols represent the average IC50s of three independent
determinations. The first number in parentheses represents IC50 for pentam-
idine, and the second number is the IC50 for DB829. No significant correlation
between pentamidine and DB829 activities was observed (Pearson r2  0.14;
P 0.37).
TABLE 3 In vitro and in vivo antitrypanosomal activity of DB829 and
pentamidine against different T. brucei strains
Organism and drug
regimen (no. of
dosesmg/kg i.p.)
DB829 Pentamidine
Mean
IC50	 SD
(nM)
No. cured/no.
infected
(MRDa)
Mean
IC50	 SD
(nM)
No. cured/no.
infected
(MRD)
T. b. rhodesiense
STIB900b
20	 4 3	 0.8
1 5 2/4 (53.5) NDd
1 20 4/4 2/4 (22.5)
4 5 4/4 1/4 (23)
4 20 ND 2/4 (28.5)
T. b. gambiense
ITMAP141267
69	 17 6	 1.2
1 5 3/3c 3/4c (48)
1 20 4/4 4/4
4 5 4/4 4/4
4 20 ND ND
T. b. gambiense
STIB930
304	 87 2	 1.1
1 5 4/4 3/4 (59)
1 20 4/4 4/4
4 5 4/4 4/4
4 20 ND ND
T. b. gambiense
130R
99	 23 53	 28
1 5 ND ND
1 20 4/4 4/4
4 5 4/4 2/3 (60)
4 20 ND 4/4
T. b. gambiense 45R 302	 113 81	 8
1 5 ND ND
1 20 4/4 4/4
4 5 4/4 3/3
4 20 ND ND
a MRD, mean relapse time in days.
b DB829 also cured 3/4 mice at 4 50 mg/kg administered orally, 4/4 mice at 1 10
mg/kg i.p. or 1 10 mg/kg i.v., and 1/4 mice at 4 5 mg/kg i.v. for STIB900-infected
animals.
c The experiment was terminated on day 60 postinfection, instead of day 90 for other
experiments with T. b. gambiense.
d ND, not done.
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DB829 efficacy in the standardmousemodel withT. b. rhodesiense
STIB900 using an i.v. dose of 4 5mg/kg and an oral dose of 4
50mg/kg.DB829 cured 1/4mice after i.v. administration, so it was
less active than with i.p. administration using the same dose regi-
men (Table 3). However, to our surprise, oral DB829 cured 3/4
mice. This was the first time that a cationic diamidine was shown
to have oral efficacy in this first-stage HAT model.
In addition to being less active, DB829 administered i.v. also
showed a narrower therapeutic window, as signs of acute toxicity
(lethal hypotension) were observed above 20mg/kg of DB829 in a
single dose. In contrast, i.p. administration was much better tol-
erated up to50mg/kg. The slow release by the i.p. route seems to
improve tolerability without any loss of efficacy. Pentamidine ex-
hibited a similar tolerability pattern in relation to the site of ad-
ministration, but in general, DB829 was more efficacious than
pentamidine.
Time of drug action in vitro. (i) Parameters to describe time
of drug action. The time of drug action of DB829 and that of
pentamidine in vitro against T. b. rhodesiense strain STIB900 and
T. b. gambiense strains ITMAP141267 and STIB930were recorded
and analyzed using isothermal microcalorimetry analysis. We
originally proposed to use three parameters (i.e., onset of drug
action, time to peak, and time to kill) to describe time of drug
action (19). Here, another parameter, the growth rate (), was
added to describe how fast the culture grows (if any growth is
observed) and hence the level of growth rate inhibition, i.e.,
1 (drug/drug free).
(ii) Time of drug action against T. b. rhodesiense strain
STIB900. The onset of drug action on T. b. rhodesiense strain
STIB900 ranged from 5 to 19 h for DB829 and from4 to 14 h for
pentamidine, depending on effective drug concentrations
(0.5 IC50). The onset of drug action of melarsoprol was more
concentration dependent than that of DB829 and pentamidine
(Table 4). At 200 nM (50 IC50), melarsoprol instantly inhib-
ited parasite growth, resulting in a heat flow curve comparable to
that of trypanosome-free control samples (Fig. 4). The time to
peak did not vary much for DB829 (17 to 32 h) at different con-
centrations (20 to 20,000 nM). Formelarsoprol and pentamidine,
the time to peak was considerably shorter, and at the high drug
concentration of 200 nM (50 to 80 IC50) it could not be cal-
culated because of complete or almost-complete inhibition. The
time to kill the parasite population ranged from approximately 3
to 4 days for DB829, showing little variation with drug concentra-
tions (ranging from 20 to 20,000 nM). In contrast, for pentami-
dine the time to kill decreased over 6-fold (89 h versus 14 h) as the
drug concentration increased. Melarsoprol (at 200 nM) killed all
parasites in so short a time that time to kill could not be measured
(Table 4 and Fig. 4). The inhibition of growth rate () by DB829
was dependent on drug concentration up to 2,000 nM and did not
reach more than 72% even at the highest drug concentration
tested (20,000 nM, 1,000 IC50) (Table 4). However, pentam-
idine and melarsoprol nearly completely inhibited parasite
growth at 200 nM. From visual inspection, the overall shapes of
the isothermal curves ofDB829 andpentamidinewere similar, but
the shape was different for melarsoprol, especially at 20 nM (Fig.
4C), presumably as a result of distinctmodes of action for cationic
diamidines and organoarsenicals.
(iii) Time of drug action against T. b. gambiense strains. In
drug-free control cultures, the growth rate of the two T. b. gam-
biense strains was lower than that of the T. b. rhodesiense reference
strain STIB900 at identical starting trypanosome densities (5 
104 trypanosomes/ml) (Fig. 5 and Table 4). The time to peak was
53 to 58 h versus 36 h for STIB900, the growth rate () was 0.024
to 0.018 h1 versus 0.029 h1 for STIB900, and the time to death
by overgrowthwas also longer, 139 to 170 h compared to 119 h for
STIB900. In cultures treated with drugs, the onset of drug action,
the time to peak, and the time to kill of DB829 and pentamidine
were generally longer for the two T. b. gambiense strains (except
pentamidine against STIB930) than for the T. b. rhodesiense refer-
ence strain STIB900 (Table 4). In particular, the time to kill the
two T. b. gambiense strains with DB829 ranged from 97 to 124 h
(or 4 to 5 days) at effective concentrations of 20,000 to 200 nM.
This is considerably longer than the standard 72 h observed in the
in vitro growth inhibition assay. The slow trypanocidal action
could be one reason for the greatly increased in vitro IC50s of
DB829 observed in the growth inhibition assays with the T. b.
gambiense strains (Table 3 and Fig. 3). However, pentamidine ap-
peared to be faster acting, with a time to kill of2 days at 20 nM
or higher concentrations (Table 4).
(iv) Effects of drug washout on parasites. To determine
whether continuous drug exposure for several days is required for
DB829 to kill the trypanosomes, experiments were carried out in
which the drug was washed out after 24 h of drug incubation, and
heat flowwas comparedwith that for parasites exposed to the drug
throughout (permanent) the isothermal microcalorimetry assay.
These measurements were compared for two strains (STIB900
and STIB930). The time to peak of the heat flow over time for the
washed, drug-free samples was delayed by 11 to 22 h compared to
that for the drug-free samples that were not washed (subjected to
permanent exposure) (Fig. 6 and Table 5). As both samples were
set up and run simultaneously, we attribute this delay to the loss of
some trypanosomes during the washing steps. Trypanosomes
were still viable, as seen by heat production right after the 24-h
DB829 exposure at 200 or 2,000 nM, but they died later on when
cultured in the drug-free medium (Fig. 6). The times to kill after
drug washout were longer than with permanent drug exposure
(96 versus 72 h for theT. b. rhodesiense reference strain STIB900 at
200 nM and 130 versus 89 h for T. b. gambiense strain STIB930 at
2,000 nM) (Table 5). A 24-h exposure with DB829 at 200 nM was
finally sufficient to kill the T. b. rhodesiense strain STIB900 and at
2,000 nM to kill theT. b. gambiense strain STIB930. A revival of the
parasite strain STIB930 occurred in a single experiment at 200
nM. These results suggest that the trypanosomes took up lethal
concentrations of DB829 at 200 nM (STIB900) or 2,000 nM
(STIB930) in the first 24 h, and this was sufficient to kill them at a
later time.
(v) Effects of inoculum on time of drug action. Inhibition of
trypanosome growth by DB829 was dependent on the initial par-
asite density (inoculum effect). With an inoculum of 5 104/ml,
the growth rate ofT. b. rhodesiense strain STIB900was inhibited by
15% and 52% with DB829 concentrations of 20 nM and 200 nM,
respectively. Considerably stronger inhibition, 72% with 20 nM
drug and 90% with 200 nM drug, was observed with an initial
inoculum of 1 104/ml (Table 5). However, the two parameters,
onset of action and time to peak of the heat flow curves, remained
similar at different inocula (Table 5 and Fig. 7).We also examined
inoculum effects with T. b. gambiense strain STIB930. At a drug
concentration of 200 nM DB829, parasite growth rate was inhib-
ited by 4% and with 2,000 nM by 52%with an initial inoculum of
5  104/ml. Significantly stronger inhibition was observed (42%
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at 200 nM and 91% at 2,000 nM) when the initial inoculum was
1 104/ml (Table 5). As with STIB900, the other two parameters
of the heat flow curves remained similar at different inocula (Ta-
ble 5 and Fig. 7). The same inoculum effects were also observed for
pentamidine (Table 5 and Fig. 7).
(vi) Time of drug action in vivo. The in vivo time of drug
action of DB829 and that of pentamidine were determined,
following a single i.p. dose of 20 mg/kg to mice infected with T.
b. rhodesiense strain STIB900 or T. b. gambiense strains
ITMAP141267 and STIB930, to compare the time of drug ac-
tion in vitro with that in vivo. For mice infected with T. b.
rhodesiense strain STIB900, the in vivo onset of drug action of
DB829 was less than 24 h, which is in accordance with the in
vitro time of the onset of action (5 to 19 h at DB829 concentra-
tions of 20 to 20,000 nM) (Table 4). The in vivo time to kill
(parasite clearance time) was on average 78 h (i.e., the first
mouse was parasite free 72 h after drug administration and the
last mouse after 80 h) (Table 6). This is in the range of the in
vitro time to kill (58 to 98 h; Table 4) at the different DB829
concentrations (20 to 20,000 nM). The time to kill in mice
infected with T. b. gambiense strain ITMAP141267 was on av-
erage 102 h (96 to 120 h), and in STIB930-infected mice, it was
TABLE 4 Drug action analysis of antitrypanosomal compounds by isothermal microcalorimetry
T. brucei strainb and
drug regimen and
concn (nM)
Mean (SD)
Inhibitione
(%)
Onset of
action (h)
Time to
peak (h)
Time to
kill (h)
Growth rate ()
(h1/1,000)
STIB900
Drug free 36 (4) 119 (13) 29 (2)
DB829
2c 19 (8)c 35 (4) 115 (10) 28 (1) 5
20 19 (4) 32 (3) 98 (5) 25 (1) 15
200 11 (2) 26 (2) 77 (13) 16 (4) 46
2,000 7 (2) 17 (4) 58 (17) 10 (3) 66
20,000 5 (1) 21 (3) 67 (10) 8 (3) 72
Pentamidine
0.2c 23 (3)c 39 (6) 138 (10) 25 (4) 12
2 14 (4) 31 (3) 89 (14) 19 (4) 34
20 4 9 (2) 25 (2) 1 98
200d 4 NM 14 (0) 1 98
Melarsoprol
2c NMa 40 (5) 135 (14) 27 (2) 3
20 7 (3) 25 (11) 107 (56) 7 (4) 74
200d NM NM NM NM 100
STIB930
Drug free 53 (2) 139 (3) 24 (2)
DB829
20c NM 51 (4) 136 (19) 25 (2) 0
200 26 (7) 52 (2) 124 (4) 23 (1) 2
2,000 17 (7) 41 (5) 99 (11) 16 (3) 33
20,000 10 (2) 41 (2) 97 (8) 14 (2) 43
Pentamidine
0.2c NM 53 (2) 140 (3) 23 (2) 4
2 8 (1) 30 (2) 75 (8) 11 (2) 54
20b 4 12 (1) 22 (2) 1 96
200b 4 NM NM 1 96
ITMAP141267
Drug free 58 (4) 170 (12) 18 (3)
DB829
20c NM 57 (5) 167 (4) 17 (3) 6
200 28 (9) 50 (3) 124 (7) 17 (4) 5
2,000 14 (5) 33 (12) 100 (13) 12 (2) 33
20,000 12 (5) 34 (14) 113 (10) 10 (2) 42
Pentamidine
2c 28 (7) 57 (2) 159 (3) 18 (3) 0
20 6 (1) 10 (1) 41 (8) 3.5 (0.7) 80
200 4 (1) 8 (2) 23 (9) 1.2 (0.4) 94
a NM, not measurable.
b Initial inoculum density was 5 104 trypanosomes/ml.
c Inhibition was too small to accurately recover parameters from every experiment performed.
d Inhibition was too strong to accurately recover parameters from every experiment performed.
e Inhibition is measured by the formula [1 (drug/drugfree)] 100.
DB829 PK, Efficacy, and Drug Action against HAT
November 2013 Volume 57 Number 11 aac.asm.org 533776
62 h (56 to 80 h) (Table 6). This is similar to or slightly faster
than the in vitro time to kill for these two parasite strains (100
to 124 h and 99 h, respectively, at approximately 10 IC50)
(Table 4).
In addition, the in vivo times to kill of pentamidine were
shorter than those of DB829 in all experiments, although some
mice infected with the T. b. rhodesiense strain STIB900 relapsed
later (Table 3). The in vivo times to kill of pentamidine were on
average 26 h, 30 h, and 48 h formice infected withT. b. rhodesiense
strain STIB900 and T. b. gambiense strains ITMAP141267 and
STIB930, respectively. These results are similar to the in vitro time
to kill at relevant drug concentrations (around 20 nM) (Table 4).
The parasite load in STIB930-infected mice was higher than in
mice with ITMAP141267 infections due to better adaptation of
STIB930 in mice.
DISCUSSION
Recent efforts to enhance the CNS activity of antiparasitic diami-
dines led to the discovery of aza analogues of furamidine. One of
these,DB829, cured allmice in the second-stageHATmodel using
T. b. brucei strain GVR35 when administered intraperitoneally
(10), in spite of the dogma that cationic diamidines cannot tra-
verse cellularmembranes via passive diffusion. This liability limits
their oral bioavailability and brain penetration, so that they are
generally considered to be effective only against first-stage HAT
and only through parenteral administration. Our discovery of
FIG 4 Microcalorimetry growth profiles of T. b. rhodesiense strain STIB900 in the presence of various concentrations of DB829 (A), pentamidine (B), and
melarsoprol (C). The drug-free experiment included parasites (5 104/ml inoculum) without drug treatment, and the trypanosome-free experiment did not
include parasites or drug treatment. Each curve represents the mean of three incubations.
FIG 5 Microcalorimetry growth profiles of T. b. gambiense strains STIB930 (A and C) and ITMAP141267 (B and D) in the presence of various concentrations
of DB829 (A and B) and pentamidine (C and D). The drug-free experiment included parasites (5  104/ml inoculum) without drug treatment and the
trypanosome-free experiment did not include parasites or drug treatment. Each curve represents the mean of three incubations.
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aza-diamidines led to the further testing of DB829 in a second-
stageHATmonkeymodel (results will be published in due course)
and in the present study to the comprehensive pharmacological
characterization of DB829 and the comparator drug pentamidine
with two human-infective T. brucei subspecies. Effectiveness
against T. b. gambiense is of special interest since most HAT pa-
tients are infected with this trypanosome subspecies.
In comparison to the activity against the reference strain T.
b. rhodesiense STIB900, the potency of DB829 in vitro against T.
b. gambiense strains was reduced, ranging from 3.5- to 15-fold
FIG 6 Effects of drugwashout onmicrocalorimetry growth profiles ofT. b. rhodesiense strain STIB900 (A) andT. b. gambiense strain STIB930 (B) in the presence
of DB829. Drug washout was performed after a 24-h exposure to DB829. The drug-free experiment included parasites (5  104/ml inoculum) without drug
treatment. Each curve represents the mean of three incubations.
TABLE 5 Effects of inoculum and drug washout on drug action of DB829 and pentamidine by isothermal microcalorimetry
T. brucei strain and
inoculum Compound
Drug concn
(nM)
Mean (SD)
Inhibitionf
(%)
Onset of
action (h)
Time to
peak (h)
Time to
kill (h)
Growth rate ()
(1,000 h1)
STIB900 0 (drug free) 37 (4) 123 (12) 28 (3)
5 104/ml DB829 20 22 (5) 34 (2) 98 (4) 22 (4) 15
200 10 (2) 24 (3) 72 (8) 13 (2) 52
Pentamidine 0.2 20 (1) 36 (4) 134 (11) 27 (2) 4
2 12 (2) 30 (2) 84 (14) 19 (5) 35
20b 3 (1) 9 (2) 21 (9) 1 98
1 104/ml 0 (drug free) 52 (5) 135 (13) 27 (1)
DB829 20 17 (4) 33 (2) 69 (7) 8 (3) 72
200b 14 (2) 16 (4) 36 (12) 2 (2) 90
Pentamidine 0.2a,c 20 (1) 42 (3) 152 (9) 28 (1) 3
2b 12 (3) 20 (4) 40 (5) 1 97
20b NMe NM NM 1 99
5 104/ml Washout 0 (drug free) 59 (5) 132 (5) 26 (2)
DB829 200c 27 46 (6) 96 (6) 9 (0.4) 64
STIB930 0 (drug free) 52 (2) 151 (9) 25 (2)
5 104/ml DB829 200 27 (6) 51 (1) 121 (4) 24 (1) 4
2,000c 16 (5) 39 (1) 89 (2) 12 (1) 52
Pentamidine 0.2d 4 53 (1) 163 (19) 23 (1) 8
2 6 (1) 29 (7) 66 (12) 8 (3) 67
1 104/ml 0 (drug free) 69 (2) 159 (11) 24 (2)
DB829 200 34 (10) 56 (4) 111 (10) 14 (3) 42
2,000b,c 15 (5) 37 (4) 66 (3) 2 (0.3) 91
Pentamidine 0.2d 6 74 (2) 161 (5) 22 (4) 12
2b 6 NM NM NM 100
5 104/ml Washout 0 (drug free) 63 (5) 154 (11) 21 (1)
DB829 200c 27 60 (2) 128 (9) 21 (0.5) 0
2,000d 27 58 (2) 130 (12) 15 (2) 28
a Inhibition was too small to accurately recover parameters from every experiment performed.
b Inhibition was too strong to accurately recover parameters from every experiment performed.
c Two independent experiments were performed (each in triplicate).
d One independent experiment was performed (in triplicate).
e NM, not measurable.
f Inhibition is measured by the formula [1 (drug/drugfree)] 100.
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(Table 3). Pentamidine also displayed a reduction in potency (2-
to 27-fold) against most T. b. gambiense strains, except for
STIB930 and DAL898R strains (Fig. 3). No cross-resistance be-
tween DB829 and pentamidine was observed in this study, which
included isolates from relapsed patients, in contrast to the cross-
resistance previously reported for pentamidine and melarsoprol
(39, 40). Transporters are known to be an important determinant
for developing resistance in trypanosomes to pentamidine and
melarsoprol (41–44). The P2 aminopurine transporter plays a
predominant role in the uptake of aza analogues of furamidine
into T. b. brucei s427 trypanosomes (45). The limited cross-resis-
tance of DB829 to pentamidine is presumably because different
transporters (41, 46)—in addition to P2—are involved in drug
uptake of both pentamidine andmelarsoprol but do not transport
DB829. The existence of less efficient transporters in the T. b.
gambiense strains may also explain the observed lower in vitro
potency of DB829 against these parasite strains.
Despite being less active against T. b. gambiense strains in vitro,
DB829 was surprisingly more efficacious in vivo, curing all mice
infected with different T. b. gambiense isolates at all dose regimens
tested (Table 3). In particular, a single dose of DB829 adminis-
tered intraperitoneally was highly effective, curing all T. b. gam-
biense-infected animals at a dose as low as 5mg/kg of body weight,
whereas the same dose ofDB829 cured only 2/4mice infectedwith
T. b. rhodesiense strain STIB900. The high efficacy of the lowest
DB829 doses used in our present study meant that the minimal
curative dose of DB829 for T. b. gambiense-infected mice has not
yet been established. In comparison, pentamidine was less effica-
cious than DB829 in T. b. gambiense-infected mice (3/4 cures at 5
mg/kg, single dose, compared with 4/4 or 3/3 cures with DB829)
and in T. b. rhodesiense-infected mice (1/4 cures compared to 4/4
cures at 4  5 mg/kg or 2/4 versus 4/4 cures at 20 mg/kg, single
dose, respectively).
Two factorsmay have contributed to the observed difference in
the activity of DB829 against T. b. gambiense in vitro and in vivo.
First, downregulation of diamidine uptake transporter(s) (e.g., P2
aminopurine transporter) under the in vitro culturing conditions
could have reduced the susceptibility of theT. b. gambiense isolates
to DB829, whereas in vivo bloodstream trypanosomes in infected
mice maintain a normal expression and function of diamidine
uptake transporter(s) and hence would be more susceptible to
DB829 than trypanosomes in in vitro culture. A striking decrease
(from 100% to 4.2%) in the functional activity of the P2 amino-
purine transporter in T. b. brucei s427 cells over a 24-h culture
period after fresh isolation from an infected rat was observed by
Ward et al. (45). However, it is yet to be demonstrated that such
downregulation of the P2 aminopurine transporter also occurred
in the T. b. gambiense isolates tested in vitro in our study. The
FIG 7 Inoculum effect on microcalorimetry growth profiles of T. b. rhodesiense strain STIB900 (A and C) and T. b. gambiense strain STIB930 (B and D) in the
presence of various concentrations of DB829 (A and B) and pentamidine (C and D). Two initial trypanosome densities were tested: standard inoculum at 5
104/ml and low inoculum at 1 104/ml. The drug-free experiment included parasites without drug treatment, and the trypanosome-free experiment did not
include parasites or drug treatment. Each curve represents the mean of three incubations.
TABLE 6 In vivo time to kill (parasite clearance time) in infected mice
administered DB829 or pentamidinea
T. brucei strains
Mean (range) time to kill (h)
DB829 Pentamidine
STIB900 78 (72–80) 26 (24–32)
ITMAP141267 102 (96–120) 30 (24–48)
STIB930 62 (56–80) 48 (48)
a Mean data for four mice per group; range, time elapsed between the first mouse and
the last mouse becoming aparasitemic. For each drug, a single dose of 20 mg/kg was
administered i.p. on day 3 postinfection.
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observed decrease in in vitro potency (IC50) of the T. b. gambiense
isolates did not seem to have a major effect on the time to kill. At
approximately 10 IC50 the in vitro and in vivo times to kill were
similar (Tables 4 and 6), which indicates that the drug uptake in
vitro was high enough to kill the parasites in a period similar to
that in vivo.
A second reason for the greater potency of DB829 against T. b.
gambiense isolates in vivo compared with T. b. rhodesiense could
have been the levels of parasitemia. Mice infected with T. b. gam-
biense strains generally have a lower parasitemia (107 trypano-
somes/ml of blood) than those infected with T. b. rhodesiense
strain STIB900 (108 trypanosomes/ml of blood) (47). An inoc-
ulum effect (i.e., initial parasite density-dependent growth inhibi-
tion) could result in a better-than-expected in vivo activity due to
lower parasitemia in mice infected with T. b. gambiense strains.
We assessed inoculum effects on time of drug action by DB829
and pentamidine in vitro using isothermal microcalorimetry and
confirmed that inhibition of trypanosome growth rate by DB829
and pentamidine depended on the initial inoculum: the lower the
density of parasites, the stronger the inhibition of growth of either
T. b. rhodesiense or gambiense strains (Fig. 7 and Table 5). Al-
though the causes of the inoculum effect are still unclear to us
(see additional discussion in the supplemental material), the
observed inoculum effect is not expected to have any untoward
effect on efficacy in HAT patients treated with pentamidine (or
potentially DB829), since parasitemia in human patients, espe-
cially those with T. b. gambiense infections, is very low (105
trypanosomes/ml).
Using isothermal microcalorimetry, we were able to make a
real-time comparison of the effects of different drugs on different
parasite strains. It provided us with a convenient tool to monitor
parasite growth and to visualize and quantify the level of growth
rate inhibition by antiparasitic drugs on a real-time basis.Wenzler
et al. (19) first described the use of this technology to characterize
the parasite growth and effects of drug treatments forT. brucei and
Plasmodium falciparum. Here we used mathematical models and
included an additional parameter, growth rate (). The new four-
parameter model (onset of drug action, time to peak, time to kill,
and growth rate) describes time of drug action in more detail.
The inoculum effect was revealed by using the same drug con-
centration but different initial inocula (Table 5). The effect on the
inhibition of growth rate is discussed above. In contrast, inoculum
effects were not as clearly apparent on onset of drug action or time
to peak. This indicates that the drug action starts almost simulta-
neously at identical drug concentrations for DB829 and pentam-
idine at the different inocula. Inhibition is considerably stronger
in the samples with lower trypanosome densities, when their
drug-free control samples are still in the exponential growth
phase. On the other hand, at higher parasite densities inhibition
may be less observable because the onset of drug action and/or
time to peak is already close to the stationary phase, when growth
of the drug-free control samples is reduced as well—not by drug
inhibition but due to overgrowth of the parasite culture. Growth
inhibition by slow-acting drugs was less visible at higher inocula
since a decreased metabolic activity may coincide with the over-
growing culture.
The time of onset of drug action is a pharmacodynamic param-
eter that is important when considering potential use for treat-
ment. A main feature of isothermal microcalorimetry is real-time
monitoring of organism growth, which can be used to readily
calculate in vitro time of drug action. Traditionally, time of drug
action was obtained through laborious multiple single time point
antiparasitic inhibition assays with variable drug exposure times.
Onset of action, time to peak, and time to kill could only be esti-
mated, and the level of inhibition was calculated at the few tested
time points (19). Microcalorimetry offers a more reliable and less
laborious method. However, as the microcalorimeter typically re-
quires a few hours to fully equilibrate 4-ml ampoules containing 2
ml of culture medium, the analysis of onset of drug action is still
difficult, especially for fast-acting compounds. Further technical
improvements (e.g., adding an injection system) will be desirable
to allow preequilibration of ampoules prior to injecting com-
pound solutions, thus reducing the equilibration time following
drug addition (48).
DB829was shown to be a slow-acting trypanocidal compound.
It was possible to obtain reliable results for the in vitro time to kill
at a range of concentrations. This ranged from 3 to 4 days for T. b.
rhodesiense strain STIB900 and from 4 to 5 days for the T. b. gam-
biense strains, depending on effective (0.5 IC50) drug concen-
trations (Table 4). In comparison, pentamidine is faster acting,
reducing parasites to below the detection limit within 1 day after
drug addition at 200 nM concentration for all three strains and at
20 nM for STIB900 and ITMAP141267. This is probably due to
differences in the parasite uptake kinetics of the two compounds,
which have been previously characterized using T. b. brucei strain
s427 (45, 49). It is noteworthy that parasites of T. b. rhodesiense
strain STIB900 grew faster than those of the two T. b. gambiense
strains in the absence of drug treatment, resulting in a shorter time
to death of the parasite culture (approximately 5 days versus 6 to 7
days, respectively) as a result of overgrowing. Since our standard
in vitro growth inhibition assays utilize a 72-h of incubation pe-
riod, we believe that the slow trypanocidal action of DB829 con-
tributed, in part, to the increases in measured IC50s against the T.
b. gambiense strains.
Activity of DB829 in vitrowas not increased with drug concen-
trations higher than 2,000 nM (Fig. 4A and 5A andB). This ismost
likely due to the saturation of the P2 transporter, which is themain
route of DB829 uptake (45). In a P2 transporter-mediated uptake
assay, the Michaelis-Menten constant, Km, of DB829 is 1.1 M,
indicating that saturation (maximum uptake rate,Vmax) is almost
reached after 2 M and therefore no significant higher inhibition
can be expected with this compound at higher drug concentra-
tions.
Parasite clearance time in vivo, following a single intraperito-
neal injection of DB829 at a dose of 20 mg/kg of body weight,
ranged from 3 to 3.3 days for mice infected with T. b. rhodesiense
strain STIB900 and from 2.3 to 5 days for mice infected with the
different T. b. gambiense strains (Table 6). These times were in
good agreement with the in vitro times to kill, given the high con-
centration in plasma of DB829 (Cmax 31.6 M) reached at this
dose level (Table 2). As predicted based on in vitro time to kill,
pentamidine is also faster acting in vivo than DB829, clearing par-
asites from the bloodstream within 1 to 1.3 days for mice infected
with T. b. rhodesiense strain STIB900 and 1 to 2 days for mice
infected with the T. b. gambiense strains. In summary, it generally
takes more time for DB829 to clear T. brucei parasites than for
pentamidine.
An interesting feature of the action of DB829 is that despite
being slow acting, it was able to kill parasites in vitro after a short
(24-h) drug exposure, as demonstrated by drug washout experi-
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ments (Fig. 6 and Table 5). This is consistent with the observation
that a single dose of DB829 could effectively cure infected mice
(Table 3), which was partially due to desirable pharmacokinetics,
with a high maximum drug concentration in plasma, relatively
long terminal elimination half-life at the dose tested, and relatively
low plasma protein binding (Table 2).
Based on the outstanding efficacy ofDB829 in themousemod-
els with acute infections and its desirable pharmacokinetic prop-
erties, it is of interest to consider the potential value of this com-
pound in the treatment of HAT. A single dose of DB829
administered intramuscularly could be suggested as a new short
treatment for first-stage HAT. An even more important property
of DB829 is that it was shown to be efficacious in mice with sec-
ond-stage infection when administered intraperitoneally (10).
This has prompted further testing of parenteral DB829 (as well as
its methamidoxime oral prodrug, DB868) in the vervet monkey
model for second-stage HAT with promising results (16).
New, safe, and effective drugs are urgently needed for treat-
ment of both stages of HAT. It is also desirable that they be easy to
administer, with a simple dosing regimen. With improved drugs,
it should be possible to control HAT effectively and perhaps even
eliminate the disease. DB829 is a promising candidate for further
development. It is CNS active (by itself, without bioconversion),
so it could be used against second-stage HAT. Inmousemodels, it
showedoutstanding efficacy against both first and second stages of
infection. Furthermore, it cured both T. b. gambiense and T. b.
rhodesiense infections at low and well-tolerated doses. Parenteral
DB829 with a short dosing regimen such as 5 days or less for the
second stage and a single dose for the first stage should be seriously
considered for further development as a new treatment for sleep-
ing sickness.
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ABSTRACT: 4,4″-Diamidino-m-terphenyl (1) and 36 analogues were prepared and assayed in vitro against Trypanosoma brucei
rhodesiense, Trypanosoma cruzi, Plasmodium falciparum, and Leishmania amazonensis. Twenty-three compounds were highly active
against T. b. rhodesiense or P. falciparum.Most noteworthy were amidines 1, 10, and 11 with IC50 of 4 nM against T. b. rhodesiense,
and dimethyltetrahydropyrimidinyl analogues 4 and 9 with IC50 values of ≤ 3 nM against P. falciparum. Bis-pyridylimidamide
derivative 31 was 25 times more potent than benznidazole against T. cruzi and slightly more potent than amphotericin B against
L. amazonensis. Terphenyldiamidine 1 and dipyridylbenzene analogues 23 and 25 each cured 4/4 mice infected with T. b.
rhodesiense STIB900 with four daily 5 mg/kg intraperitoneal doses, as well as with single doses of ≤10 mg/kg. Derivatives 5 and
28 (prodrugs of 1 and 25) each cured 3/4 mice with four daily 25 mg/kg oral doses.
■ INTRODUCTION
The vector borne protozoal diseases trypanosomiasis, malaria,
and leishmaniasis continue to affect some of the poorest areas
of the world.1−5 Human African trypanosomiasis (HAT), which
occurs in over 20 sub-Saharan African countries, was largely
controlled by the 1960s but has since re-emerged. After
continued control efforts, fewer than 10 000 new cases were
reported in 2009 for the first time in 50 years, and the World
Health Organization (WHO) estimates that 30 000 actual cases
currently exist (vs 300 000 cases in 1988).1,6 The disease
progresses from an early hemolymphatic stage to a late central
nervous system (CNS) stage and has a 100% mortality rate if
not treated.7 Two forms of HAT exist. A chronic infection due
to Trypanosoma brucei gambiense, prevalent in western and
central Africa, accounts for about 95% of reported cases. The
remaining cases arise from an acute infection of T. brucei
rhodesiense, prevalent in eastern and southern Africa.8
American trypanosomiasis, or Chagas disease, is caused by
Trypanosoma cruzi. An estimated 10 million people were
infected in 2010, and an estimated 10 000 died in 2008 because
of the disease. Originally endemic to Latin America, the disease
has now spread to other continents. It progresses from an acute
phase lasting about 2 months after infection, in which the
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parasites are concentrated in the blood, to a chronic phase, in
which the parasites are hidden in the heart and digestive
muscle. Myocardial damage can lead to death.4
Malaria is concentrated in sub-Saharan Africa but is also
endemic to other continents, affecting approximately 100
countries. The WHO has estimated 216 million cases of malaria
in 2010 and 655 000 deaths.2 Most of the deaths occur in
Africa, primarily among young children. Four Plasmodium
species are recognized as human pathogens. Among these, P.
falciparum causes the most deadly infection.2,7
Infections due to various species of Leishmania affect nearly
12 million people in 88 countries. The diseases range in severity
from a spontaneously healing cutaneous form due to L.
mexicana to a life-threatening visceral form, 90% of which
occurs in Bangladesh, India, Nepal, and Sudan (due to L.
donovani) or in Brazil (due to L. chagasi).5,8 Cases of patients
infected with both visceral leishmaniasis (VL) and human
immunodeficiency virus (HIV) continue to be reported.9−16
The need for safe, orally active, and economical drugs against
HAT persists. Available therapies are scarce, antiquated, toxic,
prone to resistance, and require parenteral (usually intra-
venous) administration.1,6,7,17−19 Suramin, a polysulfonated
naphthylurea, and pentamidine (Figure 1), an aromatic
diamidine, are the two drugs used to treat early stage HAT.
Late-stage therapies are generally more problematic. The
organoarsenical melarsoprol is associated with an encephalop-
athy leading to death in about 5% of the cases.7,20 Eflornithine
is the only new anti-HAT drug introduced in the past 60 years.
Although better tolerated than melarsoprol, eflornithine is
ineffective against T. b. rhodesiense, and high doses must be
given intravenously four times daily over long periods.6 A
combination of eflornithine and nifurtimox (nifurtimox−
eflornithine combination therapy, NECT) was licensed in
2009.1 It is easier to administer and has a shorter treatment
duration than the eflornithine monotherapy and is currently the
best choice to treat late stage patients with T. b. gambiense
infections.
Drugs of choice against Chagas disease are benznidazole and
nifurtimox, both of which are given orally. Both drugs are
highly effective in curing the disease if treatments begins at the
onset of the acute stage, but the efficacy of each diminishes with
delayed initiation of treatment.4,7 Severe side effects have also
been reported for both drugs.21 No drugs are currently
approved for the chronic phase of the disease, but at least
two drug candidates are currently in clinical trials.4,7
Although a number of economical orally active antimalarial
drugs are available, drug resistance is a growing problem.22
Resistance to chloroquine, observed in Thailand in the 1960s,
has been followed by resistance in other locations and to other
drugs, including sulfadoxine−pyrimethamine and mefloquine.
Resistance to artemisinin led to the development of
artemisinin-based combination therapy, but resistance to at
least one combination, artesunate−mefloquine, has also been
reported.7
Pentavalent antimonial compounds, including sodium
stibogluconate and meglumine antimoniate, introduced in the
1940s, continue to be the drugs of choice against VL in most
endemic countries despite their toxicity. High rates of
treatment failures have been reported in Bihar, India, since
the 1980s.23 Antimony resistant VL was treated with
pentamidine in the past, but the efficacy of pentamidine against
VL has decreased,24 and the use of pentamidine against
leishmaniasis is now restricted to some forms of cutaneous
disease that occur in South America.25 Amphotericin B is an
effective option in the treatment of VL,26 but the less toxic
liposomal formulations of the drug are limited by their expense.
The aminoglycoside paromomycin has shown high efficacy in
India and low toxicity, but a 3-week course of daily injections is
required.27 Miltefosine is orally active but is teratogenic,
nephrotoxic, and hepatotoxic.28 Various miltefosine combina-
tion therapies have been under recent investigations.8,23,28
Furamidine29 (DB75, Figure 1) is a conformationally
restricted analogue of pentamidine. These positively charged
molecules have poor oral bioavailability; however, their N′-
hydroxy and N′-methoxy derivatives with lower pKa values have
shown potential as orally active prodrugs.30 Pafuramidine
(DB289, Figure 1),31 the methamidoxime prodrug of
furamidine, advanced to phase III clinical trials against early
stage HAT and phase II trials against malaria.32,33 The
compound exhibited nephro- and hepatotoxicity in a recent
expanded phase I trial,34 resulting in a suspension of phase III
trials.35
Numerous analogues of pentamidine and furamidine,
including those with modifications of both the central and
outer rings, have been prepared and assayed against various
organisms,36−56 with the intent of finding comparably effica-
cious but less toxic drug candidates. A number of
arylimidamides (AIAs), or “reversed” amidines, have been
prepared and tested primarily against T. cruzi or Leishmania
species.57−60 A few diamidine derivatives of o-, m-, and p-
terphenyl were originally prepared as serine protease
inhibitors.61 More recently, a larger number of dicationic p-
terphenyls and their aza-analogues have been prepared as
antiprotozoals.62−64 Dicationic m-terphenyl derivatives have
remained virtually unexplored, with respect to both the number
of molecules synthesized and their potential antiprotozoal
activities. While the p-terphenyls are linear in shape, the m-
terphenyls are more conformationally similar to furamidine.
The present work describes the synthesis of a rather diverse
group of dicationic m-terphenyl derivatives and their biological
evaluation against four parasites.
■ CHEMISTRY
A total of 37 cationically substituted m-terphenyl analogues
were prepared (Table 1). This group consists of 29 diamidine
derivatives (1−29), six bis-arylimidamides (bis-AIAs, 30−35),
and two mono-AIAs (36 and 37). The amidine group includes
16 simple amidines (1, 7−8, 10−13, 19−26, and 29), seven N-
Figure 1. Structures of 1,5-bis(4-amidinophenoxy)pentane (pentamidine), 2,5-bis(4-amidinophenyl)furan (furamidine), and 2,5-bis(4-N′-
methoxyamidinophenyl)furan (pafuramidine).
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alkyl and N,N′-alkylene derivatives (2−4, 9, and 14−16), and
six prodrugs (5, 6, 17, 18, 27, and 28). Structural variations
include the orientation of the cationic groups, substituents on
the amidine nitrogen atoms and/or on the central aromatic
ring, and the insertion of nitrogen atoms in the outer aromatic
rings. Compounds 1−22 and 30−37 have m-terphenyl nuclei,
Table 1. Structures of Cationic m-Terphenyl and 1,3-Dipyridylbenzene Derivatives 1−37a
compd R1 R2 R3 R4
1 4-Am 4″-Am H H
2 4-i-PrAm 4″-i-PrAm H H
3 4-Im 4″-Im H H
4 4-DMTHP 4″-DMTHP H H
5 4-AmOH 4″-AmOH H H
6 4-AmOMe 4″-AmOMe H H
7 4-Am 4″-Am Cl H
8 4-Am 4″-Am NO2 H
9 4-DMTHP 4″-DMTHP NO2 H
10 4-Am 4″-Am NH2 H
11 4-Am 4″-Am OH H
12 4-Am 4″-Am OMe H
13 3-Am 3″-Am H H
14 3-i-PrAm 3″-i-PrAm H H
15 3-Im 3″-Im H H
16 3-DMTHP 3″-DMTHP H H
17 3-AmOH 3″-AmOH H H
18 3-AmOMe 3″-AmOMe H H
19 3-Am 3″-Am Cl H
20 3-Am 3″-Am OMe H
21 3-Am 4″-Am H H
22 3-Am 4″-Am Cl H
23 6-Am 6″-Am
24 5-Am 5″-Am
25 5-Am 5″-Am
26 5-Am 5″-Am
27 5-AmOMe 5″-AmOMe
28 5-AmDMAA 5″-AmDMAA
29 4-Am 4″-Am
30 3-PhIA 3″-PhIA Cl H
31 3-PyIA 3″-PyIA Cl H
32 3-PhIA 4″-PhIA H H
33 3-PyIA 4″-PyIA H H
34 3-PhIA 4″-PhIA Cl H
35 3-PyIA 4″-PyIA Cl H
36 4-PyIA H Cl O-i-Pr
37 5-PyIA H Cl O-i-Pr
aAll compounds were isolated as hydrochloride salts except 26 (acetate salt) and 28 (free base).
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while analogues 23−24 and 25−29 have 1,3-bis(pyridin-3-
yl)benzene and 1,3-bis(pyridin-2-yl)benzene scaffolds, respec-
tively. All 37 compounds are novel except 13, which was
previously reported but as a different salt.61 The activities of
analogues 7, 19, 23, and 24 against T. cruzi have been
reported,65,66 although details of their syntheses have yet to be
reported. All target compounds were isolated as their
hydrochloride salts except acetate salt 26 (an alternative salt
form of 25) and free base 28.
The syntheses of the symmetric m-terphenylamidines and
prodrugs 1−20 are depicted in Scheme 1. Dibromobenzene
starting materials 38, 39, and 41 were commercially available.
Nitro analogue 4067 was prepared by deamination of 2,6-
dibromo-4-nitroaniline. Methoxy derivative 42 was prepared by
bromination68−deamination67 of p-anisidine. Double Suzuki
couplings involving dibromobenzenes 38−42 and 2−2.5 equiv
of 3- or (4-cyanophenyl)boronic acid catalyzed by tetrakis-
(triphenylphosphine)palladium(0) readily gave terphenyldini-
triles 43−50 in yields of 52−81%. The nitriles (except 46) were
then subjected to modified Pinner reaction conditions (ethanol,
HCl gas, dioxane cosolvent)50,51 to generate the corresponding
imidate esters, which were then reacted immediately with
Scheme 1. Synthesis of Symmetric m-Terphenylamidine Derivatives and Prodrugsa
aReagents and conditions: (a) 3- or 4-cyanophenylboronic acid, Pd(PPh3)4, aq Na2CO3, DME, reflux (52−81%); (b) EtOH, HCl, 1,4-dioxane, and
then NH3 or amine, EtOH; (c) NH2OH·HCl, t-BuOK, DMF; (d) Ac2O, AcOH, and then H2, 10% Pd/C, EtOH, AcOH; (e) H2, 10% Pd/C, EtOH;
(f) CH3I, t-BuOK, DMSO; (g) (CH3)2SO4, aq NaOH, dioxane.
Scheme 2. Synthesis of Asymmetric m-Terphenyldiamidinesa
aReagents and conditions: (a) 4-cyanophenylboronic acid, Pd(PPh3)4, aq Na2CO3, DME; (b) (3-cyanophenyl)boronic acid, Pd(PPh3)4, aq Na2CO3,
DME; (c) EtOH, HCl, 1,4-dioxane and then NH3, EtOH; (d) LiN(TMS)2, THF.
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ammonia (for simple amidines 1, 7, 8, 12, 13, 19, and 20),
isopropylamine (for N-isopropylamidines 2 and 14), ethyl-
enediamine (for imidazolines 3 and 15), or 2,2-dimethylpro-
pane-1,3-diamine (for 5,5-dimethyl-1,4,5,6-tetrahydropyrimi-
din-2-yl (DMTHP) derivatives 4, 9, and 16). Catalytic
hydrogenation of nitro-substituted diamidine 8 gave the
amino analogue 10. Conversion of nitrile 46 to its amidoxime
derivative using excess hydroxylamine in DMSO,69 followed by
O-acylation and catalytic hydrogenation,50 gave 5′-hydroxydia-
midine 11. Amidoxime prodrugs 5 and 17 were prepared by
similar treatment of nitriles 43 and 48 with hydroxylamine.69
The amidoxime bases were converted to their hydrochloride
salts for biological testing or underwent O-methylation to
methamidoxime derivatives 6 and 18, which were also
converted to their hydrochloride salts.
Syntheses of asymmetric m-terphenyldiamidines 21 and 22
(Scheme 2) were similar to those of their symmetric
counterparts, but their dinitrile precursors were prepared by
successive single Suzuki couplings. High selectivity for single
over double coupling has resulted from the use of
bromoiodobenzene rather than dibromobenzene starting
materials.70 The coupling between bromoiodobenzene 51 and
(4-cyanophenyl)boronic acid gave biphenyl 53 in 71% isolated
yield. An analogous Suzuki coupling involving bromoiodide 52
(prepared by iodination−deamination of 4-bromo-2-chloroani-
line)71,72 gave biphenyl 54 in 59% yield. Successive couplings of
bromobiphenyls 53 and 54 with (3-cyanophenyl)boronic acid
gave the desired asymmetric terphenyldinitriles 55 and 56
(83% and 74% yields). A Pinner synthesis employing dinitrile
55 gave asymmetric diamidine 21. Similar strategy using chloro
analogue 56 failed, presumably because of the extremely low
solubility of the nitrile in the reaction medium. Diamidine 22
was successfully prepared from dinitrile 56 using lithium
bis(trimethylsilyl)amide in THF.64
The preparation of dipyridylbenzene derivatives 23−29 is
shown in Scheme 3. 3-Bromopyridyl starting materials 57 (also
commercially available) and 58 were prepared by treatment of
5-bromo-N-(tert-butyl)picolinamide73 or 5- bromonicotinamide
with phosphorus oxychloride.73 The reactions of compounds
57 and 58 with bis(pinacolato)diboron and catalytic
PdCl2(dppf)
74 gave boronate esters 59 and 60, which
underwent Suzuki coupling with 1,3-diiodobenzene under
anhydrous conditions (Pd(PPh3)4, Ag2CO3, THF)
75 to give
1,3-di(pyridin-3-yl)benzenedinitriles 61 and 62 (60% and 69%
yields). Attempted Pinner syntheses of amidines 23 and 24
from dipyridylbenzenenitriles 61 and 62 were unsuccessful.
The nitriles were treated with excess hydroxylamine in DMSO
to give amidoxime intermediates 63 and 64. The amidoximes
were treated with acetic anhydride in acetic acid to generate the
N′-acetoxy derivatives in situ, which were hydrogenated at 60
psi over 10% Pd/C in acetic acid.69 The use of neat acetic acid
in place of acetic acid−ethanol69 proved to be necessary for
selective cleavage of the oxygen−nitrogen bond (amidine
deprotection) over the oxygen−carbon bond (reversion to the
amidoxime).
Similar strategy was employed for the syntheses of the
di(pyridin-2-yl)benzene analogues except for the reversal of
functional groups for the Suzuki couplings. 2-Bromopyridylni-
triles 65 and 66 were prepared by dechlorobromination of 6-
chloronicotinonitrile76 or 2-chloro-4-cyanopyridine using phos-
Scheme 3. Synthesis of 1,3-Dipyridylbenzeneamidines and Prodrugsa
aReagents and conditions: (a) bis(pinacolato)diboron, PdCl2(dppf), KOAc, DMSO; (b) 1,3-diiodobenzene, Pd(PPh3)4, Ag2CO3, THF; (c)
NH2OH·HCl, t-BuOK, DMSO; (d) Ac2O, AcOH, and then H2, 10% Pd/C; (e) 1,3-benzenediboronic acid, Pd(PPh3)4, Ag2CO3, THF; (f) Me2SO4,
LiOH·H2O, DMF; (g) dimethylaminoacetyl chloride·HCl, K2CO3, DMF.
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Scheme 4. Synthesis of m-Terphenyl-bis-arylimidamides (Bis-AIAs)a
aReagents and conditions: (a) 3-nitrophenylboronic acid, Pd(PPh3)4, aq Na2CO3, DME, reflux; (b) SnCl2·2H2O, EtOH; (c) Et3N (for 77 only),
benzonitrile or 2-cyanopyridine, NaN(TMS)2, THF; (d) 4-nitrophenylboronic acid pinacol ester, Pd(PPh3)4, aq Na2CO3, DME; (e) H2, 60 psi, 10%
Pd/C, EtOH; (f) Fe, NH4Cl, aq EtOH.
Scheme 5. Synthesis of m-Terphenyl Monoarylimidamides (Mono-AIAs)a
aReagents and conditions: (a) phenylboronic acid, Pd(PPh3)4, aq Na2CO3, DME; (b) NBS, THF; (c) NaNO2, H2SO4, EtOH; (d) BuLi, THF and
then triisopropyl borate; (e) (CH3)2CHI, Cs2CO3, K2CO3, DMF; (f) 86 or 87, Pd(PPh3)4, aq Na2CO3, DME; (g) SnCl2·2H2O, EtOH; (h)
benzonitrile or 2-cyanopyridine, NaN(TMS)2, THF.
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phorus tribromide.77 Various attempts at preparing boronic
acids or esters from 65, 66, or their 2-chloro precursors were
unsuccessful. Suzuki couplings of 2-bromopyridines 65 and 66
with 1,3-phenyldiboronic acid under anhydrous conditions
(Pd(PPh3)4, Ag2CO3, THF)
75 gave 1,3-di(pyridin-2-yl)-
benzenedinitriles 67 and 68 (63% and 87% yields). Compound
67 was also prepared in 91% yield by the coupling of 6-
chloronicotinonitrile76 and the diboronic acid in toluene/2 M
aqueous Na2CO3.
47 Nitriles 67 and 68 were reacted with excess
hydroxylamine in DMSO to give amidoxime intermediates 69
Table 2. Antiprotozoal Activities, Cytotoxicities, and Selectivity Indices of Compounds 1−37 in Vitro
T. b. rhodesiensea T. cruzib P. falciparumc L. amazonensisd
compd IC50 (μM)
f SITb
g IC50 (μM)
f SITc
h IC50 (μM)
f SIP
i IC50 (μM)
j SIL
k cytotoxe IC50 (μM)
f
1 0.004 8494 71.6 <1 0.024 1279 31.2
2 0.047 2157 >150 <1 0.016 6583 102
3 0.068 37 18.9 <1 0.073 35 2.55
4 0.140 871 151 <1 0.002 49347 122
5 10.9 >14 >150 NDl >10 NDl >150
6 4.44 4 92.6 <1 >10 <2 19.2
7 0.031 700 65.5 <1 0.039 561 21.9
8 0.020 >7481 57.2 >2 0.018 >8376 >150
9 0.692 >217 >150 NDl 0.003 >46781 >150
10 0.004 >39791 149 >1 0.136 >1103 >150
11 0.004 >37500 >150 <1 0.038 >3947 >150
12 0.005 7266 59.1 <1 0.048 693 33.0
13 0.055 2268 35.0 4 0.038 3319 125
14 0.617 >243 141 >1 0.031 >4194 >150
15 1.60 20 20.4 2 0.619 51 31.7
16 0.809 70 45.4 1 0.006 9498 56.6
17 2.55 2 11.2 <1 8.23 <1 5.60
18 11.3 2 24.1 <1 9.31 2 20.3
19 0.044 709 50.2 <1 0.033 944 30.9
20 0.029 4695 55.9 2 0.028 4964 137
21 0.052 544 27.1 1 0.015 1947 28.5
22 0.097 130 46.6 <1 0.010 1248 12.7
23 0.006 3720 43.4 <1 0.015 1485 22.3
24 0.527 >285 >150 NDl 0.058 >2577 >150
25 0.017 >8824 >150 NDl 0.040 >3763 >150
26 0.022 >6856 >150 NDl 0.045 >3339 >150
27 26.3 >6 117 >1 3.56 >42 >150
28 9.84 6 72.3 <1 0.486 129 62.9
29 1.17 >128 >150 NDl 0.077 >1939 >150
30 0.533 8 2.09 2 0.071 58 2.43 2 4.10
31 0.019 133 0.053 47 0.006 450 0.095 26 2.50
32 0.635 4 2.14 1 0.038 66 0.907 3 2.52
33 1.94 1 0.388 7 0.208 13 0.123 22 2.72
34 0.178 13 2.04 1 0.039 58 1.02 2 2.27
35 0.109 24 1.54 2 0.219 12 0.211 13 2.64
36 32.4 <1 4.18 2 >10 <1 0.933 10 9.69
37 12.3 <1 2.98 1 3.075 1 1.88 2 3.77
PMDm 0.003 11436 0.046 1004 46.6
FMDn 0.003 2000 23.3 <1 0.014 464 6.40
MSPo 0.004 1275 5.12
BNZp 1.30 115 >150
CQq 0.125 612 76.5
ATMr 0.004 34884 150
AMBs 0.124
PPTt 0.017
aTrypanosoma brucei rhodesiense (STIB900).83 bTrypanosoma cruzi Tulahuen C2C4 Lac Z.83 cPlasmodium falciparum (K1, chloroquine resistant).83
dLeishmania amazonensis infected CD-1 mouse intracellular amastigotes.82 eCytotoxicity to L6 rat myoblast cells.83 fThe IC50 values are the mean of
two independent assays. Individual values differed by less than 50% of the mean value. gSelectivity index for T. b. rhodesiense expressed as the ratio
IC50(L6 cells)/IC50(T. b. rhodesiense).
hSelectivity index for T. cruzi expressed as the ratio IC50(L6 cells)/IC50(T. b. cruzi).
iSelectivity index for P.
falciparum expressed as the ratio IC50(L6 cells)/IC50(P. falciparum).
jThe IC50 values are the mean of three independent assays. The standard
deviations varied from the mean values by 8−64%. kSelectivity index for L. amazonensis expressed as the ratio IC50(L6 cells)/IC50(L. amazonensis).
lValue not determinable. mPentamidine. nFuramidine. oMelarsoprol. pBenznidazole. qChloroquine. rArtemisinin. sAmphotericin-B. tPodophyllotox-
in.
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and 70, which underwent O-acetylation followed by catalytic
hydrogenation to give amidine hydrochlorides 25 and 29. The
former compound was also isolated as acetate salt 26. Amidine
25 was also prepared directly from nitrile 67 using lithium
bis(trimethylsilyl)amide in THF.64 The prodrugs, methamidox-
ime 27 (hydrochloride salt) and dimethylaminoacetoxyamidine
28 (free base), were prepared by O-methylation or O-acylation
of amidoxime 69. Compound 27 was also prepared as the
hydrochloride salt (59% yield) directly from nitrile 67 using
methoxylamine hydrochloride in the presence of triethylamine
and thioglycolic acid.78
The syntheses of bis-AIAs 30−35 are depicted in Scheme 4.
A double Suzuki coupling between dibromobenzene 39 and 3-
nitrophenylboronic acid gave the symmetric dinitroterphenyl
71 in 76% isolated yield. Reduction of 71 with tin(II) chloride
dihydrate in ethanol gave the diamine 72, which was reacted
with benzonitrile or 2-cyanopyridine in the presence of sodium
bis(trimethylsilyl)amide in THF79 to give symmetric bis-
phenylimidamide 30 and the corresponding di(pyridin-2-yl)
derivative 31. Similar strategy was employed for the asymmetric
analogues 32−35 except for the requirement of successive
single Suzuki couplings. Bromoiodobenzenes 51 and 5271,72
were coupled with 4-nitrophenylboronic acid pinacol ester to
give bromobiphenyls 73 and 74, which in turn were coupled
with 3-nitrophenylboronic acid to give terphenyls 75 and 76
(52% and 55% yields overall). Hydrogenation of dinitroter-
phenyl 75 over 10% Pd in ethanol gave diamine 77 (72% yield
as the HCl salt). The chloro-substituted dinitro analogue 76
was reduced to diamine 78 (69% yield) using iron powder and
ammonium chloride in aqueous ethanol. Diamines 77 and 78
were reacted with benzonitrile or 2-cyanopyridine in the
presence of sodium bis(trimethylsilyl)amide in THF79 to give
bis-AIAs 32−35 (34−64% yields).
The syntheses of mono-AIAs 36 and 37 (Scheme 5) began
with the Suzuki coupling of bromoaniline 79 and phenyl-
boronic acid to give biphenylamine 80 (70%). This
intermediate underwent bromination to 81 (N-bromosuccini-
mide in THF, 83%), followed by deamination to bromobi-
phenyl 82 (sodium nitrite and sulfuric acid in ethanol, 86%).
The latter underwent lithiation followed by quenching with
triisopropyl borate to give crude boronic acid 83. This
intermediate underwent Suzuki couplings with bromoisopro-
poxynitrobenzenes 8680 and 8781 (prepared by Williamson
ether syntheses from the corresponding phenols 84 and 8581)
to give nitroterphenyls 88 (82%) and 89 (91%). The nitro
compounds were reduced to the corresponding amines 90
(83%) and 91 (94%) using tin(II) chloride dihydrate in
ethanol. The amines were reacted with 2-cyanopyridine in the
presence of sodium bis(trimethylsilyl)amide in THF to give
mono-AIAs 36 (41%) and 37 (50%) as their HCl salts.
■ IN VITRO ANTIPROTOZOAL ACTIVITIES,
SELECTIVITIES, AND STRUCTURE−ACTIVITY
RELATIONSHIPS
In vitro activities of target compounds against T. b. rhodesiense
strain STIB900, the intracellular amastigote form of the T. cruzi
Tulahuen strain C2C4, the chloroquine resistant P. falciparum
strain K1, and L. amazonensis intracellular amastigotes were
measured following established protocols,82,83 and the results
are shown in Table 2. Cytotoxicities against L6 rat myoblast
cells83 were determined to calculate the selectivity indices (the
ratios of cytotoxic IC50 values to antiprotozoal IC50 values) of
each compound for each of the four parasites. Standard drugs
include pentamidine and furamidine (against T. b. rhodesiense
and P. falciparum), melarsoprol (against T. b. rhodesiense),
benznidazole (against T. cruzi), chloroquine and artemisinin
(against P. falciparum), amphotericin B (against L. amazonen-
sis), and podophyllotoxin (against L6 cells).
T. b. rhodesiense. A total of 17 compounds were highly
active with IC50 values below 100 nM, and 11 of these
analogues had selectivity indices above 2000 (more selective
than furamidine and melarsoprol). Five congeners exhibited
IC50 values below 10 nM (comparable in potency to the three
standard drugs). The most potent were lead compound 1 and
derivatives 10 and 11, all exhibiting IC50 values of 4 nM and
selectivity indices above 8000, followed by analogues 12 (IC50
= 5 nM, SI = 7270) and 23 (IC50 = 6 nM, SI = 3720). Eight
congeners (2, 7, 8, 19, 20, 25, 26, and 31) exhibited IC50 values
between 10 and 50 nM, of which analogues 8, 25, and 26 had
selectivity indices above 6000 and derivatives 2 and 20 had
selectivity indices above 2000. Four derivatives (3, 13, 21, and
22) showed IC50 values between 50 and 100 nM, of which
congener 13 had a selectivity index greater than 2000. Another
nine compounds (4, 9, 14, 16, 24, 30, 32, 34, and 35) exhibited
IC50 values between 100 nM and 1.0 μM.
The group of 17 most highly active compounds with IC50
values below 100 nM included 14 simple diamidines, N-
isopropylamidine 2, imidazoline 3, and AIA derivative 31. The
diamidines included all 11 of the terphenyldiamidines (1, 7, 8,
10−13, and 19−22) and three of the five dipyridyl diamidines
23, 25, and 26.
Among the terphenylamidine derivatives 1−22, optimal
potency and selectivity were observed when both cationic
groups were oriented para to the central ring. Lead compound
1 (IC50 = 4 nM, SI ≈ 8500), was over 10 times more potent
and over 4 times more selective than its regioisomer 13 (IC50 =
55 nM), with both amidine functions situated meta to the
central ring. The asymmetric 3,4″-diamidine 21 was similar in
potency (IC50 = 52 nM) to 13 but about 4 times less selective.
The introduction of substituents on the amidine nitrogen
atoms resulted in diminished activity. The N-isopropylamidines
2 and 14 were more than 10 times less potent than the
corresponding simple amidines 1 and 13. The corresponding
imidazoline derivatives 3 and 15 showed a further 2-fold
decrease in potency. The DMTHP derivatives 4, 9, and 16
showed varied degrees of decreased potencies relative to the
corresponding amidines 1, 8, and 13. The prodrugs 5, 6, 17,
and 18 were inactive in vitro, as expected.30,33
The introduction of substituents on the central ring had
varied effects upon activity, depending upon the orientation of
the cationic groups. The potency of lead compound 1 was
retained in its amino and hydroxy derivatives 10 and 11, and
these two analogues also had the highest selectivity indices
(above 37 500). The methoxy derivative 12 was similar in both
potency and selectivity to parent molecule 1, while methoxy
analogue 20 was slightly more potent and selective than its
parent molecule 13. None of the chloro analogues 7, 19, and 22
showed advantages of both potency and selectivity compared to
parent molecules 1, 13, and 21, respectively. The nitro
analogue 8 was quite potent (IC50 = 20 nM), albeit 5 times
less potent than parent amidine 1, and showed at least
comparable selectivity.
The orientation of both amidine functions para to the central
ring was also required for optimal potency among the
regioisomeric dipyridylbenzenediamidines 23−25 and 29.
The points of attachment of the pyridine rings proved to be
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less crucial. Analogues 23 (IC50 = 6 μM, SI ≈ 3700) and 25
(IC50 = 17 μM, SI > 8800), with both cationic groups
positioned para to the central ring, were highly potent and
highly selective for the parasite, and their potencies varied by
less than 3-fold. Their regioisomers with both amidine moieties
situated meta to the central ring were over 50 times less potent
(23 vs 24, 25 vs 29). The hydrochloride salt 25 and acetate salt
26 (different salts of the same diamidine base) gave similar
results in the in vitro assays.
The AIA derivatives 30−37 were, as a whole, less potent and
less selective compared to the amidine derivatives 1−29. Even
though the bis-pyridylimidamide 31 was the sixth most potent
overall (IC50 = 19 nM), it was the least selective (SI = 133) of
the 13 compounds with IC50 values below 50 nM. None of the
other AIA derivatives had IC50 values below 100 nM.
T. cruzi. The bis-pyridylimidamides 31, 33, and 35 were
most potent against the intracellular amastigote form of the T.
cruzi Tulahuen strain. The order of decreasing potencies
continued with the bis-phenylimidamide, monopyridylimida-
mide, and diamidine derivatives. The pyridylimidamide 31
(IC50 = 53, SI = 47) showed the most promising results, being
about 25 times more potent than benznidazole (IC50 = 1.30
μM, SI = 115). The other pyridyl analogues 33 (IC50 = 388
nM) and 35 (IC50 = 1.54 μM) showed potencies greater than
or comparable to benznidazole but selectivity indices below 10.
Compound 31 merits further investigation, as selectivity indices
above 10 are a common cutoff value for in vivo testing against
T. cruzi. None of the other compounds exhibited IC50 values
below 2 μM.
P. falciparum. Twenty-one compounds exhibited IC50
values below 50 nM (compared to IC50 = 46 nM for
pentamidine) against the chloroquine resistant P. falciparum
strain K1. The two most potent derivatives 4 and 9, with IC50
values of 2 and 3 nM, respectively, and each having a selectivity
index above 45 000, were more potent and selective for the
parasite than artemisinin (IC50 = 4 nM, SI = 34 900).
Analogues 16 and 31 each had IC50 values of 6 nM, while
congener 22 had an IC50 value of 10 nM and a selectivity index
of 1250. Only analogue 16 had a selectivity index below 1000.
Four derivatives (2, 8, 21, and 23) exhibited IC50 values
between 10 and 20 nM. All had selectivity indices above 1000,
with those of 2 and 8 being above 5000. Twelve compounds (1,
7, 11−14, 19, 20, 25, 26, 32, and 34) had IC50 values between
20 and 50 nM, of which seven analogues (1, 11, 13, 14, 20, 25,
and 26) had selectivity indices above 1000. Four derivatives (3,
24, 29, and 30) were less potent, with IC50 values between 50
and 100 nM. Overall, 15 compounds (1, 2, 4, 8, 9, 11, 13, 14,
16, 20−23, 25, and 26) exhibited IC50 values below 50 nM and
selectivity indices above 1000.
The group of 21 compounds with IC50 values below 50 nM
includes 13 simple amidines (10 terphenyl and three
dipyridylbenzene derivatives), five N-alkylamidines, and three
AIA analogues. In contrast to the structural requirements for
antitrypanosomal activity, antiplasmodial potency was less
dependent on the positions of the cationic groups and was
enhanced by alkylation of the amidine nitrogen atoms. The
regioisomeric diamidines 1, 13, and 21 lacking central ring
substituents showed rather small differences in potency (IC50
values of 24, 38, and 15 nM, respectively) but with activity
favored by at least one cation in the para position. The chloro
analogue 22 (a derivative of 21) was the most potent of the
terphenyl simple diamidines (IC50 = 10 nM).
The DMTHP derivatives 4, 9, and 16 (IC50 values of 2, 3,
and 6 nM, respectively, and SI > 45 000 for 4 and 9) were the
most potent terphenyl N-alkyldiamidines, accounting for three
of the four most potent and the three most highly selective
analogues overall. They were also highly specific for this
parasite, being 70−230 times more potent against P. falciparum
compared to T. b. rhodesiense. The N-isopropylamidines 2 and
14 (IC50 of 16 and 31 nM, respectively, and SI > 4000 for each)
also exhibited enhanced potencies and selectivities relative to
corresponding amidines 1 and 13 and were the eighth and
twelfth most potent overall. The imidazoline derivatives 3 and
15 (IC50 of 73 and 620 nM, respectively) were both less potent
and less selective than the corresponding amidines 1 and 13.
Thus, diamidine 1 and its N-substituted derivatives 2−4 were
all more potent than the corresponding 3,3″-isomers 13−16.
The introduction of substituents on the central ring had
varied effects upon activity, depending on the nature of the
substituent and the position of the cationic groups. Both the
potency and selectivity of the 4,4″-diamidine 1 were diminished
by the presence of chloro, amino, and methoxy substituents on
the central ring (derivatives 7, 10, and 12). The nitro analogue
8 was slightly more potent than 1 with significantly enhanced
selectivity. The potency of 3′3″-diamidine 13 was enhanced by
a chloro or methoxy group on the central ring (analogues 19
and 20), but selectivity was enhanced only in the latter
instance. The potency of asymmetric diamidine 21 was
enhanced, but its selectivity was diminished, by a chlorine
atom on the central ring (derivative 22).
The order of potencies of the four dipyridylbenzene
diamidines was the same as that against T. b. rhodesiense.
Analogues 23 (IC50 = 15 nM) and 25 (IC50 = 40 nM), each
having both amidine groups positioned para to the central ring,
were more potent than their respective counterparts 24 (IC50 =
58 nM) and 29 (IC50 = 77 nM) having two meta-amidine
functions. Selectivity indices ranged from around 1500 for 23 to
greater than 3500 for 25. Acetate salt 26, an alternative salt
form of 25, gave results similar to those of hydrochloride salt
25. The difference in IC50 values between the most potent (23)
and the least potent (29) analogues was just over 5-fold,
compared to a nearly 200-fold differences in their IC50 values
against T. b. rhodesiense.
The AIA derivatives, as a whole, were less potent and less
selective compared to the amidine derivatives. The symmetric
bis-pyridylimidamide 31 (IC50 = 6 nM, SI = 450) was the most
potent AIA derivative and most selective for this parasite,
followed by the asymmetric bis-phenylimidamides 32 and 34,
with IC50 values around 40 nM but selectivity indices below
100. These three compounds had the three lowest selectivity
indices among the 21 compounds with IC50 values below 50
nM, despite the fact that analogue 31 was the third most potent
overall. Congener 30 was the only other AIA derivative with an
IC50 value below 100 nM.
L. amazonensis. Given that other AIAs have shown
outstanding in vitro and promising in vivo antileishmanial
activity in past work,57,59,60,84 compounds 30−37 were assayed
against L. amazonensis in the intracellular amastigote model.82
The bis-pyridylamidamides 31, 33, and 35 were the three most
potent compounds (in descending order). Analogue 31 (IC50 =
95 nM) was slightly more potent than amphotericin B (IC50 =
124 nM), while congener 33 (IC50 = 123 nM) showed
comparable potency and derivative 35 (IC50 = 211 nM)
showed lower potency. The IC50 values for the five mono- and
bis-phenylimidamides ranged between 907 nM and 2.43 μM for
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bis-AIAs 32 and 30, respectively. Thus, pyridylimidamide 31
and the corresponding phenyl analogue 30 were the most and
least potent. For the relatively small number of compounds
tested, the antileishmanial data are somewhat similar to anti-T.
cruzi data. Bis-pyridylimidamides 31, 33, and 35 were the three
most potent compounds (in descending order) against both
parasites. However, the orders of activity of the phenyl-
imidamides differed, without the clear distinction of potencies
between mono- and bis-phenylimidamides, as observed against
T. cruzi.
■ IN VIVO ACTIVITIES AND STRUCTURE−ACTIVITY
RELATIONSHIPS
T. b. rhodesiense. Twenty compounds (including six
prodrugs) were tested in mice infected with the T. b. rhodesiense
strain STIB900 (Table 3).85 The amidines and N-alkylamidines
were given intraperitoneally (four daily doses of 5 mg/kg),
while the prodrugs were given orally (four daily doses of 25
mg/kg). Mice that survived for 60 days after infection without
showing a parasitemia relapse were considered as cured. This
model is highly stringent, mimicking the acute stage of HAT,
and the low doses applied allowed for the distinction of
activities among the highly trypanocidal compounds. Pentam-
idine and furamidine attained 1/4 cures at 4 × 5 mg/kg ip, and
any compound attaining a higher cure rate is considered to
have enhanced activity in vivo.
Three diamidines, lead compound 1 and dipyridyl analogues
23 and 25, each cured 4/4 infected mice at the 4 × 5 mg/kg ip
regimen, exhibiting excellent cure rates comparable to that of
melarsoprol. These three compounds also attained 4/4 cures in
single doses of 10 mg/kg for diamidines 1 and 25 and 5 mg/kg
for analogue 23. Acetate salt 26, a different salt form of 25, also
effected 4/4 cures at the 4 × 5 mg/kg regimen. Diamidines 12
and 11 cured 2/4 and 1/4 infected mice, respectively. Prodrugs
of diamidines 1 and 25 demonstrated efficacy with the 4 × 25
mg/kg oral regimen. Compound 5, the amidoxime derivative of
1, cured 3/4 mice, while methamidoxime derivative 6 attained
1/4 cures. Compound 28, the dimethylaminoacetoxy derivative
of dipyridyl analogue 25, cured 3/4 mice, and the
methamidoxime derivative 27 attained 2/4 cures. Mean survival
rates exceeded 50 days for prodrugs 5, 27, and 28..
Two simple amidine moieties oriented para to the central
ring, regardless of the presence or position of nitrogen atoms in
the outer rings, were required for maximum efficacy in vivo
(compounds 1, 23, and 25). Among the terphenyl analogues,
the introduction of alkyl substituents on the amidine nitrogen
(1 vs 2, 1 vs 3) or meta orientations of one or both amidine
groups (1 vs 13, 1 vs 21, 12 vs 20) resulted in loss of efficacy.
In these respects, a high correlation exists between potencies in
vitro and efficacies in vivo. All analogues of diamidine 1 with
substituents on the central ring were less effective in vivo.
Derivatives 10−12 had potencies in vitro similar to that of the
parent molecule, but the methoxy (12), hydroxy (11), and
amino (10) analogues attained 2/4, 1/4, and 0/4 cures,
respectively, but all with significantly prolonged mean survival
times (exceeding 35 days) compared to untreated mice (10
days or less). The chloro and nitro derivatives 7 and 8, which
were less potent in vivo, cured no mice but with less prolonged
survival times. In cases where prodrugs exist, the prodrugs
reflected the efficacies of the parent amidines. Prodrugs of the
highly effective amidines 1 and 25 demonstrated oral efficacy,
as stated above. Neither amidine 13 nor its prodrugs (17 and
18) were effective in vivo.
L. donovani. On the basis of their in vitro antileishmanial
efficacy and selectivity, compounds 31, 33, and 35 were
selected for in vivo evaluation. These molecules were first
tested in groups of two uninfected BALB/c mice at five daily
doses of 30 mg/kg intraperitoneally to ensure that they were
well tolerated in the animals prior to evaluation of in vivo
antileishmanial efficacy in larger groups. Compounds 31 and 33
were toxic at this dose, with the animals displaying tremors and
hyperactivity after the second and first doses, respectively. Mice
were euthanized after these adverse effects were observed, and
compounds 31 and 33 were not tested further in vivo. After no
overt signs of toxicity were observed when compound 35 was
given at 5 × 30 mg/kg ip, an in vivo antileishmanial efficacy
test82 was carried out with this compound. Unfortunately, only
23 ± 11% inhibition of liver parasitemia (mean ± standard
deviation, n = 4) was observed when L. donovani-infected
BALB/c mice were given compound 35 at 5 × 30 mg/kg ip. In
the same experiment, miltefosine treatment of infected BALB/c
mice at 5 × 10 mg/kg orally resulted in 96 ± 2% inhibition of
liver parasitemia (n = 4).
Table 3. In Vivo Antiprotozoal Activity of Select m-
Terphenyl and Dipyridylbenzene Derivativesa
compd dose (mg/kg)b routec cured/infectedd MSD (days)e
1 4 × 5 ip 4/4 >60
1 × 10 ip 4/4 >60
2 4 × 5 ip 0/4 13.5
3 4 × 5 ip 0/4 9.25
5 4 × 25 po 3/4 >51.25
6 4 × 25 po 1/4 >34.25
7 4 × 5 ip 0/4 15.25
8 4 × 5 ip 0/4 20
10 4 × 5 ip 0/4 >35
11 4 × 5 ip 1/4 >41.25
12 4 × 5 ip 2/4 >38
13 4 × 5 ip 0/4 18.5
17 4 × 25 po 0/4 7.25
18 4 × 25 po 0/4 17.75
20 4 × 5 ip 0/4 10
21 4 × 5 ip 0/4 34.75
23 4 × 5 ip 4/4 >60
1 × 5 ip 4/4 >60
25 4 × 5 ip 4/4 >60
1 × 10 ip 4/4 >60
26 4 × 5 ip 4/4 >60
27 4 × 25 po 2/4 >53.75
28 4 × 25 po 3/4 >52
MLSPf 4 × 5 ip 4/4 >60
FMDg 4 × 5 ip 1/4 >46
PMDh 4 × 5 ip 1/4 >38
aFemale NMRI mice infected with Trypanosoma brucei rhodesiense
(STIB900).85 bAdministration was once per day on 4 consecutive days
for all compounds, and single doses for select compounds. cRoute of
administration: intraperitoneal (ip) or oral (po). dMice that survived
for 60 days after infection without showing a parasitemia relapse were
considered as cured. eMean survival days after infection. All mice were
used to calculate the MSD (the relapsed mice and the cured mice,
where MSD > 60 days). fMelarsoprol. gFuramidine. hPentamidine.
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■ DISCUSSION
The m-terphenyl derivatives exhibited complementary SAR
profiles against the four parasites, as summarized in Figure 2. In
general, the amidine derivatives were more active against T. b.
rhodesiense and P. falciparum, while the AIAs showed more
promising results against the other parasites. The orientation of
both amidine moieties para to the central ring, regardless of the
presence or position of nitrogen atoms in the outer rings, was
required for optimal activity against T. b. rhodesiense. Altered
positions of the amidine groups, alkylation of the amidine
nitrogen atoms, and substituents on the central ring all resulted
in diminished activity either in vitro or in vivo. A general trend
of diminished activities of N-alkyl analogues has been
observed,37,38,40,41,50,51,86,87 but the effects of substituents on
the central or outer rings have varied from one class of
compounds to another.29,38,51 The insertion of nitrogen atoms
into phenyl rings has resulted in retained or enhanced activity
in the diphenylfuran and p-terphenyl analogues.46,62,64,85 The
replacement of a central furan ring with 1,3-phenylene was
clearly beneficial with respect to the diamidine analogues but
not for the prodrugs. Compound 1 attained 4/4 cures in the
STIB900 acute model, compared to 1/4 cures for furamidine.
Its similarly efficacious dipyridyl analogues 23 and 25 were also
more active in vivo than the corresponding dipyridyl derivatives
of furamidine.46,85 Pafuramidine was more efficacious than the
corresponding amidoxime88 and has been one of few prodrugs
to attain 4/4 cures in the STIB900 model at four daily 25 mg/
kg oral doses.85 By contrast, methamidoxime 6 (a prodrug of 1)
cured 1/4 mice under the same conditions, while the
corresponding amidoxime 5 attained 3/4 cures. Methamidox-
ime 27 (a prodrug of 25) and the di(pyridin-2-yl) analogue of
pafuramidine85 each cured 2/4 mice. Another prodrug of 25,
dimethylaminoacetoxy derivative 28, attained 3/4 cures.
Antiplasmodial activity was less dependent upon the position
of the cationic groups (although still favored by at least one
para cation) and was enhanced by alkylation of the amidine
nitrogen atoms, especially in the DMTHP derivatives and to a
lesser extent in the N-isopropyl analogues. The imidazoline
derivatives, however, were less potent than the corresponding
amidines. In other examples from this lab, the effect of N-
alkylation has varied from one class of compounds to
another.36−38,50,51 The effects of substituents on the central
ring varied with the nature of the substituents and the
orientation of the cationic groups. Only one dipyridyl analogue,
the bis(6-amidinopyridin-3-yl) derivative 23, was more potent
than the corresponding terphenyldiamidine.
The bis-pyridylimidamide 31 was unique in demonstrating
activity against all four parasites in vitro. Despite its high
potencies against T. b. rhodesiense and P. falciparum, it was
much less selective for these parasites over mammalian cells
compared to the amidine derivatives. This compound, having
both cations in the meta position and a chlorine atom attached
to the central ring, was also the most active against T. cruzi and
L. amazonensis. The SAR of these compounds against T. cruzi
was rather clearly defined: the bis-pyridylimidamides were the
most potent, followed by the bis-phenylamidamides, the mono-
AIAs, and the amidine derivatives. The bis-pyridylimidamides
were also the most active against L. amazonensis; however, the
IC50 values of the less potent bis-phenylamidamides and mono-
AIAs overlapped, and the amidine derivatives were not tested in
this model.
A large number of mechanisms of antimicrobial activity have
been proposed for the diamidine class of molecules.89−101
These positively charged molecules bind to many negatively
charged surfaces and receptors and accordingly have numerous
potential sites of action. The antimicrobial action of these
compounds probably occurs at multiple sites, and the primary
site of action may vary from organism to organism. This is a
huge problem with regard to drug design but is advantageous
with regard to the potential development of drug resistance. It
has been suggested that the highly selective toxicity of many of
the compounds in this class toward pathogenic organisms over
Figure 2. Summary of antiprotozoal SARs of m-terphenyl derivatives.
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mammalian cells is due to active transport mechanisms. For
example, trypanosomes have a number of active transport
systems that allow cationic molecules to be concentrated in the
parasites at levels over 1000 times higher than in mammalian
cells.97 Thus, the only way to optimize these compounds for
specific targets is via focused parallel synthesis and in vitro
testing or focusing on the active transport systems. Unfortu-
nately, not enough is known with regard to the specificities of
the transporters to aid in the drug design process.
Because of the propensity of dications to bind to numerous
sites, the toxicity of these molecules is always a concern with
regard to drug design.85,102−108 The nature of the toxicity does
not appear class related but may vary from compound to
compound. For instance, hypoglycemia is the major concern
with regard to pentamidine,104,106 while nephrotoxicity resulted
in the cancellation of human clinical trials with pafuramine.85
An obvious approach to decreasing host toxicity is to produce
more potent compounds against the targeted organisms.
However, even the most potent diamidine compounds must
be subjected to a battery of toxicity tests.
A number of the m-terphenyl analogues, as well as diamidine
derivatives of other classes of compounds,36−41,50,51 have
shown high potencies against P. falciparum in vitro. However,
the lack of a reliable animal model has been a major obstacle in
their further development against malaria. Standard rodent
models, which must use Plasmodium species that are non-
pathogenic to humans due to the high specificity of P.
falciparum for human erythrocytes, do not necessarily predict
the efficacy of a given drug in human malaria,109 and their
relevance to human malaria has been questioned.110,111 For
example, pafuramidine, which is known to be effective in
human malaria,33 was inactive in a commonly used P. berghei
mouse model,112 as were pentamidine and other analogues of
furamidine.29,56,112 Murine P. falciparum models employing
immunodeficent mice engrafted with human erythrocytes or
hepatocytes (humanized mice)110,112−114 should more accu-
rately predict the efficacies of new therapies in human malaria,
although they are generally more costly and more difficult to
handle than standard rodent models.114 These models may be
useful in determining which standard rodent model offers
better correlation with P. falciparum for given compounds; for
example, one study suggested that P. vinckei may be a better
surrogate than P. berghei for diamidines.112 These findings may
provide at least a starting point in the further evaluation of
other diamidines.
■ CONCLUSIONS
This communication describes several novel diamidine
derivatives that show excellent in vitro potency against T. b.
rhodesiense, are curative in a mouse model of early stage HAT,
and have the potential for reduced toxicity when compared to
the prototype molecule furamidine. Most outstanding were
diamidines 1, 23, and 25, which attained 4/4 cures not only in
four daily intraperitoneal doses of 5 mg/kg but also in single
doses of 10 mg/kg or lower. Prodrugs of compounds 1 and 25
(derivatives 5 and 28) also attained 3/4 cure rates in this model
with four daily 25 mg/kg oral doses. Further evaluations of
these compounds against other T. brucei strains and a mouse
model of late stage HAT are in progress. A number of
compounds, most significantly the DMTHP derivatives 4, 9,
and 16, showed promising antiplasmodial potencies in vitro and
merit in vivo evaluation, contingent upon the selection of
appropriate animal models. Although these compounds, as a
class, did not show promising results against T. cruzi, AIA
derivative 31 proved to be 25 times more potent than the
clinical standard benznidazole and thus warrants further
evaluation against this parasite.
■ EXPERIMENTAL SECTION
General Experimental Methods. In vitro antiprotozoal activities
against T. b. rhodesiense (STIB900), T. cruzi (Tulahuen C2C4), P.
falciparum (chloroquine resistant K1),83 and L. amazonensis intra-
cellular amastigotes,82 cytotoxicities against L6 rat myoblast cells,83
and in vivo activities against T. b. rhodesiense (STIB900)85 and L.
donovani (LV82)82 were measured following established protocols. All
protocols and procedures used in the current study were reviewed and
approved by the local veterinary authorities of the Canton Basel-Stadt,
Switzerland, or the Institutional Animal Care and Use Committee at
The Ohio State University. The data in the T. b. rhodesiense model
were generated at the time when the determination of survival was still
accepted by the authorities.
Uncorrected melting points were measured on a Thomas-Hoover
capillary melting point apparatus. 1H NMR spectra were recorded in
DMSO-d6 on a Varian Gemini 2000 or Unity Plus 300 MHz
spectrometer or a Varian Inova 400 MHz spectrometer. Spectra were
recorded at 300 MHz unless the higher field strength is specified. 13C
NMR spectra were recorded in DMSO-d6 on a Varian Unity Plus
operating at 75 MHz. Anhydrous EtOH was distilled over Mg/I2
immediately prior to use. Other anhydrous solvents were purchased
from Aldrich Chemical Co., Milwaukee, WI, in Sure-seal containers
and were used without further purification. Reaction mixtures were
monitored by TLC on silica gel or by reverse phase HPLC. Organic
layers of extraction mixtures were neutralized as necessary with acidic
or basic washes, washed with saturated NaCl solution, and dried over
MgSO4 or Na2SO4 before being evaporated under reduced pressure.
Normal phase gravity and flash column chromatography were
performed using Davisil grade 633, type 60A silica gel (200−425
mesh). Reverse phase flash chromatography was performed as
previously described.41 Analytical HPLC chromatograms were
recorded on a Hewlett-Packard 1090 series II or Agilent 1200
chromatograph using a Zorbax Rx C8 column (4.6 mm × 75 mm, 3.5
μm) maintained at 40 °C and UV photodiode array detection at 230,
254, 265, 290, and 320 nm. Area % values are reported at the
wavelengths where the strongest signals of the products were
observed. Mobile phases consisted of mixtures of acetonitrile (0−
75%) or methanol (0−95%) in water containing formic acid (80 mM),
ammonium formate (20 mM), and triethylamine (15 mM). Samples
were eluted at appropriate gradients at a flow rate of 1.5 mL/min.
Similar analyses were performed on a Hewlett-Packard 1100 system
using a Zorbax SB C8 column (3.0 mm × 100 mm, 3.5 μm), eluting at
0.6 mL/min. Preparative reverse phase HPLC was performed on a
Varian ProStar chromatography workstation configured with two PS-
215 pumps fitted with 50 mL pump heads, a Dynamax Microsorb C18
(60 Å) column (41.4 cm × 25 cm, 8 μm), PS-320 variable wavelength
UV−vis detector, and a PS-701 fraction collector. Mobile phases
consisted of mixtures of acetonitrile (0−75%) or methanol (0−95%)
in water containing formic acid (40 mM) and ammonium formate (10
mM). Flow rates were maintained at 40 mL/min. Select fractions were
analyzed for purity by analytical HPLC as described above. Pooled
purified fractions were evaporated under reduced pressure, recon-
stituted in water, and lyophilized on a VirTis BenchTop 2K or 6K
lyophilizer. Low resolution ESI mass spectra were recorded on an
Agilent Technologies 1100 series LC/MSD trap mass spectrometer or
a VG analytical 70-SE spectrometer. Elemental analyses were
performed by Atlantic Microlab, Norcross, GA, and, unless stated
otherwise, were within ±0.4% of calculated values. CHN analyses were
performed by combustion using a Perkin-Elmer 2400 or Carlo Erba
1108 automatic analyzer. Chlorine analyses were performed by flask
combustion followed by ion chromatography. The compounds
reported as salts were frequently analyzed correctly for fractional
moles of water and/or other solvents; in each case 1H NMR spectra
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were consistent with the analysis. The purity of all final compounds
was determined to be ≥95% by combustion analysis.
General Procedure for Amidines 1−4, 7−9, 12−16, and 19−
21. The nitrile was added to a mixture of anhydrous EtOH and 1,4-
dioxane that had been saturated with hydrogen chloride at 0 °C in a
dry three-neck flask equipped with a gas inlet tube, a thermometer, and
a drying tube. The reaction mixture was then sealed and stirred at
ambient temperature until the nitrile was no longer detectable. The
reaction mixture was diluted with ether. The crude imidate was filtered
off, dried under high vacuum over KOH, and then reacted immediately
with an excess of ammonia or the appropriate amine in EtOH. The
reaction mixture was diluted with ether, and the crude product was
filtered off. The product was purified by direct recrystallization or by
reverse phase HPLC or flash chromatography followed by conversion
to the dihydrochloride salt using aqueous or ethanolic HCl.
4,4″-Diamidino-m-terphenyl Dihydrochloride (1). 1 was
prepared from nitrile 43 (0.56 g, 2.01 mmol) with ammonium
carbonate used in place of ammonia. After purification by preparative
HPLC, the product was recrystallized from ethanolic HCl−ether to
give a white solid (346 mg, 44%): mp >350 °C; 1H NMR δ 9.50 (br s,
3H), 9.24 (br s, 3H), 8.14 (t, J = 1.6 Hz, 1H), 8.10 (d, J = 8.7 Hz, 4H),
7.99 (d, J = 8.2 Hz, 4H), 7.87 (dd, J = 7.7 and 1.6 Hz, 2H), 7.68 (t, J =
7.7 Hz, 1H); ESI MS m/z 315.1 ([M + H]+ of free base); HPLC 100
area %. Anal. (C20H18N4·2HCl·0.7H2O) C, H, N, Cl.
4,4″-Bis(N-isopropyl)amidino-m-terphenyl Dihydrochloride
(2). 2 was prepared from nitrile 43 and isopropylamine. The product
was purified by reverse phase flash chromatography and recrystallized
from aqueous HCl to give a solid (690 mg, 61%): mp 253−254 °C; 1H
NMR δ 9.69 (d, J = 8.2 Hz, 2H), 9.57 (br s, 2 H), 9.21 (br s, 2H), 8.07
(m, 5H), 7.86 (m, 6H), 7.69 (t, J = 7.8 Hz, 1H), 4.13 (m, 2H), 1.31 (d,
J = 6.4 Hz, 12H); ESI MS m/z 399.2 ([M + H]+ of free base); HPLC
100 area %. Anal. (C26H30N4·2HCl·1.4H2O) C, H, N, Cl.
4,4″-Bis(imidazolin-2-yl)-m-terphenyl Dihydrochloride (3). 3
was prepared from nitrile 43 and ethylenediamine. The crude
precipitated product was recrystallized from aqueous HCl to give a
white solid (1.26g, 79%): mp >250 °C (dec); 1H NMR δ 10.90 (br s,
3H), 8.22 (m, 5H), 8.16 (d, J = 8.7 Hz, 4H), 7.91 (dd, J = 7.8 and 1.7
Hz, 2H), 7.68 (t, J = 7.8 Hz, 1H), 4.04 (s, 8H); ESI MS m/z 367.2
([M + H]+ of free base); HPLC 99.0 area %. Anal.
(C24H22N4·2HCl·2.8H2O) C, H, N, Cl.
4,4″-Bis[(5,5-dimethyl)-1,4,5,6-tetrahydropyrimidin-2-yl]-m-
terphenyl Dihydrochloride (4). 4 was prepared from nitrile 43 (961
mg, 3.43 mmol) and 2,2-dimethylpropane-1,3-diamine. The product
was recrystallized from aqueous HCl to give white granules (1.33 g,
74%): mp >350 °C (dec); 1H NMR δ 10.39 br s, 3H), 8.14 (t, J = 1.7
Hz, 1H), 8.11 (d, J = 8.6 Hz, 4H), 7.97 (d, J = 8.6 Hz, 4H), 7.87 (dd, J
= 7.7 and 1.6 Hz, 2H), 7.68 (t, J = 7.8 Hz, 1H), 3.24 (s, 8H), 1.07 (s,
12H); ESI MS m/z 451.2 ([M + H]+ of free base); HPLC 99.0 area %.
Anal. (C30H34N4·2HCl·1.25H2O) C, H, N, Cl.
4,4″-Bis(N′-hydroxy)amidino-m-terphenyl Dihydrochloride
(5). Potassium tert-butoxide (8.42 g, 75.0 mmol) was added to a
stirred solution of hydroxylamine hydrochloride (5.25 g, 75.6 mmol)
in dry DMSO (45 mL). After 30 min nitrile 43 (2.11 g, 7.52 mmol)
was added, and the mixture was stirred overnight. The reaction
mixture was poured over ice−water, and the precipitated amidoxime
base was filtered off (2.05 g, 79%): mp >215 °C (dec); 1H NMR δ
9.71 (br s, 2H), 7.98 (s, 1H), 7.80 (s, 8H), 7.71 (d, J = 7.3 Hz, 2H),
7.57 (t, J = 7.7 Hz, 1H), 5.89 (br s, 4 H); HPLC 100 area %. Anal.
(C20H18N4O2·0.1H2O) C, H, N.
An aliquot of the base (478 mg, 1.38 mmol) was recrystallized from
aqueous HCl to give a white solid (221 mg, 38%): mp >260° (dec);
1H NMR δ 11.33 (br s, 2H), 9.16 (br s, 4H), 8.11 (s, 1H), 8.08 (d, J =
8.5 Hz, 4H), 7.87 (m, 6H), 7.67 (t, J = 7.7 Hz, 1H); ESI MS m/z
347.2 ([M + H]+ of free base); HPLC 99 area %. Anal.
(C20H18N4O2·2HCl) C, H, N, Cl.
4,4″-Bis(N′-methoxy)amidino-m-terphenyl Dihydrochloride
(6). A mixture of amidoxime base 5 (1.56 g, 4.49 mmol) and
potassium tert-butoxide (1.07 g, 9.53 mmol) in DMSO (20 mL) was
stirred for 2 h followed by the addition of iodomethane (0.9 mL, 14
mmol). The reaction mixture was stirred overnight and poured over
ice. The precipitated crude product was chromatographed on silica,
eluting with CHCl3/MeOH (20:1) and recrystallized twice from
MeOH−H2O to give white crystals (532 mg, 32%): mp 141−142 °C;
1H NMR δ 8.04 (s, 1H), 7.96 (d, J = 8.3 Hz, 4H), 7.86 (d, J = 8.4 Hz,
4H), 7.79 (dd, J = 7.7 and 1.6 Hz, 2H), 7.03 (t, J = 8.1 Hz, 2H), 3.48
(s, 6H). Anal. (C22H22N4O2) C, H, N.
The base was converted to the HCl salt using aqueous HCl to give a
white solid (570 mg, 87% from salt conversion, 28% from the
amidoxime): mp 192 °C (dec); 1H NMR δ 8.08 (m,1H), 8.01 (d, J =
8.5 Hz, 4H), 7.46 (d, J = 8.5 Hz, 4H), 7.82 (dd, J = 7.6 and 1.6 Hz,
2H), 7.65 (t, J = 7.7 Hz, 1H), 3.87 (s, 6H); ESI MS m/z 375.5 ([M +
H ] + o f f r e e b a s e ) ; H P L C 9 9 a r e a % . A n a l .
(C22H22N4O2·1.95HCl·1.3H2O) C, H, N.
4,4″-Diamidino-5′-chloro-m-terphenyl Dihydrochloride (7).
7 was prepared from nitrile 44 (1.03 g, 3.28 mmol). The product was
purified by reverse phase flash chromatography and converted to the
HCl salt using aqueous HCl to give a solid (532 mg, 53%): mp >250
°C (dec); 1H NMR δ 9.52 (br s, 4H), 9.27 (br s, 4H), 8.16 (d, J = 8.5
Hz, 4H), 8.12 (t, J = 1.5 Hz, 1H), 8.00 (d, J = 8.5 Hz, 4H), 7.96 (d, J =
1.5 Hz, 2H); ESI MS m/z 349.2 ([M + H]+ of free base); HPLC 99.4
area %. Anal. (C20H17ClN4·2HCl·2.3H2O) C, H, N, Cl.
4,4″-Diamidino-5′-nitro-m-terphenyl Dihydrochloride (8). 8
was prepared from nitrile 45 (1.64 g, 5.03 mmol). The product was
purified by reverse phase flash chromatography and converted to the
HCl salt using aqueous HCl to give a solid (929 mg, 42%): mp >350
°C (dec); 1H NMR δ 9.58 (br s, 4H), 9.34 (br s, 4H), 8.62 (d, J = 1.5
Hz, 2H), 8.59 (t, J = 1.6 Hz, 1H), 8.25 (d, J = 8.6 Hz, 4H), 8.05 (d, J =
8.5 Hz, 4H); ESI MS m/z 360.1 ([M + H]+ of free base); HPLC 100
area %. Anal. (C20H17N5O2·2.2HCl·1.9H2O) C, H, N, Cl.
4,4″-Bis[(5,5-dimethyl)-1,4,5,6-tetrahydropyrimidin-2-yl]-5′-
nitro-m-terphenyl Dihydrochloride (9). 9 was prepared analo-
gously to 4 from nitrile 45 (1.66 g, 5.11 mmol), but the imidate
intermediate was prepared in neat ethanolic HCl. The product was
purified by preparative HPLC and converted to the HCl salt using
ethanol HCl and ether to give an off-white solid (1.37g, 47%): mp
>389 °C (dec); 1H NMR δ 10.70 (br s, 4H), 8.61 (m, 3H), 8.27 (d, J
= 8.5 Hz, 4H), 8.01 (d, J = 8.6 Hz, 4H), 3.25 (s, 8H), 1.08 (s, 12H);
ESI MS m/z 496.4 ([M + H]+ of free base); HPLC 99.0 area %. Anal.
(C30H33N5O2·2HCl·H2O) C, H, N, Cl.
4,4″-Diamidino-5′-amino-m-terphenyl Dihydrochloride (10).
Nitro compound 8 (0.536 g, 1.24 mmol) was hydrogenated for 3 h at
60 psi over 10% Pd/C (90 mg, 0.055 mmol) in EtOH/H2O (2:1, 150
mL). The reaction mixture was filtered through Celite and evaporated
to a white solid. The product was recrystallized from EtOH−H2O to
give white crystals (401 mg, 80%): mp >250 °C (dec); 1H NMR δ
9.48 (br s, 4H), 9.25 (br s, 4H), 7.97 (d, J = 9.1 Hz, 4H), 7.93 (d, J =
9.1 Hz, 4H), 7.22 (t, J = 1.5 Hz, 1H), 7.01 (t, J = 1.5 Hz, 2H), 5.53 (br
s, 2H); ESI MS m/z 330.2 ([M + H]+ of free base); HPLC 100 area %.
Anal. (C20H19N5·2HCl·2.7H2O) C, H, N, Cl.
4,4″-Diamidino-5′-hydroxy-m-terphenyl Dihydrochloride
(11). Dinitrile 46 (0.77 g, 2.6 mmol) was converted to 4,4″-bis(N′-
hydroxy)amidino-5′-hydroxy m-terphenyl (free base) in 99% yield
following the procedure for compound 5: mp 160−163 °C; 1H NMR
δ 9.68 (br s, 3H), 7.76 (d, J = 9 Hz, 4H), 7.69 (d, J = 9 Hz, 4H), 7.37
(s, 1H), 7.05 (s, 2H), 5.84 (br s, 4H); 13C NMR δ 158.4, 151.5, 141.5,
141.0, 131.6, 126.6, 126.2, 116.2, 112.9; MS (ESI) m/z 363 ([M +
H]+).
To a solution of the diamidoxime (0.36 g, 1 mmol) in glacial acetic
acid (10 mL) was slowly added acetic anhydride (0.35 mL). After
stirring overnight, the solvent was evaporated to dryness under
reduced pressure and the oily residue obtained was used without
further purification, where it was dissolved in absolute ethanol (25
mL) and glacial AcOH (10 mL) followed by addition of 10%
palladium on carbon (80 mg). The mixture was hydrogenated on a
Parr apparatus at 50 psi for 4 h at room temperature. The mixture was
filtered through a filter aid and the filter pad washed with water. The
filtrate was evaporated under reduced pressure and the residue was
collected and washed with ether to give 11 as an acetate salt. The
diamidine was purified by neutralization with Na2CO3 followed by
filtration of the resultant solid and washing with water (3×). Finally,
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the free base was stirred with ethanolic HCl overnight, diluted with
ether, and the solid formed was filtered and dried to give the diamidine
hydrochloride salt 11 (77%): mp >300 °C; 1H NMR δ 10.12 (br s,
1H), 9.48 (br s, 4H), 9.26 (br s, 4H), 7.98 (d, J = 9 Hz, 4H), 7.95 (d, J
= 9 Hz, 4H), 7.52 (s, 1H), 7.23 (s, 2H); 13C NMR (DMSO-d6) δ
165.19, 158.7, 145.1, 140.6, 128.8, 127.3, 126.9, 116.8, 114.2. HRMS
calcd for C20H19N4O m/z 331.1559 ([M + H]
+ for free base);
observed 331.1564. Anal. (C20H18N4O·2.0HCl·0.8H2O·0.5EtOH) C,
H, N.
4,4″-Diamidino-5′-methoxy-m-terphenyl Dihydrochloride
(12). 12 was prepared from nitrile 47 (1.01 g, 3.22 mmol). The
product was purified by reverse phase flash chromatography and
converted to the HCl salt using aqueous HCl to give a gray solid (960
mg, 71%): mp >225 °C (dec); 1H NMR δ 9.51 (br s, 4H), 9.28 (br s,
4H), 8.11 (d, J = 8.5 Hz, 4H), 7.99 (d, J = 8.5 Hz, 4H), 7.71 (m, 1H),
7.40 (d, J = 1.3 Hz, 2H), 3.95 (s, 3H); ESI MS m/z 345.2 ([M + H]+
of free base); HPLC 98.4 area %. Anal. (C21H20N4O·2HCl·1.6H2O) C,
H, N, Cl.
3,3″-Diamidino-m-terphenyl Dihydrochloride (13). 13 was
prepared from nitrile 48 (1.01 g, 3.60 mmol). The product was
purified by preparative HPLC and converted to the HCl salt using
aqueous HCl to give a solid (716 mg, 51%): mp >350 °C; 1H NMR δ
9.69 (br s, 4H), 9.34 (br s, 4H), 8.48 (s, 1H), (8.37, s, 2H), 8.18 (d, J
= 8.0 Hz, 2H), 7.88 (d, J = 7.8 Hz, 4H), 7.75 (t, J = 7.8 Hz, 2H), 7.67
(t, J = 2.8 Hz, 1H); ESI MS m/z 315.3 ([M + H]+ of free base);
HPLC 100 area %. Anal. (C20H18N4·2HCl·0.6H2O) C, H, N, Cl.
3,3″-Bis(N-isopropyl)amidino-m-terphenyl Dihydrochloride
(14). An aliquot (0.95 g 2.13 mmol) of the imidate intermediate
prepared from nitrile 48 was reacted with isopropylamine and purified
analogously to 2 as a white solid (681 mg, 68%): mp >240 °C (dec);
1H NMR δ 9.83 (d, J = 8.0 Hz, 2H), 9.68 (br s, 2H), 9.22 (br s, 2H),
8.50 (s, 1H), (8.23, s, 2H), 8.13 (d, J = 7.4 Hz, 2H), 7.86 (dd, J = 7.5
and 1.5 Hz, 2H), 7.78 (d, J = 7.8 Hz, 2H), 7.73 (t, J = 7.6 Hz, 2H),
7.67 (t, J = 7.7 Hz, 1H), 4.13 (m, 1H), 1.33 (d, J = 6.4 Hz, 12H); ESI
MS m/z 398.3 ([M + H]+ of free base); HPLC 98.7 area %. Anal.
(C26H30N4·2HCl·1.2H2O) C, H, N, Cl.
3,3″-Bis(imidazolin-2-yl)-m-terphenyl Dihydrochloride (15).
15 was prepared from an aliquot of the imidate above (0.99 g, 2.22
mmol) and ethylenediamine. The product was purified by reverse
phase flash chromatography and then converted to the HCl salt using
ethanolic HCl−ether to give a white solid (775 mg, 79%): mp 325−
327 °C (dec); 1H NMR δ 11.04 (br s, 3H), 8.75 (s, 2H), 8.43 (s, 1H),
8.26 (d, J = 8.0 Hz, 2H), 8.08 (d, J = 7.9 Hz, 2H), 7.90 (dd, J = 7.5 and
1.5 Hz, 2H), 7.78 (t, J = 7.9 Hz, 2H), 7.67 (t, J = 7.8 Hz, 1H), 4.05 (s,
8H); ESI MS m/z 367.4 ([M + H]+ of free base); HPLC 99.5 area %.
Anal. (C24H22N4·2HCl·1.6H2O) C, H, N, Cl.
3,3″-Bis[(5,5-dimethyl)-1,4,5,6-tetrahydropyrimidin-2-yl]-m-
terphenyl Dihydrochloride (16). 16 was prepared from nitrile 48
(1.02 g, 3.64 mmol) and 2,2-dimethylpropane-1,3-diamine. After
purification by preparative HPLC, the crude HCl salt (prepared using
aqueous HCl) was dissolved in water and treated with aqueous NaOH
to precipitate the free base. This was converted to the HCl salt using a
mixture of ethanolic HCl, dioxane, and ether to give a white solid (671
mg, 35%): mp >335 °C (dec); 1H NMR δ 10.51 (br s, 4H), 8.58 (s,
1H), 8.37 (s, 2H), 8.16 (d, J = 8.0 Hz, 2H), 7.88 (dd, J = 8.7 and 1.6
Hz, 2H), 7.85 (d, J = 7.8 Hz, 2H), 7.75 (t, J = 7.8 Hz, 2H), 7.66 (t, J =
7.8 Hz, 1H), 3.52 (s, 8H), 1.07 (s, 12H); ESI MS m/z 451.3 ([M +
H ] + o f f r e e b a s e ) ; H P LC 1 0 0 a r e a % . A n a l .
(C30H34N4·2.3HCl·0.55H2O) C, H, N, Cl.
3,3″-Bis(N′-hydroxy)amidino-m-terphenyl Dihydrochloride
(17). 17 was prepared following the procedure for amidoxime 5
from nitrile 48 (2.81 g, 10.0 mmol). The amidoxime base was
recrystallized from EtOH to give white crystals (3.57 g, 103%): mp
212−213 °C; 1H NMR δ 9.70 (br s, 2H), 8.03 (t, J = 1.6 Hz, 2H), 8.01
(t, J = 1.5 Hz, 1H), 7.78 (dm, J = 7.7 Hz, 2H), 7.73 (m, 2H), 7.71 (m,
2H), 7.60 (dd, J = 8.4 and 7.9 Hz, 1H), 7.50 (t, J = 7.8 Hz, 2H), 5.98
(br s, 4H). Anal. (C20H18N4O2·0.9EtOH.) C, H, N.
An aliquot of the base (511 mg, 1.27 mmol) was converted to the
HCl salt using ethanolic HCl−ether to give a white solid (546 mg,
88%): mp >110 °C (dec); 1H NMR δ 11.32 (br s, 2H), 9.14 (br s,
4H), 8.33 (s, 1H), 8.21 (s, 2H), 8.14 (d, J = 7.5 Hz, 2H), 7.87 (dd, J =
7.7 and 1.6 Hz, 2H), 7.78 (dm, J = 7.8 Hz, 2H), 7.73 (t, J = 7.7 Hz,
2H), 7.67 (t, J = 7.8 Hz, 1H); ESI MS m/z 347.2 ([M + H]+ of free
base); HPLC 100 area %. Anal. (C20H18N4O2·2HCl·0.7H2O·-
0.8EtOH) C, H, N, Cl.
3,3″-Bis(N′-methoxy)amidino-m-terphenyl Dihydrochloride
(18). 18 was prepared from amidoxime base 17 either by the method
employed for compound 6 or using dimethyl sulfate and aqueous
NaOH in dioxane. The combined products from multiple experiments
were chromatographed on silica, eluting with hexanes/EtOAc (2:1)
and converted to the HCl salt using ethanolic HCl−ether to give a
white solid (1.69 g, 88% from salt conversion, 21% from amidoxime):
mp 235−237 °C (dec); 1H NMR δ 8.78 (br s, 2H), 8.34 (s, 1H), 8.24
(s, 2H), 8.09 (d, J = 8.0 Hz, 2H), 7.85 (dd, J = 7.7 and 1.6 Hz, 2H),
7.80 (d, J = 8.0 Hz, 2H), 7.67 (m, 3H), 3.89 (s, 6H); ESI MS m/z
375.2 ([M + H]+ of free base); HPLC 98.4 area %. Anal.
(C22H22N4O2·2HCl·0.3H2O) C, H, N, Cl.
3,3″-Diamidino-5′-chloro-m-terphenyl Dihydrochloride
(19). 19 was prepared from nitrile 49 (973 mg, 3.09 mmol). The
product was purified by reverse phase flash chromatography and
converted to the HCl salt using aqueous HCl to give a white solid
(469 mg, 26%): mp >350 °C; 1H NMR δ 9.65 (br s, 4H), 9.32 (br s,
4H), 8.42 (s, 1H), 8.36 (s, 2H), 8.23 (d, J = 7.9 Hz, 2H), 7.99 (d, J =
1.4 Hz, 2H), 7.91 (d, J = 7.9 Hz, 2H), 7.76 (t, J = 7.8 Hz, 2H); ESI MS
m/z 349.2 ([M + H]+ of free base); HPLC 100 area %. Anal.
(C20H17ClN4·2HCl·0.75H2O) C, H, N, Cl.
3,3″-Diamidino-5′-methoxy-m-terphenyl Dihydrochloride
(20). 20 was prepared from nitrile 50 (1.00 g, 3.23 mmol). The
product was purified by reverse phase flash chromatography and
converted to the HCl salt using aqueous HCl to give a light gray solid
(990 mg, 73%): mp >325 °C; 1H NMR δ 9.64 (br s, 4H), 9.27 (br s,
4H), 8.32 (s, 2H), 8.18 (d, J = 7.8 Hz, 2H), 7.97 (s, 1H), 7.87 (d, J =
7.9 Hz, 2H), 7.74 (t, J = 7.8 Hz, 2H), 7.44 (d, J = 1.2 Hz, 2H), 3.95 (s,
3H); ESI MS m/z 345.2 ([M + H]+ of free base); HPLC 100 area %.
Anal. (C21H20N4O·2HCl·1.3H2O) C, H, N, Cl.
3,4″-Diamidino-m-terphenyl Dihydrochloride (21). 21 was
prepared from nitrile 55 (1.00 g, 3.58 mmol). The crude product was
recrystallized from aqueous HCl to give a white solid (1.18 g, 85%):
mp >220 °C (dec); 1H NMR δ 9.61 (br s, 2H), 9.52 (br s, 2H), 9.32
(br s, 2H), 9.27 (br s, 2H), 8.29 (m, 1H), 8.23 (m, 1H), 8.18 (dm, J =
8.0 Hz, 1H), 8.12 (d, J = 8.7 Hz, 2H), 8.00 (d, J = 8.7 Hz, 2H), 7.89
(m,3H), 7.75 (t, J = 7.8 Hz, 1H), 7.68 (t, J = 7.8 Hz, 1H); ESI MS m/z
315.1 ([M + H]+ of free base); HPLC 97.5 area %. Anal.
(C20H18N4·2HCl·1.8H2O) C, H, N, Cl.
3,4″-Diamidino-5′-chloro-m-terphenyl Dihydrochloride
(22). Lithium bis(trimethylsilyl)amide (1 M solution in THF, 10
mL, 10 mmol) was added dropwise to a suspension of nitrile (1.00 g,
3.18 mmol) in dry THF (15 mL). The mixture was stirred overnight
and then cooled to 0 °C (ice−salt bath) before the slow addition of
saturated ethanolic HCl. After 2 h the stirred solution was diluted with
ether to precipitate the crude product, which was purified by
preparative HPLC. Conversion to the HCl salt using EtOH−aqueous
HCl followed by recrystallization from water−acetone gave a white
powder (750 mg, 56%): mp >260 °C (dec); 1H NMR δ 9.50 (br s,
4H), 9.27 (br s, 4H), 8.30 (m, 1H), 8.23 (dm, J = 8.1 Hz, 1H), 8.20 (t,
J = 1.5 Hz, 1H), 8.17 (d, J = 8.5 Hz, 2H), 8.00 (m, 3H), 7.95 (t, J = 1.7
Hz, 1H), 7.90 (dm, J = 8.3 Hz, 1H), 7.76 (t, J = 7.8 Hz, 1H); ESI MS
m/z 349.1 ([M + H]+ of free base); HPLC 100 area %. Anal.
(C20H17ClN4·2HCl·1.75H2O) C, H, N, Cl.
General Procedure for 1,3-Dipyridylbenzenediamidines 23−
25 and 29. A solution of the amidoxime (3−5 mmol) in acetic acid
was treated with acetic anhydride (5 mL), giving a precipitate. The
mixture was transferred to a hydrogenation bottle, and more AcOH
and 10% Pd/C (10−20 mol %) were added. The mixture was
hydrogenated at 60 psi until completion and filtered through Celite.
The product was purified by preparative HPLC and converted to the
HCl salt using aqueous HCl unless stated otherwise.
1,3-Bis(6-amidinopyridin-3-yl)benzene Dihydrochloride
(23). 23 was prepared from amidoxime 63 (1.28 g, 3.65 mmol) as a
white solid (668 mg, 47%): mp 342−343 °C; 1H NMR δ 9.71 (br s,
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4H), 9.50 (br s, 4H), 9.31 (d, J = 2.2 Hz, 2H), 8.68 (dd, J = 8.4 and 2.3
Hz, 2H), 8.52 (d, J = 8.4 Hz, 2H), 8.38 (m, 1H), 8.05 (dd, J = 7.8 and
1.7 Hz, 2H), 7.75 (t, J = 7.8 Hz, 1H); ESI MS m/z 317.1 ([M + H]+ of
free base); HPLC 100 area %. Anal. (C18H16N6·2HCl·1.5H2O) C, H,
N, Cl.
1,3-Bis(5-amidinopyridin-3-yl)benzene Trihydrochloride
(24). 24 was prepared from amidoxime 64 (1.04 g, 2.97 mmol) as a
white solid (542 mg, 42%): mp >300 °C; 1H NMR δ 9.79 (br s, 4H),
9.42 (br s, 4H), 9.38 (d, J = 2.1 Hz, 2H), 9.04 (d, J = 2.1 Hz, 2H), 8.78
(t, J = 2.1 Hz, 2H), 8.57 (m, 1H), 8.04 (dd, J = 7.7 and 1.7 Hz, 2H),
7.56 (t, J = 7.8 Hz, 1H); ESI MS m/z 317.1 ([M + H]+ of free base);
HPLC 97.5 area %. Anal. (C18H18N6·2.8HC·0.8H2O) C, H, N, Cl.
1,3-Bis(5-amidinopyridin-2-yl)benzene Trihydrochloride
(25). 25 was prepared from amidoxime 69 (1.17 g, 3.35 mmol).
The product was converted to the HCl salt using ethanolic HCl−ether
to give a white solid (992 mg, 76%): mp >350 °C; 1H NMR δ 9.71 (br
s, 4H), 9.41 (br s, 4H), 9.15 (t, J = 1.1 Hz, 2H), 9.01 (s, 1H), 8.44 (d, J
= 8.5 Hz, 2H), 8.40 (dd, J = 8.7 and 2.0 Hz, 2H), 8.37 (dd, J = 7.8 and
1.8 Hz, 2H), 7.75 (t, J = 7.8 Hz, 1H); ESI MS m/z 317.1 ([M + H]+ of
free base); HPLC 100 area %. Anal. (C18H16N6·3HCl·0.6H2O) C, H,
N, Cl.
1,3-Bis(5-amidinopyridin-2-yl)benzene Diacetate 26). 26 was
prepared and chromatographed analogously to 25 from amidoxime 69
(700 mg, 2.01 mmol). The product was converted to the free base
using aqueous NaOH. A mixture of the free base in H2O (20 mL) and
AcOH (2 mL) was heated and filtered, and the filtrate was lyophilized
to give the acetate salt (319 mg, 36%): mp >227−230 °C; 1H NMR δ
10.24 (br s, 8H), 9.10 (d, J = 1.4 Hz, 2H), 8.96 (t, J = 1.5 Hz 1H), 8.33
(m. 6H), 7.73 (t, J = 7.8 Hz, 1H), 1.79 (s, 6H); ESI MS m/z 317.1
([M + H]+ of free base); HPLC 100 area %. Anal.
(C18H18N6·2.25CH3CO2H·2H2O) C, H, N, Cl.
1,3-Bis-(5-N′-methoxyamidinopyridin-2-yl)benzene Tetra-
hydrochloride 27. To a suspension of diamidoxime 69 (348 mg,
1.00 mmol) in DMF (10 mL) was added LiOH·H2O (252 mg, 6.01
mmol, in 3 mL of H2O) which was followed by dimethyl sulfate (630
mg, 4.99 mmol). The reaction mixture was stirred overnight, after
which it was poured onto ice−water and the precipitate was filtered,
washed with water, and dried to give the free base of 27 in 77% yield:
mp 157−158 °C; 1H NMR δ 8.96 (s, 2H), 8.84 (s, 1H), 8.09−8.22
(m, 6H), 7.63 (t, J = 7.8 Hz, 1H), 6.30 (br s, 4H), 3.78 (s, 6H); 13C
NMR δ 156.1, 149.0, 146.8, 138.6, 134.3, 129.4, 127.5, 127.1, 124.7,
119.8, 60.7.
The free base (200 mg, 0.53 nM) was converted to the
tetrahydrochloride salt by stirring overnight in ethanol saturated
with HCl(g) to yield a pale yellow solid (205 mg, 69%): mp 196−
197.5 °C; MS m/z 377 ([M + H]+ of free base). Anal.
(C20H20N6O2·4.0 HCl·1.1H2O·0.5EtOH) C, H, N.
1,3-Bis[(5-[N′-dimethylaminoacetoxy]amidino)pyridin-2-yl]-
benzene (28). To a stirred solution of diamidoxime 69 (348 mg, 1.00
mmol) and K2CO3 (966 mg, 7 mmol) in DMF (10 mL) was added
dimethylaminoacetyl chloride hydrochloride (632 mg, 4 mmol). The
reaction mixture was stirred overnight at room temperature and then
poured onto brine solution. The precipitate was filtered, recrystallized
from methanol to furnish 28 in a 79% yield: mp 156−157.5 °C; 1H
NMR (DMSO-d6) δ 9.02 (s, 2H), 8.90 (s, 1H), 8.19−8.25 (m, 6H),
7.66 (m, 1H), 7.05 (s, 4H), 3.39 (s, 4H), 2.30 (s, 12H); 13C NMR
(DMSO-d6) δ 167.9, 157.2, 154.8, 147.6, 138.4, 135.6, 129.5, 127.9,
126.3, 125.0, 119.9, 58.2, 44.5; MS m/z 519 ([M + H]+ of free base).
HRMS calcd for C26H31N8O4 [M + H]
+ 519.2468; observed 519.2457.
Anal. (C26H30N8O4·1.25H2O) C, H, N.
1,3-Bis(4-amidinopyryidin-2-yl)benzene Dihydrochloride
(29). 29 was prepared by the general procedure from amidoxime 70
(2.19 g,5.34 mmol). The product was converted to the HCl salt using
ethanolic HCl with a trace of water to give a pale pink solid (1.22 g,
59%): mp 309−310 °C; 1H NMR δ 9.92 (br s, 4H), 9.59 (br s, 4H),
9.14 (s,1H), 9.00 (d, J = 5.1 Hz, 2H), 8.64 (s, 2H), 8.35 (dd, J = 8.7
and 1.7 Hz, 2H), 7.84 (dd, J = 5.1 and 1.6 Hz, 2H), 7.75 (t, J = 7.8 Hz,
1H); ESI MS m/z 317.1 ([M + H]+ of free base); HPLC 97.7 area %.
Anal. (C18H16N6·2.4HCl·1.1H2O) C, H, N, Cl.
3,3″-Bis(benzimidoylamino)-5′-chloro-m-terphenyl Dihy-
drochloride (30). A solution of 5′-chloro-3,3″-diamino-m-terphenyl
(72) in THF (30 mL) was added dropwise to a mixture of sodium
bis(trimethylsilyl)amide (2 M solution in THF, 6.0 mL, 12.0 mmol)
and THF (6.0 mL). The mixture was stirred for 20 min and then split
into two portions.
To the first aliquot was added a solution of benzonitrile (0.75 mL,
7.3 mmol), and the mixture was stirred for 3 days. More sodium
bis(trimethylsilyl)amide solution (3.0 mL, 6.0 mmol) was added, and
the reaction mixture was stirred an additional 3 h before being poured
over ice and extracted into CH2Cl2. The product was purified by
preparative HPLC and lyophilized. A solution of the lyophilized
product in EtOH, water, and 1 N HCl was evaporated, dissolved in hot
water, filtered, and lyophilized to give the HCl salt as a white powder
(682 mg, 42%): mp >200 °C (dec); 1H NMR (400 MHz) δ 11.72 (br
s, 2H), 9.95 (br s, 2H), 9.18 (br s, 2H), 8.07 (s, 1H), 8.02 (s, 2H), 7.97
(m, 6H), 7.89 (s, 2H), 7.80 (t, J = 7.4 Hz, 2H), 7.70 (m, 6H), 7.53 (d,
J = 7.9 Hz, 2H); ESI MS m/z 501.3 ([M + H]+ of free base); HPLC
98.8 area %. Anal. (C32H25ClN4·2HCl·1.5H2O) C, H, N, Cl.
3,3″-Bis(picolimidoylamino)-5′-chloro-m-terphenyl Dihy-
drochloride (31). 31 was prepared analogously to 30 using the
second aliquot from above and 2-cyanopyridine (0.89 g, 8.55 mmol) in
place of benzonitrile to give an off-white powder (661 mg, 41%): mp
>170 °C; 1H NMR (400 MHz) δ 11.94 (br s, 2H), 10.19 (br s, 2H),
9.46 (br s, 2H), 8.91 (d, J = 4.0 Hz, 2H), 8.55 (d, J = 7.9 Hz, 2H), 8.24
(t, J = 7.6 Hz, 2H), 8.08 (s, 1H), 8.02 (s, 2H), 7.96 (d, J = 7.7 Hz,
2H), 7.87 (m, 4H), 7.70 (t, J = 7.8 Hz, 2H), 7.54 (d, J = 7.7 Hz, 2H);
ESI MS m/z 503.3 ([M + H]+ of free base); HPLC 98.1 area %. Anal.
(C30H23ClN6·2HCl·2H2O) C, H, N, Cl.
3,4″-Bis(benzimidoylamino)-m-terphenyl Dihydrochloride
(32). Triethylamine (1.5 mL, 10.8 mmol) was added to a stirred
suspension of 3,4″-diamino-m-terphenyl dihydrochloride (77, 1.01 g,
3.03 mmol) in THF (50 mL). After 1.5 h benzonitrile (1.0 mL, 9.80
mmol) was added, followed by the slow addition of sodium
bis(trimethylsilyl)amide (2 M solution in THF, 8.0 mL, 16.0 mmol).
The reaction mixture was stirred for 3 days, poured over ice, and
extracted into CHCl3. The product was purified by preparative HPLC
and lyophilized. A solution of the lyophilized product in EtOH and 1
N HCl was evaporated, dissolved in hot water, filtered, and lyophilized
to give the HCl salt as a white powder (558 mg, 34%): mp 216 °C; 1H
NMR (400 MHz) δ 11.70 (br s, 2H), 9.92 (br s, 2H), 9.15 (br s, 2H),
8.07 (s, 1H), 7.98 (m, 7H), 7.91 (d, J = 7.3 Hz, 1H), 7.79 (m, 4H),
7.70 (m, 6H), 7.61 (d, J = 7.8 Hz, 2H), 7.51 (d, J = 7.3 Hz, 1H); ESI
MS m/z 467.6 ([M + H]+ of free base); HPLC 100 area %. Anal.
(C32H26N4·2HCl·1.5H2O) C, H, N, Cl.
3,4″-Bis(picolimidoylamino)-m-terphenyl Dihydrochloride
(33). 33 was prepared analogously to 32 with 2-cyanopyridine used
in place of benzonitrile as a yellow powder (1.04 g, 64%): mp 190 °C;
1H NMR (400 MHz) δ 11.96 (br s, 1H), 11.95 (br s, 1H), 10.17 (br s,
1H), 10.15 (br s, 1H), 9.45 (br s, 1H), 9.39 (br s, 1H), 8.91 (s, 2H),
8.56 (d, J = 8.0 Hz, 1H), 8.52 (d, J = 8.1 Hz, 1H), 8.24 (m, 2H), 8.08
(s, 1H), 8.01 (d, J = 8.2 Hz, 2H), 7.97 (s, 1H), 7.92 (d, J = 7.7 Hz,
1H), 7.87 (m, 2H), 7.80 (m, 2H), 7.71 (t, J = 7.9 Hz, 1H), 7.76 (t, J =
7.8 Hz, 1H), 7.62 (d, J = 8.2 Hz, 2H), 7.52 (d, J = 7.8 Hz, 1H); ESI
MS m/z 469.6 ([M + H]+ of free base); HPLC 98.9 area %. Anal.
(C30H24N6·2HCl·1.9H2O) C, H, N, Cl.
3,4″-Bis(benzimidoylamino)-5′-chloro-m-terphenyl Dihy-
drochloride (34). To a solution of 5″-chloro-3,4″-diamino-m-
terphenyl (78, 1.01 g, 3.42 mmol) and benzonitrile (1.10 g, 10.7
mmol) in THF (40 mL) was slowly added sodium bis(trimethylsilyl)-
amide (2 M solution in THF, 7.0 mL, 14.0 mmol). The mixture was
stirred for 3 days. Workup and purification were analogous to 32. The
final product was recrystallized from hot water to give a gray powder
(954 mg, 49%): mp >200 °C (dec); 1H NMR (400 MHz) δ 11.71 (br
s, 2H), 9.95 (br s, 2H), 9.19 (br s, 1H), 9.17 (br s, 1H), 8.06 (m, 4H),
7.98 (m, 5H), 7.87 (d, J = 8.4 Hz, 2H), 7.80 (t, J = 7.3 Hz, 2H), 7.70
(m, 5H), 7.63 (d, J = 8.0 Hz, 2H), 7.53 (d, J = 7.7 Hz, 1H); ESI MS
m/z 501.2 ([M + H]+ of free base); HPLC 98.7 area %. Anal.
(C32H25ClN4·2HCl·2.4H2O) C, H, N, Cl.
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3,4″-Bis(picolimidoylamino)-5′-chloro-m-terphenyl Dihy-
drochloride (35). 35 was prepared analogously to 34 with 2-
cyanopyridine used in place of benzonitrile. The HCl salt was prepared
using ethanolic HCl to give a yellow powder (668 mg, 34%): mp >190
°C (dec); 1H NMR (400 MHz) δ 11.94 (br s, 2H), 10.18 (br s, 1H),
10.16 (br s, 1H), 9.47 (br s, 1H), 9.41 (br s, 1H), 8.92 (m, 2H), 8.54
(d, J = 8.0 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.24 (m, 2H), 8.06 (t, J =
7.5 Hz, 4H), 7.97 (d, J = 7.9 Hz, 1H), 7.89 (m, 2H), 7.86 (m, 2H),
7.71 (t, J = 7.9 Hz, 1H), 7.63 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 7.9 Hz,
1H); ESI MS m/z 503.5 ([M + H]+ of free base); HPLC 98.9 area %.
Anal. (C30H23ClN6·2.5HCl·1.5H2O) C, H, N, Cl.
2-Isopropoxy-4-(picolimidoylamino)-5′-chloro-m-terphenyl
Dihydrochloride (36). 36 was prepared analogously to 34 from 4-
amino-5′-chloro-2-isopropoxy-m-terphenyl (90, 1.20 g, 3.55 mmol), 2-
cyanopyridine (0.67 g, 6.44 mmol), and sodium bis(trimethylsilyl)-
amide (2 M solution in THF, 3.0 mL, 6.0 mmol) in THF (60 mL).
The product was converted to the HCl salt using ethanolic HCl and
ether to give a solid (699 mg, 41%): mp >154 °C (dec); 1H NMR
(400 MHz) δ 11.88 (br s, 1H), 10.14 (br s, 1H), 9.38 (br s, 1H), 8.91
(d, J = 4.3 Hz, 1H), 8.50 (d, J = 8.0 Hz, 1H), 8.24 (td, J = 7.8 and 1.4
Hz, 1H), 7.87 (td, J = 7.4 and 4.8 Hz, 1H), 7.76 (m, 2H), 7.74 (s, 1H),
7.71 (d, J = 1.7 Hz, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.61 (t, J = 1.5 Hz,
1H), 7.52 (t, J = 7.5 Hz, 2H), 7.43 (tt, J = 7.3 and 2.1 Hz, 1H), 7.32 (s,
1H), 7.15 (dd, J = 8.1 and 1.4 Hz, 1H), 4.71 (septet, J = 6.0 H, 1H),
1.31 (d, J = 6.0 Hz, 6H); ESI MS m/z 442.8 ([M + H]+ of free base);
HPLC 100 area %. Anal. (C27H24ClN3O·2HCl·0.25H2O) C, H, N, Cl.
2-Isopropoxy-5-(picolimidoylamino)-5′-chloro-m-terphenyl
Dihydrochloride (37). 37 was prepared analogously to 36 from 5-
amino-5′-chloro-2-isopropoxy-m-terphenyl (91, 1.42 g, 4.20 mmol) to
give a solid (1.01 g, 50%): mp 172−177 °C; 1H NMR (400 MHz) δ
11.68 (br s, 1H), 10.03 (br s, 1H), 9.26 (br s, 1H), 8.89 (dd, J = 3.9
and 0.8 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.22 (td, J = 7.8 and 1.2 Hz,
1H), 7.85 (m, 2H), 7.75 (t, J = 7 1.6 Hz, 1H), 7.73 (s, 1H), 7.71 (t, J =
1.0 Hz, 1H), 7.67 (t, J = 1.7 Hz, 1H), 7.65 (d, J = 2.6 Hz, 1H), 7.51 (t,
J = 7.5 Hz, 2H), 7.43 (m, 2H), 7.33 (d, J = 9.1 Hz, 1H), 4.76 (septet, J
= 6.0 H, 1H), 1.31 (d, J = 6.0 Hz, 6H); ESI MS m/z 442.9 ([M + H]+
of free base); HPLC 99.1 area %. Anal. (C27H24ClN3O·2HCl·0.1H2O)
C, H, N, Cl.
General Suzuki Coupling Procedure for Cyano-Substituted
Terphenyls and Biphenyls 43−45, 47−50, and 53−56. A
solution of tetrakis(triphenylphosphine)palladium(0) (5−10 mol %)
and the dibromobenzene (1 equiv) in DME (50 mL) was stirred for
15−30 min under Ar. The boronic acid (2.2−2.5 equiv for double
couplings, 1−1.2 equiv for single couplings) was added, followed by
Na2CO3 (10% solution, 75 mL). The mixture was refluxed until
reaction was complete. The cooled reaction mixture was worked up by
extraction into an appropriate solvent. The product was purified by
chromatography on silica gel and recrystallization from an appropriate
solvent.
4,4″-Dicyano-m-terphenyl (43). 43 was prepared from 1,3-
dibromobenzene (38, 1.97 g, 8.35 mmol) and 4-cyanophenylboronic
acid (2.61g, 17.8 mmol). Column chromatography by gradient elution
using hexanes/EtOAc mixtures followed by recrystallization from
EtOAc−hexanes gave an ivory colored solid (1.59 g, 68%): mp 199−
203 °C; 1H NMR δ 8.09 (t, J = 1.8 Hz, 1H), 8.04 (d, J = 8.5 Hz, 4H),
8.97 (d, J = 8.4 Hz, 4H), 7.84 (dd, (d, J = 7.7 and 1.5 Hz, 2H), 7.66 (t,
J = 7.8 Hz, 1H); HPLC 100 area %. Anal. (C20H12N2) C, H, N.
4,4″-Dicyano-5′-chloro-m-terphenyl (44). 44 was prepared
from dibromobenzene 39 (1.62g, 6.00 mmol) and 4-cyanophenylbor-
onic acid (2.21 g, 15.0 mmol). Column chromatography, eluting with
CHCl3 followed by recrystallization from toluene containing a trace of
DMF, gave a white solid (1.48 g, 78%): mp 297−301 °C; 1H NMR δ
8.09 (m, 5H), 7.98 (d, J = 8.4 Hz, 4H), 7.92 (d, J = 1.5 Hz, 2H). Anal.
(C20H11ClN2) C, H, N.
4,4″-Dicyano-5′-nitro-m-terphenyl (45). 45 was prepared from
dibromobenzene 40 (1.69 g, 6.01 mmol) and 4-cyanophenylboronic
acid (2.21g, 15.0 mmol). The reaction mixture was poured over ice to
precipitate the crude product, which was recrystallized from DMF−
EtOH to give a solid (1.18 g, 60%): mp 319−320 °C; 1H NMR δ 8.58
(d, J = 1.5 Hz, 2H), 8.55 (t, J = 1.5 Hz, 1H), 8.18 (d, J = 8.3 Hz, 4H),
8.03 (d, J = 8.3 Hz, 4H). Anal. (C20H11N3O2·0.1H2O) C, H, N.
4,4″-Dicyano-5′-hydroxy-m-terphenyl (46). To a stirred
solution of 3,5-dibromophenol (41, 1.25 g, 5.0 mmol) and
tetrakis(triphenylphosphine)palladium (200 mg) in toluene (10 mL)
under a nitrogen atmosphere was added 5 mL of a 2 M aqueous
solution of Na2CO3 followed by 4-cyanophenylboronic acid (0.37 g,
2.5 mmol) in methanol (5 mL). The vigorously stirred mixture was
warmed to 80 °C for 12 h. The solvent was evaporated, and the
precipitate was partitioned between methylene chloride (200 mL) and
2 M aqueous Na2CO3 (15 mL) containing 3 mL of concentrated
ammonia. The organic layer was dried and then concentrated to
dryness under reduced pressure to afford 46 as a white solid in 76%
yield: mp 290−292 °C; 1H NMR δ 10.00 (br s, 1H), 7.92−7.94 (m,
8H), 7.58 (s, 1H), 7.15 (s, 2H); 13C NMR δ 158.5, 144.4, 140.5, 132.8,
127.8, 118.8, 116.9, 114.2, 110.3.
4,4″-Dicyano-5′-methoxy-m-terphenyl (47). 47 was prepared
from dibromobenzene 42 (1.60 g, 6.03 mmol) and 4-cyanophenylbor-
onic acid (2.21g, 15.0 mmol). Purification by column chromatography,
eluting with C2HCl2/hexanes (4:1) followed by recrystallization from
CH3CN−H2O, gave a solid (1.51 g, 81%): mp 239−241 °C; 1H NMR
δ 8.04 (d, J = 8.6 Hz, 4H), 7.95 (d, J = 8.5 Hz, 4H), 7.66 (t, J = 1.5 Hz,
1H), 7.37 (d, J = 1.5 Hz, 2H), 3.93 (s, 3H). Anal. (C21H14N2O2) C, H,
N.
3,3″-Dicyano-m-terphenyl (48).61 48 was prepared from 1,3-
dibromobenzene (38, 2.66 g, 11.3 mmol) and 3-cyanophenylboronic
acid (3.75 g, 25.5 mmol). Column chromatography, eluting with
hexanes/EtOAc (3:1) mixtures followed by recrystallization from
CH3CN, gave a white solid (2.38 g, 75%): mp 165−167 °C (lit.61
164−165°); 1H NMR δ 8.37 (t, J = 1.5 Hz, 2H), 8.18 (ddd, J = 8.0,
1.9, and 1.1 Hz, 2H), 8.13 (t, J = 1.6 Hz, 1H), 7.87 (dt, J = 7.7 and 1.4
Hz, 2H), 7.82 (dd, J = 8.0 and 1.5 Hz, 2H), 7.71 (t, J = 7.8 Hz, 2H),
7.55 (t, J = 7.6 Hz, 1H). Anal. (C20H12N2) C, H, N.
3,3″-Dicyano-5′-chloro-m-terphenyl (49). 49 was prepared
from dibromobenzene 39 (1.63 g, 6.03 mmol) and 3-cyanophenylbor-
onic acid (2.22 g, 15.1 mmol). Purification by column chromatog-
raphy, eluting with CHCl3 followed by recrystallization from DMF,
gave a light gray solid (991 mg, 52%): mp 279−277 °C; 1H NMR δ
8.43 (t, J = 1.6 Hz, 2H), 8.23 (dm, J = 8.0 Hz, 2H), 8.11 (t, J = 1.6 Hz,
1H), 7.93 (d, J = 1.6 Hz, 2H), 7.90 (dt, J = 7.9 and 1.3 Hz, 2H), 7.71
(t, J = 7.9 Hz, 2H). Anal. (C20H11ClN2·0.1H2O) C, H, N.
3,3″-Dicyano-5′-methoxy-m-terphenyl (50). 50 was prepared
from dibromobenzene 42 (1.33 g, 5.01 mmol) and 3-cyanophenylbor-
onic acid 1.84 g, 12.5 mmol). The product was chromatographed on
silica, eluting with CH2Cl2/hexanes (4:1) and recrystallized from
CH3CN−H2O to give a solid (1.32 g, 71%): mp 194−196 °C; 1H
NMR δ 8.38 (t, J = 1.5 Hz, 2H), 8.19 (dm, J = 8.7 Hz, 2H), 7.87 (dt, J
= 7.8 and 1.3 Hz, 2H), 7.70 (t, J = 1.5 Hz, 1H), 7.69 (t, J = 7.7 Hz,
2H), 7.37 (d, J = 1.5 Hz, 2H), 3.93 (s, 3H). Anal. (C21H14N2O) C, H,
N.
3-Bromo-4′-cyanobiphenyl (53). 53 was prepared from
iodobenzene 51 (3.06 g, 10.8 mmol) and 4-cyanophenylboronic acid
(1.50 g, 10.2 mmol). The product was chromatographed on a silica
column, eluting with hexanes/EtOAc (9:1) and recrystallized from
toluene−hexanes to give white crystals (1.86 g, 71%): mp 56−57 °C;
1H NMR δ 7.97 (t, J = 1.8 Hz, 1H), 7.95 (d, J = 8.5 Hz, 2H), 7.92 (d, J
= 8.9 Hz, 2H), 7.77 (ddd, J = 7.7, 1.6, and 1.0 Hz, 1H), 7.66 (ddd, J =
8.1, 2.0, and 1.1 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H). Anal. (C13H8BrN)
C, H, N.
3-Bromo-5-chloro-4′-cyanobiphenyl (54). 54 was prepared
from iodobenzene 52 (868 mg, 2.73 mmol) and 4-cyanophenylbor-
onic acid (402 mg, 2.73 mmol). The product was purified on a silica
column, eluting with hexane/EtOAc (9:1) to give a solid (0.47 g,
59%): mp 128−129 °C; 1H NMR δ 7.96 (m, 5H), 7.86 (m, 1H), 7.81
(m, 1H); HPLC 100 area %. Anal. (C13H7BrClN) C, H, N.
3,4″-Dicyano-m-terphenyl (55). 55 was prepared from bromo-
biphenyl 53 (2.59 g, 10.0 mmol) and 3-cyanophenylboronic acid (1.77
g, 12.1 mmol). The product was chromatographed on a silica column,
eluting with CHCl3 and recrystallized from CH3CN−H2O to give
white crystals (2.35 g, 83%): mp 139−142 °C; 1H NMR δ 8.37 (t, J =
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1.5 Hz, 1H), 8.16 (dm, J = 8.0 Hz, 1H), 8.12 (t, J = 1.8 Hz, 1H), 8.06
(d, J = 8.7 Hz, 2H), 7.97 (d J = 8.7 Hz, 2H), 7.87 (dt, J = 7.8 and 1.3
Hz, 1H), 7.82 (m, 2H), 7.70 (t, J = 7.8 Hz, 1H), 7.64 (t, J = 7.7 Hz,
1H). Anal. (C20H12N2) C, H, N.
5′-Chloro-3,4″-dicyano-m-terphenyl (56). 56 was prepared
from 54 (1.20 g, 4.11 mmol) and 3-cyanophenylboronic acid (788
mg, 5.36 mmol). The reaction mixture was diluted with water to
precipitate the product, which was then recrystallized from CH3CN to
give a solid (950 mg, 74%): mp 235−236 °C; 1H NMR δ 8.42 (d, J =
1.6 Hz, 1H), 8.21 (ddd, J = 8.0, 1.8, and 1.1 Hz, 1H), 8.09 (m, 3H),
7.98 (d, J = 8.5 Hz, 2H), 7.94 (t, J = 1.7 Hz, 1H), 7.89 (m, 2H), 7.71
(t, J = 7.8 Hz, 1H); HPLC 97.1 area %. Anal. (C20H11ClN2) C, H, N.
5- (4 ,4 ,5 ,5-Tetramethyl -1 ,3 ,2-dioxaborolan-2-y l ) -
picolinonitrile (59). A mixture of 5-bromopicolinonitrile (57, 2.93 g,
16.0 mmol), bis(pinacolato)diboron (4.50 g, 17.7 mmol),
PdCl2·CH2Cl2 (401 mg, 0.191 mmol), and potassium acetate (4.75
g, 48.4 mmol) in DMSO (45 mL) was heated for 90 °C for 6 h. The
reaction mixture was partitioned between water and toluene and then
filtered through Celite, and the aqueous layer was extracted with
toluene. The dried extracts were evaporated to a solid (3.11 g, 85%)
which was used directly in the next step: 1H NMR δ 8.88 (m, 1H),
8.22 (m, 1H), 8.04 (m, 1H), 1.33 (s, 12H).
5- (4 ,4 ,5 ,5-Tetramethyl -1 ,3 ,2-dioxaborolan-2-y l ) -
nicotinonitrile (60). 60 was prepared analogously to 59 from 5-
bromonicotinonitrile (58, 5.16 g, 28.19 g) to give a solid (6.37 g, 98%)
which was used directly in the next step: 1H NMR δ 9.14 (d, J = 2.1
Hz, 1H), 8.99 (d, J = 1.5 Hz, 1H), 8.40 (t, J = 1.9 Hz,, 1H), 1.33 (s,
12H).
General Suzuki Coupling Procedure for Dipyridylbenzene
Derivatives 61, 62, 67, and 68. A mixture of the appropriate aryl
halide and boronic acid or ester, tetrakis(triphenylphosphine)-
palladium(0) (0.05 equiv), and silver carbonate (2.5 equiv) was
stirred in refluxing THF until reaction was complete (2−3 h). The
reaction mixture was filtered through Celite, and the Celite pad was
rinsed with hot THF. The evaporated filtrate was purified by column
chromatography or by direct recrystallization.
1,3-Bis(6-cyanopyridin-3-yl)benzene (61). 61 was prepared
from 1,3-diodobenzene (2.02 g, 6.12 mmol) and 5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile (59, 3.11 g, 13.5
mol). Column chromatography on silica, eluting with 2% MeOH in
CHCl3 followed by recrystallization of the crude product from
CH3CN−ether, gave a white solid (1.04 g, 60%): mp 233−236 °C; 1H
NMR δ 9.27 (d, J = 2.2 Hz, 2H), 8.53 (dd, J = 8.2 and 2.3 Hz, 2H),
8.30 (t, J = 1.8 Hz, 1H), 8.19 (d, J = 8.1 Hz, 2H), 7.98 (dd, J = 7.8 and
1.8 Hz, 2H), 7.83 (t, J = 7.8 Hz, 1H); HPLC 98.0 area %. Anal.
(C18H10N4) C, H, N.
1,3-Bis(5-cyanopyridin-3-yl)benzene (62). 62 was prepared
from 1,3-diiodobenzene (1.65 g, 5.00 mmol) and boronate ester 60
(2.88 g, 12.5 mmol). The crude product was directly recrystallized
from CH3CN−ether to give a white solid (981 mg, 69%): mp 254−
255 °C; 1H NMR δ 9.37 (d, J = 2.3 Hz, 2H), 9.07 (d, J = 1.9 Hz, 2H),
8.86 (t, J = 2.2 Hz, 2H), 8.30 (t, J = 1.8 Hz, 1H), 7.97 (dd, J = 7.8 and
1.8 Hz, 2H), 7.71 (t, J = 7.8 Hz, 1H); HPLC 98.2 area %. Anal.
(C10H10N4·0.2H2O) C, H, N.
General Procedure for Amidoximes 63, 64, 69, and 70.
Potassium tert-butoxide (10 equiv) was added to a solution of
hydroxylamine hydrochloride (10 equiv) in DMSO (0.5−0.6 mL/
mmol hydroxylamine hydrochloride). After 1 h the nitrile (1 equiv)
was added and the reaction mixture was stirred overnight. The reaction
mixture was poured over ice. The resulting precipitated product was
filtered off and dried.
1,3-Bis(6-N′-hydroxyamidinopyridin-3-yl)benzene (63). 63
was prepared from nitrile 61 (1.03 g, 3.65 mmol) to give a white
solid (1.28 g, 101%): 1H NMR δ 10.06 (s, 2H), 9.02 (d, J = 2.3 Hz,
2H), 8.26 (dd, J = 8.4 and 2.3 Hz, 2H), 8.14 (t, J = 1.6 Hz, 1H), 7.96
(d, J = 8.4 Hz, 2H), 7.84 (dd, J = 7.7 and 1.6 Hz, 2H), 7.66 (t, J = 7.4
Hz, 1H), 5.91 (br s, 4H); HPLC 97.2 area %. The product was used in
the next step without further purification.
1,3-Bis(5-N′-hydroxyamidinopyridin-3-yl)benzene (64). 64
was prepared from nitrile 62 (858 mg, 3.04 mmol) to give a light
gray solid (1.07 g, 101%): 1H NMR δ 9.92 (s, 2H), 9.02 (d, J = 2.2 Hz,
2H), 8.90 (d, J = 1.9 Hz, 2H), 8.38 (t, J = 2.0 Hz, 2H), 8.19 (m, 1H),
7.87 (dd, J = 7.8 and 1.5 Hz, 2H), 7.68 (t, J = 8.0 Hz, 1H), 6.14 (br s,
4H). The product was used in the next step without further
purification.
1,3-Bis(5-cyanopyridin-2-yl)benzene (67). 67 was prepared
analogously to 61 from bromopyridine 65 (2.02 g, 11.0 mmol) and
1,3-benzenediboronic acid (912 mg, 5.5 mmol). The product was
purified on a column of silica, eluting with a gradient of 0−2% MeOH
in CHCl3 followed by recrystallization from CH3CN to give a solid
(976 mg, 63%): mp 241−242 °C; 1H NMR δ 9.16 (dd, J = 2.0 and 0.9
Hz, 2H), 8.99 (t, J = 1.9 Hz, 1H), 8.46 (dd, J = 8.4 and 2.1 Hz, 2H),
8.37 (dd, J = 8.3 and 1.0 Hz, 2H), 8.33 (dd, J = 7.9 and 1.8 Hz, 2H),
7.73 (t, J = 7.8 Hz, 1H); HPLC 98.0 area %. Anal. (C18H10N4) C, H,
N.
1,3-Bis(4-cyanopyridin-2-yl)benzene (68). 68 was prepared
analogously to 61 from bromopyridine 66 (4.50 g, 24.6 mmol) and
1,3-benzenediboronic acid (2.00 g, 12.1 mmol). After filtration of the
reaction mixture through Celite, the filtrate was concentrated and
diluted with ether to give a precipitate (2.98 g, 87%): mp 238−239 °C;
1H NMR δ 8.96 (dd, J = 5.0 and 0.9 Hz, 2H), 8.91 (t, J = 1.7 Hz, 1H),
8.69 (t, J = 1.1 Hz, 2H), 8.32 (dd, J = 7.8 and 1.8 Hz, 2H), 7.88 (dd, J
= 5.0 and 1.4 Hz, 2H), 7.71 (t, J = 7.8 Hz, 1H); HPLC 99.0 area %.
Anal. (C10H18N4) C, H, N.
1,3-Bis(5-N′-hydroxyamidinopyryidin-2-yl)benzene (69). 69
was prepared analogously to 63 from nitrile 67 (0.960 g, 3.40 mmol)
to give a light gray solid (1.20 g, 101%): 1H NMR δ 9.92 (s, 2H), 9.01
(dd, J = 1.8 and 1.2 Hz, 2H), 8.87 (t, J = 1.6 Hz, 1H), 8.20 (dd, J = 7.8
and 1.8 Hz, 2H), 8.15 (m, 4H), 7.68 (t, J = 7.8 Hz, 1H), 6.07 (br s,
4H); HPLC 98.5 area %. The product was used in the next step
without further purification.
1,3-Bis(4-N′-hydroxyamidinopyryidin-2-yl)benzene (70). 70
was prepared analogously to 63 from nitrile 68 (1.51 g, 5.34 mmol).
The sticky, filtered precipitate was dissolved in hot ethanol, and the
solution was evaporated to a light gray solid (2.19 g, 118%, wet): 1H
NMR δ 10.12 (s, 2H), 8.88 (t, J = 1.6 Hz, 1H), 8.71 (d, J = 5.1 Hz,
2H), 8.30 (s, 2H), 8.21 (dd, J = 7.8 and 1.7 Hz, 2H), 7.66 (m, 3H),
6.20 (br s, 4H); HPLC 98.0 area %. The product was used in the next
step without further purification.
Nitro-Substituted Terphenyl and Biphenyl Derivatives 71
and 73−76. Compounds 71 and 73−76 were prepared by Suzuki
coupling reaction conditions analogous to those for compounds 43−
45, 47−50, and 53−56.
5′-Chloro-3,3″-dinitro-m-terphenyl (71). 71 was prepared from
dibromide 39 (1.35 g, 5.00 mmol) and 3-nitrophenylboronic acid
(1.85 g, 11.1 mmol). The reaction mixture was poured over ice, and
the precipitated crude product was recrystallized from DMF as a gray
solid (1.35 g, 76%): mp 242−243 °C; 1H NMR δ 8.66 (t, J = 2.0 Hz,
2H), 8.34 (dm, J = 8.5 Hz, 2H), 8.29 (dm, J = 8.2 Hz, 2H), 8.16 (t, J =
1.6 Hz, 1H), 7.97 (d, J = 1.6 Hz, 2H), 7.81 (t, J = 8.0 Hz, 2H). Anal.
(C18H11ClN2O4·0.2H2O) C, H, N.
5′-Chloro-3,3″-diamino-m-terphenyl (72). A mixture of dini-
troterphenyl 71 (2.98 g, 8.40 mmol) and tin(II) chloride dihydrate (3
× 10.0 g portions, 133 mmol) in EtOH (100 mL) was refluxed for 3 h.
The reaction mixture was diluted with water, neutralized by cautious
addition of NaHCO3, and extracted into CH2Cl2. Both layers were
filtered through Celite, and the aqueous layer was extracted with
CH2Cl2. Combined dried extracts were evaporated to a white solid
(2.16 g, 87%), which was recrystallized from EtOH to give a white
solid (1.24 g, 50%): mp 153−154 °C; 1H NMR δ 7.65 (t, J = 1.6 Hz,
1H), 7.53 (d, J = 1.6 Hz, 2H), 7.13 (t, J = 7.8 Hz, 2H), 6.92 (t, J = 1.9
Hz, 2H), 6.86 (dd, J = 7.6 and 0.9 Hz, 2H), 6.62 (ddd, J = 8.0, 2.2, and
0.9 Hz, 2H), 5.20 (br s, 4H); ESI MS m/z 295.7 ([M + H]+). Anal.
(C18H15ClN2·0.1H2O) C, H, N.
3-Bromo-4′-nitrobiphenyl (73). 73 was prepared from iodoben-
zene 51 (5.76 g, 20.4 mmol) and 4-nitrophenylboronic acid pinacol
ester (5.04 g, 20.2 mmol). The product was purified on a column of
silica, eluting with a gradient of 0−40% EtOAc in hexanes and
recrystallized from EtOAc/hexanes to give yellow crystals (4.60 g,
82%): mp 88 °C; 1H NMR δ 8.31 (d, J = 8.8 Hz, 2H), 8.01 (m, 3H),
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7.87 (dm, J = 7.8 Hz, 1H), 7.69 (dm, J = 9.0 Hz, 1H), 7.50 (t, J = 7.9
Hz, 1H); HPLC 98.8 area %. Anal. (C12H8BrN2O) C, H, N.
3-Bromo-5-chloro-4′-nitrobiphenyl (74). 74 was prepared from
iodobenzene 52 (2.55 g, 8.04 mmol) and 4-nitrophenylboronic acid
pinacol ester (2.00 g, 8.04 mmol). The product was purified on a
column of silica, eluting with hexanes/EtOAc (19:1) and recrystallized
from EtOAc−hexane to give white crystals (1.51 g, 60%): mp 147−
148 °C; 1H NMR δ 8.30 (d, J = 8.7 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H),
8.00 (t, J = 1.6 Hz, 1H), 7.92 (t, J = 1.7 Hz, 1H), 7.84 (t, J = 1.7 Hz,
1H); HPLC 100 area %.
3,4″-Dinitro-m-terphenyl (75). 75 was prepared from bromobi-
phenyl 73 (4.53 g, 16.3 mmol) and 3-nitrophenylboronic acid (2.82 g,
16.9 mmol). Column chromatography, eluting with a gradient from
hexanes/EtOAc (4:1) to neat EtOAc followed by recrystallization
from EtOH, gave a white solid (3.27 g, 63%): mp 188−189 °C; 1H
NMR δ 8.60 (t, J = 2.0 Hz, 1H), 8.34 (dm, J = 8.9 Hz, 2H), 8.28 (m,
2H), 8.17 (t, J = 1.7 Hz, 1H), 8.13 (dm, J = 8.9 Hz, 2H), 7.89 (m, 2H),
7.81 (t, J = 8.0 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H). Anal.
(C18H12N2O4·0.05H2O) C, H, N.
5′-Chloro-3,4″-dinitro-m-terphenyl (76). 76 was prepared from
bromobiphenyl 74 (2.09 g, 6.68 mmol) and 3-nitrophenylboronic acid
(1.69 g, 8.33 mmol). The reaction mixture was diluted with water. The
resulting precipitate was filtered off, dried, and purified by suspension
in hot ethanol to give a light gray solid (2.18 g, 92%): mp 216−218
°C; 1H NMR δ 8.64 (t, J = 2.0 Hz, 1H), 8.33 (m, 3H), 8.29 (ddd, J =
8.2, 2.2, and 0.9 Hz, 1H), 8.17 (d, J = 8.9 Hz, 2H), 8.14 (t, J = 1.6 Hz,
1H), 7.99 (t, J = 1.7 Hz, 1H), 7.95 (t, J = 1.7 Hz, 1H), 7.81 (t, J = 8.0
Hz, 1H); HPLC 100 area %. Anal. (C18H11ClN2O4·0.5H2).
3,4″-Diamino-m-terphenyl Dihydrochloride (77). A mixture of
dinitroterphenyl 75 (3.00 g, 9.37 mmol) and 10% Pd/C (0.60 g, 0.56
mmol) in EtOH (300 mL) was hydrogenated at 60 psi. The reaction
mixture was filtered through Celite. The filtrate was concentrated to a
small volume, treated with saturated ethanolic HCl, and diluted with
ether to give the hydrochloride salt as a white solid (2.24 g, 72%): mp
>250 °C (dec); 1H NMR δ 10.10 (br s, 4H), 7.89 (m, 1H), 7.85 (d, J
= 8.5 Hz, 2H), 7.77 (dm, J = 7.8 Hz, 1H), 7.72 (m, 2H), 7.61 (m, 3H),
7.43 (d, J = 8.5 Hz, 2H), 7.36 (dm, J = 7.8 Hz, 1H). Anal.
(C18H16N2·2HCl·0.2H2O) C, H, N, Cl.
5″-Chloro-3,4″-diamino-m-terphenyl (78). Iron powder (3.60
g, 64.5 mmol) was added to a mixture of dinitroterphenyl 76 (2.19 g,
6.15 mmol) and ammonium chloride 1.02 g, 19.1 mmol) in refluxing
EtOH/H2O (2:1 mixture, 90 mL), and refluxing was continued for 2.5
h. The reaction mixture was cooled and filtered through Celite. The
filtrate was diluted with water and extracted into ether. The extract was
concentrated to ∼50 mL and treated with saturated ethanolic HCl (3
mL) to precipitate the HCl salt (1.94 g, 85%). The salt was dissolved
in hot water, filtered, and diluted with NaOH solution to precipitate
the free base as a white solid (1.26 g, 69%) which was used directly in
the next step: 1H NMR δ 7.62 (t, J = 1.5 Hz, 1H), 7.51 (t, J = 1.7 Hz,
1H), 7.45 (d, J = 8.6 Hz, 2H), 7.39 (t, J = 1.7 Hz, 1H), 7.12 (t, J = 7.8
Hz, 1H), 6.91 (t, J = 1.9 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 6.65 (d, (t,
J = 8.5 Hz, 2H), 6.60 (d, J = 7.9 Hz, 1H), 5.34 (br s, 2H), 5.17 (br s,
2H); HPLC 96.3 area %.
4-Amino-3-chlorobiphenyl (80). 80 was prepared analogously to
compound 71 from 4-bromo-2-chloroaniline (79, 5.25 g, 25.4 mmol)
and phenylboronic acid (3.75 g, 30.8 mmol). The product was
chromatographed on a column of silica, eluting with 15−20% EtOAc
in hexanes followed by recrystallization from hexanes to give a solid
(3.62 g, 70%): mp 69−70 °C; 1H NMR δ 7.56 (d, J = 7.3 Hz, 2H),
7.50 (d, J = 2.0 Hz, 1H), 7.38 (m, 3H), 7.25 (t, J = 7.3 Hz, 1H), 6.87
(d, J = 8.4 Hz, 1H), 5.48 (s, 2H); HPLC 100 area %. Anal.
(C12H10ClN) C, H, N.
4-Amino-3-bromo-5-chlorobiphenyl (81). N-Bromosuccini-
mide (3.84 g, 21.6 mmol) was added to a solution of aminobiphenyl
80 (4.33 g, 21.3 mmol) in THF (60 mL) at 0 °C. After 1 h the
reaction mixture was quenched with NaHSO3 solution, neutralized
with NaHCO3 solution, and extracted into EtOAc. Column
chromatography on silica, eluting with hexanes/EtOAc (9:1) followed
by recrystallization from EtOAc−hexanes, gave crystals (5.00 g, 83%):
mp 111−112 °C; 1H NMR δ 7.71 (d, J = 2.1 Hz, 1H), 7.61 (t, J = 2.0
Hz, 2H), 7.59 (m, 1H), 7.41 (tm, J = 7.6 Hz, 2H), 7.30 (tm, J = 7.3
Hz, 1H), 5.54 (s, 2H); HPLC 100 area %. Anal. (C12H9BrClN) C, H,
N.
3-Bromo-5-chlorobiphenyl (82). A solution of 4-amino-3-
bromo-5-chlorobiphenyl (81, 4.51 g, 16.0 mmol) in EtOH (25 mL)
was treated dropwise with H2SO4 (5 mL). Sodium nitrite (2.74 g, 39.7
mmol) was added, and the mixture was refluxed for 30 min. The
reaction mixture was poured over ice and excess NaHCO3 and then
extracted into EtOAc. Column chromatography on silica, eluting with
hexanes, gave a clear oil that solidified upon standing (4.52 g, 86%):
mp 32−33 °C; 1H NMR δ 7.85 (t, J = 1.5 Hz, 1H), 7.77 (t, J = 1.6 Hz,
1H), 7.73 (m, 3H), 7.49 (m, 2H), 7.43 (m, 1H); HPLC 99.5 area %.
Anal. (C12H8BrCl) C, H, N.
(5-Chloro-biphenyl-3-yl)boronic Acid (83). Butyllithium (2.5
M/hexanes, 4.5 mL, 11.25 mmol) was added dropwise over 15 min to
a solution of 3-bromo-5-chlorobiphenyl (82, 2.49 g, 9.31 mmol) in
THF (150 mL) at −78 °C. The mixture was maintained for 1 h before
the dropwise addition of triisopropyl borate (4.5 mL, 19.6 mmol). The
mixture was maintained another hour at −78 °C before being warmed
to ambient temperature. The reaction mixture was quenched with 1 N
HCl (150 mL) and extracted with ether. The dried extract was
evaporated to a white solid (2.12 g, 98%) which was used in the next
step without further purification.
5′-Chloro-2-isopropoxy-4-nitro-m-terphenyl (88). 88 was
prepared analogously to compounds 43−50 from bromobenzene 86
(1.35 g, 5.17 mmol) and boronic acid 83 (1.54 g, 6.62 mmol). The
product was purified on a column of silica, eluting with hexanes/
EtOAc (50:1) followed by recrystallization from EtOH to give yellow
crystals (1.57 g, 82%): mp 100−101 °C; 1H NMR δ 7.89 (m, 2H),
7.80 (t, J = 1.8 Hz, 1H), 7.76 (m, 4H), 7.63 (t, J = 1.7 Hz, 1H), 7.50
(tm, J = 7.4 Hz, 2H), 7.42 (tm, J = 7.3 Hz, 1H), 4.87 (septet, J = 6.0
Hz, 1H), 1.30 (d, J = 6.0 Hz, 6H); HPLC 96.2 area %. Anal.
(C21H18ClNO3) C, H, N.
5′-Chloro-2-isopropoxy-5-nitro-m-terphenyl (89). 89 was
prepared analogously to compounds 43−50 from bromobenzene 87
(1.30 g, 5.01 mmol) and boronic acid 83 (1.50 g, 1.29 mmol). The
product was purified on a column of silica, eluting with hexane/EtOAc
(17:3) to give a white solid (1.68 g, 91%): mp 111 °C; 1H NMR δ
8.28 (dd, J = 7.5 and 2.9 Hz, 1H), 8.26 (d, J = 2.9 Hz, 1H), 7.80 (t, J =
1.5 Hz, 1H), 7.77 (d, J = 1.4 Hz, 1H), 7.74 (t, J = 1.8 Hz, 2H), 7.63 (t,
J = 1.7 Hz, 1H), 7.50 (t, J = 7.5 Hz, 2H), 7.41 (m, 2H), 4.91 (septet, J
= 6.0 Hz, 1H), 1.32 (d, J = 6.0 Hz, 6H); HPLC 100%. Anal.
(C21H18ClNO3) C, H, N.
4-Amino-5′-chloro-2-isopropoxy-m-terphenyl (90). A solu-
tion of nitroterphenyl 88 (1.57 g, 4.26 mmol) in EtOH (75 mL) was
brought to reflux. Tin(II) chloride dihydrate (5.18 g, 29.6 mmol) was
slowly added via the condenser, and refluxing was continued for 1.5 h.
The reaction mixture was portioned between ether and water basified
with 1 N NaOH, and the aqueous layer was extracted twice with ether.
Combined extracts were filtered through Celite. Column chromatog-
raphy on silica, eluting with hexanes/EtOAc (3:2), gave a glass (1.20 g,
83%): 1H NMR δ 7.70 (d, J = 7.2 Hz, 2H), 7.66 (t, J = 1.5 Hz, 1H),
7.48 (m, 4H), 7.40 (t, J = 7.3 Hz, 1H), 7.13 (d, J = 8.2 Hz, 1H), 6.34
(d, J = 2.0 Hz, 1H), 6.25 (dd, J = 8.2 and 2.0 Hz, 1H), 5.30 (s, 2H),
4.47 (septet, J = 6.1 Hz, 1H), 1.25 (d, J = 6.0 Hz, 6H). The product
was used in the next step without further purification.
5-Amino-5′-chloro-2-isopropoxy-m-terphenyl (91). 91 was
prepared analogously to compound 90 from nitroterphenyl 89 (1.64 g,
4.46 mmol). Column chromatography on silica, eluting with hexane/
EtOAc (2:1), gave a glass (1.42 g, 94%): 1H NMR δ 7.72 (m, 3H),
7.64 (t, J = 1.8 Hz, 1H), 7.51 (m, 3H), 7.41 (tm, J = 7.3 Hz, 1H), 6.84
(d, J = 8.7 Hz, 1H), 6.69 (d, J = 2.9 Hz, 1H), 6.57 (dd, J = 8.6 and 2.8
Hz, 1H), 4.79 (s, 2H), 4.15 (septet, J = 6.1 Hz, 1H), 1.11 (d, J = 6.0
Hz, 6H); HPLC 97.5 area %. The product was used in the next step
without further purification.
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African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed espe-
cially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple
diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed
efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness.
The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010
than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gam-
biense isolates frommelarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diami-
dines for the treatment of second-stage African sleeping sickness.
African sleeping sickness, also known as human Africantrypanosomiasis (HAT), is a tropical disease that threatens
millions of people living in sub-Saharan Africa (1). It is caused by
two subspecies of the single-celled parasite Trypanosoma brucei,
Trypanosoma brucei gambiense and Trypanosoma brucei rhod-
esiense. The protozoans are transmitted by the bite of infected
tsetse flies. The disease is fatal without effective treatment. The
burden of the disease has been reduced to some extent by in-
creased control interventions, but the disease is still one of the
most neglected tropical diseases, and it is estimated by the WHO
that there are still 25,000 to 30,000 infected patients (2, 3).
HAT progresses in two stages. In the first stage, the parasites
reside in the blood and the lymphatic system. In the second stage,
the parasites cross the blood-brain barrier (BBB) and spread the
infection to the central nervous system (CNS), leading to neuro-
logical and psychiatric disorders, including irregular and frag-
mented sleeping patterns, behavioral changes, motor weakness,
coma, and ultimately death (4).
Patients can be cured only by effective and safe drugs. Vaccines
are not available and are unlikely to be developed in the near
future, and self-healing through the body’s own immune system is
also not possible due to antigenic variation of the surface glyco-
proteins of the parasites (5). The drugs currently available have
serious disadvantages such as adverse effects, limited efficacy,
complicated treatment schedules, and the need for parenteral ad-
ministration. New drugs are therefore needed, especially for the
second stage of the disease.
In the search for new drugs, aromatic diamidines are seen as
promising candidates for use against HAT. These compounds are
known to have a broad spectrum of antiprotozoal activities (6).
Pentamidine has been in use since the 1940s for first-stage T. b.
gambiense HAT and against leishmaniasis and Pneumocystis ji-
rovecii pneumonia (7). Diminazene (8) and isometamidium (a
monoamidine) are used to treat animal trypanosomiasis. There-
fore, considerable effort has been put into the synthesis and inves-
tigation of novel aromatic diamidines with improved properties
for use against HAT.
One problem with diamidines is that they are protonated at
physiological pH and therefore do not easily cross the gastrointes-
tinal tract and the BBB by diffusion. Their cationic nature was
therefore believed to reduce their potential for use as oral drugs
and to reduce their efficacy against second-stage HAT by any
route of administration; therefore, much effort went into the de-
sign of prodrugs (6, 9). Prodrugs are inactive against trypano-
somes in vitro but can be metabolized to the active diamidine
molecules by host enzymes upon administration in vivo (10–12),
thus serving as potentially orally active drugs. The prodrug ap-
proach worked well with regard to oral bioavailability in animal
models (9, 13, 14) as well as in humans, in whom the prodrug
DB289 (pafuramidine maleate) underwent clinical trials as the
first oral drug for treatment of first-stage HAT patients (15, 16).
Several other prodrugs have been tested in the second-stage
mousemodel, but few of themwere able to cure CNS infections in
mice (14, 17).
During a series of tests in our laboratory, we discovered that the
diamidine DB829 was intrinsically active in second-stage animal
models (14, 18). This was unexpected, as simple diamidines (ami-
dines without substituents on either nitrogen atom) are thought
to be unable to cross the BBB by diffusion due to their cationic
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nature. For many years, DB829 remained the only diamidine that
showed high CNS activity in vivo (14, 19).
Recently, we found that 28DAP010 (also known as CPD0905)
and its close analogues 19DAP025 and 27DAP060 were highly
active in vitro against T. b. rhodesiense and were curative in the
stringent T. b. rhodesiense STIB900 first-stage mouse model at the
low dose of 4 5mg/kg of body weight (i.e., daily dose of 5mg/kg
given on 4 consecutive days) or as a single dose of 10 mg/kg by an
intraperitoneal (i.p.) route of administration (20). In this paper,
we present more data from our investigations of this new novel
diamidine with high CNS activity in vivo, 28DAP010, and its an-
alogues 19DAP025 and 27DAP060. We performed a full dose-
response experiment in the STIB900 acute-stage mouse model to
determine the minimal curative dose for the three compounds
and evaluated their CNS activity in theGVR35CNSmousemodel.
As 28DAP010 showed better efficacy than the analogues, we car-
ried out a detailed biological characterization of this compound.
We collected in vitro data on different T. brucei strains and sub-
species, with a particular emphasis on trypanocidal activity on T.
b. gambiense, as the majority (98%) of African sleeping sickness
patients are infected with T. b. gambiense (2). Additionally, we
assessed the time to kill of 28DAP010 in vitro usingmicrocalorim-
etry, a new method to measure drug activity on a real-time basis
(21). This was important, because aromatic diamidines typically
kill the trypanosomes rather slowly, with a time to kill of about 24
to 48 h after treatment (22). Among the diamidines, DB829 was
one of the slowest-acting compounds, with a time to kill of48 h
(23). After having analyzed the pharmacokinetic properties of
28DAP010 in mice at a curative single dose, we assessed the para-
site clearance time at an identical dose in mice infected with T. b.
rhodesiense and T. b. gambiense strains.
MATERIALS AND METHODS
Materials. Pentamidine isethionate was purchased from Sigma-Aldrich
(St. Louis, MO). Syntheses of 28DAP010 (CPD-0905) (20), 19DAP025
(20), 27DAP060 (20), DB829 (24), DB1244 (20) and deuterium-labeled
DB75 (DB75-d8; deuterated phenyl rings; internal standard) (25), all iso-
lated as their hydrochloride salts, have been previously reported.
Antitrypanosomal activities of 28DAP010 andpentamidine in vitro.
(i) Preparation of compounds. Compounds were dissolved in 100% di-
methyl sulfoxide (DMSO) and finally diluted in culture medium prior to
the in vitro assay. The DMSO concentration never exceeded 1% in the in
vitro alamarBlue assays at the highest drug concentration. For microcalo-
rimetry assays, the DMSO concentration was kept at 0.1% in all samples.
(ii) Parasites. The T. brucei strains used in this study are described in
Table 1.
(iii) In vitro growth inhibition assays using T. brucei subspecies.
The 50% inhibitory concentrations (IC50s) were determined using the
alamarBlue assay as described by Räz et al. (26), with a 3-day drug expo-
sure and minor modifications as described previously (23). Assays were
carried out at least three times independently and each time in duplicate.
The IC50s are the means of the independent assays. Coefficients of varia-
tion were less than 50%. Different culture and assay media were used for
T. b. gambiense andT. b. rhodesiense, as previously described byWenzler et
al. (23).
(iv) Microcalorimetry studies using T. brucei subspecies. In vitro
time of drug action was monitored using isothermal microcalorimetry.
With this method, the time of drug action on a parasite population can be
determined on a real-time basis (21, 23). The strain STIB900 was used as
a representative for T. b. rhodesiense and STIB930 (and sometimes addi-
tionally ITMAP141267) for T. b. gambiense.
For experiments with continuous drug exposure, bloodstream try-
panosomes (2 ml at 5 104/ml per ampoule) were spiked with different
concentrations of 28DAP010, with a final DMSO concentration of 0.1%
(vol/vol). Negative controls contained culture medium only. The heat
flow was continuously measured (1 reading/second) at 37°C in the iso-
thermal microcalorimetry instrument (thermal activity monitor, model
249 TAMIII). Each experimentwith continuous drug exposurewas set up
in triplicate and carried out a total of 3 times (21).
(v) Inoculum studies. For studies of the drug effect on different par-
asite densities in the inoculum, the parasite density was reduced to 1 
104/ml of bloodstream trypanosomes and supplemented with 28DAP010
at the desired concentrations. Inhibition of growth and viability was com-
pared with that in the samples containing the standard inoculum of 5
104/ml of bloodstream trypanosomes and the same drug concentrations
(23). Each experiment was set up in triplicate and repeated once.
(vi) Drug wash-out experiments. For the 24-h exposure experiment,
trypanosomes (T. b. rhodesiense strain STIB900 and T. b. gambiense strain
STIB930) were incubated with 28DAP010 for 24 h at 37°C and then
washed twice to remove the compound. Subsequently, the washed try-
panosomeswere resuspended in drug-free culturemedium, transferred to
ampoules, and inserted into the isothermalmicrocalorimetry instrument.
The drug-free control samples (drug free, wash-out) were washed identi-
cally to the drug-containing samples. Each 24-h exposure experiment was
set up in triplicate and repeated once (23).
(vii) Analysis of microcalorimetry heat flow data. To facilitate fur-
ther calculations, the recorded data were resampled to obtain an effective
sampling frequency of 1 data point per 1.5 min, using the manufacturer’s
software (TAM assistant version v1.2.4.0), and exported to a spreadsheet.
Forty-five minutes was added to the time data to account for the prepa-
ration of the ampoules and the transfer from the bench to the calorimeter.
Resulting data were plotted as heat flow (in W) over time. Each single
curve for heat flow (inwatts) over timewas analyzed using the R statistical
package (27). Data were smoothed using a cubic spline (smooth.spline
function) in the R statistical software (27–30). The time to onset of drug
action was determined as the time at which a divergence between the heat
flow of the drug-free controls and the drug-containing specimens could
be observed. The time to peak was determined as the time point at which
the highest heat flow was measured for each samples. The time to kill the
parasite population was defined as the time point when the heat produc-
tion was reduced to the level of the sterile medium control (base level)
(23).The growth rate () of each culture was calculated using the heat-
over-time data (integrated heat flow data over time). For this calculation,
the Gompertz growth model was fitted over the whole curve using R
software and the Grofit package as described previously (23, 31). The
growth rate calculated based on the heat released by themetabolic activity
TABLE 1 T. brucei isolates used in this study
Trypanosome
strain(s)a Subspecies
Year of
isolation Origin Reference
STIB900,
STIB704
T. b. rhodesiense 1982 Tanzania 52
BS221, S427 T. b. brucei 1960 Uganda 42
BS221AT1 T. b. brucei 42
GVR35, S10 T. b. brucei 1966 Serengeti 53
STIB930,
STIB754
T. b. gambiense 1978 Côte d’Ivoire 54
ITMAP141267 T. b. gambiense 1960 DRC 55
130R T. b. gambiense 2005 DRC 56
40R T. b. gambiense 2005 DRC 56
45R T. b. gambiense 2005 DRC 56
349R T. b. gambiense 2006 DRC 56
DAL898R T. b. gambiense 1985 Côte d’Ivoire 52
K03048 T. b. gambiense 2003 South Sudan 57
a Strains labeled with an “R” were isolated from patients after a relapse after
melarsoprol treatment.
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in the culture is considered only as a proxy for the growth rate calculated
from the exponential growth phase by conventional approaches, since
lysis and chemical processes due to the nature of the medium might also
contribute to the overall heat signal (23, 31).
In vivo studies. (i) Efficacy and time to kill in mice. The efficacy and
time-to-kill experiments were performed at the Swiss Tropical and Public
Health Institute. Adult female NMRI (Naval Medical Research Institute)
mice were obtained from Janvier, France, or from Harlan, the Nether-
lands. Theyweighed between 20 and 25 g at the beginning of the study and
were housed under standard conditions with food pellets and water ad
libitum. All protocols and procedures were reviewed and approved by the
veterinary authorities of Canton Basel-Stadt, Switzerland. For experi-
ments with mice, the compounds were dissolved in DMSO and further
dilutedwith distilledwater to a finalDMSOconcentration of 10%prior to
administration to the animals.
(ii) Efficacy in an acute-stage T. b. rhodesiense STIB900 mouse
model. The STIB900 acute-stage mouse model mimics the first (hemo-
lymphatic) stage of HAT. Experiments were performed as previously re-
ported (23). Briefly, four female NMRI mice per group were infected
intraperitoneally (i.p.) with 5  103 STIB900 bloodstream forms. Drug
administration (i.p.) began 3 days after infection. A control group was
infected but remaineduntreated. Allmiceweremonitored for parasitemia
by microscopic examination of tail blood twice a week until day 30, fol-
lowed by once a week until 60 days after infection. The time to parasite
relapse was recorded to calculate the mean relapse time in days after in-
fection. Mice were euthanized after parasitemia relapse detection. Mice
were considered cured if they survived andwere aparasitemic until day 60.
(iii) Efficacy in acute-stage T. b. gambiense mouse models. Experi-
ments were performed as previously reported (23). Briefly, four female
NMRImice per group were immunosuppressed with 200mg/kg of cyclo-
phosphamide (Endoxan, Baxter, Deerfield, IL) 2 days prior to infection
with 105 bloodstream forms with one of the four T. b. gambiense strains
(i.e., ITMAP141267, STIB930, 130R, or 45R). Immunosuppression with
cyclophosphamide followed every secondweek until the end of the exper-
iment. Drug administration (i.p.) began 3 days after infection. A control
group was infected but remained untreated. Mice were monitored for
parasitemia twice a week until day 30 and then once a week until 90 days
after infection. Mice were considered cured if they survived and were
aparasitemic until day 90.
(iv) Efficacy in a CNS stage T. b. brucei GVR35 mouse model. The
GVR35mouse CNSmodelmimics the second stage of the disease. GVR35
is a less virulent strain than STIB900 and crosses the BBB of mice around
7 days after infection (32). Experiments were performed as previously
reported (14), with minor modifications. Five female NMRI mice per
experimental group were used. Each mouse was inoculated i.p. with 2
104 bloodstream forms. The drug administration was i.p. for diamidines
and per os (p.o.) for prodrugs on five consecutive days from day 17 to 21
after infection. Some experimental groups were treated for 10 consecutive
days (day 17 to 26 after infection). A negative-control group was treated
on day 17 with a single dose of diminazene aceturate at 40 mg/kg of body
weight i.p., which is subcurative since it clears the trypanosomes only
from the hemolymphatic system and not from the CNS, leading to a
subsequent reappearance of trypanosomes in the blood (33). Parasitemia
was monitored twice a week from the time after treatment until day 50
after infection, followed by once a week until 180 days after infection.
Mice were considered cured when there was no parasitemia relapse de-
tected over the 180-day observation period. Surviving and aparasitemic
mice were euthanized on day 180.
(v) In vivo time to kill. Infection with T. b. rhodesiense and T. b.
gambiense and immunosuppression for T. b. gambiense-infected mice
were carried out as described for the efficacy experiments. In different
mousemodels the parasite load varied, an observation that was alsomade
in the efficacy experiments. Mice were treated with a single dose of 20
mg/kg i.p. 3 days postinfection. The first microscopic examination of
blood was done 24 h after treatment, and examination was done subse-
quently twice per day until all parasites had disappeared. When micros-
copy was not sensitive enough to detect any parasites, a hematocrit buffy
coat examination was performed. The first time point at which no try-
panosomeswere detected on themicroscopic slide or in the buffy coat was
considered the clearance time (or time to kill) inmice. The detection limit
by buffy coat examination was 100 trypanosomes/ml of blood. Mice
were kept and further observed by tail blood examination until the end of
the experiment to verifywhether the administered dosewas curative in the
infected mice (23).
Pharmacokinetic studies. (i) Animals for PK studies. The pharma-
cokinetic (PK) studies were performed at the University of Kansas. Pro-
tocols for the animal studies were approved by the Institutional Animal
Care andUse Committee of the University of Kansas.Male SwissWebster
mice (weighing 20 to 25 g) were purchased from the Charles River Labo-
ratories (O’Fallon,MO).Micewere housed in a clean roomunder filtered,
pathogen-free air, in a 12-h light/dark cycle, and with food pellets and
water available ad libitum. Although a different strain and sex ofmicewere
used in our PK studies compared to efficacy studies, we did not expect that
diamidine PKwould differ significantly betweendifferent strain and sex of
mice.
(ii) Pharmacokinetics and brain exposure in mice. The single-dose
pharmacokinetics of 28DAP010 was evaluated inmice (in triplicate) after
intravenous (i.v.) and i.p. administration. 28DAP010 was dissolved in
sterile saline. The doses were 7.5 mol/kg (approximately 2.4 mg/kg) for
i.v. administration and 65 mol/kg (approximately 21 mg/kg) for i.p.
administration, which was the dose used in the in vivo time-to-kill study.
The dose volume was 5 ml/kg. No overt adverse effects were observed in
mice at these dose levels. Blood sampling occurred at 0.25, 0.5, 1, 2, 4, 6, 8,
12, 24, 48, and 72 h postdose. Additional earlier sampling times, at 0.0167
and 0.083 h, were included for the i.v. administration. Bloodwas collected
via the submandibular vein (0.04 ml per bleed) or heart (0.8 ml) into
lithium heparin-coated Microvette tubes (Sarstedt Inc., Newton, NC).
Terminal blood and brain samples were collected at 4, 12, and 72 h post-
dose. Plasma was obtained by centrifugation. Excised mouse brain sam-
ples were quickly rinsed with distilled water, blotted dry with tissue paper,
and weighed. All samples were stored at 20°C until further processing
for quantification by ultrahigh-performance liquid chromatography-tan-
dem mass spectrometry (UPLC-MS/MS).
(iii) Plasma and tissue binding assays. Binding of 28DAP010 to
mouse plasma andbrainwas evaluated by the equilibriumdialysismethod
using a rapid equilibrium dialysis device (Thermo Scientific Pierce, Rock-
ford, IL) as previously described (34). Briefly, blank (untreated and unin-
fected) mouse brains were collected and homogenized in 2 volumes (vol/
wt) of water (3-fold dilution). 28DAP010 was spiked into blank plasma or
brain homogenates to yield a final drug concentration of 1 M. Spiked
plasma or brain homogenates (in triplicate) were added to the dialysis
device and dialyzed against phosphate-buffered saline (PBS) for 6 h at
37°C to reach equilibrium between the plasma/tissue compartment and
the buffer compartment. At the end of incubation, samples from the plas-
ma/tissue compartment and the buffer compartment were collected and
analyzed for total and unbound concentrations by UPLC-MS/MS. Un-
bound fractions in themouse brain (fu, brain) were calculated by correcting
for dilution (35).
(iv)UPLC-MS/MS analysis. (a) Sample preparation.Plasma samples
(2l) weremixed with 200l of 7:1 (vol/vol) methanol-water containing
0.1% trifluoroacetic acid and an internal standard (1 nM DB75-d8) and
then vortexmixed for 30 s, followed by centrifugation (2,800 g) to pellet
proteins. The supernatant was transferred to a new tube and dried using a
96-well microplate evaporator (Apricot Designs Inc., Covina, CA) under
N2 at 50°C and reconstituted with 100 l of 15% methanol containing
0.1% trifluoroacetic acid.
(b) Determination of drug concentration.The reconstituted samples
(5-l injection volume) were analyzed for drug concentration using a
Waters Xevo TQ-S mass spectrometer (Foster City, CA) coupled with
a Waters Acquity UPLC I-Class system. Compounds were separated on a
Wenzler et al.
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Waters UPLC BEH C18 column (2.1 mm by 50 mm by 1.7 m) equili-
brated at 50°C. UPLC mobile phases consisted of water containing 0.1%
formic acid (solution A) and methanol containing 0.1% formic acid (so-
lution B). After a 0.15-min initial holding period at 10% solution B, mo-
bile phase composition started with 10% solution B and was increased to
80% solution B over 2.2 min with a flow rate of 0.4 ml/min. Then the
column was washed with 90% solution B for 0.5 min and was reequili-
brated with 5% solution B for 1.1min before injection of the next sample.
The characteristic single reaction monitoring (SRM) transition for
28DAP010 and DB75-d8 were m/z 317.1¡283.1 and 313.2¡296.3, re-
spectively, under positive electrospray ionization mode. The calibration
curves for 28DAP010 ranged from 0.5 nM to 50 M. The intraday coef-
ficient of variation (CV) and accuracy were determined by measuring the
same preparation of three standards three times on the same day. At
concentrations of 5, 1,000, and 25,000 nM, the intraday CV and average
accuracy of 28DAP010 quantification were 11.2% and 103%, 5.33% and
104%, and 0.70% and 106%, respectively.
(v) Pharmacokinetic analysis. The total area under the plasma con-
centration-time curve (AUC), terminal elimination half-life (t1/2), maxi-
mumplasmadrug concentration (Cmax), time to reachCmax (Tmax), clear-
ance (CL), steady-state volume of distribution (Vss), and mean residence
time (MRT) were calculated using the trapezoidal rule-extrapolation
method and noncompartmental analysis (WinNonlin version 5.0; Phar-
sight, Mountain View, CA).
RESULTS
Acute-stage T. b. rhodesiense mouse model. 28DAP010 and its
two analogues 19DAP025 and 27DAP060 (Fig. 1) are highly active
in vitro as well as in vivo against African trypanosomes (20).
Within this study we analyzed the minimal curative dose in the
stringent STIB900 acute-stage mouse model. All three com-
pounds showed superior activity, curing all mice at 4  5 mg/kg
i.p. or at single doses of 10mg/kg i.p. (28DAP010 and 19DAP025)
or 5 mg/kg i.p. (27DAP060) (20) (Table 2). Pentamidine cured
only 1/4 mice at 4  5 mg/kg i.p. (23). In vivo efficacies of
28DAP010 and 19DAP025 were comparable. Cure rates of 3/4 or
2/4 mice were attained at a daily dose of 5 mg/kg i.p. or 1 mg/kg
administered on 4 consecutive days. 27DAP060 was slightly more
effective than 28DAP010 and 19DAP025. With the low dose of
4  0.25 mg/kg i.p., none of the 3 compounds were able to cure
any of themice, and the parasitemia relapseswere detected already
around 4 days after the last drug administration. 28DAP010 and
its dipyridylfuran analogueDB829 showed similar efficacies in the
STIB900 acute-stage mouse model (Table 2).
CNS T. b. brucei mouse model. The high efficacies in the
acute-stage mouse model showed that the compounds merited
further testing in the GVR35 CNS mouse model. 28DAP010 was
the most potent compound among the three diamidines, curing
all infected mice at 10  20 mg/kg i.p. (Table 3). The high CNS
activity is exceptional, having been observed so far with only one
other diamidine, DB829 (14).
The two analogues of 28DAP010—19DAP025 and
27DAP060—were both less effective and did not achieve any
cures. Additionally, 19DAP025 was toxic and killed most of the
mice at the dosages administered. 28DAP010 was also tested at 25
mg/kg for only 5 days and was almost as potent as DB829. This is
only a slightly higher total dose than 10 mg/kg i.p. administered
for 10 days but was clearly more effective (Table 3). 28DAP010
was well tolerated in NMRI mice at 5  25 mg/kg and 10  20
mg/kg i.p., without any overt toxicity observed.
The prodrug DB1244 is a methamidoxime derivative of
28DAP010 (analogous to DB868 being the methamidoxime de-
rivative of DB829). It has been tested orally at 100 mg/kg admin-
istered on 5 consecutive days. At identical oral doses, DB1244 was
FIG 1 Chemical structures of 28DAP010, its prodrug DB1244, and its ana-
logues.
TABLE 2 In vivo antitrypanosomal activities of 28DAP010 and its analogues 19DAP010 and 27DAP060 (along with dipyridylfuran analogue
DB829) in mice with acute-stage STIB900 T. b. rhodesiense infectionsa
Dose regime (no. of
dosesmg/kg)
28DAP010 (in vitro IC50
[nM], 17	 4)
19DAP025 (in vitro IC50
[nM], 4	 1)
27DAP060 (in vitro IC50
[nM], 6	 1)
DB829 (in vitro IC50 [nM],
20	 4)
No. of mice cured/
no. infected MRD
No. of mice cured/
no. infected MRD
No. of mice cured/
no. infected MRD
No. of mice cured/
no. infected MRD
1 5 i.p. 3/4 17 2/4 17 4/4 2/4 53.5
1 10 i.p. 4/4 4/4 ND 4/4
4 0.25 i.p. 0/4 12 0/4 9.25 0/4 13 0/4 14.75
4 1 i.p. 3/4 14 2/4 19 4/4 3/4 14
4 5 i.p. 4/4 4/4 4/4 4/4
a DB1244, the methamidoxime prodrug of 28DAP010, cured 2/4 mice at 4 25 mg/kg p.o. (20). IC50s are from references 20 and 23 and are expressed as means	 standard
deviations. No. of dosesmg/kg, one daily dose administered on consecutive days; MRD, mean relapse day; ND, not determined.
TABLE 3 In vivo antitrypanosomal activity of 28DAP010 in mice with
GVR35 CNS infections
Dose regime
(no. of
doses
mg/kge)
No. of mice cured/no. infected
28DAP010 19DAP025 27DAP060 DB1244
DB829 or
diminazene
5 25 i.p. 2/5, 5/6a 0/1d 4/5,b 6/6a,b
10 10 i.p. 0/5, 1/6a
10 20 i.p. 5/5 0/1d 0/4
5 100 p.o. 0/5
1 40 i.p. 0/5c
a Cure obtained in a previous experiment.
b Result for DB829.
c Result for diminazene.
d Several mice died or were euthanized due to compound toxicity.
e No. of dosesmg/kg, one daily dose administered on consecutive days.
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less potent in the CNS mouse model (no cures [Table 3]) than
DB868 (5/5 mice cured) (14).
In vitro activity against different trypanosome strains. We
analyzed the in vitro activity of 28DAP010 against different try-
panosome isolates in the alamarBlue viability assay. Asmost sleep-
ing sickness patients suffer from T. b. gambiense infections, we
tested 28DAP010 against several T. b. gambiense field isolates. The
strains and culture conditions were identical to those used to de-
termine the trypanocidal activity of DB829 (23), so the IC50s of
28DAP010 and DB829 can therefore directly be compared. The in
vitro IC50s of 28DAP010 were higher for all tested T. b. gambiense
isolates (IC50 
 45 to 215 nM [Fig. 2]) than for T. b. rhodesiense
strain STIB900 (IC50 
 17 nM) and T. b. brucei strain BS221
(IC50
 25 nM). Among the T. b. gambiense strains, there was no
clear correlation between isolates from patients suffering from a
relapse after melarsoprol treatment (strains whose name includes
“R”) and reduced potency of 28DAP010 (Fig. 2), whereas pent-
amidine appeared to be less active against strains that had been
recently isolated (since 2003), which has also previously been
shown (23). 28DAP010 was more active against the four “R”
strains (130R, 349R, 40R, and DAL898R) than against the refer-
ence melarsoprol-sensitive strain STIB930. ITMAP141267 was
the oldest isolate tested in this study (isolated in 1960 from the
Democratic Republic of the Congo [DRC]), and it was the strain
most sensitive to 28DAP010 and among those most sensitive to
pentamidine (Fig. 2). However, no correlation in reduced
trypanocidal activity among T. b. gambiense strains was observed
between 28DAP010 and pentamidine (r2 
 0.019) or with the
isolates from melarsoprol-refractory patients.
We additionally studied the dependency of the P2 trans-
porter for the uptake of 28DAP010 into trypanosomes using
BS221AT1, a P2 knockout strain (IC50
 400 nM), and its cor-
responding wild type, BS221 (IC50 
 25 nM), by comparing the
IC50s determined in the alamarBlue assay. The resistance factor
(RF) obtained with 28DAP010 on the P2 knockout strain (RF 

16) was comparable to the RF obtained by DB829 (14), suggesting
that both compounds are taken up primarily by the P2 trans-
porter.
In vivomousemodels with acute-stage infection with differ-
ent T. b. gambiense isolates. We assessed the efficacy of
28DAP010 in mice against four different T. b. gambiense isolates
and compared the activity with that against T. b. rhodesiense
STIB900 (Table 4). This was a crucial experiment since in vitro,
28DAP010 had been shown to be less active against the testedT. b.
gambiense isolates than against T. b. rhodesiense strain STIB900
and T. b. brucei strain BS221. However, in in vivo experiments in
mice, 28DAP010 was at least as efficacious for T. b. gambiense
strains as for T. b. rhodesiense STIB900. 28DAP010 was curative at
1 20mg/kg i.p. and at 4 5mg/kg i.p. in STIB900-infectedmice
as well as in mice infected with either of the four T. b. gambiense
strains (ITMAP141267, STIB930, 130R, and 45R), two of which
(130R and 45R) were isolated from melarsoprol relapse patients.
At a single dose of 5 mg/kg i.p., 28DAP010 cured 3/4 STIB900-
infectedmice, whereas all mice were cured of infection with the T.
b. gambiense strains ITMAP141267 and STIB930 at the identical
dose (Table 4). A group given a dose of 1 5 mg/kg i.p. was not
included in the in vivo experiments with 130R and 45R, as the high
efficacy with a 100% cure rate at a single dose of 20 mg/kg i.p. had
not been expected prior to the experiment.
Time course of drug action in vitro. The time course of drug
action of 28DAP010 in vitro versus the T. b. rhodesiense strain
STIB900 and the two T. b. gambiense strains STIB930 and
ITMAP141267 was recorded using isothermal microcalorimetry.
Drug action was studied at different drug concentrations in 10-
fold dilution steps ranging from 2 to 20,000 nM concentrations
against the T. b. rhodesiense strain STIB900 or from 20 to 20,000
nM against the two T. b. gambiense strains. Four parameters were
FIG 2 In vitro activities of pentamidine versus 28DAP010 against different T.
b. gambiense strains. Symbols represent the average IC50 of at least three inde-
pendent determinations. The first number in each set of parentheses repre-
sents the IC50 for pentamidine and the second number that for 28DAP010. No
significant correlation was observed between pentamidine and 28DAP010 ac-
tivities (r2
 0.019).
TABLE 4 In vitro and in vivo antitrypanosomal activities of 28DAP010 against different T. brucei strainsa
28DAP010 dose
regime (no. of
dosesmg/kg)
No. of mice cured/no. infected
T. b. rhodesiense STIB900
(in vitro IC50 [nM], 17	 4)
T. b. gambiense
ITMAP141267 (in vitro
IC50 [nM], 45	 6)
STIB930 (in vitro IC50
[nM], 215	 56)
130R (in vitro IC50
[nM], 71	 33)
45R (in vitro IC50
[nM], 195	 50)
1 5 i.p. 3/4 4/4 3/3 ND ND
1 20 i.p. 4/4 3/3 4/4 4/4 4/4
4 5 i.p. 4/4 4/4 4/4 4/4 4/4
a IC50s are expressed as means	 standard deviations. No. of dosesmg/kg, one daily dose administered on consecutive days; ND, not determined.
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calculated from the curves for heat flow over time to describe the
time course of drug action quantitatively: (i) the onset of drug
action, (ii) the time to peak, (iii) the time to kill, and (iv) the
growth rate () and hence the level of growth inhibition (1 

drug
/drug free) (23).
The time of drug action of 28DAP010 was concentration de-
pendent (Fig. 3). The higher the concentration, the faster
28DAP010 acted and killed the parasites (in contrast to DB829,
with which saturation was observed at 2,000 nM [23]). The
onset of drug action on T. b. rhodesiense strain STIB900 ranged
from 4 to 16 h, and the time to kill the parasite culture ranged
from 24 to 92 h at concentrations of 20,000 to 20 nM (Table 5). At
the highest tested drug concentration of 20,000 nM, drug action
was so strong that not all parameters could be calculated. Also, the
inhibition of the growth rate () was dependent on the drug con-
centration, ranging from 7% at 2 nM up to 93% at the highest
tested concentration of 20,000 nM.
Drug action of 28DAP010 in vitro was slower for T. b. gam-
biense strains ITMAP141267 and STIB930 (Fig. 3; Table 5) than
for T. b. rhodesiense strain STIB900. This is consistent with the
reduced activity (higher IC50s) of 28DAP010 observed for T. b.
gambiense in the alamarBlue assay. Growth of the two T. b. gam-
biense strains was also slightly slower in drug-free control cultures
( 
 0.018 to 0.024 h1, time to peak 
 53 to 58 h, and time to
overgrowth 
 144 to 172 h) than that of T. b. rhodesiense strain
STIB900 ( 
 0.029 h1, time to peak
 34 h, and time to over-
growth 
 111 h) at identical trypanosome inocula of 5  104
trypanosomes/ml (Table 5). The onset of drug action for the two
T. b. gambiense strains ranged from 5 to 30 h and the time to kill
ranged from 46 to 126 h (2 to 5 days) at effective concentrations of
200 to 20,000 nM 28DAP010. Also, the inhibition of the growth
rate () was dependent on the drug concentration, ranging from
0.6 to 4% at 20 nM up to 82% at 20,000 nM for both T. b.
gambiense strains (Table 5).
An inoculum effect is a phenomenon that has previously been
observed with several diamidines. We studied the effect of two
FIG 3 Microcalorimetry heat flow profiles ofT. b. rhodesiense strain STIB900 (A) andT. b. gambiense strains STIB930 (B) and ITMAP141267 (C) in the presence
of various concentrations of 28DAP010. Drug-free samples included parasites (5 104/ml inoculum) without drug treatment, and trypanosome-free experi-
ment did not include any parasites or drug. Each curve represents the mean of three samples.
TABLE 5 Drug action analysis of 28DAP010 by isothermal microcalorimetry
T. brucei strainc Concn (nM)
Onset of action,
mean (SD) (h)
Time to peak,
mean (SD) (h)
Time to kill,
mean (SD) (h)
Growth rate (), mean
(SD) (h1/1,000) Inhibition (%)d
STIB900 None (drug free) 34 (4) 111 (10) 29 (1)
2a NMe 32 (8) 113 (7) 27 (1) 7
20a 16 (3) 30 (7) 92 (5) 22 (2) 24
200 7 (1) 10 (2) 49 (17) 7 (4) 76
2,000 5b 10 (1) 32 (10) 3 (2) 90
20,000b 4b 9b 24 (7) 2b 93
STIB930 None (drug free) 53 (2) 144 (8) 24 (2)
20a NM 53 (2) 146 (5) 24 (1) 0.6
200 30 (9) 50 (1) 126 (8) 23 (1) 4
2,000 9 (2) 36 (3) 90 (8) 11 (2) 52
20,000b 5b 13 (5) 46 (9) 4b 82
ITMAP141267 None (drug free) 58 (4) 172 (11) 18 (3)
20a NM 57 (4) 172 (7) 17 (3) 4
200 21 (6) 47 (3) 124 (12) 16 (3) 11
2,000 11 (4) 18 (6) 79 (7) 8 (1) 55
20,000 6 (1) 10 (1) 47 (19) 3 (1) 85
a Inhibition is too small to recover parameters from every experiment performed accurately.
b Inhibition is too strong to recover parameters from every experiment performed accurately.
c Initial inoculum density was 5 104 trypanosomes/ml.
d Inhibition was determined as follows: (1drug/drug free) 100.
e NM, not measurable.
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different initial parasite densities (5 104/ml and 1 104/ml) on
the sensitivity to 28DAP010 by isothermal microcalorimetry (see
Fig. S1 in the supplemental material). With an inoculum of 5 
104/ml, the growth rate of T. b. rhodesiense strain STIB900 was
inhibited by 19% at 20 nM and 81% at 200 nM (Table 6). Consid-
erably stronger inhibition was observed at the lower inoculum of
1  104/ml. The parasite culture was inhibited by 85% at 20 nM
and98% at 200 nM (Table 6; see also Fig. S1). In contrast, onset
of drug action and time to peak of the heat flow curves remained
similar with the different inocula (Table 6). The same phenome-
non was observed in the experiments with T. b. gambiense strain
STIB930.With an initial inoculum of 5 104/ml, parasite growth
rate was inhibited by 6%at a drug concentration of 200 nMand by
58% at 2,000 nM. Stronger inhibitions were observed at the lower
inoculum, with 51% at 200 nM and93% at 2,000 nM (Table 6).
The other two parameters, onset of action and time to peak of the
heat flow curves, remained again similar at the different inocula.
No clear inoculum effect was observed at 2 nM 28DAP010 (see
Fig. S1).
Diamidines are normally taken up rapidly into trypanosomes,
but parasite death is usually delayed. We tested whether continu-
ous drug exposure is required for 28DAP010 to kill the trypano-
somes or if an exposure of 24 h is sufficient to kill the parasites at
a later time point. Inhibition of trypanosome cultures that were
incubated for 24 h with 28DAP010 and then washed was moni-
tored in drug-free culture medium bymicrocalorimetric analysis.
The heat flow of preexposed trypanosome samples in drug-free
culturemediumwas comparedwith that of parasites continuously
exposed to the drug. The wash-out experiments were performed
with two strains (STIB900 and STIB930).
The time to peak of the washed, drug-free samples was delayed
by 14 to 17 h compared to the drug-free samples that were not
washed (Table 6; see also Fig. S2 in the supplemental material).
This delay was attributed to loss of some trypanosomes during the
washing steps since both samples were set up and run simultane-
ously. The trypanosome culture was still alive, as seen by heat flow
rate above baseline at the 24-h time point, and heat production
did increase in the wash-out samples after any drug was removed.
This indicates that the cells were still multiplying after the drug
preexposure at a 200 or 2,000 nM concentration. However, the
cultures in the drug-free medium did die after some time (see Fig.
S2). The times to kill after drug wash-out were delayed compared
to those with continuous drug exposure (82 versus 37 h) for T. b.
rhodesiense strain STIB900 at 200 nM and for T. b. gambiense
strain STIB930 (130 versus 85 h) at 2,000 nM (Table 6). However,
the 24-h exposure was sufficient to kill STIB900 at 200 nM and
STIB930 at 2,000 nM at the later time, which confirms that lethal
concentrations were taken up within the first 24 h. With lower
drug concentrations, a revival of the parasite culture after wash-
out was observed in some cases: with STIB900 at 20 nM and with
STIB930 at 200 nM (data not shown).
Pharmacokinetics andbrain exposure of 28DAP010 after i.v.
and i.p. administration in mice. The mean plasma concentra-
tion-time profiles of 28DAP010 were determined after a single i.v.
dose of 7.5mol/kg (2.4mg/kg) or a single i.p. dose of 65mol/kg
(21 mg/kg) (Fig. 4). Both profiles exhibited at least a biphasic
decline with an initial distribution phase and a terminal elimina-
tion phase. Pharmacokinetic outcomes were determined using
noncompartmental analysis (Table 7). Following i.v. administra-
tion, the average plasma concentration of 28DAP010 reached
70.2 M about 1 min after i.v. administration, but it quickly de-
creased, to below 1 M by 2 h postdose and below 0.1 M by 8 h
postdose (Fig. 4A). The steady-state volume of distributionwas 15
liters/kg, markedly greater than the physiologic fluid volume. The
TABLE 6 Effects of inoculum and drug wash-out on drug action of 28DAP010 by isothermal microcalorimetry
T. brucei strain and inoculum Concn (nM)
Onset of action,
mean (SD) (h)
Time to peak,
mean (SD) (h)
Time to kill,
mean (SD) (h)
Growth rate (), mean
(SD) (1,000) (h1) Inhibitione (%)
STIB900
5 104/ml None (drug free) 38 (3) 118 (7) 27 (2)
20 14 (2) 33 (1) 93 (4) 22 (2) 19
200 6 (1) 12 (1) 37 (3) 5 (1) 81
1 104/ml (low inoculum) None (drug free) 50 (3) 125 (5) 27 (1)
20 12 (7) 29 (2) 59 (2) 4 (1) 85
200b 9b 13b 25b NMa,b 98
5 104/ml, wash-out None (drug free) 55 (4) 132 (11) 26 (2)
200 30 45 (7) 82 (19) 6 (2) 77
STIB930
5 104/ml None (drug free) 50 (2) 148 (9) 24 (2)
200 26 (4) 50 (1) 121 (8) 23 (1) 6
2,000 8 (2) 36 (3) 85 (7) 10 (2) 58
1 104/ml (low inoculum) None (drug free) 68 (1) 160 (10) 24 (2)
200 27 (3) 52 (5) 100 (11) 12 (2) 51
2,000b 15b 31 (5) 60 (3) 2b 93
5 104/ml, wash-out None (drug free) 64 (5) 154 (11) 21 (1)
200c 30 61 (2) 128 (9) 21 (1) 0
2,000d 30 60 (4) 130 (12) 15 (2) 28
a NM, not measurable.
b Inhibition is too strong to recover parameters from every experiment performed accurately.
c Only two independent experiments were performed (in triplicate).
d Only one independent experiment was performed (in triplicate).
e Inhibition was determined as follows: (1drug/drug free) 100.
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average brain concentration of 28DAP010 was 4.2 M at 72 h
postdose, approximately 190-fold higher than the corresponding
plasma concentration (Table 7). Following i.p. administration,
28DAP010 was rapidly absorbed into blood circulation, reaching
a plasmaCmax of 69.6Mat 15min postdose. The average plasma
concentration of 28DAP010 decreased below 1 M by 8 h post-
dose but remained above 0.1 M for at least 72 h after injection
(Fig. 4B). The average brain concentration of 28DAP010 was 9.3
M at 72 h postdose, approximately 69-fold higher than the cor-
responding plasma concentration (Table 7).
The nonspecific binding of 28DAP010 to mouse plasma pro-
teins and brain tissues was determined (Table 7). 28DAP010
showed moderate binding to mouse plasma (fu, plasma 
 26.3%)
but bound avidly to brain tissues (fu, brain
 0.69%).
Time of drug action in vivo. The time of drug action of
28DAP010 in vivowas determined following a single i.p. dose of 20
mg/kg tomice infectedwithT. b. rhodesiense strain STIB900 or the
T. b. gambiense strains ITMAP141267 and STIB930. The in vivo
time to kill (parasite clearance time) of 28DAP010was determined
in the same experiment as the previously reported data for DB829
(23). Typically, diamidines are rather slow-acting compounds, es-
pecially DB829. Therefore, the first blood sample collected was 24
h after treatment. This time point is close to the parasite clearance
time of 28DAP010, as in each group one mouse (STIB930 and
ITMAP141267) or three of four mice (STIB900 infected) were
already parasite free 24 h after drug administration.
The parasite clearance time was, on average, 26 h (24 to 32 h)
whenmice were infected with the T. b. rhodesiense strain STIB900
(Table 8). This is in the range of the in vitro time to kill at 2,000 to
20,000 nM concentrations (24 to 32 h [Table 5]). The time to kill
for the T. b. gambiense strain ITMAP141267 was, on average, 42 h
(24 to 56 h); that in STIB930-infected mice was 40 h (24 to 48 h)
(Table 8), which is slightly faster than the in vitro time to kill at the
two highest concentrations of 2,000 and 20,000 nM (Table 4).
DISCUSSION
Our studies of the diamidine 28DAP010 and its two analogues
27DAP060 and 19DAP025 showed that they are highly active
against African trypanosomes in vivo. In the STIB900 acute-stage
mouse model, the mice were cured by a single i.p. dose (Table 2)
(20). However, among the three analogues, only 28DAP010 cured
mice with second-stage infections in the GVR35 CNS mouse
model (Table 3).
The availability of more efficacy data for a number of diami-
FIG 4 Plasma (filled circles) and brain (open squares) concentration-time profiles of 28DAP010 following intravenous (A) and intraperitoneal (B) adminis-
tration to uninfectedmice. The doses were 7.5mol/kg (or 2.4mg/kg) for i.v. administration and 65mol/kg (or 21mg/kg) for i.p. administration. Symbols and
error bars represent means and standard errors of triplicate determinations, respectively.
TABLE 7 Pharmacokinetic parameters of 28DAP010 after i.v. and i.p.
administration to uninfected mice
Compartment Parametera
Value for dosing route
i.v. i.p.
Plasma Dose, mol/kg
(mg/kg)
7.5 (2.4) 65 (21)
C5 min, mol/liter 20.8	 0.7
b NCc
Cmax, mol/liter 70.2
d 69.6
Tmax, h NC 0.25
AUC0-, mol/liter · h 15 102
t1/2, h 68 26
CL, liter/h/kg 0.50 NC
Vss, liters/kg 15 NC
MRT, h 30 NC
fu, plasma, % 26.3	 2.2
b
Brain Cbrain_72h, mol/liter 4.2	 4.5
b 9.3	 0.5b
AUCbrain_0–72h, mol/
liter · h
202 469
B/P at 72 h 190 69
fu, brain, % 0.69	 0.07
b
a C5 min, plasma concentration at 5 min postdose; Cmax, maximum plasma
concentration; Tmax, time to reach Cmax; AUC0-, area under the plasma
concentration-time curve from time zero to infinitity; t½, terminal elimination half-life;
CL, clearance; Vss, steady-state volume of distribution; MRT, mean residence time;
Cbrain_72h, brain concentration at 72 h postdose; AUCbrain_0–72h, area under the brain
concentration-time curve from time zero to 72 h postdose; B/P, brain-to-plasma
concentration ratio; fu, drug unbound fraction; C5 min, plasma concentration at 5 min
postdose; B/P, brain-to-plasma concentration ratio.
b Mean	 standard deviation of triplicate determinations.
c NC, not calculated.
d Plasma concentration at 1 min postdose.
TABLE 8 In vivo time to kill (parasite clearance time) in infected mice
after 28DAP010 treatment
T. brucei strain Time to kill (h), mean (range)a
STIB900 26 (24–32)
ITMAP141267 42 (24–56)
STIB930 40 (24–48)
a 28DAP010 was given as a single dose at 20 mg/kg i.p. 3 days after infection. Values are
means of four mice per group; ranges represents the time when the first and last mouse
became aparasitemic.
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dines makes it possible to consider some structure-activity re-
lationships. 28DAP010 is chemically closely related to DB829
(Fig. 1). In the present study, 19DAP025 was less CNS potent and
more toxic than its diaza analogue 28DAP010 (Table 3). Most of
the infected mice died during or shortly after treatment with
19DAP025 at 5 25 mg/kg or 10 20 mg/kg i.p. A similar com-
parison can be made between furamidine and DB829 (14).
27DAP060, a regioisomer of 28DAP010, was highly active in vivo
in the acute-stagemousemodel (Table 2) but less CNS active than
28DAP010 (Table 3). This has been observed in previous experi-
ments with aza analogues of furamidine (DB75) (24), in which
onlyDB829 curedCNS-infectedmice (14). The two pyridyl nitro-
gen atoms introduced in DB75 decreased the pKa value of DB829
by only 1 unit, and it was still above physiological pH (36). The
higher BBBpenetration can therefore not be attributed to an effect
on pKa alone. The identical positions of the nitrogen atoms in the
outer pyridine rings in both DB829 and 28DAP010 (Fig. 1) may
play a crucial role in CNS potency and in the recognition of the
molecules by a presumed transporter protein located at the BBB,
which supports the penetration of 28DAP010 and DB829 into the
brain. The CNSmousemodel results for these twomolecules con-
firm that certain diamidines do indeed have potential for curing
not only first-stage but also second-stage HAT by the parenteral
administration route.
There is still some interest in the use of prodrugs, particularly
because of their potential for oral administration. Since the ana-
logue DB868, the methamidoxime prodrug of DB829, curedmice
showing CNS infection after oral administration (14), we ana-
lyzed the potency of DB1244, which is a methamidoxime prodrug
of 28DAP010, in the GVR35 CNS mouse model at the same dos-
age. However, DB1244 was much less CNS active than DB868
(Table 3) (14), although its acute-stage mouse model activity was
similar (Table 2) (14, 20). Further metabolism and pharmacoki-
netic studies of DB1244 are needed to explain the observed effi-
cacy difference.WhenDB868was tested by the oral route in vervet
monkeys with second-stage infections, the therapeutic window
was smaller for the prodrug DB868 than for its active diamidine
DB829 (18). Measurement of the efficacy of 28DAP010 in the
second-stage vervetmonkeymodel will be needed for comparison
with DB829.
Our greatest concern was to test the susceptibilities of different
T. b. gambiense isolates to 28DAP010, as 98% of all HAT cases
are due T. b. gambiense infections (2). Most of our strains were
isolated from patients from the Democratic Republic of the
Congo (DRC), the country harboring most HAT patients (1). We
observed considerable reduction in the in vitro activity of
28DAP010 against the different T. b. gambiense strains compared
to T. b. rhodesiense and T. b. brucei strains. This phenomenon has
been observed previously withDB829 (against all testedT. b. gam-
biense isolates) and with pentamidine against recent isolates
(K03048, 40R, 45R, 130R, and 349R) that were derived from pa-
tients within the last 10 years (23). However, our in vivo experi-
ments with T. b. gambiense infections with four different isolates
(ITMAP141267, STIB930, 130R, and 45R) were encouraging.
28DAP010 proved to be highly active against T. b. gambiense as
well asT. b. rhodesiense isolates. TheT. b. gambiense-infectedmice
were cured at doses comparable to, or even lower than, those used
for mice infected with T. b. rhodesiense STIB900 (Table 4). The
reduced in vitro activities of 28DAP010 and DB829 may be the
result of factors that do not influence activity in vivo. They could
be due to the slower growth of T. b. gambiense isolates or be the
result of different culture conditions leading, for example, to a
downregulation of a diamidine uptake transporter(s) (37) and
thus to a reduced susceptibility of the T. b. gambiense isolates in
vitro (23).
Cross-resistance between pentamidine and melamine-based
arsenicals such as melarsoprol is a well-known phenomenon (38–
40) involving the P2 transporter (41, 42). Therefore, we were con-
cerned about a possible cross-resistance between 28DAP010 and
these drugs or the possible development of more resistant trypano-
some strains. Tests using a P2 knockout (KO) T. brucei strain indi-
cated that the uptake of 28DAP010 is dependent on the P2 trans-
porter.We observed a resistance factor (IC50 P2-KO/IC50 wild type) of
16, which was similar to that for DB829 and diminazene in the
72-h alamarBlue assay (14). Recently another transporter, aqua-
porin 2 (AQP2), was identified which is also involved in drug
uptake and the development of resistance to pentamidine and
melarsoprol (40, 43, 44). However, cross-resistance seems to be
limited to the two diamidines pentamidine and 28DAP010, as the
IC50s of the two diamidines for different T. b. gambiense field
isolates do not correlate (r2
 0.019) (Fig. 2). A similar effect was
observed between pentamidine and diminazene (44). Analysis of
T. b. gambiense field isolates with reduced susceptibility to pent-
amidine did reveal rearrangements of the TbAQP2/TbAQP3 locus
accompanied by TbAQP2 gene loss (44). The mutant T. b. gam-
biense field isolates were less susceptible to pentamidine and me-
larsoprol but still susceptible to diminazene (44) and DB829 (23)
and, as can be seen in Fig. 2, also to 28DAP010. Additionally,
28DAP010 was able to cure mice that were infected with recent T.
b. gambiense isolates that were less susceptible to pentamidine
in vitro (Table 4). Lack of AQP2 dependency for uptake of
28DAP010 and DB829 would explain why the recent T. b. gam-
biense isolates that were less susceptible to pentamidine were still
sensitive to 28DAP010 and DB829.
An understanding of the pharmacokinetics and pharmacody-
namics of drugs is necessary to develop effective treatment sched-
ules. The time of drug action on trypanosomes can be determined
in vitro using isothermal microcalorimetry (21). This method is
based on the heat production ofmetabolically active parasites and
thus allows studying the growth of cultures in the presence and
absence of drugs (21, 23). It is simple to use and offers constant
monitoring of a parasite population on a real-time basis (21).We
analyzed the time of drug action of 28DAP010 at different con-
centrations on 3 different trypanosome strains. The time course of
drug action was concentration dependent. No saturation could be
observed with 28DAP010, whereas in experiments with DB829,
saturation was found above 2,000 nM (23). This was probably due
to saturation of the P2 transporter with DB829 (23, 37). It is pos-
sible that 28DAP010 is taken up by an additional high-capacity,
low-affinity transporter at high drug concentrations, leading to a
stronger drug action at concentrations above 2,000 nM.
We studied the inoculum effect of 28DAP010 by using identi-
cal drug concentrations but different initial parasite densities (in-
ocula), 1 104/ml and 5 104/ml (see Fig. S1 in the supplemental
material). We observed a strong inoculum effect on the growth
rate () and on the time to kill. However, the onset of drug action
and the time to peak were less affected at the different trypano-
some starting densities at identical drug concentrations, as can be
observed at 20 and 200 nM concentrations with STIB900 or at 200
and 2,000 nM concentrations with STIB930 (Table 6). This indi-
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cates that the drug action starts almost concurrently at the differ-
ent starting densities using the same drug concentration. This
phenomenon has been previously observed with DB829 and pen-
tamidine in microcalorimetric studies (23). The major reason for
the inoculum effect in vitro seems to be the concurrent onset of
drug action, which appears at a much lower trypanosome density
at the lower inoculum. Therefore, the inhibition of these com-
pounds is more pronounced than for the drug-free control sam-
ples at the lower inoculum than at the higher inoculum.
The time taken to kill parasites is an important parameter to
measure treatment efficacy. It has been shown that several diami-
dines (such as pentamidine, DB75, and DB829) are rapidly taken
up by African trypanosomes; however, trypanosome death oc-
curred much later (9, 23, 45, 46). We studied the drug action at
effective concentrations (200 nM for STIB900 and 2,000 nM for
STIB930) for an exposure time of 24 h, after which the drug was
washed out (see Fig. S2 in the supplementalmaterial). Growthwas
followed by isothermalmicrocalorimetry. After the drug had been
washed out from the trypanosome culture, the parasites seemed to
grow for at least one more day (see time to peak in Table 6). The
trypanosomeswere finally killed as a consequence of the 24-h drug
exposure, but death occurred almost 2 days later than in contin-
uously exposed trypanosomes (Table 6; see also Fig. S2). Micro-
calorimetric studies with multiple concentrations of 28DAP010
and multiple time points would be needed to examine this phe-
nomenon in detail, but this was beyond the scope of this study.
The performed wash-out experiments suggest that the high max-
imum drug concentration in plasma (Cmax) after i.p. administra-
tion (Table 7) resulted in the high in vivo efficacy observed after a
single i.p. dose with 28DAP010. The great in vivo efficacy in T. b.
rhodesiense- and T. b. gambiense-infected mice (Tables 2 and 4) is
not surprising considering the high Cmax combined with the long
half-life of 28DAP010.
28DAP010 showed a high brain-to-plasma concentration
(B/P) ratio at 72 h postdose (Table 7), suggesting good CNS pen-
etration. The high B/P ratio appears to be largely driven by the
more extensive binding of 28DAP010 to brain tissue than to
plasma (fu, plasma/fu, brain). However, it has been previously ob-
served using fluorescence microscopy that DB75 did not distrib-
ute into brain parenchyma but sequestered within endothelial
cells lining the BBB and blood-cerebrospinal fluid barrier. It is
unknown whether 28DAP010 was also sequestered within the en-
dothelial cells or distributed more extensively into brain paren-
chyma. Nonetheless, the observed high B/P ratio and efficacy in
the CNS T. b. brucei mouse model support 28DAP010 as a CNS-
active trypanocide.
The speed at which drugs act is of varying clinical importance.
Fast elimination of the parasite is not as vital forHATpatients as it
is for patients infected with some other parasites, likemalaria par-
asites, which cause much more rapid death. However, fast-acting
drugs are of advantage to minimize the risk of resistant parasite
selection in the patient and to reduce the hospitalization time. In
vitro as well as in vivo, 28DAP010 was faster acting than DB829.
However, a short exposure to 28DAP010 or to DB829 (23) was
sufficient to kill the trypanosomes in a delayed manner (Table 6).
High drug levels therefore do not need to be maintained over the
entire parasite clearance time in vivo.
More problematic than a relatively slow speed of action are
undesirable side effects such as hepatotoxicity or nephrotoxicity.
Such effects have been observed for pentamidine (47) and DB289
(pafuramidine) (15, 16, 48), and the nephrotoxicity of pafurami-
dine actually led to the termination of the clinical studies (16). It is
encouraging that studies with rats and mice indicate that nephro-
toxicity is not clearly class related (49). DB829 (resulting from
DB868 administration) accumulated less in liver and kidneys than
did DB75 (after pafuramidine administration) (16). The toxicity
profile of 28DAP010 may also differ from that observed for pa-
furamidine.
Second-stage efficacy of DB829 has been demonstrated in the
mouse (14) and monkey (18) models. In the present study,
28DAP010 revealed similar efficacies inmousemodels. Bothmol-
ecules are able to cure both disease stages and infections with both
studied subspecies, T. b. gambiense and T. b. rhodesiense, at low
and tolerated doses. Extensive toxicity studies of 28DAP010 and
DB829 side by side are still needed. Drug tolerability will be an
important criterion for choosing the better of these two diami-
dines for further drug development.
There is a continuing discussion about the relative advantages
and disadvantages of prodrugs and intrinsically active com-
pounds. The use of an orally active prodrug to cure second-stage
HAT could be helpful in resource-poor settings. However, paren-
teral administration also has advantages. The use of an active di-
amidine will simplify the pharmacokinetic and toxicity analyses
thatwill be needed if the drug is to be used, and treatmentwith one
of the backup compounds, 28DAP010 or DB829, could be short
and simple. Treatment duration of 5 days or less for second stage
could well be feasible and could be tested for further development
for HAT on the basis of the favorable pharmacokinetics after par-
enteral administration.
A sustained drug development pipeline will increase the
chance of getting a new and improved treatment into the market
(19). This will help to control, and eventually to eliminate, the
disease (50, 51).With 28DAP010, we have found a new promising
backup diamidine as a preclinical candidate for the treatment of
first- and second-stage African sleeping sickness.
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General Discussion and Conclusion 
 
This PhD thesis was embedded in the international and nonprofit ‘Consortium for 
Parasitic Drug Development’ (CPDD) with the aim to discover new treatments for second 
stage human African trypanosomiasis.  
 
We focused on the discovery of novel aromatic diamidines. Lead optimization efforts 
resulted in compounds that cured trypanosome-infected animals by the oral route and 
animals with second stage disease by an oral or parenteral route of administration without 
overt toxicity. These two achievements are great advances in the diamidine research since 
the mother molecule pentamidine has to be administered parenterally and only cures the 
first stage of the disease.  
 
In this thesis we characterized in vitro and in vivo the most promising novel diamidines 
and prodrugs thereof and finally were able to identify two new preclinical candidates, 
DB829 and 28DAP010, for a parenteral treatment of second stage and one preclinical 
candidate, DB868, for oral treatment of first stage sleeping sickness. 
 
 
Stimulated by the poor oral bioavailability of diamidines, we searched for prodrugs that 
are neutral, in contrast to their parent diamidines, which contain charged amidine groups. 
Especially the di-O-methylamidoxime (methamidoxime) prodrug derivatives exhibited 
enhanced oral activity and reduced acute toxicity in animal models for trypanosomiasis 
(Ansede et al., 2004).  A prodrug is a precursor molecule that shows no in vitro activity. 
After oral absorption it is converted by host enzymes to its active form, the parent 
diamidine (Saulter et al., 2005; Werbovetz, 2006). The prodrug approach was successful 
with regard to oral bioavailability in animal models (Chapters 3 and 4; Hu et al., 2013; 
Midgley et al., 2007; Wenzler et al., 2009; Werbovetz, 2006) as well as in humans, where 
the prodrug DB289 (pafuramidine maleate) underwent clinical trials as the first oral drug 
for treatment of first stage HAT patients (Burri, 2010; Paine et al., 2010). 
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During the clinical trials with pafuramidine, drug discovery of diamidines and their 
prodrugs continued. We screened over 2000 molecules in vitro and found almost 500 
compounds that had IC50s below 100 nM against the T. b. rhodesiense strain STIB900 
and an in vitro selectivity index (SI) >1000 versus L6 cells, a rat myoblast cell line. Thus 
diamidines were highly potent in vitro and selective against the parasite. 
 
The most active diamidines in vitro and their prodrugs were tested for efficacy in mouse 
models for African trypanosomiasis. Several backup compounds were identified that 
were more potent orally than pafuramidine and could serve as second-generation 
diamidine prodrugs (Chapters 3, 4 and 8; Hu et al., 2013; Patrick et al., 2013; Wenzler et 
al., 2009). Two of the new prodrugs, DB844 and DB868, were particularly superior to 
pafuramidine in CNS infected mice. The blood-brain-barrier (BBB) is a membrane that 
hinders diamidines from penetrating into the brain which is a prerequisite for CNS 
activity. Both CNS potent prodrugs were aza analogues of pafuramidine (Chapter 3; 
Wenzler et al., 2009).  
 
Safety and second stage efficacy of DB844 was additionally studied in a vervet monkey 
model of CNS stage HAT (Thuita et al., 2012). DB844 efficacy was superior to 
pentamidine and pafuramidine which were both non-curative in the same monkey model. 
Unfortunately, toxicity was higher than that of pafuramidine and thus the therapeutic 
window not large enough to follow up on DB844 as a new preclinical drug candidate for 
the treatment of HAT (Thuita et al., 2012). 
 
The most promising prodrug for HAT is currently DB868. Its safety was assessed in two 
different monkey species and DB868 was tolerated in vervet monkeys up to a dose of 30 
mg/kg per day for 10 days (Thuita et al., 2013). Plasma biomarkers indicative of liver 
injury were not significantly altered by drug administration and kidney-mediated 
alterations in creatinine and urea concentrations were not observed either.  Follow-up 
efficacy experiments demonstrated that DB868 is capable to cure all infected monkeys 
with T. b. rhodesiense infection during first stage disease at a cumulative dose 14-fold 
lower than the maximum tolerated dose (Thuita et al., 2013). However, only one out of 
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four infected monkeys with second stage disease were cured at both 10 and 20 mg/kg p.o. 
per day for 10 days (Thuita, 2013).  Since DB868 is significantly better tolerated, cures 
infected monkeys at lower doses, and has thus a larger therapeutic window than 
pafuramidine, DB868 can be considered a backup clinical candidate for a new and safe 
oral treatment of first stage HAT. 
 
We tested many other diamidine prodrugs in the GVR35 CNS mouse model by the oral 
administration route. However, only very few showed CNS activity and none exceeded 
that of DB844 and DB868 (Chapters 3 and 4; Hu et al., 2013; Wenzler et al., 2009). The 
third most potent compound was the curved 2,6-diarylpyrazine diamidine prodrug 
DB1227 (compound 12 in (Chapter 4; Hu et al., 2013)) in the highly stringent GVR35 
mouse model of CNS stage HAT (Figure 1). It cured two out of five infected mice at 100 
mg/kg p.o. per day administered on 5 consecutive days and three out of four infected 
mice when administered for 10 days. This compound merits further evaluation for an oral 
treatment of HAT (second to DB868).  
 
 
 
Figure 1: Chemical structures of the 2,5-diphenyl pyrazine diamidine DB1547 and the 2,6-diphenyl 
pyrazine diamidine DB1210 and its methamidoxime prodrug DB1227. Figure adapted from (Hu et al., 
2013). 
 
These examples show that the prodrug approach was successful. It improved in vivo 
efficacy by the oral route and in some cases even cured second stage HAT in animal 
models, implying good absorption across the intestinal barrier and sometimes even across 
the BBB (Chapters 3 and 4; Hu et al., 2013; Wenzler et al., 2009). 
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The DNA binding to the minor groove was higher for DB1210 (∆Tm = 15.1°C) 
(compound 10 in (Chapter 4; Hu et al., 2013)), the parent diamidine of DB1227 (Figure 
1), than for the linear 2,6-diarylpyrazine diamidine DB1547 (∆Tm = 8.0°C), probably due 
to the crescent shape of DB1210 that fits better to the DNA curvature. The DNA binding 
of the linear compound DB1547 was probably achieved by incorporation of water 
molecules to form a complex with the DNA minor groove (Chapter 4; Hu et al., 2013; 
Miao et al., 2005). Not only the DNA binding but also the in vitro and in vivo activity 
was improved with the curved 2,6-diarylpyrazine diamidine DB1210 compared to its 
linear 2,5 isomer (Chapter 4; Hu et al., 2013). This is another example were DNA 
binding correlates with trypanocidal activity, which has been observed in many instances 
but not all, indicating that binding to kDNA or binding to genomic DNA is an important 
part of the mode of action of these diamidines. 
 
CNS activity of the parent diamidine DB1210 was studied in the GVR35 CNS mouse 
model by a intraperitoneal (i.p.) route at 20 mg/kg per day administered on 10 
consecutive days that cured one out of three infected mice (unpublished data).  This 
compound is more active than expected by a cationic diamidine but its CNS activity is 
still not sufficient for considering it as a new lead for a parenteral treatment for second 
stage HAT. 
 
Several other parent diamidines were tested by the i.p. route not only in the STIB900 
acute mouse model which mimics the first stage of HAT but also in the GVR35 CNS 
mouse model. As hypothesized, most of them were inactive, as these compounds are 
protonated at physiological pH. However, one diamidine, DB829 (CPD0801) was able to 
cure CNS infected mice at 20 mg/kg i.p. per day administered for 10 days (Chapter 3; 
Wenzler et al., 2009) or 25mg/kg i.p. per day for 5 days (Chapter 9; Wenzler et al., 
2013a). This was unexpected. For several years this was the only diamidine - a singleton 
- that was able to cure CNS infected mice. Just recently we identified another diamidine 
with CNS activity which is 28DAP010 (CPD0905) (Chapters 8 and 9; Patrick et al., 
2013; Wenzler et al., 2013a). Interestingly, both are chemically highly related compounds 
(Figure 2). Our data confirm that certain diamidines can indeed cross the BBB and be 
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CNS active. We hypothesize that a transporter located at the BBB recognizes these two 
structurally highly related compounds and transports them actively across the BBB into 
the brain since passive diffusion across the BBB is unlikely. 
 
 
 
Figure 2: Chemical structures of the diamidines 28DAP010 and DB829 and their methamidoxime prodrugs 
DB1244 and DB868. Figure adapted from Wenzler et al.,( 2013a). 
 
DB1244, the methamidoxime prodrug of 28DAP010 was similarly active in the STIB900 
acute mouse model as DB868 the methamidoxime prodrug of DB829. Both prodrugs 
cured two out of four mice at 25 mg/kg p.o. when administered for 4 days (Chapters 3 
and 8; Patrick et al., 2013; Wenzler et al., 2009). However, DB1244 was less active in the 
GVR35 CNS mouse model, resulting in no cures at the same dose at which DB868 was 
curative (Chapters 3 and 9; Wenzler et al., 2013a, 2009). DB1244 is bioconverted to 
28DAP010 as indicated by the high efficacy of DB1244 in the STIB900 acute mouse 
model. It is therefore more likely that the level of plasma protein- and tissue-binding of 
the prodrug or metabolites determine whether the compound is CNS active or inactive 
than differences in bioconversion. 
 
Membrane transporters at the trypanosome cell surface that recognize diamidine 
compounds as a substrate are important for the selective uptake. The P2 transporter, 
encoded by the gene TbAT1, has been identified in 1999 (Mäser et al., 1999).  It is 
involved in drug uptake of diamidines and melamine-based arsenicals and causes cross-
resistance between pentamidine and melarsoprol which are both used to treat HAT. 
TbAT1 gene deletion or mutated P2 transporters with impaired function were described in 
drug resistant strains induced in the laboratory or in trypanosome isolates from the field 
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(Baker et al., 2013). Recent studies revealed that there is another transporter, 
aquaglyceroporin 2 (AQP2), that is involved in cross-resistance between melarsoprol and 
pentamidine (Baker et al., 2012).  
 
The selective uptake improves the selectivity of these compounds towards the parasite. 
However, genetic changes (unless deleterious to the parasite) can lead to altered and 
reduced drug uptake and thus to drug resistance.  A big threat for a new compound is its 
potential of cross-resistance with current drugs. Especially since the novel diamidines are 
chemically analogous to pentamidine, an understanding of the mechanism underlying 
drug resistance is of help to estimate its potential for cross-resistance. 
 
AQP2-related resistance to melarsoprol and pentamidine has been observed in laboratory-
induced resistant trypanosomes (Baker et al., 2012).  We investigated if AQP2 
impairments also occur in the field and analyzed twelve T. b. gambiense field isolates, 
among which eight were from melarsoprol-refractory patients.  We found that six of the 
analyzed T. b. gambiense strains isolated from melarsoprol relapse patients carried a 
chimeric TbAQP2/3 gene in both or at least in one allele (Chapter 5; Graf et al., 2013). 
These six strains had a significantly lower in vitro susceptibility to pentamidine and 
melarsoprol than the TbAQP ‘wild-type’ isolates.  This demonstrates that rearrangements 
of TbAQP2 - TbAQP3 locus occur also in the field and are not just an artificial laboratory 
product. 
 
Interestingly, the occurrence of the chimeric TbAQP2/3 genes correlated with reduced in 
vitro susceptibility to pentamidine and melarsoprol but not with reduced susceptibility to 
diminazene (Chapters 5 and 9; Graf et al., 2013; Wenzler et al., 2013a).  Diminazene, in 
contrast to pentamidine and melarsoprol, is taken up exclusively by the P2-transporter (de 
Koning et al., 2004). Therefore it is not unexpected, that diminazene uptake is 
independent of AQP2.  Additionally, Baker et al. (2012) showed that deletion of AQP2 
caused only resistance to pentamidine and melarsoprol but not to other diamidines such 
as diminiazene or the monoamidine isometamidium.  
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We have tested DB829 and 28DAP010 in a TbAT1-KO cell line and observed a 
resistance factor (RF = IC50 AT1-KO / IC50 wild type) of 16 to 18  which is comparable 
to that of DB75 and diminazene (Chapters 3 and 9; Wenzler et al., 2013a, 2009). This 
suggests that DB829 and 28DAP010 are both also taken up primarily by the P2 
transporter.  This bears some risk of cross-resistance to melarsoprol. However, we do not 
know whether loss of TbAT1 really causes treatment failures nor how well trypanosomes 
with P2 deletions are transmitted by the tsetse fly. Eighteen T. b. gambiense isolates have 
been collected from patients in South Sudan from an area where a high melarsoprol 
treatment failure rate (20%) was reported with the aim to identify drug resistant isolates 
or TbAT1(resistant)-type alleles (Maina et al., 2007). However, no evidence for an 
impaired P2 transporter was found. The strains were collected in the year 2003.  
Interestingly, the first-line drug for the second stage disease had been switched from 
melarsoprol to eflornithine already in 2001 (Maina et al., 2007). If resistance based on 
mutated P2 transporters existed in that area, they might have been acquired but carried 
some fitness cost negatively affecting the transmission. A similar result has been 
observed at the Omugo focus in North Western Uganda (Kazibwe et al., 2009).  In 
Omugo, base-line genotypes were available when melarsoprol treatment failure was 
prevalent and could be compared with the data several years after melarsoprol had been 
withdrawn.  The mutant TbAT1 alleles found in isolates from melarsoprol relapse patients 
in the year 1998 have disappeared in 2006, suggesting that drug pressure is responsible 
for circulating trypanosomes with impaired P2 transporters (Kazibwe et al., 2009).  
 
The AQP2 mediated uptake may have a greater impact on the cross-resistance of 
pentamidine and melarsoprol than the P2 transporter (Baker et al., 2013).  The resistance 
factor in TbAT1 null mutants is only slightly increased in vitro to melarsoprol and 
pentamidine (RF = 2 to 5) (Chapter 3; Matovu et al., 2003; Wenzler et al., 2009) whereas 
resistance in TbAQP2 null mutants is more pronounced, especially to pentamidine (RF > 
15) (Baker et al., 2012). 
 
The T. b. gambiense field isolates from melarsoprol refractory patients that contained a 
chimeric TbAQP2 gene (40R, 45R, 130R, 349R and K03048; IC50s = 47 to 81 nM) were 
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all 8 to 80-fold less sensitive to pentamidine than trypanosomes with a wild type TbAQP2 
gene (STIB930, ITMAP141267 and DAL898R; IC50s = 1 to 6 nM) (Chapters 5, 7 and 9; 
Graf et al., 2013; Wenzler et al., 2013a, 2013b). Interestingly, loss of resistance did not 
correlate to the same extent to DB829 or 28DAP010 (Chapters 7 and 9; Wenzler et al., 
2013a, 2013b). We suppose based on these data that the AQP2 of T. brucei does not 
mediate DB829 and 28DAP010 uptake and conclude that the AQP2 is unlikely a source 
for potential cross-resistance of melarsoprol or pentamidine with one of the novel 
diamidines DB829 or 28DAP010.  Further analysis to determine the resistant factor for 
DB829 and 28DAP010 with a TbAQP2 null mutant and herewith the final evidence for 
our hypothesis will probably be done in other laboratories (e.g. Horn et al).  
 
The potential for cross-resistance is not only related to drug uptake as e.g. was observed 
for diamidines and melarsoprol via P2 or AQP2.  The activation of the prodrugs 
fexinidazole and nifurtimox rely on the same enzyme (a parasite type I nitroreductase) for 
its activation (R. Wilkinson et al., 2011). This could also bear some risk of cross-
resistance development. 
 
Time of drug action of diamidines is often long and the parasite clearance time or its 
dependency on drug concentrations important to know to predict clinical outcome and to 
optimize dosing regimens. Time to kill analyses are particular time- and labor-intensive 
or expensive with conventional laboratory methods. Within this thesis we established a 
new method to determine time of drug action, in particular the time to kill pathogenic 
protozoans in vitro (Chapter 6; Wenzler et al., 2012). We exploited the capacity of viable 
cells to produce heat. The highly sensitive microcalorimeters are able to measure heat 
flow, which correlates with the density of viable cells in a culture (Figure 3). The main 
advantages of this method are that microcalorimetry is simple to use, the samples do not 
need any fluorescence or other kind of labeling, and it measures the heat flow of the 
parasite culture on a real time basis (1 measurement per second) (Chapter 6; Wenzler et 
al., 2012).  Heat flow measurements are unspecific. Onset of drug action by a small 
change in the heat flow can be detected already by a reduced metabolic activity of drug 
treated cells, which can be detected earlier than by standard viability measurements. 
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 Figure 3: Microcalorimetric heat flow 
measurements of T. b. rhodesiense at 
different initial parasite densities of 
106 cells, 105 cells and 104 cells / ml 
(Wenzler et al., 2012). 
 
 
 
 
 
One drawback of this methodology is the sample numbers. A typical calorimeter e.g. 
TAM III from TA instruments, contains 48 channels. The throughput is therefore 
significantly lower compared to conventional viability analysis in the 96- or 384-well 
format. Routine drug screening to measure inhibition (e.g. IC50s) of a large number of 
diverse compounds will most likely continue with established methods such as the 
Resazurin / Alamar blue assay. However, microcalorimetry is a promising tool for 
gathering extra information for lead compounds, such as onset of drug action and time to 
kill of the parasite culture (Chapter 6; Wenzler et al., 2012).  
 
We applied this method to analyze time of drug action of our two most promising 
diamidines DB829 and 28DAP010.  Both diamidines were similarly potent in vitro 
against the T. b. rhodesiense strain STIB900, the T. b. brucei strain BS221, against 
several T. b. gambiense strains, and in vivo models of acute and CNS infection (Chapters 
3, 7 and 9; Wenzler et al., 2013a, 2013b, 2009).  Nevertheless, we could distinguish these 
two compounds based on their time of drug action. 28DAP010 was acting significantly 
faster than DB829 in vitro especially at concentrations above 10x IC50s. The clearance 
time in vivo was also faster in mice treated with 28DAP010 (1 to 2 days) than with 
DB829 (3 to 5 days) and more homogenous versus the different trypanosome strains 
STIB900 (26h / 78h), STIB930 (40h / 62h), and ITMAP141267 (42h / 102h) (Chapters 7 
and 9; Wenzler et al., 2013a, 2013b).  
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We observed a saturation at concentrations above 2,000 nM of DB829 in our 
microcalorimetry results (Chapter 7; Wenzler et al., 2013b). Up to 2,000 nM, the 
inhibition increased dose-dependently, whereas above 2,000 nM no further inhibition was 
observed versus any of the three trypanosome strains. This is likely related to the 
saturation of the P2 transporter.  In a P2 transporter-mediated uptake assay, the 
Michaelis-Menten constant, Km, of DB829 was 1.1 µM (Ward et al., 2011), indicating 
that the maximum uptake rate is almost reached around 2 µM and therefore no 
significantly higher inhibition can be expected at higher drug concentrations (Chapter 7; 
Wenzler et al., 2013b). 
 
Interestingly, no such saturation was observed with 28DAP010 (Chapter 9; Wenzler et 
al., 2013a). In addition to P2, there may be a low affinity - high capacity transporter 
involved in drug uptake of 28DAP010 but not of DB829, and this hypothetical additional 
transporter increases drug import at high 28DAP010 concentrations. 
 
DB829 showed some efficacy by the oral route. We have tested DB829 in the acute 
mouse model and found that it cured three out of four mice at 50 mg/kg p.o. when 
administered for 4 days, which is more than 10-fold higher than what is required by an 
i.p. route (Chapters 3 and 7; Wenzler et al., 2013b, 2009).  28DAP010 has not yet been 
tested orally but a similar effect can be expected. Interestingly another diamidine, 
Synthalin, a previous anti-diabetic drug, was also active orally (Synthalin and Insulin, 
1927). This shows that certain diamidines have better intestinal absorption than others. 
Oral bioavailability increased from DB75 (0.2%) to DB820 (0.4%) to DB829 with the 
highest oral bioavailability of 1.2% (personal communication Michael Wang).  However, 
the oral bioavailability of DB829 would be far too low to cure CNS infections. Therefore, 
to maximize efficacy, this compound still needs to be administered by a parenteral route. 
 
One issue of diamidines is the hepato- and nephrotoxicity that was observed with several 
diamdines such as synthalin, pentamidine and pafuramidine (Burri, 2010; Harrill et al., 
2012; Paine et al., 2010; Turner and Denny, 1996). Especially problematic is the delayed-
onset of renal insufficiency observed in an expanded Phase I study, which resulted in the 
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cancellation of pafuramidine development. Interestingly, the novel aza analog DB829 
accumulated in rat kidney cells more than ten-times less than furamidine after a single 
intravenous dose of 10 µmol/kg (Brun et al., 2011; Paine et al., 2010). The low kidney 
exposure with DB829 may provide the necessary safety margin that is required to 
develop this CNS-active diamidine to a second stage HAT medication. 
 
Variations in uptake rate, accumulation, oral bioavailability, pharmacokinetics, and BBB 
penetration show that diamidines have different characteristics. Discarding the entire 
class of compounds from the HAT pipeline because several diamidines have a small 
therapeutic window because of the risk of hepato and renal toxicity, may not be sensible. 
Fexinidazole was a similar case (Tweats et al., 2012).  This compound was dropped in the 
80s because of potential mutagenicity but was recollected by DNDi almost 30 years later 
and it is now one of the most promising clinical candidates for the treatment of HAT. We 
propose a careful toxicity evaluation of DB829 and 28DAP010 instead of discarding the 
entire diamidine class from the HAT pipeline.  
 
A pharmacological effect can persist beyond the time trypanocidal drug concentrations 
are detectable in the plasma. It has been shown that several diamidines are taken up to 
high concentrations (mM) into African trypanosomes within minutes or hours but 
trypanosome death occurred up to days later (Mathis et al., 2007; Werbovetz, 2006; 
Wilson et al., 2008). We performed a wash-out experiment with DB829 and 28DAP010 
with a 24 hours drug exposure time (i) because a single curative dose of 20 mg/kg i.p. 
gave a high and long exposure with plasma levels after 24 h of 0.483 µM for DB829 and 
0.982 µM for 28DAP010 (Chapters 7 and 9; Wenzler et al., 2013a, 2013b) and (ii) 
because the uptake rate of DB829 is slower than that of pentamidine, DB75, or DB820 
(Ward et al., 2011). Using microcalorimetry, we studied drug action on pre-exposed 
trypanosome cultures after the drug had been removed and observed that concentrations 
of 200 nM for STIB900 (Figure 4) and 2,000 nM for STIB930 were sufficient to kill the 
parasite culture in vitro 2.5 to 4.5 days after the drug was removed (Chapters 7 and 9; 
Wenzler et al., 2013a, 2013b). The accumulated drug in the parasite was killing the 
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parasites in a delayed manner. Our data show that the plasma drug levels do not need to 
be maintained until all the parasites are killed. 
 
Activity and time of drug action of different diamidines was thought to correlate with 
uptake (Ward et al., 2011).  The time to peak and the time to kill were comparable after 
drug washout for DB829 and 28DAP010 at 200 nM on STIB900 (Figure 3) or at 2,000 
nM on STIB930 (Chapters 7 and 9; Wenzler et al., 2013a, 2013b). The same killing 
kinetics may indicate same mechanism of action and the faster time to kill at high 
28DAP010 concentrations could indeed be related due to a higher uptake rate only. 
 
 
Figure 4: Effect of drug washout after a 24 hours exposure with DB829 and 28DAP010 at 200 nM on the T. 
b. rhodesiense strain STIB900.   Parasites were still viable after 24 hours of exposure. The heat flow further 
increased for 1 additional day after drug wash-out, and then the parasite culture died off and was killed 
around 3 days after the drug was washed out.  
 
With these studies we have shown that DB829 and 28DAP010 are highly active in vivo 
against the human pathogenic T. brucei subspecies and that both are highly active on 
either disease stage. Whether one of the two could be used for HAT patients without the 
need of staging is still unclear.  However, treatment for the first stage disease is likely to 
be shorter than the one for second stage disease. The question remains whether parenteral 
application would be accepted for first stage infections. 
 
Interindividual differences in patients’ response have been observed in the clinical 
development for pafuramidine. Bioconversion to the active diamidine, which involved 
different activation steps, varied between patients (personal communication Christian 
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Burri). Administration of an active diamidine itself, rather than a prodrug, will simplify 
pharmacokinetic predictions and will help to select the optimal dosage for a safe and 
effective treatment (Chapters 7 and 9; Wenzler et al., 2013a, 2013b). 
 
A well-tolerated drug is desired that cures first as well as second stage by an oral route 
and with a short treatment, preferably single dose. The current drugs, however, are far 
from that. Finally, great advancements have been made and the pipeline has been filled 
up with new HAT drug candidates (Chapter 1; Mäser et al., 2012).  Fexinidazole has 
entered clinical trials Phase II/III to investigate safety and efficacy of a 10 days oral 
treatment, and development of the oxaborole compound SCYX-7158 for second stage 
HAT has been initiated with a Phase I study with a single oral dose. Whether one of these 
two compounds will make it to the market is not yet clear. Statistically, two compounds 
entering the clinical trials are not sufficient to ensure a new treatment option for HAT. 
We have experienced with pafuramidine, how fast a compound can drop out from clinical 
development. Pafuramidine had looked highly promising until the delayed renal toxicity 
was observed in mid-phase III, which instantly terminated the development program 
(Burri, 2010; Harrill et al., 2012; Paine et al., 2010).  
 
Most likely, the development of a third compound will not be funded as long as 
fexinidazole and SCYX-7158 are under clinical testing. Otherwise, a parenteral treatment 
may be still acceptable in particular for the severe second stage of the disease. A 
treatment with DB829 or 28DAP010 will be cheaper, and simpler to administer than the 
NECT therapy which is already an improvement over current drugs on the market. 
Furthermore, DB829 and 28DAP010 will cure by shorter treatment duration. A single 
dose for first stage and a 5-day treatment for second stage disease can be realistically 
considered for the clinical development for the treatment of HAT. 
 
A safe and effective treatment is a prerequisite for the control and elimination of African 
sleeping sickness. With DB829 and 28DAP010 we identified promising preclinical 
backup candidates for the development of a new treatment of 2nd stage HAT.  
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